













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
The role of macrophage colony stimulating factor-1 
(CSF-1) in postnatal growth 
 
 












Thesis submitted for the degree of Doctor of Philosophy 
 
College of Medicine and Veterinary Medicine 








Contributions of work xi 
Abstracts xii 
Oral presentations xii 
Poster presentations xii 
Publications xiv 
Manuscripts in preparation xv 
Abbreviations xvi 
List of figures and tables xx 
Chapter 1: Introduction 1 
1.1 Macrophages and the Mononuclear Phagocyte System 1 
1.2 Monocyte subsets 3 
1.3 Colony Stimulating Factor-1 (CSF-1) 4 
1.3.1 CSF-1 gene and isoforms 7 
1.3.2 CSF-1 structure 9 
1.3.3 CSF-1 deficient animals 10 
1.3.4 CSF-1 biological activity 12 
1.3.5 CSF-1 and bone formation 15 
1.3.6 CSF-1 dependent macrophage populations 15 
1.3.7 Roles of different forms of CSF-1 17 
1.4 Colony stimulating factor-1 receptor (CSF-1R) 18 
1.4.1 CSF-1R gene and gene regulation 19 
1.4.2 CSF-1R protein structure and function 21 
1.5 Interleukin -34 (IL-34) 22 
1.5.1 Discovery of a second CSF-1R ligand 22 
1.5.2 IL-34 gene and isoforms 23 
1.5.3 IL-34 expression 23 
1.5.1 IL-34 structure 24 
1.5.2 Biological activity of IL-34 26 




1.6.1 CSF-1 binding to the CSF-1R 27 
1.6.2 IL-34 binding to the CSF-1R 28 
1.6.3 CSF-1R phosphorylation 29 
1.7 CSF-1 and CSF-1R in disease 30 
1.7.1 CSF-1 and CSF-1R associated tumours 30 
1.7.2 Therapeutic applications of manipulation of CSF-1R signaling 31 
1.8 Insulin like growth factor-1 (IGF-1) 33 
1.9 Aims of this thesis 36 
1.10 Hypothesis 37 
Chapter 2: Materials and Methods 38 
2.1 Cell culture 38 
2.1.1 Ba/F3 cells 38 
2.1.2 HEK293T 38 
2.2 Cloning methods – chapters 3 and 4 38 
2.2.1 Total RNA extraction 38 
2.2.2 First strand cDNA synthesis 39 
2.2.3 Primer design 39 
2.2.4 PCR amplification and visualization 41 
2.2.5 PCR product purification 41 
2.2.6 TOPO cloning 41 
2.2.7 Bacterial transformation 42 
2.2.8 Preparation of ampicillin agar plates 42 
2.2.9 Isolation and purification of plasmid DNA 42 
2.2.10 Plasmid DNA purification using QIAprep spin miniprep kit and 
micro-centrifuge 43 
2.2.11 Analytical digestion 43 
2.2.12 Confirmation of correct DNA insert by sequencing 43 
2.2.13 Bacterial expression of porcine CSF-1 44 
2.2.14 Generation of stable cell lines 45 
2.2.15 Immunoblotting 45 
2.3 Primary cell harvest and culture conditions 46 
2.3.1 Porcine bone marrow harvest and culture 46 




2.3.3 Feline bone marrow aspirate harvest and culture 47 
2.3.4 Feline bone marrow femur flushing cell harvest and culture 47 
2.3.5 Feline PBMC collection and isolation 47 
2.3.6 Feline peripheral PBMC and BMC stimulation with recombinant human 
CSF-1 47 
2.3.7 Mouse bone marrow harvest and culture 48 
2.4 Preparation of cells for cytospin 48 
2.5 Phagocytosis assay 48 
2.6 Cell viability assays (optimized) 48 
2.7 EC50 calculation 49 
2.8 3D modelling of contact amino acids 49 
2.9 Generation of porcine Fc CSF-1 50 
2.9.1 Cloning and expression 50 
2.9.2 Isolation of pig Fc CSF-1 fusion protein 50 
2.9.3 Porcine CSF-1 Fc-fusion quantitation in blood plasma by ELISA 51 
2.9.4 Pig pharmacokinetic studies (PK) 51 
2.10 In-vivo methods – chapters 5 and 6 52 
2.10.1 Experimental design - mice 52 
2.10.2 Experimental design - piglets 53 
2.10.3 Blood collection 55 
2.10.4 Complete blood count analysis 55 
2.10.5 Isolation of peripheral blood mononuclear cells (PBMC) from piglets
 55 
2.10.6 Isolation of bone marrow cells (BMC) 56 
2.10.7 Isolation of porcine alveolar macrophages (AM) from piglets 57 
2.10.8 Spleen single cells suspension (mice) 57 
2.10.9 Flow cytometry analysis 57 
2.10.10 Analysis of MHC II expression by flow cytometry 58 
2.10.11 Tissue processing 58 
2.10.12 Immunohistochemistry 59 
2.10.13 ELISA 60 
2.10.14 Analysis of bone density using bone imaging 61 
2.10.15 Bone histology 62 




2.10.17 Microarray 62 
Chapter 3: Cloning of porcine Colony Stimulating Factor-1 (CSF-1), Colony 
Stimulating Factor -1 Receptor (CSF-1R) and Interleukin 34 (IL-34) 65 
3.1 Introduction 65 
3.2 Results 69 
3.2.1 Cloning and sequence of porcine CSF-1, IL-34 and CSF-1R 69 
3.2.2 Production of stable cell lines expressing porcine CSF-1, CSF-1R and 
IL-34 78 
3.2.3 Assessment of biological activity of CSF-1, CSF-1R and IL-34 86 
3.3 Discussion 96 
Chapter 4: Analysis of the species specificity of CSF-1 and IL-34 101 
4.1 Introduction 101 
4.2 Results 104 
4.2.1 Production of a stable cell line expressing feline CSF-1R 104 
4.2.2 Species specificity of CSF-1 106 
4.2.3 Species specificity of IL-34 114 
4.3 Discussion 118 
Chapter 5: Effects of porcine CSF-1 and Fc CSF-1 on adult mice 127 
5.1 Introduction 127 
5.2 Results 131 
5.2.1 Comparing biological activity of porcine CSF-1 with porcine Fc CSF-1 
in-vitro131 
5.2.2 In-vivo studies comparing porcine CSF-1 with porcine Fc CSF-1 132 
5.2.3 Dose titration study of porcine Fc CSF-1 137 
5.2.4 Effect of 1 µg/g porcine Fc CSF-1 on adult mice 152 
5.2.5 Microarray data of liver gene expression 165 
5.3 Discussion 171 
Chapter 6: Effects of porcine Fc CSF-1 on neonatal pigs 179 
6.1 Introduction 179 
6.2 Results 183 
6.2.1 Effect of porcine Fc CSF-1 on TNFα and IL-1β production in-vitro 183 
6.2.2 Effect of porcine Fc CSF-1 on growth of neonatal piglets 184 




6.2.4 Effect of porcine Fc CSF-1 on CD14, CD16, CD163 and CD172α 
populations in BMC and AM 195 
6.2.5 Effect of porcine Fc CSF-1 on MHCII expression in PBMC 196 
6.2.6 Effect of porcine Fc CSF-1 on IGF-1 197 
6.2.7 Histological analysis of the effects of porcine Fc CSF-1 200 
6.2.8 Effect of porcine Fc CSF-1 on bone density 204 
6.3 Discussion 206 
Chapter 7: Conclusions and future perspectives 214 
Chapter 8: References 224 
Chapter 9: Appendices 270 
9.1 Appendix 1:  Antibody table  
9.2 Appendix 2:  EGFP
+
 lung images  
9.3 Appendix 3:  Microarray gene list  



















The thesis presented is the work of the author except stated otherwise by reference 
and /or acknowledgement.  Any work presented, which has been conducted by (or in 
collaboration with) others is explicitly acknowledged.  No part of this work has been 
submitted for any other degree or professional qualification. 
 








Colony-Stimulating Factor (CSF-1) is required for the proliferation, differentiation 
and survival of cells of the mononuclear phagocyte lineage. Mice with a mutation in 
their CSF-1 gene demonstrate abnormal development in many organ systems and 
severe growth retardation. These defects can be corrected by administration of rh-
CSF-1, and when similarly administered to wild-type mice, can increase organ and 
body weight, thus highlighting the importance of CSF-1 in postnatal growth.  CSF-1 
is known to be elevated in the circulation in the immediate postnatal period of both 
mice and humans.  It remains to be seen whether CSF-1 deficiency underlies 
important clinical issues such as low birth weight, and whether there are any 
functionally important variations in expression or biology of CSF-1, or the 
alternative CSF-1R ligand IL-34 that contributes to variation in somatic growth 
between individuals. This thesis aimed to use the pig as a model for human innate 
immunity and disease based upon recent publications that highlighted the similarities 
in their immune systems. 
To investigate the effects of CSF-1 on postnatal growth the first aim was to 
characterise the CSF-1R system in pigs and produce reagents.  Biologically active 
porcine CSF-1 and IL-34 were produced along with expression of full length 
functional porcine CSF-1R and production of anti-CSF-1R antibodies. A bioassay 
was developed and optimised to assess the biological activity of these proteins. The 
cross-species reactivity of a range of species CSF-1 and IL-34 proteins was 
investigated in-vitro using the bioassay and cell culture systems. Recombinant CSF-1 
is known to have a short half-life.  Since conjugation of proteins to the Fc region of 
immunoglobulins has been used extensively to improve circulating half-life; a 
porcine Fc CSF-1 fusion protein was generated by commercial partners, Pfizer 
Animal Health. The conjugated and un-conjugated CSF-1 proteins had identical 
activity in cell line and primary cell assays in-vitro.  The in-vivo activity of porcine 
Fc CSF-1 was tested initially in the Csf1r-EGFP
+
 mouse reporter line and C57BL/6 
mice. The Fc CSF-1 protein was more active than the native protein in promoting 
increased monocyte and tissue macrophage numbers, increasing body weight and 




macrophage infiltration and hepatocyte proliferation, identified by gene expression 
profiling as well as immunohistochemistry.  Fc CSF-1 was then tested in neonatal 
pigs.  They were found to have an immature immune system that develops with age.  
No postnatal surge of CSF-1 was detected.  Fc CSF-1 administration increased blood 
monocyte and neutrophil numbers confirming that CSF-1 is not saturating at this 
time. Nevertheless, no influence on postnatal growth rate was identified.   This is 
discussed in terms of the differences in placental architecture in the pig compared to 
human and mouse. This thesis demonstrates the effectiveness of porcine Fc CSF-1 in 
both mice and porcine and highlights the important role that CSF-1 and macrophages 
play in liver homeostasis. Fc CSF-1 is identified as candidate therapeutic agent in 
humans and companion animals for tissue regeneration, and a tool for the study of 

















Many people have helped me during the course of my PhD and I thank everyone who 
has been involved.  In particular, special thanks must go to my supervisor Professor 
David Hume for all his help and support during my PhD, and his amazing amount of 
patience!  I am very grateful for all the time David has given me over the last 5 years.  
My second supervisor Dr David Sester, who left The Roslin Institute whilst I was on 
maternity leave was a great help in the first year of my studies.  I thank David Sester 
very much for all the time he spent with me in the early days.  My funding council, 
(BBSRC) and industry sponsor (Pfizer) must also be thanked and acknowledged, 
especially Tom Wilson who has always shown an interest in my work and helped 
plan the piglet experiments.  
The one person in the lab who has been my “rock” is Valerie Garceau.  It was 
Valerie who took me under her wing on my very first day and has shown and taught 
me most of the techniques I can perform today.  Although, it was a little bit of a 
shock when she had to teach me how to use a pipette!!  Without the help and support 
from Valerie in particular, I would not have stayed to complete my PhD.  Darling, 
you know how important you are to me and I am so lucky to have found such an 
amazing friend for life.  
After returning from maternity leave, I had to plan my in-vivo experiments.  I found 
this very stressful and overwhelming since it was not something I had done before.  
Everyone in the Hume Lab was so supportive and all gave their time to help.  In 
particular my amazing “team mouse and “team pig” deserve special thanks.  Dr 
Kristin Sauter and Dr Clare Pridans have been without doubt the driving force behind 
my in-vivo studies.  Without their expert knowledge and understanding of how to 
develop and implement such studies, I would not have proceeded to this step in my 
PhD.  Both Kristin and Clare were key helpers harvesting the tissues on cull day and 
often gave up their time well into the night on these days that lasted for 15 hours.  
(Although we did have an endless supply of Percy Pigs to eat our way through!). 
Other vital members of the lab who helped me immensely are Lindsey Moffat,  and 
Dr Ronan Kaptanovic who again worked long hours on cull days and helped with 




the samples (most of the time >300 samples) through the FACS machine that was not 
the most fun job in the world.  Again, they gave up their time to help me, for which I 
am so grateful.  Also a massive thank you to everyone in the Hume, Summers and 
Freeman labs for their help and support. 
 
On a personal note, I would like to thank my wonderful Husband (Adam Gow) for 
always believing in me and helping me believe in myself.  Without his unconditional 
love and support, this thesis would not have been completed or written.  Our amazing 
bundle of joy, Joseph has also helped to give me the strength to continue by always 
making me see the importance of life.  Jumping in muddle puddles with a 3 year old 
is much more fun than writing a thesis!  Of course, all my friends and family (my 
parents, my in-laws, brothers and their families) have also provided a much needed 
support network.  Both my parents (Tim and Jacqy Gibson) and my parent in-laws 
(George and Carol Gow) have helped enormously with looking after Joseph when I 
had to work.  Joseph’s godparents (Sarah and Glen) have also been fantastic in 
helping with last minute child care arrangements.  My three wonderful cats Bungle, 
Zippy and Bobbles have provided a great service in keeping me warm and my blood 
pressure down while working from home over the winter.  And then there is my 











Contributions of work 
Chapters 3 and 4:  Production and purification of porcine CSF-1 produced from 
E.coli by Pfizer Animal Health, USA (Tomas Wilson, Ted Oliphant, John Shelly, 
Greg Fici, Roger Martin, Pamela Boner, Wendy Collard, Sandra James).  Mouse 
bone marrow harvest for culture performed by Valerie Garceau.  Assistance in 
collection of cat and dog bones and tissues, Adam Gow, Prof. Danielle Gunn-Moore, 
Dr. Kerry Simpson.  Generation of porcine anti-CSF-1R antibodies and 
characterization (Lindsay Moffat).   
 
Chapters 5 and 6:  Assistance with in-vivo experimental design and implementation 
of experiment including day of sacrifice (Dr Kristin Sauter, Dr Clare Pridans, Dr 
Ronan Kapetanovic, Lindsey Moffat).  Tissue processing including IHC for F4/80, 
IGF-1, preparation of bones for TRAP staining (The R(D)SVS clinical pathology 
lab).  Pathology examination of mouse and pig tissues (Dr Pip Beard).  Examination 
of mouse bones, Prof. Elspeth Milne. Production and purification of porcine Fc CSF-
1 by Pfizer Animal Health (Tomas Wilson, Ted Oliphant, John Shelly, Greg Fici, 
Roger Martin, Pamela Boner, Wendy Collard, Sandra James).  IGF-1 ELISA 
performed by Pfizer.  Pathology examination of pig tissues, (Dr Pip Beard and 
Pfizer).  Microarray analysis performed by Dr Sobia Raza.  Experiment to determine 














The effects of porcine Fc CSF-1 on neonatal pigs.  Presented at The Roslin 
Institute student research seminar series July 2012. 
 
Gow, D.J., Gow, A.G., Pridans, C., Garceau, V., Simpson, K.E., Gunn-Moore, D., 
Hume, D.A  (2013) In-vitro assessment of cross-species activity of Colony 
Stimulating Factor-1 (CSF-1) and Interleukin-34 (IL-34) on the feline Colony 
Stimulating Factor-1 Receptor (CSF-1R). Clinical research abstract presented at 
BSAVA congress 2013. 
 
Poster presentations 
Gow DJ, Garceau, V, Sester, DP, Hume, DA. (2009) Cloning and Expression of 
pig CSF-1 and CSF-1R.  Poster abstract presented at European Macrophage and 
Dendritic Cell Society (EMDS) annual meeting, Regensburg, Germany.  
 
Gow DJ, Garceau, V, Sester, DP, Hume, DA. (2010)  Update on the Cloning and 
Expression of pig CSF-1 and CSF-1R.  Poster abstract presented at The Roslin 
Institute & R(D)SVS student research day 
 
Gow DJ, Garceau, V, Sester, DP, Hume, DA. (2010) Update of Cloning and 
Expression of pig CSF-1 and CSF-1R.  Poster abstract presented at UK Animal 
Science Forum, York 
 
Deborah J Gow , David P Sester,  Thomas L Wilson, Raksha Tiwari, Poston, 
Rebecca, John Shelly, Stephen Lyle, Greg Fici, Nancy Forester, Catherine Rugg, 
Sandra S. Johnson, Pamela Boner, Valerie Garceau, and David A Hume (2010) 




the CSF1/CSF1R system in pigs. Poster abstract presented at EMDS annual 
meeting, Edinburgh 
Gow DJ, Garceau, V, Sester, DP, Hume, DA. (2010) Production and 
characterization of porcine anti-CSF-1R antibodies.  Poster abstract presented at 
The Roslin Institute & R(D)SVS student research day 
 
Gow, D.J., Gow, A.G.  Simpson, K.E., Sester, D.P.,  Hume, D.A. Production of 
feline bone marrow derived macrophages, reagents for studying the CSF-
1/CSF1-R system in cats. Clinical research abstract presented at BSAVA congress, 
April 2011.  
 
D.J. Gow, V. Garceau, D. Sester, D.A. Hume. Cross species reactivity of IL-34.  
Poster presented at European Congress of Immunology, Glasgow, September 2012. 
Published in Immunology Vol137, pg 265. 
 
D.J. Gow, L. Moffat, V. Garceau, R. Kapetanovic, D. Sester, D.A. Hume. The 
production of porcine anti-CSF-1R antibodies: Reagents to evaluate the effects 
of CSF-1 on postnatal growth.  Poster presented at European Congress of 
Immunology, Glasgow, September 2012. Published in Immunology vol 137 pg 653. 
 
D.J. Gow, K. Sauter, C.Pridans  L. Moffat, G. Bainbridge, T. Oliphant, J. Shelly, 
T.L. Wilson and D.A. Hume. The effects of porcine Fc-CSF-1 on body and organ 
weight of adult mice. Poster presented at the European Workshop of Veterinary 
Immunology 2012.  
 
Kristin A.D. Sauter, Clare Pridans, Lindsey Moffat, Deborah Gow, Philippa Beard & 
David A. Hume.  An antibody against the colony-stimulating factor 1 receptor 




MacGreen mice.  Poster presented by Kristin Sauter at EMDS 2012 and Keystone 
Symposium on Myeloid Cells 2013. 
 
Gow, D.J., Gow, A.G., Pridans, C., Garceau, V., Simpson, K.E., Gunn-Moore, D., 
Hume, D.A  (2013) In-vitro assessment of cross-species activity of Colony 
Stimulating Factor-1 (CSF-1) and Interleukin-34 (IL-34) on the feline Colony 
Stimulating Factor-1 Receptor (CSF-1R). Clinical research abstract presented at 
BSAVA congress 2013. 
 
Publications 
Gow DJ, Sester DP, Hume DA (2010) CSF-1, IGF-1, and the control of postnatal 
growth and development. Journal of  Leukocyte Biology. Sep;88(3):475-81. 
 
Deborah J. Gow, Valerie Garceau, Ronan Kapetanovic, David P. Sester, Greg J. Fici, 
John A. Shelly, Thomas L. Wilson, and David A. Hume (2012), Cloning and 
Expression of Porcine Colony Stimulating Factor-1 (CSF-1) and Colony 
Stimulating Factor -1 Receptor (CSF-1R) and analysis of the species specificity 
of stimulation by CSF-1 and Interleukin 34. Cytokine 2012 Dec;60(3):793-805. 
 
Deborah J. Gow, Valerie Garceau, Clare Pridans, Kerry Simpson, Danielle Gunn-
Moore, Adam Gow and David A. Hume (2013), Cloning and expression of feline 
Colony Stimulating Factor Receptor (CSF-1R) and analysis of the species 
specificity of stimulation by Colony Stimulating Factor-1 (CSF-1) and 







Manuscripts in preparation 
Deborah J. Gow, Valerie Garceau, Ronan Kapetanovic, David P. Sester, Greg J. Fici, 
John A. Shelly, Thomas L. Wilson, and David A. Hume. Generation and 
evaluation of Fc conjugates of pig and chicken CSF-1 with improved in-vivo 
efficacy.  
 
Stutchfield, B.M., Gow, D.J., Sauter, K., Wilson, T., Forbes, S.J., and Hume, D.A.  
The effects of porcine Fc CSF-1 in hepatic injury models.   
 
Kristin A.D. Sauter, Clare Pridans, Lindsey Moffat, Deborah Gow, Philippa Beard & 
David A. Hume.  An antibody against the colony-stimulating factor 1 receptor 
depletes tissue-associated macrophages and inhibits bone resorption in female 
MacGreen mice. 
 
Moffat L., Rothwell L.
, 
Garcia-Morales C., Gow D., Wilson, T., Kaiser P. & Hume 
D.A. Production and characterisation of monoclonal antibodies specific against 














ACD:  Acid citrate dextrose 
ALS: Acid lable subunit 
AM:  Alveolar macrophage 
BAEP:  Brain stem auditory evoked potential 
BMC:  Bone marrow cell 
BMDM:  Bone marrow derived macrophage 
bp:  Base pair 
CAGE:  Cap analysis of gene expression 
CSF-1:  Colony stimulating factor 
csCSF-1:  Cell surface colony stimulating factor 
CSF-1R:  Colony stimulating factor receptor 
DAVID:  Database for annotation, visualization and integrated discovery 
DC:  Dendritic cell 
DMEM:  Dulbecco’s modified eagle medium 
DMSO:  Dimethyl sulfoxide 
DTT:  Dithio treitol 
EDTA:  Ethylenediaminetetraacetic acid 




ELISA:  Enzyme-linked immunosorbent assay 
FACS:  Fluorescence-activated cell sorting 
FCS:  Foetal calf serum 
GSCF:  Granulocyte colony stimulating factor 
GH:  Growth hormone 
GM-CSF:  Granulocyte macrophage colony stimulating factor 
GO:  Gene Ontology 
H&E:  Haematoxylin and Eosin 
HGF:  Hepatocyte growth factor 
HI:  Heat inactivated 
IFN:  Interferon 
IGF-1:  Insulin like growth factor-1 
IGF-1R:  Insulin like growth factor receptor 
IGFBP:  Insulin like growth factor binding proteins 
IHC:  Immunohistochemistry 
KO:  Knockout 
IL-3:  Interleukin 3 
IL-6:  Interleukin 6 
IL-34:  Interleukin 34 




MAPK:  Mitogen-activated-protein kinase 
MHC:  Major histocompatibility complex 
MPS:  Mononuclear phagocyte system 
MCFU:  Macrophage colony forming unit 
MCSF:  Macrophage colony stimulating factor 
MGDF:  Megakaryocyte growth and developmental factor 
MTT:  3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide 
PBMC:  Peripheral blood mononuclear cell 
PBS:  Phosphate buffered saline 
PCNA:  Proliferating cell nuclear antigen 
PCR:  Polymerase chain reaction 
PCV:  Packed cell volume 
PDGF (R):  Platelet derived growth factor (receptor) 
PH:  Partial hepatectomy 
RACE:  Remote analysis computation for gene expression data 
RANKL:  Receptor activator of NFκB 
RBC:  Red blood cell 
Rh-CSF-1:  Recombinant human colony stimulating factor 
R(D)SVS:  Royal (Dick) School of Veterinary Studies 




SCF:  Stem cell factor 
TRAP:  Tartrate-resistant acid phosphatase  
VEGF:  Vascular endothelial growth factor 



















List of figures and tables 
 
Figure 1.1:  Differentiation of the cells of the mononuclear phagocyte system. 2 
Figure 1.2: Expression of mouse CSF-1 in tissues and cells. 6 
Figure 1.3: Schematic diagram showing the different mRNA precursors of CSF-1 and the 
sites of proteolytic cleavage. 8 
Figure 1.4:  Schematic diagram demonstrating the structure of CSF-1α, CSF-1β and CSF-1γ.
 10 
Figure 1.5: Expression of mouse IL-34 in tissues and cells. 25 
Figure 3.1: Plasmid maps of porcine CSF-1 and CSF-1R pEF6 expression constructs. 70 
Figure 3.2:  Porcine CSF-1 demonstrates high level of homology with human, mouse, feline 
and canine CSF-1. 71 
Figure 3.3:  Porcine CSF-1R demonstrates high level of homology with human, mouse, 
feline and canine CSF-1R. 73 
Figure 3.4:  Plasmid map of porcine IL-34pEF6 expression construct. 74 
Figure 3.5:  Schematic diagram of porcine IL-34. 75 
Figure 3.6: Porcine IL-34 demonstrates high level of homology with human, mouse, feline, 
rat, cow and canine IL-34. 76 
Figure 3.7:  Phylogram tree demonstrating the phylogenetic relationship between multiple 
species of IL-34. 77 
Figure 3.8:  Expression of cloned porcine CSF-1 and IL-34. 79 
Figure 3.9:  Expression of cloned porcine CSF-1R. 80 
Figure 3.10:  Characterization of naïve and transfected Ba/F3 cells expressing porcine CSF-
1R by flow cytometry for CD11b and F4/80. 82 
Figure 3.11:  Morphology of porcine CSF-1R expressing Ba/F3 cells cultured in either IL-3 
or rh-CSF-1. 83 
Figure 3.12:  Growth curve of un-transfected and transfected Ba/F3 cells with porcine CSF-
1R. 84 
Figure 3.13:  Optimization of Ba/F3pCSF-1R MTT bioassay. 86 
Figure 3.14:  Biological activity of cloned secreted porcine CSF-1 transfected into HEK293T 
cells. 87 





Figure 3.16:  Biological activity of cloned secreted porcine IL-34 transfected into HEK293T 
cells. 89 
Figure 3.17:  Bioassay of Ba/F3pCSF-1R cells with porcine IL-34 supernatant to assess the 
effect of storage on biological activity. 90 
Figure 3.18:  Demonstration of correct size and sequence of secreted porcine IL-34 from 
HEK293T cells. 91 
Figure 3.19:  Adaption of HEKpEF6_pIL-34 cells from adherent to suspension cells in 
culture. 92 
Figure 3.20:  Bioassay of Ba/F3pCSF-1R cells comparing the effects of using HEK-
pEF6_pIL34 from adherent and suspension cells. 93 
Figure 3.21:  Bioassay of Ba/F3pCSF-1R cells with HEKpEF6_pIL34 and 
HEKpEF6_pIL34_Stop supernatant collected from cells after 5 days in culture. 94 
Figure 3.22: Culture of Ba/F3pCSF-1R cells with HEKpEF6_pIL34 supernatant. 95 
Figure 3.23:  Culture of porcine bone marrow cells with HEKpEF6_pIL34 supernatant. 95 
Figure 3.24:  Analysis of porcine CSF-1R expressing cells by flow cytomerty using porcine 
anti-CSF-1R antibodies. 100 
Figure 4.1:  Plasmid map of feline CSF-1R pEF6 expression construct. 105 
Figure 4.2:  Western blot of transfected Ba/F3 cells expressing feline CSF-1R. 106 
Figure 4.3:  The activity of recombinant human and mouse CSF-1 on porcine CSF-1R 
expressed in Ba/F3 cells. 107 
Figure 4.4:  The activity of cloned secreted porcine CSF-1 transfected into HEK293T cells 
and purified recombinant porcine CSF-1 on mouse BMDM. 108 
Figure 4.5:  The activity of recombinant human CSF-1 on feline CSF-1R expressed in Ba/F3 
cells. 109 
Figure 4.6: The activity of recombinant human, mouse or purified recombinant porcine CSF-
1 on feline CSF-1R expressed in Ba/F3 cells. 110 
Figure 4.7:  The effect of human and purified recombinant porcine CSF-1 on canine and 
feline bone marrow cells. 111 
Figure 4.8: Culture of feline monocyte derived and bone marrow derived macrophages with 
rh-CSF-1. 113 
Figure 4.9:  The phagocytic activity of feline bone marrow (BMC) and monocyte derived 
(PBMC) macrophages using FITC-labelled Zymosan particles. 113 
Figure 4.10:  The activity of recombinant human IL-34 and CSF-1 and mouse IL-34 on 




Figure 4.11:  The activity of recombinant human and mouse IL-34 on mouse bone marrow 
macrophages. 115 
Figure 4.12:  Culture of mouse bone marrow derived macrophages with either human or 
mouse IL-34 or human CSF-1. 116 
Figure 4.13:  The activity of recombinant human and mouse IL-34 on feline CSF-1R 
expressed in Ba/F3 cells. 117 
Figure 4.14:  The activity of recombinant human and mouse IL-34 and CSF-1 on feline CSF-
1R expressed in Ba/F3 cells. 117 
Figure 4.15:  3D models of non-conserved contact amino acids between human and mouse 
and porcine CSF-1 and CSF-1R. 121 
Figure 4.16:  3D models of non-conserved contact amino acids between mouse, human and 
porcine CSF-1 binding sites of CSF-1R. 121 
Figure 4.17:  3D models of non-conserved contact amino acids between human and mouse 
CSF-1R and IL-34. 124 
Figure 4.18: 3D models of non-conserved CSF-1 and IL-34 contact amino acids between 
human, mouse and cat CSF-1R. 125 
Figure 5.1: The effect of recombinant porcine CSF-1 and porcine Fc CSF-1 on Ba/F3pCSF-
1R cells and primary bone marrow cells. 132 
Figure 5.2:  Effect of porcine CSF-1 and Fc CSF-1 on body weight of adult Csf1r-EGFP
+ 
mice. 133 











populations of adult Csf1r-EGFP
+ 
mice. 135 
Figure 5.5:  Effect of porcine Fc CSF-1 on adult Csf1r-EGFP
+
 mice tissue populations. 136 










Figure 5.8:  Effect of porcine Fc CSF-1 on white blood cell counts of adult Csf1r-EGFP
- 
mice. 140 






























Figure 5.14:  Effect of porcine Fc CSF-1 on liver pathology of adult wild-type Csf1r-EGFP
- 
mice. 150 




Figure 5.16:  Effect of porcine Fc CSF-1 on body weight of adult C57BL/6 mice. 152 
Figure 5.17:  Effect of porcine Fc CSF-1 on organ-body weight ratio of adult C57BL/6 mice.
 153 
Figure 5.18:  Effect of porcine Fc CSF-1 on white blood cell count of adult C57BL/6 mice.
 154 
Figure 5.19:   Effect of porcine Fc CSF-1 on bone density of adult C57BL/6 mice. 156 
Figure 5.20:  Effect of porcine Fc CSF-1 on bone marrow F4/80 and Gr1 populations of 
adult C57BL/6 mice. 157 
Figure 5.21:  Effect of porcine Fc CSF-1 on liver and serum IGF-1 of adult C57BL/6 mice.
 159 
Figure 5.22:  Effect of porcine Fc CSF-1 on liver pathology of adult C57BL/6 mice. 160 
Figure 5.23:  Effect of porcine Fc CSF-1 on spleen pathology of adult C57BL/6mice. 161 
Figure 5.24:  Effect of porcine Fc CSF-1 on liver PCNA in adult C57BL/6 mice. 163 
Figure 5.25:  Effect of porcine Fc CSF-1 on spleen, kidney and lung PCNA in adult 
C57BL/6 mice. 164 
Figure 5.26:  Top 60 genes either repressed or induced by porcine Fc CSF-1. 166 
Figure 5.27:  Main gene functional groups influenced by porcine Fc CSF-1 using DAVID 
gene groups. 167 
Figure 5.28:  Network analysis of transcripts found to be differentially expression between 
control and CSF-1 treated livers. 169 
Figure 5.29:  The average expression profiles of transcripts within the five largest clusters of 
co-expressed genes. 170 
Figure 6.1:  Circulating plasma half-life of porcine CSF-1 and Fc CSF-1. 181 




Figure 6.3:  Effect of porcine Fc CSF-1 on TNFα and IL-1β production from porcine 
BMDMs. 184 
Figure 6.4:  The effect of porcine Fc CSF-1 on total weight change of neonatal pigs. 185 
Figure 6.5:  The effect of porcine Fc CSF-1 on the change in body weight of neonatal pigs 
during the duration of the experiment. 186 
Figure 6.6:  The effect of low-dose porcine Fc CSF-1 on liver, spleen, lung and kidney 
weights. 187 
Figure 6.7: The effect of high-dose porcine Fc CSF-1 on liver, spleen, lung and kidney 
weights. 188 
Figure 6.8:  The effect of porcine Fc CSF-1 on carcase weight of neonatal pigs. 189 
Figure 6.9:  The effect of low-dose porcine Fc CSF-1 on the complete blood count of 
neonatal pigs. 190 
Figure 6.10: The effect of high-dose porcine Fc CSF-1 on the complete blood count of 
neonatal pigs. 191 
Figure 6.11: Effect of PBS or porcine Fc CSF-1 on CD14, CD16, CD163 and CD172a 
expression on PBMC of day 24 piglets. 192 
Figure 6.12:  Effect of PBS or porcine Fc CSF-1 on PBMC CD163 and CD14 expression 
overtime. 194 
Figure 6.13:  The effect of Fc CSF-1 on porcine alveolar macrophage CD163 expression. 194 
Figure 6.14:  Effect of PBS or porcine Fc CSF-1 on CD14, CD16, CD163 and CD172α 
expression on BMC and AM. 196 
Figure 6.15:  Effect of PBS or porcine Fc CSF-1 on MHCII expression on PBMC. 197 
Figure 6.16:  The effect of porcine Fc CSF-1 on plasma IGF-1 concentrations. 198 
Figure 6.17:  The effect of high-dose porcine Fc CSF-1 on liver IGF-1 expression using 
immunohistochemistry. 199 
Figure 6.18: The effect of high-dose porcine Fc CSF-1 on liver pathology. 201 
Figure 6.19:  The effect of porcine Fc CSF-1 on lung pathology. 202 
Figure 6.20:  The effect of porcine Fc CSF-1 on liver proliferation using PCNA. 203 
Figure 6.21:  The effect of porcine Fc CSF-1 on femur bone density. 204 
Figure 6.22:  The effect of porcine Fc CSF-1 on femur length and cortex thickness. 205 
Figure 8.1:  Effect of porcine Fc CSF-1 on adult Csf1rEGFP
+







Table 2.1:  Table of porcine primers used to clone porcine CSF-1, CSF-1R, IL-34 and feline 
CSF-1R. 40 
Table 4.1:  Table of contact amino acids between mouse, human and porcine CSF-1 and 
CSF-1R. 119 
Table 5.1:  Table of genes involved in liver regeneration induced by porcine Fc CSF-1 in 
mouse liver. 177 






Chapter 1:  Introduction  
1 
 
Chapter 1: Introduction 
 
1.1 Macrophages and the Mononuclear Phagocyte 
System 
Cells of the mononuclear phagocyte system are a heterogeneous population of cells 
originally considered to be derived from pluripotent progenitor cells in the bone 
marrow, which differentiate and migrate into the blood as monocytes, and thence 
become tissue macrophages (Hume, 2006).  Macrophages were first discovered by 
Elie Metchnikoff in 1884 where he identified their importance in phagocytosis of 
micro-organisms to defend against infection, inflammation and immunity (Gordon, 
2008).  Although macrophages are traditionally viewed as components of the innate 
immune system, they have many trophic roles in embryonic growth and development 
and homeostasis (Hume, 2006, 2008; Hume et al., 2002; Martinez et al., 2008; 
Pollard, 2009).  Every organ and tissue within the body contains macrophages where 
they may be 10-15% of the total cells (Gordon and Taylor, 2005). During embryonic 
development of mice, macrophages first appear in the yolk sac that have 
differentiated from mesenchymal progenitor cells, around 8 days post coitus (dpc), 
from whence they infiltrate the head of the embryo and the circulation as it forms 
(Hume, 2006).  By embryonic day 10.5 and 11, the primitive liver becomes the main 
site of production of cells of the blood, while after birth haematopoiesis moves to the 
bone marrow.   
 
Monocytes are produced in the marrow from a common myeloid progenitor cell 
(CMP) that is shared with granulocytes.  The functional definition in-vitro is a cell 
with the ability to form mixed colonies of myeloid cells in semi-solid medium in 
response to appropriate growth factors, the granulocyte macrophage colony forming 
unit (GM-CFU).  The CMP has a more restricted capacity for differentiation 
compared to pluripotent stem cells from which they originate.  The GM-CFU can 
further commit to the specific lineages: macrophage colony-forming unit (M-CFU) 
or the granulocyte-colony forming unit (G-CFU).  Proliferation and differentiation of 
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cells from pluripotent stem cells to GM-CFU cells can be directed by several growth 
factors e.g. colony stimulating factor (CSF-1) (also known as macrophage colony-
stimulating factor or M-CSF), granulocyte-macrophage colony stimulating factor 
(GM-CSF, or CSF-2), IL-3 (multi-CSF), IL-6 and stem cell factor (SCF).  Beyond 
development of the M-CFU, stimulation of a specific receptor, the colony stimulating 
factor-1 receptor (CSF-1R), appears both necessary and sufficient to promote 
terminal macrophage differentiation (Pollard, 2009) (Figure 1.1).  This may be 
mediated by CSF-1, or by the recently-discovered second ligand for the CSF-1 
receptor, Interleukin 34 (IL-34).  The role of CSF-1 and IL-34 in macrophage 
development has become clear in part through the study of natural mutant mice 
(op/op), and later, knockout mice of the CSF-1R and IL-34 ligand (Dai et al., 2002; 
Marks and Lane, 1976; Wang et al., 2012 ). 
 
Figure 1.1:  Differentiation of the cells of the mononuclear phagocyte system.    
Cells of the mononuclear phagocyte system are derived for pluripotent haematopoietic stem cells 
(HSC).  Differentiation of these cells to M-CFU requires synergy between several growth factors; 
examples include CSF-1, IL-1, IL-3, SCF.  Beyond the M-CFU stage, CSF-1 is the only growth factor 
absolutely required for macrophage differentiation.  Image from www.macrophages.com, adapted 
from Gordon and Taylor, 2005. 
Chapter 1:  Introduction  
3 
 
Committed progenitors become progressively differentiated through monoblast and 
pro-monocyte stages, enter the blood and subsequently extravasate, and during 
normal tissue turn-over, inflammation, infection, stress and tumour invasion, give 
rise to inflammatory or resident tissue macrophages.  The traditional model of 
monocyte contribution to resident tissue macrophage populations in the mouse has 
been challenged by a number of recent papers which suggest that these cells are 
seeded during embryonic development, and thereafter maintained by local 
proliferation (Geissmann et al., 2010; Greter and Merad, 2012; Yona et al., 2013).  
These findings do not detract from the fact that tissue macrophage numbers in most 
organs depend upon continued CSF-1R signalling (MacDonald et al., 2010).  
 
1.2 Monocyte subsets 
Monocytes are a heterogeneous population of cells, and have been subdivided based 
upon their expression of surface markers that vary between species, since few cell 
markers are common to all cells of the MPS between species.  Human blood 
monocytes can be divided into three subsets based on their expression of CD14 and 
CD16 (Ziegler-Heitbrock et al., 1988; Ziegler-Heitbrock et al., 2010).  Classical 
human  monocytes or “inflammatory” are so called because their phenotype 





represent 80-90% of blood monocytes (Auffray et al., 2009b; Passlick et al., 1989; 
Robbins and Swirski, 2010).  The remaining two human monocyte subset 
populations are both CD16
+
.  Those that lack CD14 are referred to as “non-classical” 
whilst those that retain low levels of CD14 have been termed intermediate (Fingerle-
Rowson et al., 1998; Robbins and Swirski, 2010).  The populations have distinct 
gene expression profiles, and can respond differently to pro-inflammatory stimuli 
such as bacterial lipopolysaccharide (LPS) (Geissmann et al., 2010).   
 
As is the case with human monocytes, two populations of monocytes exist in mice 
based upon selective expression of the Ly6C marker, detected with the antibody, 
Gr1.  Mice monocytes can be further subdivided into three subsets based on their 
expression of CD43, CX3CR1 and Ly6C.  Classical monocytes are Ly6C
high
 














.  The third subgroup is the 




.  Similar to the human non-classical 
monocyte population they are derived from the classical populations.  The mice 
Ly6C
high
 population of cells are homologous to human CD14
+
 based upon their gene 
expression profiles (Ingersoll et al., 2010).  Ly6C
lo
 monocytes appear to play a role 
in renewal of resident macrophage populations.  Additionally, Ly6C
lo  
monocytes 
appear to act as “patrolling” cells on endothelium where they may play roles in 
scavenging and may be responsible for early inflammatory responses (Auffray et al., 
2007; Auffray et al., 2009b). 
 
Porcine monocytes can be divided into two approximately equal subpopulations 
based on expression of CD14, CD163, CD16 and Cd172α (Fairbairn et al., 2011; 
Sanchez et al., 1999; Ziegler-Heitbrock et al., 1994).  CD14 and CD163/CD16 vary 
inversely with each other.  Monocytes that are CD163
high
 (resident) are CD14
lo
 and 







 resembles human CD14
+
 inflammatory (classical) monocytes (Fairbairn et 
al., 2013; Fairbairn et al., 2011).  The division of monocytes into subsets is based in 
some measure on the setting of arbitrary gates on a flow cytometer to define high and 
low expression.  It is largely accepted that monocyte subsets represent a maturation 
series driven by CSF-1 (Fairbairn et al., 2013; Hume and Macdonald, 2012; 
MacDonald et al., 2010; Munn et al., 1990).  The classical monocytes have a 
relatively short half-life, but if they are retained for a sufficient period in the 
circulation they mature and their half-life increases (Hume and Macdonald, 2012; 
MacDonald et al., 2010; Yona et al., 2013; Ziegler-Heitbrock et al., 2010).  
 
1.3 Colony Stimulating Factor-1 (CSF-1) 
The colony-stimulating factors were first discovered through their ability to promote 
the formation of colonies from precursor cells in-vitro (Bradley et al., 1967).  Colony 
stimulating factor-1 (CSF-1) is so-called because it was the first such haematopoietic 
growth factor to be purified as a discrete protein (Stanley and Heard, 1977).  Three 
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different forms of the cDNA encoding human CSF-1 were cloned in the 1980s 
(Cerretti et al., 1988; Kawasaki et al., 1985; Ladner et al., 1987; Wong et al., 1987). 
The first demonstration that CSF-1 acutely regulated the mononuclear phagocyte 
system in an intact animal was achieved by administration of intravenous 
recombinant human CSF-1(rh-CSF-1) to adult mice for four consecutive days.  This 
resulted in an increase of circulating monocytes, as well as peritoneal and tissue 
macrophage populations (Hume et al., 1988).  This finding demonstrated that the 
absolute availability of CSF-1 in the circulation is limiting, and that CSF-1 
production is regulated and variation in those levels is biologically significant.  
 
The main source of CSF-1 is cells of mesenchymal lineages, including endothelial 
cells lining blood vessels, fibroblasts, myoblasts and osteoblasts, (Sweet and Hume, 
2003), so that almost every tissue in the body can produce CSF-1 (Stanley, 2000). 
Figure 1.2 highlights the mesenchymal cell production of CSF-1.  In keeping with an 
inferred role in monocyte maturation, active CSF-1 is present in the circulation.  
Serum CSF-1 concentrations are reported to be 2.4ng/ml for healthy humans and 
9ng/ml for mice with this basal level increasing during infection (Cheers et al., 
1988).  The levels are also increased in pregnancy in mice, both in the circulation 
(1.4 fold) and uterus (1000 fold) (Ryan et al., 2001; Stanley et al., 1997).  Clearance 
of up to 95% of CSF-1 from the circulation is achieved by the Kupffer cells of the 
liver via CSF-1R mediated internalisation of the ligand (Stanley, 1998; Stanley et al., 
1997), with renal filtration and elimination accounting for the remainder of CSF-1 
clearance.  A recent study concluded that monocytes also contribute to CSF-1 
clearance and homeostasis (Yona et al., 2013).  
 




Figure 1.2: Expression of mouse CSF-1 in tissues and cells.  
The image is a screen shot of the expression of CSF-1 in mouse tissues and cells demonstrating that 
CSF-1 is produced by almost every tissue within the body and highly expressed in mesenchymal cells 
(osteoblasts, mouse embryonic cells, fibroblast cells lines).  Data from Biogps.org.   
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1.3.1 CSF-1 gene and isoforms 
The human CSF1 gene is 21 kb in length and composed of 10 exons, from which 
three CSF-1 isoforms are produced.  Exon 1 of the human CSF1 gene encodes the 5’ 
un-translated region (UTR), exons 2-6 encodes the CSF-1 precursor domain, 
transmembrane region and a portion of cytoplasmic domain.  Exons 7 & 8 encode the 
remainder of cytoplasmic domain and 9 & 10 encode the 3’ UTR (Stanley, 2000). 
This structure is retained in most mammals, including the CSF1 locus on 
chromosome 3 in mice, and chromosome 4 in the pig (Douglass et al., 2008; Stanley, 
2000), and probably also in birds (Garceau et al., 2010).  Alternative splicing of the 
human CSF1 gene produces five mRNA species; 4kb, 3.7kb, 3.1kb, 2.6kb and 1.6kb.  
Figure 1.3 demonstrates these five mRNA precursors of CSF-1 and the sites of 
proteolytic cleavage as referred to in the text.  
 
The 2.6kb and 4kb mRNAs arise from inclusion of a 3’un-translated region encoded 
by exons 9 and 10 respectively.  These two RNA products encode the 554 amino 
acid full length CSF-1, CSF-1β, which is also known as CSF-1 long.  CSF-1β can 
then be processed within cells to give rise to a proteoglycan or glycoprotein. The 3.7 
kb mRNA transcript also encodes a secreted glycoprotein that is shorter in length 
than CSF-1β (438 amino acids) and has been called CSF-1 intermediate or CSF- 1γ.  
The final two RNA products, the 1.6kb and 3.1kb are similar to the 2.6kb and 4kb 
transcripts in terms of addition of the exon 9 and exon 10 un-translated regions 
respectively, but shorter due to exon 6 splicing.  These transcripts give rise to the 
smallest isoform (256 amino acids); membrane bound CSF-1, also known as CSF-
1α.  As the CSF-1 precursors enter the lumen of the endoplasmic reticulum, the 32 
amino acid signal peptide sequence is cleaved by a signal peptidase followed by 
post/co-translational glycosylation within the endoplasmic reticulum, and formation 
of disulphide bonds producing dimerization.  As CSF-1β travels towards the Golgi, 
modification of N-linked sugars and the addition of O-linked sugars ensues, 
including the random addition of an 18 kDa chondroitin sulphate chain attached to 
Ser277
 
(human) or Ser276 (mouse).  Once within the secretory vesicle, proteolytic 
cleavage by β covertase near Arg 223 results in the release of a soluble glycoprotein 
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of 80-100kD from both CSF-1β and CSF-1γ precursors.  Alternatively, CSF-1β 
modified by the addition of the chondroitin sulphate chain cannot be processed by β 
convertase, hence α convertase cleaves this modified form nearer to the membrane, 
releasing a larger 456 amino acid, (130-160 kDa) proteoglycan (Figure 1.3).  
Proteolytic cleavage of CSF-1α also by α convertase within the Golgi results in 
expression of a 158 amino acid membrane bound CSF-1 glycoprotein.  (Douglass et 
al., 2008; Pixley and Stanley, 2004; Stanley, 2000). 
 
In summary, complex alternative splicing from the CSF-1 locus and post 
translational modifications generates three CSF-1 isoforms: secreted glycoprotein, 
secreted proteoglycan, and membrane spanning cell surface glycoprotein.  
 
 
Figure 1.3: Schematic diagram showing the different mRNA precursors of CSF-1 and the sites of 
proteolytic cleavage.    
Black arrows represent cleavage of signal peptide by signal peptidase, blue arrows represent cleavage 
by α convertase and red arrows represent cleavage by β convertase.  Green circles represent addition 
of chondroitin sulphate chain producing proteoglycan CSF-1 (CSF-1 pg).  Picture adapted from 
Douglass et al. (2008). 
 
Exocytosis of both glycoprotein CSF-1 and proteoglycan CSF-1 by fusion of the 
secretory vesicle with the cell membrane allows them to rapidly accumulate in the 
circulation with  proteoglycan CSF-1 identified as the predominant secreted CSF-1 
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(Price et al., 1992; Stanley, 2000; Stanley et al., 1997).  The secreted isoforms have 
similar CSF-1R binding properties and biological activity and can act systemically. 
An additional local activity of proteoglycan CSF-1 is due to its preferential attraction 
to the extracellular matrix by the presence of chondroitin sulphate chains (Stanley, 
2000; Stanley, 1998; Stanley et al., 1997).   
 
1.3.2 CSF-1 structure 
CSF-1 is a member of the four helix bundle cytokine family, most closely-related to 
stem cell factor which in turn binds the closely-related receptor, c-kit.  The biological 
activity of human CSF-1 is contained within the 149 amino acid growth factor 
domain; the carboxyl terminus is involved in processing and anchorage to the plasma 
membrane but is not required for in-vitro activity (Moore, 1997; Pandit et al., 1992; 
Stanley et al., 1997).   The crystal structure of the 149 amino acid active recombinant 
human CSF-1 was resolved by Pandit et al. (1992).  The helical structure is stabilised 
by three intra-chain disulphide bonds (Cys7-Cys90, Cys48-Cys139, Cys102-
Cys146), and dimer formation is stabilised by an inter-chain disulphide bond (Cys31-
Cys31), (Deng et al., 1996).  Site directed mutagenesis of each of the cysteines led to 
deficiencies in transport of CSF-1 to the cell surface and/or biological activity (Deng 
et al., 1996).  Avian CSF-1 lacks the inter-chain disulphide bond, but like stem cell 
factor, still forms an active dimer through a hydrophobic interaction (Garceau et al., 
2010).   
 
All isoforms share a general composition consisting of an N-terminal 32 amino acid 
signal peptide, a 149 residue growth factor domain, a 24 residue transmembrane 
region and a 35 amino acid cytoplasmic tail (Douglass et al., 2008) (Figure 1.4).  




Figure 1.4:  Schematic diagram demonstrating the structure of CSF-1α, CSF-1β and CSF-1γ.   
Both CSF-1β and CSF-1γ share a common variable spacer domain, with CSF-1β also containing a 
sequence unique to this isoform.  Picture adapted from Pandit et al., 1992. 
 
1.3.3 CSF-1 deficient animals 
The non-redundant biological importance of CSF-1 became evident with the 
discovery of natural mutations.  Mice with a homozygous mutation in their Csf1 gene 




), are deficient in biologically active CSF-1 and born 
with congenital osteopetrosis (termed op/op mice) (Felix et al., 1990b; Marks and 
Lane, 1976; Wiktor-Jedrzejczak et al., 1982).  This natural mutation is an insertion of 
thymidine at position 262 of exon 4 within the coding region of the CSF-1 gene, 
resulting in shifting of the reading frame, creation of a stop codon, and production of 
a truncated (94 amino acid) biologically inactive CSF-1 (Yoshida et al., 1990).  
Op/op mice have several striking features apart from the osteopetrosis including: 
skeletal deformities, failure of tooth eruption, low birth weights and reduced growth 
rates, reduced tissue macrophage populations, reproductive, endocrine and neuronal 
deficits and reduced life expectancy compared to wild-type mice (Marks and Lane, 
1976; Pollard and Hennighausen, 1994; Stanley, 2000; Wiktor-Jedrzejczak et al., 
1990; Wiktor-Jedrzejczak et al., 1991).  Both the osteopetrosis and skeletal 
abnormalities are a direct result of reduced osteoclast numbers leading to increased 
bone density, particularly evident in the distal metaphyseal region of the femur (Dai 
et al., 2002).  
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Congenital osteopetrosis in the rat, known as the toothless rat (tl/tl) is also caused by 
an insertional mutation in the coding region of the CSF-1 gene resulting in CSF-1 
with reduced biological activity, reduced osteoclast numbers and therefore 
osteopetrosis and the associated toothless phenotype (Dobbins et al., 2002; Van 
Wesenbeeck et al., 2002).  Daily administration of rh-CSF-1 to tl/tl rats can improve 
some of the phenotype such as tooth eruption; however, complete rescue is not 
possible (Dobbins et al., 2002; Marks et al., 1997; Marks et al., 1992). 
Op/op mice can spontaneously recover progressively after 6 weeks of age, even 
without CSF-1 administration, with bone marrow cellularity normalizing by 22 
weeks of age (Begg and Bertoncello, 1993; Nilsson and Bertoncello, 1994).  This is 
likely to be due to other growth factors taking over as stimulators of 
osteoclastogenesis such as vascular endothelial growth factor (VEGF), which is 
capable of correcting the osteopetrosis associated with op/op mice (Niida et al., 
1999; Niida et al., 2005).  Recombinant human CSF-1 or VEGF injected into op/op 
mice resulted in osteoclast recruitment, although the number of osteoclasts in mice 
treated with rh-VEGF was 60-70% that of mice treated with rh-CSF-1 (Niida et al., 
1999).  Additionally, Flt3 ligand has been identified for its ability in the absence of 
CSF-1 to promote functional osteoclasts formation from haematopoietic progenitor 
cells, since these cells express Flt3 receptor (Matthews et al., 1991).  Flt3 ligand 
could also contribute to the spontaneous correction of osteopetrosis that occurs in 
op/op mice (Lean et al., 2001).  Other growth factors involved may include IL-3 and 
GM-CSF (Hattersley and Chambers, 1990; Myint et al., 1999). Additionally, the 
op/op mouse phenotype can be rescued by an IL-34 transgene expression which can 
fully correct the associated osteopetrosis and restore the number of tartrate-resistant 
acid phosphatase-positive (TRAP
+
) cells in these mice (Wei et al., 2010). 
 
Surprisingly, no functional mutations of the CSF-1 gene in humans have been 
described in association with severe birth defects such as osteopetrosis.  The severe 
bone resorption in Paget’s disease has been linked to a single nucleotide 
polymorphism (snp) in the vicinity of the CSF1 locus (Albagha et al., 2010; Chung et 
al., 2010).   The nature of the phenotype would suggest that this allele is associated 
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with over-expression of CSF-1.  The data from the 1000 genomes project
1
 suggests 
that there are substantial numbers of loss-of-function alleles due to frame-shifts and 
non-synonymous substitutions in the human population.  The absence of known 
major birth defects associated with homozygous loss of function suggests either that 
CSF-1 is redundant, or absolutely required for normal development in humans.  The 
latter possibility could relate to the role of CSF-1 in the placenta (Daiter et al., 1992).  
Apparent loss of function mutation of the CSF1R gene has been described in the rare 
neurological disease hereditary diffuse leukoencephalopathy with spheroids 
(Rademakers et al., 2012). 
 
1.3.4 CSF-1 biological activity 
As noted above, CSF-1 is present in the circulation and tissues constitutively and is 
required for both adult and embryonic macrophage development and maintenance in 
the steady state (Chitu and Stanley, 2006; Gow et al., 2010; Hamilton and Achuthan, 
2012; MacDonald et al., 2010).  In this respect, CSF-1 differs from GM-CSF and G-
CSF, which are induced during inflammation and contribute to emergency 
myelopoiesis.  Nevertheless, CSF-1 is also elevated in the circulation in response to 
stress and infection, and has been shown to directly instruct myeloid gene expression 
and differentiation of individual HSCs through induction of the lineage-specific 
growth factor PU.1 (Mossadegh-Keller et al., 2013).  Aside from its growth and 
differentiation function, CSF-1 has many acute regulatory impacts on macrophages 
and through these, actions on physiological as well as immune functions.  Early 
studies emphasised the acute regulation of urokinase plasminogen activator and 
extracellular proteolysis and fibrinolysis (Stacey et al., 1995), and its ability to act as  
chemokinetic and chemotactic factor for macrophages (Stanley and Heard, 1977; 
Webb et al., 1996).  CSF-1 stimulated macrophages to destroy invading pathogens 
such as Listeria monocytogenes (Kayashima et al., 1991) and primed macrophages to 
induce pro-inflammatory cytokines TNFα, IL-6, IL-1 and GM-CSF (Evans et al., 
1992; Evans et al., 1995; Kamdar et al., 1996).  In mice, at least, CSF-1 regulates the 
                                                 
1
 www.ensembl.org, variation table for CSF-1 
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expression of the toll-like receptor (TLR-9) that mediates recognition of potential 
pathogens (Sweet et al., 2002). 
 
Macrophages and CSF-1 play an important role in tissue repair in most tissues where 
it has been examined including kidney, liver, heart, brain and lung (Duffield et al., 
2005; Leor et al., 2006; Nakamura et al., 2005; Ricardo et al., 2008; Vinuesa et al., 
2008).  CSF-1 administration has been shown to promote regeneration in a number 
of models, presumably by the induction of local macrophage proliferation and 
expression of growth factors e.g. IGF-1, PDGFb and VEGFA (Hume and 
Macdonald, 2012).  Work performed in the late 80s demonstrated that administration 
of CSF-1 to mice causes an increase in the “non-classical” resident tissue 
macrophage populations as defined by high expression of the surface marker F4/80 
(Hume et al., 1988).  These tissue macrophages and CSF-1 play an important role in 
the development of many tissues and organs by regulating the growth, remodelling 
and organisation of other cells (Pollard, 2009).  Many of the trophic functions of 
macrophages and the role of CSF-1 in tissue development have been highlighted by 
the discovery and use of the CSF-1 deficient mouse (op/op) which has deficiencies in 
development of many tissues  (Pollard, 2009).  Administration of recombinant 
human CSF-1 to mice following renal injury can promote renal repair by 
macrophage recruitment, demonstrating that CSF-1 also plays a role in tissue 
homeostasis following injury or inflammation (Alikhan et al., 2011; Alikhan and 
Ricardo, 2012; Menke et al., 2009).  The promotion of epithelial repair by 
proliferation and differentiation of macrophages is dependent on local CSF-1 
production (Zhang et al., 2012).  CSF-1 has been tested as a therapeutic agent in 
mice and humans in many disease models and in several clinical trials reviewed by 
Hume and Macdonald (2012), but has yet to enter clinical use.    
 
CSF-1 is highly-expressed and regulated in reproductive tissues including ovary, 
placenta, testes and mammary gland.  In female mice, the production of CSF-1 is 
regulated by oestradiol-17 β and progesterone (Pollard, 1997).  The main action of 
CSF-1 in reproduction is the regulation of the hypothalamic-pituitary-gonadal axis.  
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CSF-1 stimulates the release of luteinizing hormone, required to produce testosterone 
in male mice and for ovulation in female mice. CSF-1 also enhances in-vitro embryo 
development in the mouse (Pampfer et al., 1991) and acts as an extrinsic stimulator 
of mouse spermatogonial stem cell self-renewal (Oatley et al., 2009).  From 
numerous studies using CSF-1-deficient mice, the reproductive deficits include 
reduced male libido, reduced sperm count (60% less compared to wild-type mice) 
(Cohen et al., 1996), reduced female fertility, reduced implantation rates, irregular 
oestrus cycles, low ovulation rate and impaired mammary gland development 
(Pollard, 1997).  Such deficits can be partially or fully corrected by daily 
administration of recombinant human CSF-1 or expression of a full length or cell 
surface CSF-1 transgene (Dai et al., 2004; Ovadia et al., 2006; Ryan et al., 2001; 
Wiktor-Jedrzejczak et al., 1991).  
 
In the brain, expression of the CSF-1R appears restricted to the brain macrophages or 
microglia (Luo et al., 2013; Wang et al., 1999).  CSF-1 deficient mice have loss of 
connectivity and neuronal deficits, but appear to demonstrate normal balance and 
behaviour and motor functions (Pollard, 1997; Roffler-Tarlov et al., 1996).  More 
recently, Erblich et al. (2011), demonstrated that mice with a homozygous mutation 
in the Csf1r gene (Csf-1r-/Csf-1r-) have a <99% depletion in microglial cells with 
severely disrupted brain morphology highlighting the essential role of CSF-1 
responsive microglia in regulating brain development.  The op/op mice neuronal 
deficiencies include deficiencies in both visual and auditory processing, with these 
mice being unresponsive to external stimuli (Pollard, 1997).  Scalp recorded brain 
stem auditory evoked potentials (BAEP) show delay in propagation of electrical 
signals of op/op mice compared to wild-type littermate controls, which in part can be 
explained by compression of auditory nerves as a result of skeletal abnormalities.  
Recently, Luo et al. (2013) identified expression of CSF-1R mRNA in hippocampal 
neurones of mice and claimed that neurones expressing CSF-1R are important for 
neuronal protection and survival.  
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1.3.5 CSF-1 and bone formation 
Osteoclasts are specialised multinucleated cells that resorb bone.  Osteoclast 
precursor cells originate from macrophage/monocyte lineage cells and express CSF-
1R.  These precursor cells exist in the bone marrow and blood stream where they 
circulate systemically before migrating to bony surfaces covered in osteoblasts 
expressing receptor activator of NF-κB (RANK) ligand (Kikuta and Ishii, 2012).  
Together with RANK ligand produced by osteoblasts and stromal cells, CSF-1 
regulates osteoclast production and function (Pixley and Stanley, 2004; Wei et al., 
2006).  Both RANK ligand and CSF-1 activate multiple intracellular signalling 
pathways resulting in osteoclast-specific genes involved in proliferation, survival and 
differentiation such as tartrate-resistant acid phosphatase (TRAP) (Kikuta and Ishii, 
2012).  In addition, CSF-1 also stimulates the expression of RANK on osteoclast 
precursor cells (Yavropoulou and Yovos, 2008).  Mature osteoclasts attach tightly 
via integrins to the bone surface where they act to degrade, remove and resorb bone.  
Demonstration of the importance of RANK ligand and CSF-1 in osteoclastogenesis 
comes from findings that mice with CSF-1 deficiency (op/op), or knockout RANK 
ligand mice, have an almost complete absence of osteoclasts resulting in 
osteopetrosis (Cecchini et al., 1997; Felix et al., 1990a; Kong et al., 1999; Marks and 
Lane, 1976).  
 
1.3.6 CSF-1 dependent macrophage populations 
By contrast to the traditional mononuclear phagocyte model, and as introduced in 
Section 1.1, some macrophage populations such as microglia, Langerhans cells, 
Kupffer cells in liver, and macrophages in the spleen and  pancreas, do not appear to 
be dependent on the classical pluripotent haematopoietic stem cells for self-renewal 
in the steady state (Geissmann et al., 2010; Gomez Perdiguero et al., 2012).  The 
ability of local macrophage precursors to contribute to tissue macrophage 
maintenance has been known for many years (Hume, 2006; Hume et al., 2002). In 
mice, Langerhans cells, the macrophages of the epidermis appear to be produced 
from embryonic precursors from the yolk sac that colonize the epidermis before 
birth, and are renewed by local proliferation thereafter (Greter and Merad, 2012; 
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Hume, 2012).  Microglia, the macrophages of the brain, account for 5-20% of the 
non-neuronal glial cells and may be produced in part by self-renewal of macrophages 
that seed from the yolk sac (Gomez Perdiguero et al., 2012; Greter and Merad, 
2012), although there is substantial infiltration of monocytes in the postnatal period 
(Perry et al., 1985).  Both Langerhans cells and microglia can arise from embryonic 
myeloid cells in development, populate  the skin and central nervous system  before 
birth and early postnatal life, can self-renew, and are controlled by Interleukin-34 
(IL-34), the most recently discovered second ligand of CSF-1R  for their 
development (Greter et al., 2012; Greter and Merad, 2012; Wang et al., 2012 ).  
Additionally, some macrophage populations such as alveolar macrophages may be 
derived both from precursors in peripheral blood, and from local proliferation, 
primarily in response to GM-CSF.  These cells appear not to be absolutely dependent 
on CSF-1 for proliferation (Gordon and Taylor, 2005; Nakata et al., 1991), although 
they are depleted in mice treated with anti-CSF1R antibody (MacDonald et al., 
2010).  A complication in many of the studies of the role of monocytes in tissue 
macrophage homeostasis is that CSF-1 levels are controlled by monocytes and tissue 
macrophages (Yona et al., 2013).  So, any perturbation of the monocyte pool could 
stimulate compensatory proliferation of tissue macrophages in response to the 
elevated CSF-1 levels.   
Detailed comparative analysis of macrophage populations in both wild-type and 
CSF-1-deficient mice before and after restoring CSF-1 levels, revealed macrophage 
populations as being  CSF-1 dependent (partially or fully) or CSF-1 independent 
(Cecchini et al., 1994; Wiktor-Jedrzejczak and Gordon, 1996).  Injection of op/op 
mice with rh-CSF-1 corrected some defects including the osteopetrosis, and deficits 
in splenic, hepatic, renal and bone marrow macrophage numbers (Felix et al., 1990a; 
Kodama et al., 1991; Wiktor-Jedrzejczak et al., 1990; Wiktor-Jedrzejczak et al., 
1991), but some macrophage populations, including dermis, bladder, salivary glands 
and stomach, were only partially restored by rh-CSF-1 injection (Cecchini et al., 
1994).  The macrophages of muscle and tendon required CSF-1 to be present during 
prenatal development; macrophages of the bladder and salivary gland required CSF-
1 during the postnatal period, while renal macrophages required the presence of both 
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pre and postnatal CSF-1 (Cecchini et al., 1994).  CSF-1 dependent macrophages may 
be further classified according to their requirement for local CSF-1 or systemic CSF-
1.  Where liver macrophage (Kupffer cell) numbers were restored by CSF-1 
administration,  pleural and peritoneal could not be corrected by subcutaneous, 
intravenous or intramuscular injections of rh-CSF-1, but only corrected by intra-
peritoneal or intra-pleural rh-CSF-1 administration (Wiktor-Jedrzejczak and Gordon, 
1996; Wiktor-Jedrzejczak et al., 1991). 
 
1.3.7 Roles of different forms of CSF-1  
Body weights of op/op mice were shown to be severely compromised even in the 
first weeks of life (Marks and Lane, 1976; Wiktor-Jedrzejczak et al., 1991).  Further 
evidence for the role of CSF-1 in postnatal growth has been produced by the 
administration of anti-CSF-1 antibody to wild-type mice.  This produced a similar 
phenotype to that of op/op mice including osteopetrosis, delayed tooth eruption and a 
30-40% decrease in body weight (Wei et al., 2005). 
One function of CSF-1 that may be relevant to the growth retardation of op/op mice 
is evident in the pancreas.  Macrophages are present in substantial numbers in all the 
major endocrine organs (Hume et al., 1984) including pancreatic islets.  Geutskens et 
al. (2005)  were the first to note the association between macrophage infiltration and 
pancreatic islet development.  Subsequently, Banaei-Bouchareb et al. (2004) reported 
a selective loss of insulin-producing cells in op/op mouse islets.  The possibility that 
CSF-1-dependent macrophages control endocrine function/development in other sites 
critical to growth regulation, such as the pituitary and adrenals, has not been 
investigated in detail.  
Aside from correction of the skeletal abnormalities and reduced macrophage 
populations, administration of rh-CSF-1 to op/op mice resulted in only partial 
restoration of body weights, still 60-70% of the weight of saline injected wild-type 
littermate controls despite complete tooth eruption (Wiktor-Jedrzejczak et al., 1991).  
The reasons why CSF-1 injection alone cannot complement the op/op phenotype 
became evident from the rescue of the op/op mice phenotype using the expression of 
full length transgene encoding CSF-1 precursor (Ryan et al., 2001).  The transgene 
Chapter 1:  Introduction  
18 
 
corrected gross osteopetrosis, neurological (blindness, deafness) deficits, 
reproductive deficits, toothless phenotype, haematopoietic defects, and the weight 
deficits associated with the op/op mouse.  Dai et al. (2004) investigated the 
biological activity of cell surface CSF-1 (cs-CSF-1) using transgene expression of 
this isoform.  Using this model they were able to fully correct op/op mice growth 
retardation.  By contrast, transgenic expression of only the secreted proteoglycan or 
glycoprotein isoforms of CSF-1 on the op/op background failed to correct the growth 
retardation, whereas reproductive, haematopoietic, tooth eruption and macrophage 
deficits, including osteopetrosis were corrected, with the secreted proteoglycan more 
potent than the glycoprotein.  These findings suggest that the regulated expression of 
the distinct CSF-1 isoforms is biologically significant.  
 
CSF-1 is known to be elevated in the circulation in the immediate postnatal period of 
both mice and humans (Roth and Stanley, 1995, 1996).  To further support the role 
of CSF-1 in the postnatal growth, Alikhan et al. (2011) studied the impact of further 
supplementing this burst of expression.  Intra-peritoneal injections to neonatal Csf1r-
EGFP
+
 mice with rh-CSF-1 on the first three days of life resulted in increased tissue 
macrophage numbers, and caused a significant increase in body weight by day 21 
compared to litter mate control mice (Alikhan et al., 2011).  This increase in body 
weight was correlated to significant increases in the organ weight of both the kidney 
and liver and accelerated maturation of the lung.  
 
1.4 Colony stimulating factor-1 receptor (CSF-1R) 
The CSF-1R, (CD115) is encoded by the CSF1R gene, otherwise known as the c-fms 
proto-oncogene, and is expressed on all mononuclear phagocytes and their precursors 
(Arceci et al., 1992; Arceci et al., 1989; Cecchini et al., 1997; Roth and Stanley, 
1996; Sherr and Rettenmier, 1986; Sweet and Hume, 2003).  The CSF1R gene was 
first discovered as the oncogene responsible for Feline McDonough Sarcoma (SM-
FeSV), hence its other name fms (Donner et al., 1982; El-Gamal et al., 2012).  
Another transformed version of the CSF1R gene has also been identified in a further 
feline viral isolate, the Hardy-Zukerman 5 strain of feline sarcoma virus (HZ5) 
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(Besmer et al., 1986).  These transformed receptors were identified in fibrosarcomas 
from domestic cats with feline leukaemia virus (FeLV).  Both SM-FeSV and HZ5 
contain an intact ligand binding domain compared to CSF-1R (Woolford et al., 
1988).  SM-FeSV differs from CSF-1R by 17 nucleotide differences which results in 
a nine point amino acid substitution mutation and a C-terminal truncation (Sherr, 
1990; Woolford et al., 1988).  Expression of these oncogenic versions of CSF-1R 
(vFMS), can transform cultured cat fibroblasts to tumorigenic derivatives (Sherr, 
1988).  
 
CSF-1R expression in adult animals is largely restricted to myeloid cells.  CSF-1R 
may also be expressed in mouse colonic crypts and small intestinal Paneth cells 
where it has been suggested to contribute to control of enterocyte development and 
homeostasis (Akcora et al., 2013; Huynh et al., 2013; Huynh et al., 2009).  Cells 
from tissues undergoing pathological processes have also been identified as 
expressing CSF-1R including smooth muscle cells of atherosclerotic lesions (Inaba et 
al., 1992), retinas of diabetic rats (Liu et al., 2009), neurones of the central nervous 
system after ischemic and other injury (Luo et al., 2013; Wang et al., 1999), and B 
cells in patients’ recovering from cytotoxic therapy for lymphoma or lymphocytic 
leukaemia (Baker et al., 1993).   
 
1.4.1 CSF-1R gene and gene regulation 
The CSF1R gene is located on chromosome 5 in humans and chromosome 18 in 
mice, is 58 kb in length and comprised of 21 introns and 22 exons (Stanley, 1998).  
The gene encodes a 972 amino acid transmembrane glycoprotein with tyrosine 
kinase activity.  Both the mouse and human CSF1R gene contain a separate promoter 
that is expressed specifically in placental trophoblasts.  In humans, this is located in 
the 3’ end of the upstream PDGFR locus (Visvader and Verma, 1989).  In mice the 
trophoblast promoter is present around 500bp upstream of the first coding exon 
(Sasmono et al., 2003).  Recent evidence indicates that osteoclasts in mice utilise a 
separate promoter from macrophages (Ovchinnikov et al., 2010).  The major 
macrophage promoter of mice and humans lacks the presence of conventionally 
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found proximal promoter elements such as a TATA box, a CCAAT box, or GC-rich 
sequences found in “housekeeping” genes which normally determine the site of 
transcription initiation (Bonifer and Hume, 2008; Hume et al., 2008; Ross et al., 
1998).  PU.1, a transcription factor from the Ets family of transcription factors, is 
unique to macrophages, B cells, mast cells and neutrophils, is essential for 
macrophage differentiation, and must be constantly expressed at high levels to 
induce and maintain macrophage differentiation (Hume, 2012; Lawrence and Natoli, 
2011).  These proximal promoter regions of the mouse and human CSF1R gene 
differ in relation to the number of PU.1 binding sites; PU.1 has two binding sites in 
exon 1 of the human CSF1R promoter and one binding site in exon 1 of the mouse 
Csf1r promoter (Lichanska et al., 1999; Ross et al., 1998).  Targeted disruption of 
PU.1 reduces myeloid differentiation.  However, PU.1 alone is unlikely to be the 
only protein required for initiation of transcription in the macrophage Csf1r 
promoter, since Csf1r expressing phagocytes can be detected in PU.1 knockout mice, 
at least on an outbred genetic background (Lichanska et al., 1999).  Hume (2012) has 
summarised the contributions of other transcription factors, including multiple Ets 
family members to the regulation of transcription initiation in the Csf1r promoter.  
 
Within intron 2 of the mouse Csf1r gene there are macrophage specific DNAse 
hypersensitive sites (DHSs) referred to as the Fms Intronic Regulatory Element 
(FIRE) that are conserved between the human and mouse Csf1r gene (Bonifer and 
Hume, 2008; Himes et al., 2001).  The presence of the FIRE sequence is absolutely 
required for expression of a CSF-1R transgene in mice (Sasmono et al., 2003), or in 
stably transfected RAW264 macrophage cells (Himes et al., 2001).  Recent 
publication from our laboratory has confirmed that the FIRE element is orientation-
dependent, and its action depends upon antisense promoter activity (Sauter et al., 
2013).  Interestingly, a conserved element can be seen in a similar location in avian 
CSF1R loci (Garceau et al., 2010) and this element also drives macrophage-specific 
expression of transgenes in both birds and mammals
2
.   
                                                 
2
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During haematopoietic development, Csf1r transcription is switched on in myeloid 
cells, and switched off in lymphoid cells.  Subsequent regulation can also occur post-
transcriptionally.  Granulocytes, which express PU.1, express Csf1r mRNA but do 
not produce the protein (Sasmono et al., 2007).  Haematopoietic stem cells express 
Csf1r, however, the promoter is not fully active at this stage of development, 
therefore mRNA levels are low.  High levels of CSF-1R mRNA and protein are only 
expressed in cells destined to be responsive to CSF-1 signalling (Krysinska et al., 
2007).  PU.1 interacts with other transcription factors, including Egr-2 and JunB, in a 
bi-phasic manner, and with activation of full promoter and FIRE activity, the level of  
CSF-1R mRNA and protein increases as the cells mature (Bonifer and Hume, 2008; 
Krysinska et al., 2007).  Conversely, Csf1r is epigenetically silenced during B cell 
lymphopoiesis.  After the common lymphoid progenitor (CLP) stage of 
haematopoiesis, DNase I hypersensitivity around FIRE is lost and mRNA expression 
of Csf1r ceases.  The B cell specific transcription factor,  Pax5, is directly recruited 
to the Csf1r promoter and FIRE to Csf1r causing a rapid loss of  RNA polymerase II 
binding at the promoter followed by immediate loss of transcription factor binding 
and DNaseI hypersensitivity at all cis-regulatory elements (Ingram et al., 2011; 
Tagoh et al., 2006).  Csf1r can be reactivated in mature B lymphoid cells by 
conditional inactivation of Pax5 (Mikkola et al., 2002; Tagoh et al., 2004). 
 
 
1.4.2 CSF-1R protein structure and function 
The CSF-1R is a member of the type III tyrosine kinase receptors (RTK III), which 
broadly function to stimulate cell growth and differentiation (Schubert et al., 2007). 
Other members of this family include platelet derived growth factor receptors α and 
β (PDGFRα and PDGFRβ), stem cell factor receptor (c-Kit) and Flt-3 receptors. The 
members of this family share overall structure, five extracellular immunoglobulin-
like domains, a single transmembrane region, a juxtamembrane region and a kinase 
domain.  RTK III receptors all produce ligand-induced tyrosine-specific protein 
kinase activity that phosphorylates both tyrosine residues in the intracellular domain 
of the receptor and other cellular targets (Schubert et al., 2007).   
Chapter 1:  Introduction  
22 
 
The 3-dimensional structure of the CSF-1/CSF1-R and IL-34/CSF-1R complexes has 
been reported (Chen et al., 2008; Liu et al., 2012; Ma et al., 2012b).  Interestingly, 
although CSF-1 is present in birds and fish as well as mammals, both CSF-1 and  its 
receptor have diverged substantially across species so that the precise binding sites 
are not well conserved (Garceau et al., 2010).   The precise nature of this interaction 
is discussed in Section 1.6. 
 
1.5 Interleukin -34 (IL-34) 
1.5.1 Discovery of a second CSF-1R ligand 
In 2002, a knockout mouse line was generated by targeted disruption of the mouse 
Csf1r gene by insertion of a PGKneo cassette containing stop codons into exon 3 that 
failed to produce CSF-1R mRNA or protein (Dai et al., 2002).  As one would expect, 
these mice were severely deficient in CSF-1 dependent tissue macrophage 
populations thus demonstrating the effects of CSF-1 are mediated via its receptor, the 
CSF-1R.  Nevertheless, the phenotypic consequences were a great deal more severe 
than in the op/op mouse.  In particular, microglia and Langerhans cells are present in 
op/op mice and absent in Csf1r deleted mice (Ginhoux et al., 2010; Ginhoux et al., 
2006; Witmer-Pack et al., 1993).  These observations and findings suggested that 
there must be a second ligand for the CSF-1R.  That ligand, named Interleukin-34 
(IL-34) was first identified by Lin et al. (2008).  These authors produced recombinant 
secreted proteins and extracellular domains of transmembrane proteins and assessed 
each protein for metabolic, growth or transcriptional responses in diverse cell types 
(adipose cells, muscle cells, B and T lymphocytes, monocytes, cancer cells, 
cardiomyocyte, fibroblasts).  Among known cytokines and growth factors identified 
such as CSF-1 and VEGF, an uncharacterised protein that stimulated monocyte 
viability was identified and further characterised.  This protein was designated IL-34 
isoform 1.  By screening the extracellular domains (ECD) of membrane-spanning 
proteins and using the CSF-1R ECD to block binding of biotinylated IL-34, 
unlabelled IL-34, CSF-1 or CSF-1R antibody, CSF-1R was identified as the receptor 
for IL-34.  No such alternative ligand has been identified for Kit and Flt3, the 
haematopoietic receptors that are structurally closely related to CSF-1R.  Conversely, 
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the related PDGF system comprises four ligands and two receptors that have partly 
non-redundant functions (Andrae et al., 2008).  The activity of IL-34 on monocyte 
viability was blocked by antibodies to IL-34 but not to CSF-1 and CSF-1 activity 
was blocked by CSF-1 antibodies and not by IL-34 antibodies, indicating that IL-34 
activity on monocytes is independent of CSF-1 (Lin et al., 2008).  
 
1.5.2 IL-34 gene and isoforms 
The IL34 gene is located on chromosome 16 in humans and chromosome 8 in mice, 
comprised of 6 coding exons and is conserved across species including chimpanzee, 
Rhesus monkey, dog, cow, mouse, rat and chicken.  Two isoforms of IL-34 have 
been identified in humans as a result of alternative splicing of a CAG indel 
producing isoforms with and without glutamine at position 81 (Q81).  Isoform 1 
which is a 242 amino acid protein (GenBank accession number EU599219), has Q81 
(+Q81), while the 241 amino acid isoform 2 (GenBank accession number 
NP_689669) lacks Q81 (-Q81).  For mice, the same alternative splicing exists to 
produce a 235 amino acid isoform 1 and a 234 amino acid isoform 3.  Isoform 2 in 
the mouse (219 amino acids) has an apparent deletion/insertion from amino acid 135 
which remains to be functionally assessed.  The presence of Q81 is predicted to alter 
the structure from coiled (+Q81) to helix (-Q81) which may alter the biological 
activity of the protein. Mouse IL-34 +Q81 was more potent than –Q81 at promoting 
macrophage proliferation (Wei et al., 2010).  Truncated human IL-34 (222 amino 
acids) is as active as CSF-1 at stimulating human monocyte proliferation and slightly 
more active than full length (Ma et al., 2012b).  However, a truncated 162 amino acid 
IL-34 had reduced biological activity (Chihara et al., 2010). 
 
1.5.3 IL-34 expression 
IL-34 is produced mainly by keratinocytes and neurones (Greter et al., 2012; Wang 
et al., 2012 ), but has been identified in many tissues and cells including the embryo, 
extra-embryonic tissue and the pregnant uterus (Figure 1.5).  High levels of IL-34 
mRNA have been noted within the spleen with IL-34 protein expressed by sinusoidal 
endothelium in splenic red pulp, implicating IL-34 in myeloid growth and 
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differentiation (Lin et al., 2008).  The spatiotemporal expression patterns of IL-34 
and CSF-1 differ in an apparently reciprocal manner suggesting they have 
complementary regulation (Wei et al., 2010).  IL-34 and CSF-1 have non-
overlapping distributions and apparently distinct functions in the development of 
microglia in the developing mouse brain (Nandi et al., 2012; Wang et al., 2012 ). 
 
1.5.1 IL-34 structure 
IL-34 and CSF-1 share very little in the way of similarity in amino acid sequence, 
but IL-34 was predicted to be a member of the four helix bundle family (Garceau et 
al., 2010) based upon structural modelling, a prediction that was largely confirmed in 
the crystal structure.  A  Clustal W
3
 alignment of human CSF-1 and IL-34 reveals 
just 12% homology between the two cytokines.  In fact, IL-34 is most similar to 
Stem Cell Factor (SCF) in terms of structure.  IL-34 structure is comprised of a four 
helix bundle consisting of αA, αB, αC and αD (Ma et al., 2012b), (called α1, α3, α4 
and α6 in Liu et al. (2012)).  Similar to the structure of CSF-1, outside the core 
domain there are crossing β strands β1 and β2 (α2 and α5 in Liu et al. (2012)) (Chen 
et al., 2008; Ma et al., 2012b).  Like CSF-1, IL-34 has multiple Cysteine residues. 
Unlike CSF-1, which has an inter-chain disulphide bond to form a dimer, as well as 
three intra-chain disulphides, IL-34 forms a non-covalent dimer.  Cysteine residues 
form intra-chain disulphide bonds between Cys35 and Cys180 (connects helices αA 
and αD), and between Cys177 and Cys191 (connects αD to C-terminal helix α4) in 
the human ligand.  Cys168 and Cys170 remain unpaired, and not essential for proper 
folding.  The rigidity of the IL-34 structure is more consistent with Flt3 ligand and is 
quite different to CSF-1 or SCF structures that must undergo local structural 
arrangements to accommodate receptor binding (Chen et al., 2008; Liu et al., 2007; 
Verstraete et al., 2011).  
 
                                                 
3
 http://www.ebi.ac.uk/Tools/msa/clustalw2/ 




Figure 1.5: Expression of mouse IL-34 in tissues and cells.  
The image is a screen shot of the expression of IL-34 in mouse tissues and cells demonstrating that 
IL-34 is produced by almost every tissue within the body and highly expressed in osteoblasts, brain 
and skin.  Data from Biogps.org.   
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1.5.2 Biological activity of IL-34 
Most of the available evidence suggests that IL-34 is indistinguishable from CSF-1 
in its biological activity on the CSF-1R; its separate roles are based upon differential 
expression and the lack of compensatory mechanisms when CSF-1 is absent 
(Foucher et al., 2013; Lin et al., 2008; Wei et al., 2010).  Recently,Wei et al. (2010) 
introduced a transgenic construct in which the Csf1 promoter and first intron were 
used to drive full-length mouse IL-34 isoform 1 onto the op/op mouse background.  
This transgene was able to fully correct the op/op mice defects that Ryan et al. 
(2001) described.  Recombinant mouse IL-34 injected into mice promoted 
proliferation as measured by an increase in CD11b
+
 cells from bone marrow, spleen 
and peripheral blood (Chen et al., 2011).  Comparisons of the two factors in-vitro 
have suggested some distinct signalling outcomes, by the apparent dose-
responsiveness and subtly different morphological characteristics, although no 
mechanistic basis has been suggested (Chihara et al., 2010).   
 
IL-34  can completely substitute CSF-1 in human primary cell cultures of CD14
+
 
cells to induce osteoclastogenesis in a dose dependent manner (Baud'huin et al., 
2010; Chen et al., 2011).  IL-34 induced osteoclastogenesis can be inhibited by 
GW2580 (CSF-1R inhibitor), demonstrating that IL-34 induces osteoclastogenesis 
through CSF-1R, and CSF-1 and IL-34 overlap.  Further evidence of the role of IL-
34 in bone resorption and osteoclast differentiation comes from in-vivo studies 
injecting mice with recombinant mouse IL-34 which can alter the phenotype of bone.  
After 1 week of IL-34 injections, the mice demonstrated decreased bone mass of 
proximal tibias, reduced bone volume, reduced trabecular number and increased 
trabecular separation (Chen et al., 2011).  
 
Specific biological effects of IL-34 include the finding that it promotes microglia 
proliferation by the induction of microglial TGFβ mRNA and protein to regulate 
microglial proliferation and enhance the neuroprotective effect of microglia (Ma et 
al., 2012a).  Consistent with the restricted expression in brain and skin shown in 
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Figure 1.5, IL-34 deficiency in a knockout mouse appears to generate a specific 
deficiency in microglia and Langerhans cells (Greter et al., 2012; Wang et al., 2012 ).  
These populations of cells were not depleted in the op/op mouse.  So, collectively, 
the data suggest that IL-34 differs from CSF-1 primarily in its site of expression and 
action rather than any intrinsic difference in signalling.  
 
1.6 Two ligand one receptor relationship 
Both CSF-1 and IL-34 bind to the CSF-1R producing similar effects both in-vitro 
and in-vivo (Chihara et al., 2010; Elegheert et al., 2011; Wei et al., 2010).  However, 
the original discovery of IL-34 (Lin et al., 2008) suggested in contrast to human 
CSF-1, it does not cross species.  Human IL-34 is much less potent at stimulating 
mouse CSF-1R mediated macrophage proliferation; EC50 for human IL-34 was 30 
fold higher than for human CSF-1 (Wei et al., 2010).  Garceau et al. (2010) noted 
that the two ligands have evolved differently between species, and the known contact 
residues of CSF-1 were not conserved in IL-34.  They suggested that the two ligands 
were likely to bind to distinct regions of the CSF-1R.  The molecular basis of the two 
ligands:one receptor biology was revealed by the solution of the crystal structures of 
receptor complexes.  Both full length and truncated CSF-1 and IL-34 can bind to the 
CSF-1R in a 2:2 cytokine/receptor stoichiometry in solution, producing a shape 
similar to SCF:KIT binding (Chen et al., 2008; Ma et al., 2012b).  Whereas IL-34 
could dimerize CSF-1R D1-D3 in isolation from the rest of the receptor, CSF-1 was 
not able to dimerize this region without involvement of  D4 and D5 (Chen et al., 
2008).  The details of binding are discussed below.  
 
1.6.1 CSF-1 binding to the CSF-1R 
Binding of CSF-1 to the CSF-1R occurs via immunoglobulin domain 2 (D2) and 3 
(D3) of the extracellular region.  The orientation of D2 away from the ligand is of 
particular importance (Chen et al., 2008).  Human CSF-1 is almost as effective as 
mouse CSF-1 at stimulating the mouse CSF-1R (Das et al., 1980, 1981), and indeed 
is equally active on all mammalian species tested (mouse, cat, sheep, dog, and pig).  
Conversely, mouse CSF-1 bioactivity is restricted to non-primate species (Abrams et 
Chapter 1:  Introduction  
28 
 
al., 2003; Francey et al., 1992; Garceau et al., 2010; Gow et al., 2012; Stanley and 
Guilbert, 1981; Woolford et al., 1988; Yoshihara et al., 1998).  In fact, mouse CSF-1 
binds 500 times less tightly to human CSF-1R than to mouse CSF-1R (Elegheert et 
al., 2011).  
 
1.6.2 IL-34 binding to the CSF-1R 
Binding of IL-34 to the CSF-1R is similar in geometry to the CSF-1:CSF-1R 
complex involving two site recognition through D1-D3 of the receptor, in particular 
D2 (Felix et al., 2013; Liu et al., 2012).  Site 1 involves interactions between 
negatively charged αB and αC helices, the intervening loop and α3 of IL-34 and the 
positively charged D2 region (CD and EF loops) of CSF-1R.  The smaller site 2 is 
formed between D3 region of CSF-1R and αA, αC and α4 IL-34 helices and is 
further divided into 2 polar sub-regions.  The first region formed by D3 and IL-34 α4 
region produces hydrogen bonds (Ma et al., 2012b).  Residues in the α4 region of IL-
34 (N187, S184, L186) are important for biological activity with deletion of this 
region resulting in reduced ability to stimulate growth of TF-1-fms cells (Chihara et 
al., 2010; Ma et al., 2012b).  The second polar region of site 2 is comprised of three 
side chain hydrogen bonds.  Additionally there are van der Waals interactions 
between IL-34 and the CSF-1R.  Structural features outside the four helix bundle, 
mainly the α4 region mean that the interaction sites are more spread out in IL-34 
compared to CSF-1.  This creates a more flattened interface requiring a more 
extended conformation.  To accommodate this, there is a 20 degree rotation of D3 
region of the receptor relative to D1 and D2 to produce a linear arrangement upon 
IL-34 binding (Liu et al., 2012). 
 
Receptor dimerization is produced by the binding of one monomeric unit of the CSF-
1 or IL-34 dimer to one CSF-1R chain, which permits the second monomeric unit of 
the dimer to recruit a further CSF-1R molecule (Chen et al., 2008).  For CSF-1, 
initially this dimerization is non-covalent.  Following initial signalling, covalent 
dimerization and modification of one receptor chain results in a heterodimer which 
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eventually becomes deactivated followed by internalization of the ligand-receptor 
complex (Li and Stanley, 1991).   
 
1.6.3 CSF-1R phosphorylation 
Binding and activation of the CSF-1R initiates a signalling cascade involving 
receptor autophosphorylation, and activation of the classical Ras-Raf-ERK (MAPK) 
and PI-3-kinase signalling pathways shared by many protein tyrosine kinases 
(Fowles et al., 1998; Hamilton, 1997; Kelley et al., 1999; Pixley and Stanley, 2004; 
Sweet and Hume, 2003).  Both IL-34 and CSF-1 stimulate ERK/12 phosphorylation 
and activate MAPK to a similar degree, although differences in the tyrosine residues 
phosphorylated may exist (Chihara et al., 2010; Wei et al., 2010).  In the mouse, six 
tyrosine residues are auto-phosphorylated by protein kinase in response to CSF-1; 
Y559, Y697, Y706, Y21, Tyr807 and Y974 (Pixley and Stanley, 2004; Yu et al., 
2008; Yu et al., 2012).  In addition to these six tyrosine residues, a further two, 
(Y544 and Y921) are phosphorylated in v-fms, (Joos et al., 1996; Mancini et al., 
1997; Yu et al., 2008).  Autophosphorylation allows specific adaptor proteins to be 
recruited to particular phosphorylated tyrosines which in turn initiate the various 
signal transduction pathways.  These signalling pathways trigger specific genes that 
require CSF-1 stimulation that are involved in cellular survival, proliferation, 
differentiation, or mature macrophage functions such as phagocytosis e.g. scavenger 
receptor A (Guidez et al., 1998), and matrix re-modelling e.g. expression of 
urokinase plasminogen activator, thus producing a CSF-1 mediated response 
(Douglass et al., 2008; Fowles et al., 1998; Fowles et al., 2000; Yu et al., 2008).  The 
CSF-1 mediated response can be recognised in-vitro by polarization, increased 
motility and rapid (within one minute) morphological changes including cell 
spreading, extension of lamellopodia, formation of membrane ruffles and 
intracellular vesicles (Boocock et al., 1989; Webb et al., 1996).  In the absence of 
CSF-1, macrophage cells are rounded and lack intracellular vesicles.   
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Each individual tyrosine residue in the mouse receptor has been shown to contribute 
to distinct aspects of macrophage proliferation and differentiation. The most 
important tyrosine residue for proliferation and differentiation is Y807 (Yu et al., 
2012).  The morphological responses of macrophages to CSF-1 are mediated through 
Y706, Y721 and Y974 and mutations of Y544 and Y559 (the juxtamembrane domain 
tyrosine residues), reduced CSF-1R kinase activity (Yu et al., 2008).  CSF-1R 
deficient cell lines expressing CSF-1Rs with mutations of each tyrosine residue to 
phenylalanine, and one mutation in which all eight tyrosines were mutated to 
phenylalanine have been studied (Yu et al., 2008).  Mutation of all eight tyrosine 
residues ablated signalling from CSF-1R.  Cells with a single mutation of either 
Y807 and Y559 were the most severely affected amongst single mutations, 
demonstrating a 2-3 fold increase in cell cycle length compared to cells expressing 
wild type CSF-1R. Y807 is involved in autoinhibition of the receptor in the absence 
of ligand, binding into the active site of the kinase domain.  This autoinhibition is 
removed upon the initial phosphorylation of Y559 (Yu et al., 2012).  
 
1.7 CSF-1 and CSF-1R in disease 
1.7.1 CSF-1 and CSF-1R associated tumours 
Constitutive production of CSF-1 is a common feature of tumour cells (Espinosa et 
al., 2009).  CSF-1 expressing tumours include reproductive tumours such as: 
epithelial ovarian cancer cells (Chambers et al., 1997), uterine leiomyosarcoma 
(Espinosa et al., 2009), breast carcinoma (Beck et al., 2009; Kacinski, 1997), and 
uterine adenocarcinoma (Kacinski, 1997).  Non-reproductive tumours expressing 
CSF-1 include: pancreatic tumours (Groblewska et al., 2007), lung tumours 
(Horiguchi et al., 1988), myeloid and lymphoid leukaemias (Janowska-Wieczorek et 
al., 1991), and multiple myelomas (Nakamura et al., 1989).  The poor prognosis 
associated with these tumours is likely to reflect the fact that these cells are more 
invasive, motile and metastatic (Toy et al., 2009).  This increased metastasis and 
poor prognosis may be associated with the ability of CSF-1 to recruit and modulate 
tumour associated macrophages (TAMs) attracted to the tumour, since tumours 
expressing high numbers of CSF-1 expressing cells are infiltrated by large number of 
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macrophages (Chambers et al., 1995; Hamilton, 2008).  The CSF-1 target gene, Ets2, 
expressed in tumour-associated macrophages, appears critical for tumour progression 
(Zabuawala et al., 2010).  Macrophage produced epidermal growth factor (EGF) may 
promote tumour cell migration and stromal invasion (Pollard, 2008).  
 
The co-expression of CSF-1 and CSF-1R on tumour cells may generate autocrine 
signalling.  Ectopic expression of CSF-1R has been reported in prostatic neoplasia 
(Ide et al., 2002), mammary neoplasia (Kluger et al., 2004),  and uterine 
adenocarcinoma (Li et al., 2006), and is also a poor prognostic indicator of such 
cases (Maher et al., 1998; Toy et al., 2009).  Co-expression of both CSF-1 and CSF-
1R is also associated with some tumours, e.g. uterine leiomyosarcoma (Espinosa et 
al., 2009), and epithelial tumours of the breast, uterus and ovary (Lin et al., 2002).   
As noted above, activating mutations of the CSF1R gene have been described in the 
feline retroviral v-fms oncogene (Sherr, 1990).  Binding of CSF-1 to this mutated 
receptor produces prolonged receptor activation and up-regulation of kinase activity 
in a ligand dependent manner, providing prolonged signals for cellular growth 
(Sherr, 1990).  Mutations of Csf1r have been associated with an increased 
predisposition to myeloid malignancies, an example includes mutation at codon 31 
resulting in constitutive tyrosine kinase activity of the receptor thus inducing 
neoplastic transformation (Such et al., 2009).   
 
1.7.2 Therapeutic applications of manipulation of CSF-1R 
signaling  
CSF-1 is elevated in the serum and lesions in many inflammatory and auto-immune 
diseases including arthritis, lupus, nephritis and rheumatoid arthritis (Hamilton, 
2008; Hamilton and Achuthan, 2012; Lenda et al., 2004).  In rheumatoid arthritis the 





 tissue infiltrative blood monocytes which release pro-
inflammatory cytokines thus producing chronic joint inflammation (Chitu and 
Stanley, 2006; Kawanaka et al., 2002).  Based upon the function of macrophages in 
many different pathologies, both stimulation and inhibition of the receptor could 
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have therapeutic benefit.  Recombinant colony stimulating factors, various specific 
kinase CSF1-R inhibitors and/or antibodies directed against the ligand or the receptor 
have been tested in a range of animal models and human patients (Hume and 
Macdonald, 2012; Martinez et al., 2012; Nemunaitis et al., 1993; Wei et al., 2005).  
Therapeutic applications of CSF-1 include its use in bone marrow transplant patients, 
where administration of recombinant human CSF-1 post-operatively has been used to 
reduce the likelihood of developing post-transplant fungal infections and has 
successfully increased survival rates in these patients (Nemunaitis et al., 1993). 
Paradoxically, since CSF-1 promotes osteoclast production, both CSF-1 and CSF-1R 
antagonists could alter bone calcium homeostasis therapeutically. CSF-1 treatment of 
mice induced matrix deposition and mineralisation and significantly increase bone 
density (Alexander et al., 2011; Lloyd et al., 2009), whereas on-going experiments in 




Chronic disease associated with CSF-1 (e.g. rheumatoid arthritis) may be targeted 
with anti-CSF-1 antibodies to block the in-vivo effects of CSF-1(Wei et al., 2005).  
CSF-1 administration has been shown to promote regeneration in a number of 
models.  For example, in ischemia reperfusion, a model of acute renal injury in mice, 
recombinant human CSF-1 administration was able to stimulate macrophage 
infiltration to promote epithelial repair and prevent interstitial fibrosis (Alikhan et al., 
2011; Menke et al., 2009).Hepatocyte progenitor cells are activated during chronic 
liver injury to supply hepatocytes.  Recent studies investigating the role of 
macrophages for liver therapy in mice have identified that macrophages improve 
liver fibrosis and enhance regeneration and function in these animals, with 
macrophages involved in biliary and hepatocyte regeneration  (Boulter et al., 2012; 
Thomas et al., 2011).   
Several pharmaceutical companies have produced CSF-1R kinase inhibitors, and 
have claimed possible therapeutic actions in inflammatory and other macrophage-
                                                 
4
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mediated pathologies, reviewed by Hume and Macdonald (2012).  The alternative to 
the use of kinase inhibitor is blocking monoclonal antibodies.  Two anti-mouse CSF-
1R antibodies, AFS98 and M279, have been tested in a range of models.  This area 
has also been reviewed (Hamilton and Achuthan, 2012; Hume and Macdonald, 
2012).  The antibodies have somewhat different actions, and it has been suggested 
that AFS98 may have direct effects to remove macrophages, since it depletes them 
more rapidly and extensively than M279 (Hume and Macdonald, 2012; MacDonald 
et al., 2010).  Treatment of mice with M279 selectively depleted the Ly6C
lo
 
monocyte precursor of resident tissue macrophages, and most tissue macrophage 
populations, but did not deplete the inflammatory Ly6
hi 
cells.  Accordingly, it had no 
effect in a range of inflammatory biologies, in fact it greatly exacerbated pathology 
in a graft-versus-host disease model (MacDonald et al., 2010).   
 
1.8 Insulin like growth factor-1 (IGF-1) 
As noted above, the CSF-1-deficient op/op mouse has a severe postnatal growth 
deficiency.  The major regulator of postnatal growth is insulin-like growth factor-1 
(IGF-1).  IGF-1 acts via its receptor, IGF-1R, a type II tyrosine kinase receptor (Liu 
and LeRoith, 1999; Liu et al., 1993).  The classical somatomedin hypothesis 
identified that IGF-1 acts as a mediator of the systemic effects of growth hormone 
(GH) (Le Roith et al., 2001).  The hypothesis has been challenged by the observation 
that GH directly infused into the growth plate of hypophysectomised rat tibias 
stimulated longitudinal bone growth (Isaksson et al., 1982).  A further challenge 
came from studies by Sjogren et al. (1999) and Yakar et al. (1999), who both 
produced conditional liver-specific IGF-1 knockout mice, (ablation of Igf1 exon 4), 
using either albumin enhancer/promoter Cre/loxP system or interferon-α (IFN-α) 
induction of mice with Cre recombinase under the control of an IFN promoter (Mx-
Cre).  Both these liver knockouts ablated liver IGF-1 mRNA and produced 
significant reductions in circulating IGF-1 but the body weights of the knockout mice 
were indistinguishable from wild-type littermate controls.  These studies suggest that 
extra-hepatic sources of IGF-1 acting in an autocrine/paracrine role are important for 
postnatal growth and development (Isaksson et al., 2001; Liu et al., 2000; Pass et al., 
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2009; Sjogren et al., 1999; Yakar et al., 1999).  Stratikopoulos et al. (2008) and  
Lupu et al. (2001) have suggested that the cre-induced mutations acted only after the 
critical post weaning period of growth spurt, so the role of liver IGF-1 is not 
completely discounted.  The former study (Stratikopoulos et al., 2008) took the 
reverse approach, and restored appropriately-regulated liver IGF-1 production in 
mice lacking Igf1 gene expression in all other tissues.  The outcomes indicated that 
endocrine IGF-1 does contribute around 30% of adult body size and can partly 
sustain postnatal development (Stratikopoulos et al., 2008).  Hence, both endocrine 
and autocrine/paracrine IGF-1 roles likely contribute to postnatal growth. 
 
Aside from the growth retardation of CSF-1-deficient animals discussed above, the 
link between CSF-1 and IGF-1 is suggested by numerous reports that macrophages 
can produce IGF-1 in response to CSF-1 and other stimuli (Arkins et al., 1993; 
Arkins et al., 1995; Baxter et al., 1991; Kirstein et al., 1992; Nagaoka et al., 1990; 
Noble et al., 1993; Rom et al., 1988; Uh et al., 1998).  Recent papers confirmed that 
microglia, the brain macrophages, are the major source of IGF-1 in the brain 
(Hristova et al., 2010) and two others demonstrated that macrophages are a major 
source of IGF-1 in muscle wound repair, and in compensatory muscle hypertrophy, 
both situations in which another CSF-1-responsive gene, urokinase plasminogen 
activator was also implicated (Bryer et al., 2008; Stacey et al., 1995).  Other colony 
stimulating factors have been investigated for their ability to induce IGF-1, with cells 
cultured in the presence of either GM-CSF or G-CSF also expressing abundant IGF-
1 mRNA, albeit at a lesser level than cells cultured with CSF-1.  Further evidence 
that CSF-1 is involved in up-regulation of macrophage IGF-1 comes from 
immunohistochemical identification of IGF-1 and IGF-1R localised in the tibia of 
normal and tl/tl rats following treatment with rh-CSF-1 (Joseph et al., 1999). 
Interestingly, IGF-1 deficiency appears to decrease both CSF-1 and CSF-1R 
expression in bone marrow (Cao et al., 2007) and CSF-1 also regulates expression of 
GH receptor in bone (Joseph et al., 1999; Symons et al., 1996).  Furthermore, the 
IGF-1 receptor is expressed at high levels in bone marrow-derived macrophages 
grown in CSF-1 (www.biogps.org).  So, the three regulators are linked at many 
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levels.  In the tl/tl rat, there is gross deficiency of circulating IGF-1 in animals up to 7 
weeks of age that correlates with the defective postnatal growth
5
, and conversely in 
the mouse, injection of CSF-1 can increase circulating IGF-1 alongside the increase 
in postnatal growth (Alikhan et al., 2011).  Neither of these observations necessarily 
implies a direct role of macrophages as the sole or even the major source of the   
IGF-1.  The liver undergoes a substantial alteration in function as it ceases to be a 
haemopoietic organ, acquires functional bile ducts, and adapts to changes in inputs 
from the portal blood.  This transition is associated with the acquisition of the mature 
macrophages of the liver, the Kupffer cells.  By analogy to the role of CSF-1 in the 
pancreas, it is entirely possible that CSF-1-dependent macrophages also control the 
maturation of hepatocytes, and their ability to respond subsequently to GH.  
The level of IGF-1 mRNA in macrophages is comparable with liver, but unlike other 
cells and tissues that make IGF-1, mouse macrophages treated with CSF-1 do not 
make mRNA encoding any of the IGF-1 binding proteins that regulation biological 
activity and stability (www.biogps.org).  A previous study of the IGF-1 promoter in 
macrophages examined basal IGF-1 transcription in RAW264 cells (Wynes and 
Riches, 2005), which express the transcript at a fraction of the level in CSF-1-
stimulated primary macrophages (www.biogps.org).  Genome-scale 5’ RACE 
(CAGE) data revealed that macrophage production of IGF-1 is controlled 
independently of the liver, using quite distinct transcription start site (TSS) (Carninci 
et al., 2006).  There are actually at least five promoter regions, two each exclusive to 
macrophages and one shared between the two major sources of IGF-1, amongst all of 
the samples polled.  The implication is that IGF-1 expression in macrophages serves 
a distinct function from expression in the liver.  The macrophage promoter regions 
are also highly conserved at the sequence level across mammalian species, strongly 
suggesting that this is a biology that is common to mammalian growth regulation and 
that CSF-1-dependent macrophage  IGF-1 production will also be important in large 
animals and humans (Gow et al., 2010). 
                                                 
5
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If we link all of these studies together, it is clear that IGF-1 is produced in a 
regulated manner in macrophages; they are likely to be the major extrahepatic source 
and are likely to also regulate production by the liver.  Accordingly, the 
somatomedin hypothesis should be expanded to accommodate the role of CSF-1, 
especially in the postnatal period.   Current studies in our laboratory aim to assess the 
impact of a macrophage-specific KO of IGF-1. 
 
1.9 Aims of this thesis 
At the start of this project, work by Alikhan et al. (2011) had demonstrated that 
administration of CSF-1 could increase postnatal growth and maturation of the 
kidney and lung.  By comparison to large animals, mice are effectively born 
premature and the organs are considerably smaller.  The aim of this project was to 
create and test the reagents needed to translate these findings into pigs and humans.  
One constraint on this application is the fact that recombinant CSF-1 is relatively 
small, and is cleared by the liver and kidney (Bartocci et al., 1987).  With the 
discovery of IL-34, a secondary question was whether this factor might be more 
active.  Essentially, the question was, can the trophic actions of CSF-1 (or IL-34) be 
utilised in animal production or human medicine and tissue repair.  
To address this question, the aim was to utilise the pig as a model.  Although it was 
already known that human CSF-1 can stimulate the pig CSF-1 receptor
6
, it was felt 
that prolonged treatment might generate an immune response against the ligand.  
Accordingly, my aim was to produce porcine specific CSF-1, IL-34 and anti-CSF-1R 
antibodies.  A stable porcine CSF-1R expressing cell line was generated to assess the 
in-vitro activity of the CSF-1R ligands.  To extend the findings to other possible 
applications, feline and bovine CSF-1R were cloned and expressed to allow further 
investigation into the species cross-reactivity of CSF-1.  The species cross-reactivity 
of IL-34 was also investigated. 
                                                 
6
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The project was in collaboration with Pfizer Animal Health.  During the course of the 
project, our colleagues there developed a novel CSF-1 fusion protein which 
increased the efficacy of the protein by reducing renal clearance.  The discovery led 
to a secondary aim of the project, to test the safety and biological efficacy of this 
novel form of pig CSF-1 in mice, and to compare with earlier studies with 
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2.1 Cell culture 
2.1.1 Ba/F3 cells 
The Ba/F3 cell line, transfected Ba/F3 cells and primary bone marrow cells were 
cultured in RPMI 1640 medium (Sigma-Aldrich, Dorset, UK) containing 10% HI-
FCS (Sigma), 2mM L-glutamine (35050-61 Invitrogen Ltd, Paisley, UK), 100µg/ml 
streptomycin, and 100U/ml penicillin (15140 Invitrogen Ltd, Paisley, UK).  Unless 
otherwise stated,
 
transfected Ba/F3 cells and primary bone marrow cells were 
maintained in medium with 10
4
 U/ml rh-CSF-1 (a gift from Chiron Corp, 
Emeryville, CA, USA).  
 
2.1.2 HEK293T 
HEK293T cells (American Type Culture Collection, Manassas, VA, USA) were 
cultured in DMEM (Sigma-Aldrich, Dorset, UK) supplemented with 10% HI-FCS 
(Sigma), 2mM L-glutamine (Invitrogen), 100µg/ml streptomycin (Invitrogen), 
100U/ml penicillin and 0.1mM nonessential amino acids (Invitrogen).  All cell lines 
and primary bone marrow cells were incubated at 37
o
C with 5% CO2. 
 
2.2 Cloning methods – chapters 3 and 4 
2.2.1 Total RNA extraction 
All procedures performed on these animals were in accordance with national 
regulations and established guidelines and were reviewed and approved by the 
Institutional Animal Care and Use Committee or Ethical Review Panel.  Spleen, liver 
and mesenteric lymph node samples were collected from a healthy, three-year-old 
male, Large White x Landrace pig, euthanized by intramuscular injection of 
ketamine followed by captive bolt.  With the owner’s consent, tissues were collected 
from a 5-year-old male Siamese cat that was being euthanized for medical reasons. 
Samples were dissected, cut into slices less than 0.5 cm thick and immediately fully 
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submerged in 10 volumes of RNAlater  RNA Stabilization Reagent (Qiagen, 
Crawley, UK) to stabilize the RNA.  Tissue was stored for 24 hours at room 
temperature before being processed for RNA extraction.  From each tissue stabilized, 
30 mg was weighed, mashed with a scalpel blade and homogenized using a pestle 
and mortar.  Total RNA was prepared using Qiagen RNeasy kit (Qiagen, Crawley, 
UK) according to manufacturer’s instructions, including a DNase digestion step.   
 
2.2.2 First strand cDNA synthesis 
Porcine and feline specific cDNA was produced using 1ug of total RNA and reversed 
transcribed using ImPromII (Promega, Southampton, UK).  The experimental 
reaction was prepared by combining the components of the ImProm-II R-system 
together on ice to make a total volume of 15 µl. The transcription mix consisted of 4 
µl 5X reaction buffer, 3 µl MgCl2, 1 µl dNTPs, 1 µl ImProm-II RT, 1 µg RNA and 
PCR grade water to make the total volume of 15 µl.  Negative controls were included 
with the omission of reverse transcription to check for genomic contamination. 
Samples were incubated at 25
o
C for 5minutes followed by 42
o
C for one hour. 
Successful cDNA production without genomic DNA contamination was 
demonstrated using porcine and feline HPRT primers (Nygard et al., 2007).  
 
2.2.3 Primer design 
For mammalian expression of feline CSF-1R and porcine CSF-1, IL-34 and CSF-1R, 
PCR primer pairs (Table 2.1) were designed for amplification of biologically active  
porcine CSF-1 (amino acids 1-149), full length IL-34 (amino acids 1-235) and full-
length CSF-1R from the predicted porcine CSF-1 and IL-34 cDNA sequences (Pre-
Ensemble BLA_hbFhA8F3M and NCBI EU872447), and based on homologous 
regions of human, mouse and bovine CSF-1R for porcine CSF-1R, since the 
corresponding porcine genomic sequence was not available at the time of primer 
design. Feline PCR primer pairs (Table 2.1) were designed for amplification of full-
length CSF-1R from the incomplete published feline CSF-1R cDNA sequence 
(Ensembl ENSFCAP00000003348).  All primers were designed and thermodynamic 
properties analysed using Vector NTI oligo analysis (Invitrogen).  Primers were 
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designed to be between 18-25 base pairs with a similar TM for each primer pair. 
Primers were purchased from Invitrogen.co.uk as a 25 nmole desalted lyophilised 
stock which were re-suspended with DNAse/RNAse free water to a stock 






Table 2.1:  Table of porcine primers used to clone porcine CSF-1, CSF-1R, IL-34 and feline CSF-
1R.  










P CSF-1 forward AGTATGGCCGCGCCGGG 60.0 543 
P CSF-1 reverse CTGGCTGGAGCATTTAGCAAAGCT 60.0    - 
P CSF-1R forward ACCATGGGCCTGGGCACGC 56.0 2904 
P CSF-1R reverse GCAGAACTGGTAGGTGTTGGGTTGCAG 56.0    - 
P IL-34 forward ATGCCCCGGGGACTCGCT 60.0 705 
P IL-34 reverse GGGATCCAGGGATCCAGCCG 60.0    - 
P IL-34 reverse_STOP TCAGGGATCCAGGGAT 60.0 706 
P HPRT forward GGACTTGAATCATGTTTGTG 60.0 91 
P HPRT reverse CAGATGTTTCCAAACTAAC 60.0   - 
F CSF-1R forward GCC ATG GGC CCA AGG GCT 61.5 2946 
F CSF-1R reverse GCA GAA CTG GTA GTT GTT GGG CTG 61.5 - 
F HPRT forward ACTGTAATGACCAGTCAACAGGGG 60.0 210 
F HPRT reverse TGTATCCAACACTTCGAGGAGTCC 60.0 - 
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2.2.4 PCR amplification and visualization 
Amplification was achieved using porcine and feline cDNA and Expand
 
high fidelity 
enzyme (Roche, Mannheim, Germany) with 3mM MgCl2 (CSF-1R) or 1mM MgCl2 
(CSF-1 and IL-34) using an initial cycle of 94
o
C for 2 minutes (3 minutes for CSF-
1R), followed by 30 cycles (35 for CSF-1R) of 94
o
C for 30 seconds, 60
o
C for 30 
seconds (56
o
C for CSF-1R) , 72
o
C for 3 minutes and one cycle of 72
o
C for 10 
minutes.  8 µl of PCR products were run on a 0.5% (CSF-1R) or 2% (CSF-1 and IL-
34) TAE buffer syber safe (Invitrogen) agarose gel for approximately 40 minutes at 
110 volts and visualised using a light box.  Single bands of the expected product size 
were cut from the gel using a scalpel blade and any extra gel removed before being 
placed in a clean Eppendorph tube.  
 
2.2.5 PCR product purification  
PCR products were gel-purified using QIAquick gel extraction kit (Qiagen) 
following manufacturer’s instructions. Due to the 3’ to 5’ exonuclease activity of 
Expand High Fidelity enzyme and gel purification the 3’ A-overhangs which are 
required for TOPO TA cloning may have been removed.  To add 3’ adenines, 1 unit 
of Taq polymerase (Invitrogen) was added to each tube and incubated for 10 minutes 
at 72
o
C.  Samples were placed on ice prior to the ligation into pEF6/V5-His-TOPO 
vector.  
 
2.2.6 TOPO cloning  
The pEF6/V5-HIS-TOPO TA Expression kit (Invitrogen) was used to clone porcine 
CSF-1, CSF-1R and IL-34 and feline CSF-1R due to its highly efficient 5 minute, 
one step cloning protocol.  The addition of 3’ A-overhangs to the cloned PCR 
product allows the PCR insert to ligate efficiently into the vector due to 3’ T residues 
on the linearized plasmid.  Topoisomerase is covalently bound to the plasmid which, 
upon addition of PCR products, produces covalent bonds between PCR product and 
plasmid backbone.  All PCR products were cloned in frame with V5-His C-terminal 
tag of pEF6/V5-His expression construct using TOPO cloning kit (Invitrogen) 
following manufacturer’s instructions. 
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2.2.7 Bacterial transformation 
One vial/clone of chemically competent E.coli TOP10 cells was defrosted slowly in 
ice. 2 µl of the TOPO reaction (from above) was added to a single vial of the Top10 
cells and mixed by gently tipping up and down.  The transformation mixture was 
incubated on ice for 15 minutes before being heat shocked at 42
o
C for 30 seconds.  
Cells were immediately placed on ice and 250 µl of room temperature S.O.C 
medium (Invitrogen) was added to each tube and then placed horizontally in an 
automatic shaker at 200 rpm, 37
o
C for 1 hour.  Ampicillin agar plates were pre-
warmed at 37
o
C prior to 30 µl of transformation mixture added to each agar plate 
using a sterile bacterial loop spreader.  Plates were incubated at 37
o
C overnight.  
Following incubation, 6 single colonies from each transformation reaction were 
picked using a sterile pipette tip and placed in a 15 ml flacon tube. 
 
2.2.8 Preparation of ampicillin agar plates 
Ampicillin agar plates were made 24 hours prior to cloning and stored at 4
o
C until 
use. 250 mls of LB growth medium (solid) was dissolved in a microwave and left to 
cool at room temperature.  250 µl of ampicillin stock (100mg/ml) was added to the 
cooled LB medium to make a stock of 100 µg /ml and mixed by swirling the bottle.  
17 mls of LB ampicillin medium was added to clean, sterile, 10 cm round culture 
dishes (Sterilin, UK), lid replaced and left to set at room temperature before storage 
at 4
o
C.  During the hour’s incubation as above, plates were removed from 4
o
C and 
pre-warmed in a 37
o
C incubator prior to use.  
 
2.2.9 Isolation and purification of plasmid DNA 
For isolation and purification of plasmid DNA, QIAprep (Miniprep, Qiagen) was 
used according to manufacturer’s instructions to achieve bacterial lysis of cells under 
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2.2.10 Plasmid DNA purification using QIAprep spin 
miniprep kit and micro-centrifuge 
Each single colony picked was used to inoculate 3mls LB medium and 3 µl 
ampicillin in a 15 mLs flacon tube.  The bacterial cultures were incubated for 16 
hours at 37
 o
C while shaken vigorously.  After incubation, cells were harvested by 
pouring 1.5 mLs of the bacterial culture into Eppendorph tubes and centrifuging for 3 
minutes at 8000 rpm room temperature.  Supernatant was removed by tipping. 
Purification was then achieved following manufacturer’s instructions.  
 
2.2.11 Analytical digestion 
Purified plasmid DNA constructs for CSF-1, IL-34 and CSF-1R were added to 1 µl 
of the appropriate restriction enzyme, 1 µl of buffer and 4 µl of water to make  a total 
volume of 10 µl. PvuII was used to generate 4 restriction sites for pEF6_pCSF-1R 
and 5 restriction sites for pEF6_pIL34. ApaI was used to generate 3 restriction sites 
for pEF6_pCSF-1. 
 
2.2.12 Confirmation of correct DNA insert by sequencing 
Following analytical digestion, digestion mixtures were separated using gel 
electrophoresis to identify constructs with the correct DNA insert by identifying the 
correct digestion analysis.  Positive clones (600ng of plasmid DNA in 30 µl H20 
with 3.2 pmole of primer) were sent for DNA sequencing performed by DNA 
Sequencing & Services (MRCPPU, College of Life Sciences, University of Dundee, 
Scotland, www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry 
on an Applied Biosystems model 3730 automated capillary DNA sequencer. The 
sequencing results obtained were analysed using DNASTAR Lasergene MegAlign 
(DNASTAR, Madison, WI) and aligned to either the published sequences or the 
predicted sequence in the case of porcine CSF-1R.  The chromatogram files 
(Chromas Lite 2.01, Technelysium Pty, Ltd) were also analysed for the presence of 
any mis-called nucleotides or irregularities within the sequence.  For CSF-1R, further 
primers were designed based on the sequence results obtained thus far to sequence 
the full length inset since due to the inset size of 3 Kb, it could not be sequenced 
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fully with one set of primers.  Multiple species alignments were also performed to 
identify species variation in the sequences.  Constructs with the correct sequence 
were further purified using an endotoxin free plasmid purification kit (Maxi Prep, 
Qiagen). 
 
2.2.13 Bacterial expression of porcine CSF-1 
The generation of recombinant porcine CSF-1 was carried out by Dr Thomas Wilson 
of and colleagues at Pfizer Animal Health, USA.  The sequence corresponding to the 
active fragment of porcine CSF-1 (Ser36-Arg189) was codon optimized for 
expression in Escherichia coli and synthesized by Blue Heron Biotechnologies (WA, 
USA).  The sequence was engineered with a BspHI restriction site at the 5’ end and 
an EcoRI restriction site at the 3’ end and cloned into the expression plasmid pET-
28(b) using the complementary restriction sites NcoI and EcoRI.  The resulting 
plasmid, pTLW53, was transformed into MAX Efficiency® DH5α™ Chemically 
Competent E. coli according to the manufacturer’s protocol (Invitrogen, CA, USA).  
A kanamycin resistant transformant was selected and the plasmid sequenced to verify 
the error-free ORF.  The pTLW53 plasmid was isolated via QIAprep® spin miniprep 
kit (Qiagen, CA, USA) according to the manufacturer’s recommendations and 
transformed into One Shot® BL21 Star™ Chemically Competent E. coli (Invitrogen, 
CA, USA).   
An overnight TB/Kan
50 
broth of pTLW53/One Shot® BL21 Star™ E. coli incubating 
at 37ºC with 225 rpm shaking was refreshed 1:10 into 1L of TB/Kan
50 
broth into 
baffled, vented 2L flasks.  Protein expression was induced with 0.5mM IPTG, final 
concentration, with incubation conditions continued at 37ºC and 300 rpm shaking.  
After 2 hours induction, the culture was centrifuged and the E. coli pellet was stored 
at -80ºC.   
Frozen cell pellets from an E. coli cell culture were suspended in 5 volumes of lysis 
buffer (50 mM Tris pH 8.5, 5 mM EDTA) and lysis was completed by passing the 
suspension through a Microfluidizer.  Lysate was centrifuged and insoluble pellets 
were washed in 1% Trition X-100, and 5 mM EDTA.  Inclusion body pellets were 
suspended in  DEAE  buffer  (15 mM Tris pH8.5, 8M Urea, 10 mM DTT, 1 mM 
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EDTA), and mixed at room temperature for 60 minutes.  Following clarification, the 
soluble protein was loaded onto a DEAE Sepharose column and eluted with a 
gradient of 0-150 mM NaCl in a buffer containing 8M Urea.  Protein fractions 
containing pCSF-1 were pooled and diluted slowly into 2 parts redox buffer (50 mM 
Tris pH 8.5, 5 mM EDTA, 1 mM reduced glutathione, 1 mM oxidized glutathione).  
Protein was dialyzed against the redox buffer overnight and the dialysis buffer 
exchanged to contain 0.5 mM reduced glutathione and 1 mM oxidized glutathione.  
Refolded pCSF-1 dimer was loaded onto a Q Sepharose column equilibrated with 50 
mM Tris pH 8.5, 5 mM EDTA.  Protein was eluted with a 10 BV gradient of 0-250 
mM NaCl.  The pooled porcine CSF-1 was dialyzed against PBS and sterile filtered 
prior to use.   Protein concentration was calculated by UV absorbance at 280 nm.    
 
2.2.14 Generation of stable cell lines 
For generation of stable Ba/F3 cells expressing porcine or feline CSF-1R, 5x10
6
 
Ba/F3 cells were transfected by electroporation (300V, 975µF) with 10μg DNA 
(pEF6_pCSF-1R or empty pEF6 DNA), or no DNA, and selected with 30μg/ml 
blasticidin (Invitrogen) and 10% IL-3 for 6 days prior to further selection with 
30μg/ml blasticidin and 10
4 
units/ml of rh-CSF-1.  For the generation of stable 
pEF6_pCSF-1 and pEF6_pIL-34 HEK293T cells, 0.8x10
6
cells/well of a 6 well plate 
were plated with antibiotic-free DMEM for 24 hours, followed by transfection with 
4μg DNA (pEF6_pCSF-1, pEF6_pIL34 or empty pEF6 DNA), or no DNA, using 
Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions.  Selection 
of stable cells was achieved by the addition of 10μg/ml blasticidin (Invitrogen) after 
48 hours.  
 
2.2.15 Immunoblotting 
Whole cell lysate was prepared by lysing 0.5x10
6
 CSF-1R expressing cells  in 2% 
SDS 10mM Tris buffer and boiling for 10 minutes at 100
 o
C.  100μl of centrifuged 
supernatant from stably transfected HEK293T cell cultures of pEF6_pCSF-1, and 
empty pEF6 was also prepared.  Protein concentration was determined using DC 
protein assay (Bio-Rad, Hercules, CA, USA) with 10µg of protein mixed with 
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Laemmli buffer (Invitrogen) and 5mM DTT.  Samples were run on a 4-12% gradient 
precast SDS-PAGE gel (Bio-Rad) and transferred onto polyvinylidene difluoride 
membrane, as per manufacturer’s directions (Bio-Rad).  The membrane was blocked 
with 5% skimmed milk powder in TBS-Tween 20 at 4
o
C overnight, prior to being 
washed and probed with 1:5000 dilution of mouse anti-v5 tag antibody (MCA1360G, 
AbD Serotec, Raleigh, NC, USA) and 1:5000 dilution of anti-mouse IgG HRP 
conjugated antibody (7076, Cell Signalling Technology, Beverly, USA,) and 
detected using enhanced chemiluminescence (ECL) reagents (Amersham, GE 
Healthcare, UK).  β-Actin (Santa Cruz Biotechnology INC, sc-4778) was used at 
1:200 dilution as a loading control. 
 
2.3 Primary cell harvest and culture conditions 
2.3.1 Porcine bone marrow harvest and culture 
Pig bone marrow cells were obtained by flushing the bone marrow from five caudal 
ribs with 20mls of complete RPMI with 5mM EDTA using a bone marrow 
biopsy/aspirate needle (Cardinal Health, USA).  For each condition, 10 x10
6
 cells 
were pelleted and re-suspended in 4mls of complete RPMI containing supernatant 
from empty pEF6 or pEF6_pCSF-1 transfected HEK293T cells (100%, 80%, 50% 
and 20%).  Cells were plated into 60mm bacteriological plates and incubated for 10 
days at 37
 o
C with 5% CO2.   
 
2.3.2 Canine bone marrow harvest and culture 
Canine bone marrow was collected post-mortem with the owner’s consent from a 3-
year-old male entire Staffordshire Bull Terrier dog which was euthanized for 
behavioural reasons.  Bone marrow was flushed from the left femur with 20mls of 
RPMI and 5mM EDTA using a bone marrow biopsy/aspirate needle (Cardinal 
Health, USA).   10x10
6
 cells were cultured in 60mm bacteriological plates with 4mls 
RPMI, supplemented with either 10
4
 Units/ml rh-CSF-1, or 300ng/ml porcine CSF-1 
and incubated for 12 days at 37
 o
C with 5% CO2. 
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2.3.3 Feline bone marrow aspirate harvest and culture 
With the owner’s consent, 0.5ml of surplus feline bone marrow from clinical 
diagnostic investigation of a 2 year old, neutered male, DSH cat was obtained from a 
bone marrow aspirate of the left humerus using a bone marrow biopsy/aspirate 
needle (Cardinal Health, USA) and placed in EDTA.  10x10
6
 cells were cultured in 
60mm bacteriological plates with 4mls RPMI, supplemented with either 10
4
 Units/ml 
rh-CSF-1, or 300ng/ml porcine CSF-1 and incubated for 12 days at 37
 o
C with 5% 
CO2. 
 
2.3.4 Feline bone marrow femur flushing cell harvest and 
culture 
A 6-year-old male neutered domestic short-haired cat was euthanized by 
pentobarbitone for medical reasons and owner’s consent obtained to collect 20mls of 
blood and one femur.  The femur was dissected, placed in a zip-lock bag and placed 
on ice.  Both the proximal and distal ends of the femur were removed and using an 
18g needle, cells were flushed with 10ml RPMI (Sigma) containing 5mM EDTA to 
prevent clotting.  Cells were washed and re-suspended in red cell lysis buffer (Bio 
Legend, San Diego, CA) for 5 minutes, followed by a further 2 washes in PBS.   
 
2.3.5 Feline PBMC collection and isolation 
From the same cat as detailed above, 20mls of blood was collected into a syringe 
containing Acid-citrate-dextrose at 1:10 dilution and placed on ice following 
collection.  Feline PBMC were isolated using Lymphoprep (Axis-Shield, Oslo, 
Norway) following manufacturer’s instructions, including the addition of red cell 
lysis buffer as above.   
 
2.3.6  Feline peripheral PBMC and BMC stimulation with 
recombinant human CSF-1 
Ten million PBMC and BMC were cultured in 60mm bacteriological plates with 
4mls RPMI supplemented with 10
4
 Units/ml rhCSF-1, and incubated for 8 days at 37
 
o
C, 5% CO2. 
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2.3.7 Mouse bone marrow harvest and culture 
Mouse bone marrow cells were flushed from the femurs of an 8-week-old male 
BALB/c mouse with 10mls complete RPMI and a 27g needle, and plated in 100mm 
bacteriological plates with complete RPMI supplemented with 10
4
 Units/ml rh-CSF-
1 for 5 days at 37
 o
C with 5% CO2.  Kindly performed by Valerie Garceau of the 
Hume Lab.  
 
2.4 Preparation of cells for cytospin 
After 8 days in culture, adherent cells from both blood and BMC cultures were 
recovered by repeated flushing of medium over the bottom of the culture dish until 
all adherent cells were removed.  Cells were counted and 0.5x10
6
 cell/ml were 
collected with 100µl of cell suspension, placed into the cytospin chamber (Thermo) 
and centrifuged at 300rpm for 3 minutes.  Slides were air-dried and fixed in 100% 
methanol for 5 minutes prior to staining with Leishman’s stain (Sigma L6254) for the 
identification of macrophage nuclei.  Cytospins were examined under x20 
magnification for cellular morphology.  
 
2.5 Phagocytosis assay 
Following the harvest of day 8 adherent cells from both blood and BMC cultures (as 
above), 1x10
6
 cells/ml were plated/well of a 6-well plate in duplicate and cultured 
overnight at 37
o
C, 5% CO2.  Phagocytosis was initiated by the addition of FITC 
conjugated Zymosan bio-particles (Molecular Probes) at a particle:cell ratio of 10:1, 
followed by further incubation for 1 hour.  Phagocytosis was stopped by the addition 
of 500µl/well of ice-cold PBS, followed by 2 PBS washes.  Cells were analysed for 
Zymosan particle uptake using fluorescence microscopy (Zeiss LSM710). 
 
2.6 Cell viability assays (optimized) 
Stable Ba/F3 cells expressing porcine CSF-1R were maintained in culture with 
complete RPMI supplemented with 10
4
 Units/ml rh-CSF-1 prior to MTT assay. 
2x10
4 
cells/well (Ba/F3 cells and Ba/F3 transfectants), or 5x10
4 
cells/well (mouse 
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BMM) of a 96 well plate were plated in triplicate or quadruplicate and appropriate 
treatment (serial dilutions of rh-CSF-1, rm-CSF-1 (R&D systems 416-ml) rhIL-34 
(R&D Systems 5265), or rmIL-34 (R&D Systems 5195), or supernatant from 
pEF6_pCSF-1or pEF6_pIL-34 were added to make a total volume of 100μl per well.  
Cells were incubated for 48 hours at 37
o
C with 5% CO2.  For Ba/F3 cells, 10μl of 
MTT (Sigma Aldrich M5655) stock solution (5mg/ml) was added directly to each 
well to achieve a final concentration of 0.5mg/ml and incubated at 37
o
C for 3 hours 
prior to solubilisation overnight.  For adherent mouse BMM cells, the culture 
medium was replaced with 50µl of 1mg/ml MTT solution and incubated for 1 hour at  
37
o
C.  The MTT solution was removed and tetrazolium salt solubilised with 100μl of 
solubilisation agent (0.1M HCL, 10% Triton x -100 and isopropanol) followed by 
incubation at 37
o
C with 5% CO2 for 10 minutes.  Plates were read at 570nm with 
reference wavelength of 405nm.   
 
2.7 EC50 calculation 
The EC50 for rh-CSF-1 and bacterially produced porcine CSF-1 in the Ba/F3pCSF-
1R MTT cell viability assay were calculated from dose responses performed in 
triplicate or quadruplicate.  Data was analysed using GraphPad Prism software using 
nonlinear regression curve fit.  The R
2
 (coefficient of determination) values for all 
curve fits were >0.90. 
 
2.8 3D modelling of contact amino acids 
3D models in PDB format were generated with 3D-Jigsaw
7
 using structure-based 
alignments (performed by Domain Fishing) (Contreras-Moreira and Bates, 2002) 
(cancerresearchuk.org/3djigsaw). 3D models of human IL-34-CSF-1R (PDB 4DKD), 
mouse IL-34-CSF-1R (PDB 4EXP), and mouse CSF-1 (PDB 3EJJ) were obtained 
and viewed in FirstGlance in Jmol
8
.  Human and pig CSF-1 were generated using 
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3D-Jigsaw with the mouse CSF-1 structure as template (3EJJ) and pig CSF-1R was 
generated using human CSF-1R as template (4DKD chain X). Contact amino acids 
between IL-34, CSF-1 and CSF-1R were identified using recently published data 
(Chen et al., 2008; Liu et al., 2012; Ma et al., 2012b).  The non-conserved contact 
amino acids of human and mouse IL-34, CSF-1 and CSF-1R were highlighted.  The 
3D model of feline CSF-1R was generated using 3D-Jigsaw with the mouse CSF-1R 
structure as template (3EJJ).  Non-conserved contact amino acids for IL-34 and CSF-
1 binding of the CSF-1R were identified using recently-published data (Chen et al., 
2008; Liu et al., 2012; Ma et al., 2012b) and highlighted.   
 
2.9 Generation of porcine Fc CSF-1  
2.9.1 Cloning and expression  
Performed and produced by Pfizer Animal Health, USA.  The sequence 
corresponding to the active fragment of porcine CSF-1 (SENCSHMIGDGHLKVLQ 
QLIDSQMETSCQIAFEFVDQEQLTDPVCYLKKAFLQVQDILDETMRFRDNTP
NANVIVQLQELSLRLNSCFTKDYEEQDKACVRTFYETPLQLLEKIKNVFNET
KNLLKKDWNIFSKNCNNSFAKCSSQHERQPEGR) was linked to the hinge-CH3 




FLYSKLAVDKARWDHGETFECAVMHEALHNHYTQKSISKTQGK).  This 
entire region was codon optimized for mammalian expression by GeneArt 
(Invitrogen, CA, USA) and cloned into the expression plasmid pS00524 using 
HindIII and NotI restriction sites engineered into the 5’ and 3’ ends respectively. The 
resulting plasmid was sequenced to ensure ORF integrity and protein was expressed 
from transfected HEK293F or CHO cells.   
 
2.9.2 Isolation of pig Fc CSF-1 fusion protein  
Porcine CSF-1 FC fusion protein was isolated using Protein A affinity 
chromatography.  Briefly, conditioned medium from cell culture was clarified and 
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loaded onto Protein A Sepharose that was equilibrated with PBS.  Following loading 
the column was washed with 2 BV of PBS and 2 BV of 35 mM Na Acetate pH 5.5.  
Protein was eluted using a step gradient of 80% B Buffer (35 mM Acetic acid, no pH 
adjustment), 85% B buffer and 100% B buffer.  The 80 and 85% B fractions were 
pooled based on lack of aggregated protein (analytical SEC) and the 100% B fraction 
was not included.  Pooled protein was pH adjusted to 7.2 and dialyzed against PBS.   
 
2.9.3 Porcine CSF-1 Fc-fusion quantitation in blood plasma 
by ELISA  
Porcine CSF-1 Fc-fusion plasma levels were detected using an in-house developed 
conventional sandwich ELISA utilizing commercially available antibodies.  Capture 
antibody was Abcam ab9693 (0.3 µg/mL) and detection antibody was Rabbit anti-pig 
IgG (Fc) biotinylated Alpha Diagnostic 90440 (1:5000 dilution).  Standard protein 
was generated and purified in-house (lot 2/24/11 JAS).  Standards were added to 
each plate along with the samples resulting in an 11 point standard range of 2700 
ng/mL to 0.046 pg/mL. This allowed for quantitation of each sample to a standard 
curve on every assay plate.  Assay detection was done using Pierce High Sensitivity 
Streptavidin-HRP (1:10,000 dilution) and TMB Microwell Peroxidase Substrate 
System solution (KPL). 
 
2.9.4 Pig pharmacokinetic studies (PK)  
Pharmacokinetic studies all performed by Pfizer Animal Health, USA.  All 
procedures performed on these animals were in accordance with national regulations 
and established guidelines and were reviewed and approved by the Institutional 
Animal Care and Use Committee or Ethical Review Panel (Pfizer).  Weaner age 
barrows (<14kg) were assigned to three treatment groups receiving a single 
intravenous (IV) or subcutaneous (SC) dose as follows.  Three pigs received 0.5 
mg/kg CSF-1 non-fusion dosed SC.  Two pigs received 1.2mg/kg CSF-1:Fc fusion 
dosed IV.  Two pigs received 1.2mg/kg CSF-1:Fc dosed SC.  One ml plasma 
samples were obtained via the jugular vein in EDTA anticoagulant tubes and placed 
on ice until centrifuged.  The plasma was transferred to sterile tubes stored at -10°C 
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until analysis.  Serial plasma samples were obtained from each animal at pre-dose 
and 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8, hours, 24 hours, 48 
hours, and 72 hours post-dose. CSF-1 and CSF-1:Fc fusion protein levels were 
quantitated in plasma using ELISA assays.  
 
2.10 In-vivo methods – chapters 5 and 6 
2.10.1 Experimental design - mice 
Csf1r-EGFP
+
 (MacGreen) and Csf1r-EGFP
- 
wild-type mice were bred, genotyped 
and obtained from The Roslin Institute Biological Research Facility.  C57BL/6 mice 
were purchased from Charles River Laboratories (UK), a SPF facility.  These mice 
were isolated for seven days prior to entering The Roslin Institute Biological 
Research Facility.  Littermate male and female mice were caged separately in a 
specific pathogen free facility. All mice received normal chow and autoclaved water 
and were maintained in accordance with UK Home Office guidelines for the care and 
use of laboratory animals.   Approval for the experiment was obtained from The 
Roslin Institute’s and The University of Edinburgh’s Protocols and Ethics 
Committees. The experiment was carried out under the authority of a UK Home 
Office Project Licence (604259, protocol 5), under the regulations of the Animals 
(scientific procedures) Act 1986. 
 
Experiment 1 
12x male and 12x female 6-10 week Csf1r-EGFP
+
 (MacGreen) mice. Treatment 
groups consisted of PBS, 1ug/g porcine CSF-1 or 1ug/g porcine Fc-CSF-1, each with 
4 male and 4 female mice in each group. 
Experiment 2 (dose titration) 
11x male and 9x female 6-10 week Csf1r-EGFP- wild-type (MacGreen) mice. 
Treatment groups consisted of PBS, 1ug/g, 0.5ug/g, 0.1ug/g or 0.05ug/g of porcine 
Fc-CSF-1 (n=4).  




12x male and 12x female C57BL/6 mice, treated with either PBS (n=6) or 1ug/g 
porcine Fc-CSF-1(n=6). 
For all experiments, mice were injected subcutaneously once daily performed in the 
morning so mice could respond to CSF-1 at time of lowest concentration of 
glucocorticoid which may desensitize CSF-1 (Hume et al., 1988).  The injection was 
performed by the same person and mice received total volume of 100 µl/mouse of 
either PBS, or the appropriate treatment dose.  Mice were weighed every day prior to 
injection and before cull with the weight recorded.  24 hours after the last (4
th
) 
injection, mice were sedated with ketamine and humanely culled using CO2 
intoxication (UK Home Office Schedule One method).  One mouse from each 
treatment group was tissue perfused with 4% PFA (experiments 1).  Briefly, 4% PFA 
was prepared fresh the morning of cull.  Mice were sedated with ketamine and the 
thoracic cavity opened to expose heart and ascending aorta.  A 20g half inch needle 
connected via tubing to a 20 ml syringe containing 4% PFA was inserted through the 
left ventricle into the ascending aorta. Mice were slowly perfused with 20 ml of 4% 
PFA until the forelimbs were fully extended and the tail was stiff.  
 
2.10.2 Experimental design - piglets 
Approval for the experiment was obtained from The Roslin Institute’s and The 
University of Edinburgh’s Protocols and Ethics Committees. The experiment was 
carried out under the authority of a UK Home Office Project Licence (604259, 
protocol 5), under the regulations of the Animals (scientific procedures) Act 1986. 
Two 8 month old Large White x Landrace healthy sows were serviced naturally and 
pregnancy confirmed by palpation.  Two litters of piglets were produced by natural 
delivery and used for the experiments.  The sows farrowed in isolation inside a 
farrowing pen (Temp 18-20
o
C) with straw bedding and free access to water and food 
at all times.  The piglets had access to a heat lamp set at 30
o
C.  Additional creep feed 
was offered from day 11 in both litters.  To limit the stress on the sows and piglets, 
no visualization or contact with other pigs was allowed.  Sow number 1 produced 17 
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piglets, 5 of which were culled due to low birth weights and concern that the sow 
would be unable to successfully nurse all piglets.  Sow number 2 produced 13 
piglets.  24 hours after birth, one piglet from sow 2 developed diarrhoea, was placed 
on oral antibiotics and subsequently removed from any further analysis.  Twenty-
four hours after birth, 1 ml of blood was collected into EDTA tubes; piglets were 
weighed, sexed and divided into matched treatment and control groups. Piglets were 
injected subcutaneously with the appropriate volume of porcine Fc-CSF-1 or PBS 
according to the experimental design (see below).  Each injection was performed in 
the morning by the same person.   
 
Piglets from sow 1 (low-dose) 
A total of 11 piglets were dosed with either PBS (n=5) or 0.12mg/kg porcine Fc 
CSF-1 (n=6) subcutaneously every other day for a total of 3 treatments. Piglets were 
weighed every 2-3 days until sacrifice (Day 20).  The dose of Fc CSF-1 was 
calculated based on piglet weight day 1.  
 
Piglets from sow 2 (high-dose) 
A total of 12 piglets were dosed with either PBS (n=5) or 0.5mg/kg porcine Fc-CSF-
1(n=7) subcutaneously every other day for total of 6 treatments. Piglets were 
weighed every 2-3 days until sacrifice (Day 24).  The dose of Fc CSF-1 was adjusted 
on injection day according to body weight. Piglets were monitored for any adverse 
effects before each injection (body temp, presence of lymphadenopathy, demeanour, 
and excessive weight gain or loss).  
All piglets were sedated with ketamine (6mg/kg) and azaperone (1mg/kg), and were 
left alone quietly before being euthanized by a captive bolt humane killer described 
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2.10.3 Blood collection 
In the mice experiments, blood was collected by cardiac puncture using a 26g needle 
and 1 ml syringe into a 1 ml Lithium heparin tube as soon as possible to prevent 
blood clotting.  For the pig studies, blood was collected by intra-cardiac puncture 
into a blood collection bag containing Acid Citrate Dextrose (ACD) buffer (Sarstedt, 
Germany).   
 
2.10.4 Complete blood count analysis  
A 1 mL aliquot of blood collected into the blood collection bag (pigs) was collected 
for assessment of the complete blood cell count.  The entire blood fraction harvested 
from mice was sent for analysis.  Total WBC, RBC, PCV were all measured on the 
ABX Pentra 60 haematology analyser performed by the R(D)SVS Clinical Pathology 
Laboratory (Yvonne Crawford). WBC differential counts were performed by making 
a blood smear and counterstaining with Giema stain prior to 100 cells counted.  The 
absolute value for each white blood cell type was determined by using the total WBC 
and % of each leukocyte type.  
To prepare mouse whole blood for FACS, blood was centrifuged at 400g for 5 
minutes followed by aspiration of the supernatant.  2mls of room temperature RBC 
lysis buffer (Bio Legend) was added to the cell pellet, mixed and incubated for 3-5 
minutes whilst protecting from light.  The reaction was stopped by adding 10 mLs 
PBS and spun again at 400g for 5 minutes. The supernatant was removed and the 
pellet re-suspend in PBS for counting prior to FACS analysis.  Any remaining cells 
were cryopreserved following pelleting the cells and re-suspending in a drop wise 
fashion of 80% FCS and 20% DMSO.  1 mL of cells were placed in cryo-vials and 
frozen in isopropanol freezing units (Mr Frosty) at -80
o





2.10.5 Isolation of peripheral blood mononuclear cells 
(PBMC) from piglets 
Blood was collected by intra-cardiac puncture into a blood collection bag containing 
Acid Citrate Dextrose (ACD) buffer (Sarstedt, Germany).  Whole blood was poured 
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into 2, 50ml falcon tubes and centrifuged for 1200g for 20 minutes with no brake. 
Following centrifugation, the buffy coat was removed and mixed with an equal 
volume of complete RPMI. 20 mLs of the diluted buffy coat was then layered into 10 
mLs of Lymphoprep (Axis-Shield, Norway) and centrifuged for a further 25 minutes 
at 1200g with no brake.  After centrifugation, PBMCs were seen as a distinct band 
which was removed and washed twice with complete RPMI with centrifugation of 
400g for 5 minutes each time.  5 mLs of red cell lysis buffer (Bio legend) was added 
to the PBMC pellet for 5 minutes and washed with a further centrifugation as above.  




 free) prior to 
counting for FACS analysis. 
 
2.10.6 Isolation of bone marrow cells (BMC) 
Piglets 
Pig bone marrow cells were obtained by flushing the bone marrow from five caudal 
ribs with 20mls of complete RPMI with 5mM EDTA using a bone marrow 
biopsy/aspirate needle (Cardinal Health, USA).  Cells were washed in RPMI then 5 
mLs of red cell lysis buffer (Bio legend) was added to the PBMC pellet for 5 minutes 
and washed with a further centrifugation as above.  The final pellet was re-suspended 




 free) prior to counting for FACS analysis.  
 
Mice 
Bones were stripped carefully of any tissue/muscle to avoid contamination of cells 
and placed in 70% ethanol for 1 minute prior to being dipped in PBS for 1 minute 
and dried with a Kim-tech tissue. The proximal and distal ends of the femur were cut 
and a 26g half inch needle attached to a 2 ml syringe containing warm RPMI was 
inserted. Cells were flushed into a 15 ml flacon tube.  Bones were flushed twice with 
fresh RPMI for each flush.  Cells were re-suspended prior to centrifugation at 400g 
for 5 minutes and counted.  
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2.10.7 Isolation of porcine alveolar macrophages (AM) 
from piglets 
Alveolar macrophages were harvested by Dr Ronan Kapetanovic, Roslin Institute, 
using lung lavage technique. The thoracic cavity was opened using a sterile scalpel to 
visualise the lungs and the trachea.  The trachea was clamped using artery forceps to 
stop blood entering the lungs prior to the removal of the lungs.  After the lungs were 
weighed, they were filled with approximately 500 ml PBS, massaged for 20 seconds 
and emptied, repeated twice whilst within a class 2 biological containment hood.  
The lavage fluid was collected, and centrifuged for 5 minutes at 400g. The pellet was 
re-suspended in PBS prior to counting for FACS analysis.  
 
2.10.8 Spleen single cells suspension (mice) 
Dissected sections of spleen were mechanically disaggregated by mincing the tissue 
with a scalpel blade prior to digestion in 0.1U/ml Collagenase and 0.8U/ml Dispase 
(Roche) in PBS/20% FCS for one hour at 37
 o
C.  Cells were then passed through a 
100 µm cell strainer (BD Falcon) and re-suspended in Hi-block as for blood and 
bone marrow for FACS analysis.  
 
2.10.9 Flow cytometry analysis 
Cells for FACS analysis were harvested as above and prepared at a concentration of 
5x 10
6
 cell/sample.  Cells were washed, pelleted and re-suspended in chilled Hi-
block (1x PBS, 0.1% NaN3, 2% heat inactivated FCS, 0.1% BSA) with 2% heat 
inactivated normal mouse serum (200 µl/sample), followed by 200 µl sample placed 
into a well of 96 well plate (V-bottom) and incubated on ice for 20 minutes.  The 
plate was centrifuged for 5 minutes at 400g followed by removal of the supernatant 
and 2x washes with 100 µl Lo-block (1x PBS, 0.1% NaN3, 0.2% heat inactivated 
FCS, 0.1% BSA). After the second wash, cells were re-suspended in a total volume 
of 100 µl of Lo-block containing the appropriate antibody or isotype control 
(appendix).  Samples were incubated at 4
o
C in the dark for 30 minutes before 
washing a further 3 times with Lo-block.  Cells were re-suspended in 400 µl of Lo-
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block with 0.1% Sytox Blue (Invitrogen) for FACS analysis using the CyAn (Dako).  
Analysis was performed using Summit 4.1 software (Dako).  
 
2.10.10 Analysis of MHC II expression by flow cytometry 
Following isolation of pig BMC (as above), 1x10
6 
cell/mL were cultured for 16 hours 
per well of a 6 well plate with 1000ng/mL porcine Fc CSF1-, 1000ng/mL porcine 
CSF-1 or 1000ng/mL rh-CSF-1.  Cells were harvested and prepared for flow 
cytometry using anti-human MHCII antibody (VMRD H42A). 
 
2.10.11 Tissue processing 
Pigs 
Tissues harvested included lung, spleen, liver, kidney, duodenum, pre-scapular 
lymph node, and biceps femoris.  Tissues were dissected and placed in 10% neutral 
buffered formalin or RNALater.  For tissue histology, tissues were processed 
overnight using Excelsior tissue processor (Thermo Fisher Scientific) through a 
series of increasing ethanol baths (70,90,100%) to displace the water, a series of 
xylene washes to clear the alcohol and then infiltrated with wax.  Sections were then 
placed in moulds, embedded in paraffin wax 4µm sections cut and mounted onto 
slides (Superforst Plus, Thermo Fisher Scientific).  Slides were dried overnight at 37
 
o
C before a final drying at 60
o
C for 25 minutes (performed by R(D)SVS clinical 
pathology department). Sections were stained with H&E using an automatic 
processor or immunohistochemistry performed.  
 
Tissue processing – perfused mice 
Tissues collected included, spleen, liver, lung, small intestine, ear, injection site skin 
and placed into 4% PFA for 2 hours followed by overnight incubation in 18% 
sucrose at 4
o
C.  The following day, tissues were embedded in Tissue-Tek OCT 
compound and frozen in isopentane.  Frozen sections were cut (8-12um thick) at -
16
o
C using LEICA cryostat and mounted with DAKO fluorescent mounting medium 
(DAKO).  The fluorescence of the EGFP was visualised using Zeiss confocal and 
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pictures taken under oil at x400 magnification.  Additional tiled images composed of 
9 images as above were also generated.  The total fluorescence was analysed using 
Image J. 
 
Tissue processing – Non-perfused mice 
Organs were removed and weighed (spleen, liver, lung, and kidney). Tissue samples 
collected included; spleen, liver, lung, small intestine, ear, injection site skin, ovary, 
uterus, kidney.  The right femur was removed and with as much of the muscle and 
tissue removed prior to being placed in 10 ml of PBS for bone marrow cell harvest. 
The left femur after thorough muscle and tissue stripping was placed in formalin at 
room temperature overnight followed by transfer into 70% ethanol the following day.  
Tissue sections were cut and placed in appropriate amount of formalin, and RNA 
later. RNA later preserved tissues were placed at -80
o
C for long term storage.  
 
2.10.12 Immunohistochemistry 
IGF-1 Immunohistochemistry  
Antigen retrieval was achieved using 0.01M Citric acid (pH6.0) at 110
 o
C for 15 
minutes. Endogenous peroxidase activity was blocked using REAL peroxidase 
blocking solution (Dako S2023)  for 10 minutes at room temperature.  The primary 
antibody was goat anti IGF-1 (Sigma, SAB20501424) diluted 1/50 in TBST pH 7.4, 
incubated for 1 hour at room temperature. The secondary antibody was rabbit anti 
goat HRP (Dako P0049) diluted 1/100 incubated for 30 minutes at room temperature.  
Antigen detection was performed using DAB
+
 (Dako K4007) for 10 minutes at room 
temperature. Slides were counterstained using Harris haematoxylin. 
 
F4/80 Immunohistochemistry 
Antigen retrieval was carried out in Proteinase K (Dako S302030) for 10 minutes at 
25
o
C. Non-specific protein binding was blocked using 2.5% normal goat serum for 
20 minutes at room temperature (Vector Laboratories). Endogenous peroxidase 
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activity was blocked using Dako REAL peroxidase blocker (Dako REAL blocking 
agent S202386) for 10 minutes following antibody incubations. Sections were 
incubated at room temperature for 30 minutes using rat anti-F4/80 (Serotec 
MCA497G) diluted 1/400 in TBST.  Negative controls were carried out using rat IgG 
at the same concentration as the primary antibody. Visualisation was carried out 
using the secondary reagent Immpress anti rat HRP ( Vector Labs MP-7444-15) for 
15 minutes at room temperature followed by DAB (Newmarket Scientific Monosan 
Dab substrate kit   Cat No. MON-APP177) for 10 minutes and DAB enhancer for 3 
minutes (Newmarket Scientific DAB concentrate Cat No.CO7-25). 
 
PCNA Immunohistochemistry  
Immunohistochemistry for Proliferating Cell Nuclear Antigen (PCNA) was 
performed on 4 µm liver sections prepared as above on poly-L-lysine coated slides.  
Liver sections were antigen retrieved in boiling 10 mmol/L sodium citrate buffer 
followed by blocking for endogenous peroxidase activity with 3% H2O2 in methanol 
for 10 minutes. Immunohistochemistry was performed using PCNA staining kit 
(Invitrogen, 93-1143) as per manufacturer’s instructions.  
 
2.10.13  ELISA 
IGF-1 ELISA 
IGF-1 ELISA was performed by Dr Susan Alexander-Bowman of Pfizer Animal 
Health, Kalamazoo, USA, using a commercially available ELISA kit (IGF-1 ELISA 
AC-271 from Immuno Diagnostic Systems, USA) following manufacturer’s 
instructions.  Data was then transferred to Deborah Gow for analysis.  
  
TNFα and IL-1β ELISA 
Porcine bone marrow cells were recovered from cryopreservation and cultured for 7 
days with 1000ng/mL rh-CSF-1.  After 7 days in culture, cells were harvested and 
washed twice in PBS before plating at 1 x10
6
 cell/mL/well of a 24 well plate in 500 
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µl total volume.  Cells were cultured with either 1000ng/mL porcine CSF-1, porcine 
Fc CSF-1, human CSF-1 or RPMI only.  Supernatant was harvested at time points 0, 
1, 2,6,12, and 24 hours for assessment of cytokines in the supernatant following 
manufacturer’s directions from commercially available ELISA kits (porcine TNF α 
and IL-1 β DuoSet, R&D Systems).  Cells were also treated with LPS from 
Salmonella enterica serotype Minnesota Re 595 (L9764, Sigma Aldrich ) at 
100ng/mL as a positive control for each time point.  Cells were plated in duplicate. 
 
2.10.14  Analysis of bone density using bone imaging 
Mice: Micro-computed tomography (Micro-CT) 
Mouse femurs were scanned using a micro-computed tomography system by Dr Rob 
Van’t Hof of the Centre for Molecular Medicine, The University of Edinburgh, to 
evaluate trabecular architecture.   The left femur was collected into 10 mLs of PBS 
followed by thorough muscle and tissue stripping.  The femur was placed in formalin 
at room temperature overnight followed by transfer into 70% ethanol the following 
day.  MicroCT analysis was performed at the left distal femoral using a Skyscan 
1172 instrument set (Kontlich, Belgium) at 60 kV, and 150 μA at a resolution of 5 
μm. The images were reconstructed using the Skyscan NRecon program and 
analyzed using Skyscan CTAn software.  A volume of 200 slices was measured 100 
µm proximal to the primary spongiosa.  The following parameters were analysed 
using CTAn software (Skyscan, Belgium): in trabecular bone, percent bone volume 
(% BV/TV), trabecular number (Tb.N; /mm), bone mineral density (BMD; g/cm3), 
trabecular thickness (Tb.Th; mm), trabecular separation (Tb.Sp) and structure model 
index (SMI) were evaluated. 
 
Pigs:  Computerized Tomography (CT) bone  
The right femur from each piglet was removed intact post-mortem and stored in 10% 
normal saline for 16 hours prior to long-term storage in 70% ethanol.  Bones were 
scanned individually using a spiral scan sequence of 1.5mm thickness using a 
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Siemens Somatom Esprit single slice CT scanner by Kirsty McLean of SRCU.  
Images were analysed using STAR image analysis software.  Results were graphed 
using GraphPad Prism 5.0 (GraphPad Software Inc, San Diego, CA). 
 
2.10.15  Bone histology 
Following micro-CT scan, mouse femurs were decalcified using 14% EDTA (pH7) 
for 3 days at room temperature, dehydrated and embedded in wax for cutting of 
sections.  TRAP
+
 cells were identified using an Acid Phosphatse kit (Sigma-Aldrich 
387) according to manufacturer’s instructions.  Briefly, de-waxed bone sections were 
fixed in 25% Citrate, 65% acetone and 8% formaldehyde for 30 seconds followed by 
2 minutes wash in de-ionised water.  Sections were then incubated for 2 hours at 
37
o
C and protected from light in the staining solution (de-ionised water, Fast Garnet, 
Naphthol Phosphate solution, Acetete and Tartrate).  Sections were washed in de-
ionised water for 3 minutes, air dried and examined for the presence of TRAP
+
 
osteoclasts using Nikon E600.  Pictures were obtained at x100 and x200 
magnification.  The numbers of osteoclasts in the diaphysis, zone of hypertrophy and 
epiphysis were counted. 
 
2.10.16  Statistical analysis 
Data on body weight changes, complete blood counts, organ weights, CSF-1, Fc 
CSF-1 and IGF-1 ELISA were analysed using a Mann-Whitney test or Kruskal-
Wallis test with Dunn’s multiple comparison test.  Results are presented as either 
individual value with the mean + standard error of the mean (SEM) or group mean + 
SEM.  All analyses were performed using GraphPad Prism 5.0 (GraphPad Software 
Inc, San Diego, CA).  A P value < 0.05 was considered statistically significant.  
 
2.10.17  Microarray 
RNA was extracted from mouse liver using RNA Bee as per manufacturer’s 
instructions.  RNA integrity and quality was assessed using Following the RNA 6000 
LabChip Kit (Agilent).  Samples with a RNA integrity number (RIN) greater than 7 
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was used for microarray.  Microarray was performed by ARK Genomics, The Roslin 
Institute.  50ng Total RNA was amplified using the Nugen Pico SL kit, 2.5ug of the 
resulting cDNA was biotin labelled using the Nugen Encore labelling kit using the 
half volume protocol.  The biotin labelled product was prepared for hybridisation 
according to the Nugen protocol for Affymetrix Gene Titan hybridisation, using the 
Affymetrix  Gene Titan Hybridization Wash & Stain Kit for WT Array Plates (PN 
901622).  The samples were hybridized to Affymetrix Mouse Gene 1.1 ST Array 
plates using the appropriate Hyb-Wash-Scan protocol for this plate and the Gene 
Titan Hyb Wash Stain kit for the reagents (Affymetrix).  Image generation and the 
resulting CEL files for analysis were produced in Affymetrix® GeneChip® 
Command Console® Software (AGCC) version 3.0.1. Initial QCs were performed in 
Expression Console. The obtained AffymetrixCEL files were imported into the 
Genomics Suite software package version 6.13.0213 (Partek software. Copyright, 
©2012. Partek Inc.) 
Expression data from the liver +/- Fc CSF-1 study was analysed alongside that of 
bone marrow derived macrophage (BMDM) data generated from the same strain of 
mice (C57BL/6) (see BMDM method below).  A network analysis of the normalized 
expression data was performed using BioLayout Express
3D
 (Freeman et al., 2007), 
performed by Dr Sobia Raza.  Using this tool, a Pearson correlation matrix of a 
transcript-to-transcript profile comparison was used to filter for expression 
correlation relationships of r > 0.96 across the microarray samples. Nodes within the 
network graph represent transcripts and the edges between them represent expression 
correlations above the set threshold (r >0.96 in this case). To identify groups of 
tightly co-expressed genes, the graph was clustered using the graph-based clustering 
algorithm MCL (van Dongen and Abreu-Goodger, 2012) set at an inflation value 
(which determines the granularity of the clusters) of 1.8.  Gene  lists associated with 
the clusters were exported for GO annotation analysis (Biological and Metabolic 
Processes Level-FAT) using the DAVID (Database for Annotation, Visualization 
and Integrated Discovery) tool. 
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BMDM production for microarray 
Bone marrow macrophage microarray data used for comparison with the response to 
CSF-1 in liver was produced by Dr Sobia Raza, The Roslin Institute.  Bone marrow 
derived macrophages (BMDM) were prepared from femurs of 7-8 week old male 
C57BL/6J mice (Charles River, UK).  Complete culture media was composed of 
RPMI 1640 medium (Sigma-Aldrich, Gillingham, UK) supplemented with 10% heat 
inactivated fetal bovine serum (FBS) (Sigma-Aldrich), 25 U/ml penicillin 
(Invitrogen, Paisley, UK), 25 μg/ml streptomycin (Invitrogen), and 2 mM L-
glutamine (Invitrogen).  Briefly, bone marrow cells were cultured for 6 days in 
complete medium in the presence of 10,000 U/ml CSF-1 on 10 cm
2
 bacteriological 
plastic plates, with a re-supplement of CSF-1 on day 5.  On day 6 cells were 
harvested, counted, re-suspended in complete medium with 10,000 U/ml CSF1 and 
seeded into 24-well tissue culture plates at a density of 200,000 cells/well.  24 h later, 
(day seven) C57BL/6 derived macrophages were treated with 50ng/ml LPS at 
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Chapter 3: Cloning of porcine Colony 
Stimulating Factor-1 (CSF-1), Colony 
Stimulating Factor -1 Receptor (CSF-1R) and 
Interleukin 34 (IL-34)  
 
3.1  Introduction 
As discussed in detail in the introduction (Chapter 1), the growth factor Macrophage 
Colony-Stimulating Factor (CSF-1) is required for the proliferation, differentiation 
and survival of cells of the mononuclear phagocyte lineage (Chitu and Stanley, 2006; 
Pollard, 2009; Sweet and Hume, 2003).  CSF-1 signals through a protein tyrosine 
kinase receptor, CSF-1R, which in adults is restricted in its expression to myeloid 
cells (Bonifer and Hume, 2008).  The three-dimensional structure of the CSF-1/CSF-
1R complex has been reported (Chen et al., 2008).  
Mice and rats with a homozygous mutation in their CSF-1 gene are deficient in 
biologically active CSF-1 (op/op mice and tl/tl rats) and are born with congenital 
osteopetrosis, reduced tissue macrophage populations and multiple developmental 
abnormalities (Chitu and Stanley, 2006; Gow et al., 2010; Pollard, 2009).  
Expression of full-length CSF-1 transgene or cell surface CSF-1 can fully correct the 
op/op mice weight defects (Dai et al., 2004; Ryan et al., 2001).  These findings 
suggest that the regulated expression of the distinct CSF-1 isoforms is biologically 
significant (Gow et al., 2010).   
A second ligand for the CSF-1R, interleukin 34 (IL-34), has been identified in 
humans and mice (Lin et al., 2008), perhaps explaining the more penetrant phenotype 
of a Csf1r (-/-) mutation in mice compared to the op/op (Dai et al., 2002).  Recent 
solution of the crystal structure of human IL-34 confirmed the prediction (Garceau et 
al., 2010) that it belongs to the short four helical cytokine family that includes stem 
cell factor and Flt3L as well as CSF-1 (Lin et al., 2008; Liu et al., 2012).  The two 
ligands, one receptor relationship was found to be conserved in birds and a co-
evolution analysis indicated that the two ligands probably bind to distinct regions of 
the receptor (Garceau et al., 2010).  Solution of the crystal structure of IL-34 bound 
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to CSF-1R indicated that although both IL-34 and CSF-1 bind to the CSF-1R D2 and 
D3 domains, no single interaction with CSF-1R is shared between IL-34 and CSF-
1(Liu et al., 2012; Ma et al., 2012b).  In keeping with this view, antibodies have been 
produced which can block CSF-1, but not IL-34 binding to the receptor (Chihara et 
al., 2010).  Nandi et al. (2012) have reported non-overlapping distributions of the two 
ligands in developing brain, and implicated IL-34 in brain development.  IL-34 
deficiency in a knockout mouse appears to generate a specific deficiency in 
microglia and Langerhans cells (Wang et al., 2012 ). 
 
Antibodies against the CSF-1R developed for the mouse and human ligands (CD115) 
are commonly used as markers to enable purification of blood monocytes in the two 
species (Auffray et al., 2009a; Cros et al., 2010).  Injection of recombinant CSF-1 
into mice and humans increases monocyte and macrophage numbers (Chitu and 
Stanley, 2006; Hume et al., 1988).  Conversely, antibodies that block receptor 
binding can deplete a subset of monocytes and the majority of tissue macrophages 
(MacDonald et al., 2010).  For these reasons, CSF-1 and its receptor have been 
recognised as candidate drug targets in humans (Burns and Wilks, 2011; Conway et 
al., 2005; Hume and Macdonald, 2012; Irvine et al., 2006).  
 
Much of our knowledge of CSF-1 biology derives from studies of rodents.  I have 
reviewed the evidence of a role for macrophages, and CSF-1, in the growth 
hormone/insulin like growth factor-1 axis and the control of somatic growth (Gow et 
al., 2010).  By comparison to human infants, mice are born comparatively immature 
(Puiman and Stoll, 2008).  Furthermore, the responses of mouse and human 
macrophages to the addition of CSF-1 are quite different; in mice CSF-1 is 
associated with induction of genes involved in wound repair, such as urokinase 
plasminogen activator, whereas in humans, CSF-1 induces genes involved in 
cholesterol biosynthesis (Irvine et al., 2008).  The domestic pig has many similarities 
with humans, especially in terms of innate immune responses (Fairbairn et al., 2011) 
and is, of course, economically important in its own right.  The overall aim of this 
thesis was to examine the function of CSF-1/IL-34/CSF-1R in the pig.  At the start of 
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the project, IL-34 had only recently been identified and it was not known whether it 
was functional in mammalian species other than mice and humans.  Neither pig CSF-
1 cDNA, nor the receptor, had been cloned, sequenced or expressed and there was no 
available antibody to detect the CSF-1R (CD115) in pigs.  The work in this chapter 
aimed to express porcine CSF-1, IL-34 and the CSF-1 receptor, and to develop a 
simple bioassay to enable the study of CSF-1 and IL-34 biology in this species. 
 
As discussed in Section1.5.2, IL-34 in mouse and human has multiple isoforms 
depending upon the inclusion of an indel encoding Q81.  It was not known whether 
these two isoforms exist in other species.  Another reason to study the pig was the 
observed species specificity of the ligands, with very limited cross-species reactivity 
of human and mouse IL-34 (Lin et al., 2008).  CSF-1 also shows this kind of species 
restriction, in that the mouse ligand has very limited ability to activate the human 
receptor (Koths, 1997).  Such species-restricted activity can provide clues about 
ligand-receptor interactions, but also suggests that optimal biological activity is 
likely to require homologous agents.  In any case, for prolonged studies of efficacy 
in-vivo, it would be desirable to avoid the problem of immunogenicity.  
 
Clearly the initial expression and purification of recombinant pig CSF-1 and IL-34 
would require the development of a convenient in-vitro bioassay.  Alternatives 
include traditional colony assays, monocyte differentiation/maturation  used by Lin 
et al. (2008), and culture of bone marrow macrophages and monocyte-derived 
macrophages in-vitro using CSF-1 (Irvine et al., 2008).  In fact, bone marrow-
derived macrophages (BMDM) grown in CSF-1 have been used extensively in 
studies of mouse and human macrophage biology (Hume et al., 1987; Hume and 
Gordon, 1983; Stacey et al., 1995).  Recently, other laboratory members have 
demonstrated that porcine bone marrow cells can be cryopreserved, thawed and 
cultured with rh-CSF-1 to generate BMDMs (Kapetanovic et al., 2012).  This system 
allows for large numbers of cells to be harvested and stored until further analysis is 
required.  
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Transfected factor-dependent cell lines expressing the receptor of interest can 
provide a convenient alternative to primary cells.  Numerous receptors and 
oncogenes have been tested in Ba/F3 cells for their ability to generate factor-
independent or novel factor-dependent growth (de Brito et al., 2011; Dosil et al., 
1993; Irvine et al., 2006).  Ba/F3 cells were originally isolated by Palacios and 
Steinmetz (1985) from mouse bone marrow cells, cultured in IL-3 and described as a 
pro-B cell line.  An earlier study reported their stable transfection with human CSF-
1R, or the related flt3 or c-kit receptor, to develop assays for specific inhibitors 
(Irvine et al., 2006).  In that study, Ba/F3 cells were stably-transfected with the 
human CSF-1R expression construct containing a blasticidin resistance cassette, 
selected in blasticidin, then subjected to secondary selection for the ability to grow in 
rh-CSF-1 in the absence of IL-3.  This approach generated stable transfectants with 
both the human receptor and a mouse-human chimeric receptor (Irvine et al., 2006).  
More recently, Ba/F3 cells have been used to express full length chicken CSF-1R to 
dissect the relationships between CSF-1 and IL-34 in domestic chickens (Garceau et 
al., 2010).  Another factor-dependent cell line, FDC-P1 cells was used to dissect the 
proliferation and differentiation signals of the CSF-1R (Bourette et al., 1995; 
McArthur et al., 1995; Rohrschneider and Metcalf, 1989; Tapley et al., 1990).  CSF-
1R activity has also been analysed in non-haematopoietic cells. For example, 
expression of the feline CSF-1R in Rat-2 cells permitted the  formation of colonies in 
soft agar upon the addition of human CSF-1 as well as the analysis of oncogenic 
mutations (Woolford et al., 1988).  The mouse fibroblast cell line NIH-3T3 can be 
transformed by expression of the CSF-1R, and was used in several studies aimed at 
dissecting the signalling pathway and the role of Ras (Bortner et al., 1991; Langer et 
al., 1992).  
An additional use of a mouse cell line expressing a foreign species protein (Ba/F3 
cells expressing porcine CSF-1R), would be the use of such cells as an immunogen 
to generate or to screen anti-CSF-1R antibodies.  Similar to Ashmun et al. (1989) 
who produced monoclonal antibodies against human  CSF-1R by immunizing rats 
with v-ras cells (rat cells) expressing human CSF-1R, I aimed to use the mouse pro-B 
cell line expressing porcine CSF-1R to immunize mice to generate porcine anti-CSF-
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1R antibodies.  The generation of antibodies to a receptor may either activate the 
receptor via cross-linking or inhibit the response to CSF-1.  Both activities would be 
useful. A simple cell assay could be screened for either activity.   
 
3.2 Results 
3.2.1 Cloning and sequence of porcine CSF-1, IL-34 and 
CSF-1R 
A partial fragment of porcine CSF-1 cDNA was cloned previously and used to 
demonstrate the existence of multiple isoforms, similar to those in humans, in 
conceptus and uterine tissues of the pig (Tuo et al., 1995).  However, the sequence 
was not reported.  For my study, porcine CSF-1 cDNA encoding the biological active 
N-terminal 150 amino acids was PCR-amplified from liver, mesenteric lymph node 
and spleen cDNA templates.  Agarose gel electrophoresis of the PCR products 
revealed the expected single band size of approximately 550 base pairs in all three-
tissue samples, with the spleen sample producing the most product (data not shown).    
For CSF-1R, PCR amplification using porcine spleen cDNA template identified the 
expected single band size of approximately 3000 base pairs.  The coding regions for 
porcine CSF-1 and CSF-1R were cloned in frame with V5-His C-terminal tag of 
pEF6 V5-His TOPO plasmid (Figure 3.1).  Following analytical digestion, the DNA 
and protein sequences were confirmed by sequence analysis.  Multiple species 
alignments of CSF-1 and CSF-1R were consistent with the available porcine CSF-1, 
and CSF-1R sequences (ENSEMBL ENSSSCT00000007466 for CSF-1 and 
ENSSSCP00000015371 for CSF-1R) and the sequences from other mammalian 
species.   
The cloned porcine CSF-1 shares 99% amino acid homology with the reference 
genomic sequence in ENSEMBL.  A single nucleotide change in the signal peptide 
was associated with a single amino acid change at position 2 of the CSF-1 signal 
peptide from Thr to Ala.  This mutation may be due to a PCR proof-reading error 
rather than single nucleotide polymorphism (SNP) since other species (cow, human, 
mouse, guinea pig and rat) all have Thr present at amino acid 2.  The cloned porcine 
CSF-1 cDNA sequence is 543 base pairs in length and encodes a 32 amino acid 
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signal peptide (Met1- Ala32) and a 149 amino acid mature protein in which the 
biological activity is predicted to be maintained (Glu33 – Ser190).  The porcine CSF-
1 peptide sequence has 87% and 84% homology with human and mouse CSF-1 
amino acid sequences respectively, while human and mouse share 80% homology.  
The pig sequence is more closely-related to cat and dog; alignments of the five 
species are shown in (Figure 3.2).  The seven cysteine residues that form the three 
intra-chain disulphide bonds and the single inter-chain disulphide bond required for 




Figure 3.1: Plasmid maps of porcine CSF-1 and CSF-1R pEF6 expression constructs.  
PCR amplified CSF-1 and CSF-1R cDNA sequence in frame with pEF6 expression construct that 
confers blasticidin resistance. The restriction sites used for analytical digestion are also shown in red. 
Restriction enzyme ApaI was used for analytical digestion of CSF-1 to generate three fragments and 
PvuII was used for analytical digestion of CSF-1R to generate five fragments.  
 




Figure 3.2:  Porcine CSF-1 demonstrates high level of homology with human, mouse, feline and 
canine CSF-1.   
Alignment was performed using Clustal W (http://www.ebi.ac.uk/Tools/msa/clustalw2/). The red 
colour represents small hydrophobic amino acids, the blue colour represents acidic amino acids, the 
magenta denotes basic amino acids, and the green colour corresponds to hydrophilic or polar amino 
acids. Identical amino acids are represented by “*”, conserved substitutions are represented by “:” and 
semi-conserved substitutions are represented by “.”. (Note: signal peptide amino acid sequence is 
missing from feline CSF-1). 
 
The cloned porcine CSF-1R cDNA is 2,904 base pairs in length which encodes full-
length CSF-1R of 969 amino acids, including a 19 amino acid signal peptide (Met1 – 
Gly19) and a 950 amino acid mature chain (Val20 – Cys969).  The 520 amino acid 
extracellular segment contains the predicted ligand binding domains (D1-D5) and a 
25 amino acid hydrophobic transmembrane region.  The 430 amino acid intracellular 
region contains the tyrosine kinase domain and ATP binding region required for 
catalytic activity of the receptor upon binding of CSF-1 or IL-34 to the extracellular 
domain.  Comparison between species of CSF-1R sequences demonstrates that 
porcine CSF-1R shares 80% homology with human CSF-1R and 72% homology 
with the mouse CSF-1R amino acid sequence, while human and mouse CSF-1R 
share 75% amino acid homology.  The alignments of these species, as well as cat and 
dog, are shown in (Figure 3.3).  The ten cysteine residues present in the extracellular 
domain that are most likely responsible for the tertiary structure of CSF-1R are 
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conserved between human, mouse and the cloned porcine CSF-1R (Figure 3.3, red 
stars).  The presence of these residues is a feature shared by other type III receptor 
kinases family members e.g. cKIT and PDGF, thus highlighting the evolutionary 
origins of these receptor family members (Qiu et al., 1988).  The five tyrosine 
residues (Tyr546, Tyr699, Tyr708, Tyr723, Tyr809 and Tyr923) located within the 
CSF-1R intracellular domain, which are phosphorylated in response to CSF-1 
binding, thus activating downstream signalling, are also conserved between human, 
mouse and porcine CSF-1R.   




Figure 3.3:  Porcine CSF-1R demonstrates high level of homology with human, mouse, feline and 
canine CSF-1R.   
Alignment was performed using Clustal W (http://www.ebi.ac.uk/Tools/msa/clustalw2/).  The red 
colour represents small hydrophobic amino acids, the blue colour represents acidic amino acids, the 
magenta denotes basic amino acids, and the green colour corresponds to hydrophilic or polar amino 
acids. Identical amino acids are represented by “*”, conserved substitutions are represented by “:” and 
semi-conserved substitutions are represented by “.”  SP = signal peptide, TM = trans-membrane 
region. Red stars represent the 10 conserved cysteine amino acids conserved across species.  
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Porcine IL-34 cDNA was PCR amplified from spleen, liver and mesenteric lymph 
node cDNA.  Agarose gel electrophoresis of the PCR products revealed the expected 
single band size of approximately 700 base pairs in all three-tissue samples.  After 
gel purification and the addition of 3’ overhangs, porcine IL-34 PCR product from 
mesenteric lymph node was successfully cloned in frame with V5-His C-terminal tag 
of pEF6/V5-His expression construct (Figure 3.4).  To test whether the C-terminal 
tag might constrain biological activity, a second expression construct was made in 
which the IL-34 coding sequence ended with the addition of a stop codon at the 3’ 
end of cDNA.  The cDNA and protein sequences were confirmed and multiple 
species alignments of IL-34 were performed.   
 
 
Figure 3.4:  Plasmid map of porcine IL-34pEF6 expression construct.   
PCR amplified cDNA sequence in frame with pEF6 expression construct that confers blasticidin 
resistance. The restriction sites used for analytical digestion are also shown in red. Restriction enzyme 
PvuII was used for analytical digestion of CSF-1R to generate five fragments.  
 
The cloned porcine IL-34 is 235 amino acids in length and is identical to the putative 
porcine IL-34 available on NCBI (EU972447.1).  The porcine IL-34 protein includes 
a 20 amino acid signal peptide (Met1 – Gly20) and a 215 mature peptide (Asn21 -
Pro235) (Figure 3.5). 





Figure 3.5:  Schematic diagram of porcine IL-34.   
The two inter-chain di-sulphide bonds are represented by red lines and the nitrogen atom (N) of the 
predicted N-linked glycosylation site is represented by Asn76 and a blue line. 
 
Multiple species alignments of IL-34 demonstrate that porcine IL-34 shares 84%, 
74%, 71%, and 70%, homology with bovine, human (isoforms 1 & 2), rat, and 
mouse (isoforms 1 & 3) IL-34 (Figure 3.6).  The shorter mouse isoform 2 of 219 
amino acids, only shares 48% homology with porcine IL-34.  Assessment of the 
genetic distance as a measure of the genetic divergence between species of IL-34 
using a phylogenic tree confirms the alignment result indicating that pig and cow IL-
34 are more related to human IL-34 than to mouse isoforms 1 and 3, while mouse 
isoform  2 shares the least homology (Figure 3.7).  As discussed in the introduction, 
there are different isoforms of IL-34 as a result of alternative splicing of a CAG indel 
producing isoforms with and without glutamine at position 81 (Q81).  The pig and 
cow IL-34 amino acid sequences have glutamine at position 81 (+Q81), whereas rat 
does not (–Q81).  From the porcine cDNA that was PCR amplified and sequenced, 
no isoform without the Q81 was identified even though the duplicated splice 
acceptor sequence in intron 4 of human and intron 5 of mouse that encodes the CAG 
indel is conserved in the pig intron 5.  
 




Figure 3.6: Porcine IL-34 demonstrates high level of homology with human, mouse, feline, rat, cow 
and canine IL-34.   
Alignment was performed using Constraint-based Multiple Alignment Tool (COBALT) 
(www.ncbi.nlm.nih.gov/tools/cobalt). The protein sequences for human isoforms 1 and 2 
(NM152456.2 and NM001172771.1), mouse isoforms 1,2 and 3 (NM001135100.1, NM029646.2 and 
UP33A081F6099F1C12), cow (NM001100324 XM_585050) , rat( NMAAH98808) and my cloned 
porcine IL-34 were entered into COBALT alignment tool.  Highly conserved amino acids are in red 
and blue and indicate less conserved amino acids.  The grey amino acids identify where there are gaps 
in the column.   The red star indicates amino acid 81.  
 
 




Figure 3.7:  Phylogram tree demonstrating the phylogenetic relationship between multiple species 
of IL-34.   
The protein sequences for human isoforms 1 and 2, mouse isoforms1-3, cow, rat and cloned porcine 
IL-34 were first aligned using MUSCLE 3.7 before “one click” phylogeny analysis was performed to 
generate the tree using www.phylogeny.fr/version2 (Dereeper et al., 2008).  The numbers in red relate 
to the evolutionary distance of the protein. 
 
Closer examination of the features of IL-34 that are required for correct 
conformation and biological activity have been possible due to the recent 
publications of the IL-34/CSF-1R crystal structure (Liu et al., 2012; Ma et al., 
2012b).  These features will be discussed as follows.  The presence of a 
glycosylation sequence in human and mouse IL-34 suggests the presence of an N-
linked glycosylation site which is vital for IL-34 to undergo post-translational 
modification to fold and form correctly.  The Asn76-Val77-Thr78 sequence of the 
glycosylation site in mouse and human oligosaccharide chain is conserved in porcine 
IL-34, suggesting porcine IL-34 also undergoes glycosylation.  In mouse IL-34, there 
is a second predicted glycosylation site at Asn100 but this is not conserved in human 
or porcine molecules.   
 
The biological activity of IL-34 appears to require the presence of its α4 region 
(Ser184, Leu186 and Asn187) (Ma et al., 2012b), with deletion of this region 
reducing in-vitro activity (Chihara et al., 2010).  This sequence is also conserved in 
pig IL-34.  The two inter-chain di-sulphide bonds (Cys35 bonds with Cys180, and 
Cys177 bonds with Cys191) that are required to lock and connect helices αA and αD 
and connect αD to C-terminal helix α4 to stabilize the C-terminal, are conserved 
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across species and are also present in porcine IL-34.  Two additional cysteine 
residues (Cys168 and Cys179) conserved in porcine IL-34 as in other species do not 
form disulphide bonds and are apparently not required for biological activity. 
Dimerization of IL-34 involves a large number of hydrophobic interactions (but no 
inter-molecular disulphide bond).  The human IL-34 dimer is formed by His56, 
Tyr57, Phe58, Pro59 and Try62 of one protomer against Pro114, His113, Leu110, 
Leu109, Val108, Tyr62, Pro59,  Phe58 from a neighbouring monomer (Ma et al., 
2012b).  These hydrophobic residues at the dimer interface are highly conserved 
among orthologs from other species, and they are also conserved in porcine IL-34.    
 
 
3.2.2 Production of stable cell lines expressing porcine CSF-
1, CSF-1R and IL-34 
To provide an initial source of porcine CSF-1 and IL-34 for in-vitro studies, the 
pEF6_CSF-1 expression plasmids encoding porcine CSF-1 and IL-34 were 
transfected into HEK293T cells using Lipofectamine 2000.  Secreted CSF-1 and IL-
34 in the HEK293T supernatant was successfully detected using western blotting for 
the V5 epitope tag encoded by the expression plasmid.  The CSF-1 protein has a 
predicted weight of 27 KDa.  Under non-reducing conditions, two bands of 
approximately 37 KDa and 50 KDa were detected, whereas two smaller bands (20 
and 25 KDa) were detected in the presence of dithiothreitol (DTT) (Figure 3.8A).    
The IL-34 protein has a predicted weight of 26 KDa.  Under reducing conditions, 
two bands (25 and 30 KDa) were detected in the presence of dithiothreitol (DTT) 
(Figure 3.8B) and with non-reducing conditions, one band of approximately 30 KDa 
was detected.  No bands of this size in the supernatant of HEK cells transfected with 
the empty vector (Figure 3.8C).  These findings suggest that both porcine CSF-1 and 
IL-34 recombinant proteins are expressed and secreted as a disulphide-linked dimer, 
and may be variably glycosylated.  A faint band around 25 KDa was detected in 
HEKpEF6_pIL34 cell lysate (Figure 3.8B), which suggested little un-secreted 
protein is retained in the cell. 
 




Figure 3.8:  Expression of cloned porcine CSF-1 and IL-34.  
Supernatant and cells were harvested from HEKpEF6_pCSF-1 (A) and HEKpEF6_pIL34 (B&C) cells 
in culture for 7 days for immunoblotting (see materials and methods).  Immunoblotting was performed 
using the V5-epitope for detection.   
 
Production of porcine CSF-1R expressing Ba/F3 cells 
To produce a bioassay for the secreted CSF-1R agonists in the pig, the IL-3 
dependent Ba/F3 cell line (Palacios and Steinmetz, 1985) was transfected with the 
cloned pig CSF-1R expressed plasmid described above, as previously described for 
the human receptor (Irvine et al., 2006).  Stable clones were initially selected for 
their survival in blasticidin, followed by further selection in rh-CSF-1.  As 
anticipated, the enforced expression of porcine CSF-1R in the Ba/F3 cells abrogated 
the absolute IL-3 dependence of the cells and permitted a proliferative response in 
response to CSF-1.  Parent Ba/F3 cells and Ba/F3 cells transfected with the empty 
expression construct (pEF6) which did not express CSF-1R did not survive in the 
presence of rh-CSF-1 upon removal of IL-3.  
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Western blot analysis of these cells based upon detection of the V5-epitope tag 
demonstrated successful expression of porcine CSF-1R.  A major band of the 
expected size of around 150 kDa was detected; a smaller minor band could be due to 
variable glycosylation.  Prior selection of these cells with rh-CSF-1 and/or IL-3 
altered the levels of receptor expression (Figure 3.9).  Growth of Ba/F3 cells 
expressing porcine CSF-1R in rh-CSF-1 produced a reduction in the detectable levels 
of receptor expression compared to cells grown in the presence of IL-3.  Since the 
ligand is known to cause internalisation and degradation of the CSF-1R (Chitu & 
Stanley) this is not surprising.  IL-3 appeared to overcome the reduced expression of 
the receptor, perhaps suggesting that IL-3 is used in preference to CSF-1 when both 
are available. 
 
Figure 3.9:  Expression of cloned porcine CSF-1R.  
Ba/F3 cells expressing porcine CSF-1R or transfected with empty vector (pEF6) were cultured with 
either no growth factors, rh-CSF-1, IL-3 or both factors combined for 7 days prior to harvesting of 
cells and preparation of cell lysate.  Immunoblotting was performed (see material and methods) by 
detection of the V5-epitope.  
 
The Ba/F3pCSF-1R stable transfectants apparently grew well in rh-CSF-1 for several 
weeks, and then went through a crisis when the majority of the cells died.  The 
remaining cells recovered and could then be maintained in rh-CSF-1 long term (4 
weeks).  In other cell lines, such as the FDC-P1 IL-3/GM-CSF-dependent cell line 
(Bourette et al., 1995; Metcalf et al., 1992),  and the M1 myeloid leukemia (Marks et 
al., 1999), transfection with the CSF-1R generates cells that can grow initially in 
CSF-1 (albeit more slowly than in IL-3 in the case of FDC-P1) but eventually 
undergo growth arrest associated in some cases with expression of macrophage 
Chapter 3: Cloning porcine CSF-1, CSF-1R & IL-34 
81 
 
differentiation markers.  In fact, the transformation of CSF-1R expressing cells has 
been shown to result in a variety of phenotypes including monocyte/macrophage 
differentiation, suppression of proliferation and autocrine transformation (McArthur 
et al., 1995).  The crisis observed in the transfected Ba/F3 cells growing in CSF-1 
alone, the apparent rescue of the pig CSF-1R, and similar findings with the human 
CSF-1R
9
, led me to re-examine whether Ba/F3 might actually be capable of myeloid 
differentiation.  I first examined the expression of commonly-studied myeloid 
markers, CD11b and F4/80 in the Ba/F3 cells cultured in IL-3.  Surprisingly, both 
markers were expressed; CD11b (31.08%) and F4/80 (91.26%) (Figure 3.10).  This 
is intriguing since the Ba/F3 cell line was originally claimed to be a pro-B cell and 
expressed low levels of F4/80 and no CD11b (Mac-1) (Palacios and Steinmetz, 
1985).  I then examined the expression of the markers on the stable pig CSF-1R 
expressing line growing in rh-CSF-1, IL-3 and both factors combined.  The cells 
expressing porcine CSF-1R have less CD11b (reduced to 5.06% cultured in IL-3 and 
2.16% cultured in rh-CSF-1).  The expression of F4/80 was also somewhat reduced 
from 91.26% in Ba/F3 cells cultured in IL-3 to 85.71%, 67% and 71% with CSF-1R 
expressing cells cultured in IL-3, rh-CSF-1 or both growth factors combined.  The 
level of F4/80 reduced to an even greater extent when cultured in rh-CSF-1 
compared to IL-3.  Hence, the expression of porcine CSF-1R and selection in rh-
CSF-1 apparently co-selected for the loss of myeloid markers (Ba/F3pCSF-1R cells 
are CD11b negative and show reduced F4/80 expression).   
                                                 
9
 Prof. David Hume, personal communication 





Figure 3.10:  Characterization of naïve and transfected Ba/F3 cells expressing porcine CSF-1R by 
flow cytometry for CD11b and F4/80.   
Populations of Ba/F3 and Ba/F3 cells expressing porcine CSF-1R were cultured in IL-3, rhCSF-1 or 
both growth factors combined for 3 days.  Cells were harvested and stained with either isotype control 
(red), CD11b (green) or F4/80 (blue).  Graphs show CD11b and F4/80 positive cells on Ba/F3 cells 
cultured in IL-3, Ba/F3pCSF-1R  rhCSF-1, IL-3 or both factors combined  (A).  The total percentage 
of each marker of the cell populations is graphed (B). Experiment repeated twice. 
 
The morphology of Ba/F3pCSF-1R cells cultured with rh-CSF-1 or IL-3 was also 
apparently altered compared to un-transfected Ba/F3 cells cultured with IL-3 (Figure 
3.11).  The Ba/F3pCSF-1R cells do not have the large cytoplasmic granules present 
in un-transfected Ba/F3 cells which are a marker of monocytic differentiation 
(Kubota et al., 1998).  The appearance of Ba/F3 cells expressing CSF-1R contrasts to 
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Bourette et al. (1995) who demonstrated FDC-P1 cells expressing CSF-1R cultured 
with CSF-1 display dramatic morphological changes compared to cells cultured with 
IL-3 with the appearance of vacuolated cytoplasm and multiple protrusions and 
ruffles.  These morphological changes are reminiscent of macrophage morphology 
and suggested that CSF-1R was transducing a differentiation signal.  Furthermore, 
transfected Ba/F3pCSF-1R cells demonstrated reduced growth rates compared to 
Ba/F3 cells, evident from the finding that Ba/F3 and Ba/F3pCSF-1R cells plated with 
the same number of cells (0.5 x10
6
 cell/mL) show different proliferation rates within 
the same time period e.g. the number of cells (indicated by MTT assay) increased 4-
fold with Ba/F3 cells, whereas with Ba/F3pCSF-1R cells in rh-CSF-1 the increase 
was only 1.8 fold in 96 hours (Figure 3.12).  The crisis that occurred during the 
generation of this line may have involved selection of cells that cannot undergo 
differentiation whereas the myeloid cells growth arrested in response to CSF-1 
signalling.  In summary, Ba/F3 cells are not functionally clonal and are myeloid 
rather than (exclusively) lymphoid, which confirms earlier findings that Ba/F3 cells 
do not express the B cell-specific marker BCF-1 , suggesting that they are an early 
progenitor of B cells or non-lymphoid (Sigvardsson et al., 1997). 
 
 
Figure 3.11:  Morphology of porcine CSF-1R expressing Ba/F3 cells cultured in either IL-3 or rh-
CSF-1.   
Ba/F3pCSF-1R cells were maintained in IL-3 or washed twice before culturing with rh-CSF-1 for 3 
days.  Following cell harvest, cytospin slides were prepared; air dried, stained with Giemsa stain and 
morphology examined using x600 magnification.  Experiment repeated twice.  





Figure 3.12:  Growth curve of un-transfected and transfected Ba/F3 cells with porcine CSF-1R.   
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and seeded at 0.5 
x10
6
 cells/mL/well of a 6 well plate.  Un-transfected Ba/F3 cells were cultured in IL-3 and 
Ba/F3pCSF-1R cultured in either IL-3 or rh-CSF-1.  Cells were counted after 48 and 96 hours and 
results graphed.  Experiment repeated three times. 
 
The assay of cell viability shown in Figure 3.13 uses the dye 3-(4,5-dimethylthiazol-
2yl)-2,5-diphenyltetrazolium bromide (MTT).  The MTT cell viability assay relies on 
the conversion of soluble tetrazolium into insoluble blue formazan crystals by 
reduction in the mitochondria by succinate-tetrazolium reductase (Stoddart, 2011).  
The MTT assay was used successfully by Irvine et al. (2006) to demonstrate activity 
of human CSF-1R expressed in Ba/F3 cells.  Other derivatives of MTT have been 
used such as MTS, WST and XTT which are reported to have increased sensitivity 
(Scudiero et al., 1988).   
To improve the sensitivity and reproducibility as a CSF-1 bioassay, both cell number 
and incubation time of the bioassay were optimized.  Figure 3.13A shows the dose 
response curve of Ba/F3pCSF-1R cells with rh-CSF-1 using 20,000 and 40,000 
cells/well of a 96 well plate and both 24 and 48 hour incubation times. Although 
using 40,000 cells/well and a 48 hour incubation produced the highest level of MTT 
reduction (i.e. cell proliferation/survival) and a good dose response to CSF-1, the 
baseline of MTT reduction did not decline completely (Figure 3.13A).  At high 
density, the cells may carry over sufficient growth factor to survive.  Therefore, 
using 20,000 cells/well and 48 hour incubation produced a good proliferative 
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response with rh-CSF-1 and a significantly lower baseline, so that the sensitivity was 
greater.  These conditions were therefore adopted as a standard assay.  
The presence of rh-CSF-1 in the culture medium with Ba/F3pCSF-1R cells 
expressing CSF-1R could promote receptor-mediated endocytosis and degradation of 
the CSF-1R (Bartocci et al., 1987), the normal manner in which CSF-1R expression 
is regulated.  Therefore, Ba/F3pCSF-1R cells were cultured with either IL-3, rh-CSF-
1 or both factors combined for 7 days prior to assay to test whether previous 
exposure to CSF-1 altered the sensitivity of the assay (Figure 3.13B).  As shown in  
Figure 3.13B there was no difference in the response of the Ba/F3pCSF-1R cells in 
the bioassay with these different culture conditions. Similarly, starving the cells for 
18 hours prior to the bioassay, which might have up-regulated the CSF-1R, had no 
effect on the sensitivity of the assay (Figure 3.13C).  Although IL-3 was equivalent 
to rh-CSF-1 in the bioassay in terms of cellular viability and proliferative response of 
the Ba/F3 cells expressing CSF-1R, rh-CSF-1 was used as the standard culture 
growth factor to maintain selection pressure for CSF-1R expression.  In conclusion, 
in the optimized assay, Ba/F3pCSF-1R cells cultured in rh-CSF-1, washed and plated 
at 20,000 cells/well of a 96 well plate, and incubated for 48 hours prior to assessment 
of viability using MTT reduction was used for all cell viability assays. 
 




Figure 3.13:  Optimization of Ba/F3pCSF-1R MTT bioassay.   
Ba/F3pCSF-1R cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the MTT 
assay with rh-CSF-1 at different densities (20,000 or 40,000 cells/well) for either 24 or 48 hours prior 
to assay (A).  A further MTT was performed using Ba/F3pCSF-1R that had been maintained in culture 
for 7days with either rh-CSF-1, IL-3 or both factors combined prior to assay (B).  To assess the effect 
of starvation on the cells, Ba/F3pCSF-1R cells were harvested, washed twice in PBS and cultured in 
RPMI alone or with rh-CSF-1 for 18 hours prior to assay.  Cells were then cultured as above with 
different growth factors comparing the starved population (S) to the population maintained in rh-CSF-
1 (C).  Results are average of triplicate determinations + SEM. Experiment repeated three times. 
 
3.2.3 Assessment of biological activity of CSF-1, CSF-1R 
and IL-34 
Following culture of the stable HEK293T cells expressing porcine CSF-1 for 14 days 
under blasticidin selection, fresh supernatant was harvested, filtered and used in the 
fully optimized bioassay, as described earlier.  The presence of 10% conditioned 
medium from an IL-3-expressing cell line allowed survival of both parent Ba/F3 and 
Ba/F3 cells expressing porcine CSF-1R (Figure 3.14A).  The supernatant from 
transfected HEK293T with porcine pEF6_pCSF-1 also maintained the viability of 
the Ba/F3 cells expressing porcine CSF-1R , with the best results demonstrated using 
80% of the transfected HEK293T CSF-1 supernatant (Figure 3.14A).  As discussed 
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in the introduction, bone marrow-derived macrophages (BMDM) grown in CSF-1 
have been used extensively in studies of mouse macrophage biology (Hume et al., 
1987; Stacey et al., 1995).  I therefore tested whether porcine CSF-1 in the HEK293T 
cell supernatant would be active on the porcine CSF-1R in its native context to 
stimulate bone marrow progenitor cells to differentiate into BMDMs.  Porcine bone 
marrow progenitor cells isolated from a pig’s rib, cultured for 7 days in either 100%, 
80%, 50% or 20% HEK293T pEF6_pCSF-1 supernatant, grew and differentiated 
into adherent macrophages (Figure 3.14B) whereas control cells died (Figure 
3.14C).  In combination, these experiments confirmed both functionality of the 
expressed porcine CSF-1R and biological activity of HEK293T pEF6_pCSF-1 
supernatant on both the CSF-1R expressing cell line, and porcine primary cells. 
 
Figure 3.14:  Biological activity of cloned secreted porcine CSF-1 transfected into HEK293T cells.  
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and used in an MTT 
assay with either IL-3 or fresh HEKpCSF-1 supernatant (A).  Cells were cultured for 48 hours.  
Following addition of MTT solution and solubilization, optical density was read at 570nm using a 
plate reader.  Results show the average of triplicate determinations + SEM.  Bone marrow cells were 
flushed from an adult pig rib and placed in culture (1x10
6
 cells/mL) with 20% HEKpCSF-1 
supernatant (B) or RPMI only for 7 days (C).  Experiment repeated three times. 
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The recombinant human CSF-1 used here and in studies on pig marrow carried out 
by other laboratory members (Kapetanovic et al., 2012) was expressed in E.coli.  The 
advantage of an E.coli expression system is not only the high yield which enables 
both preclinical and structural studies, but also the possibility of introducing defined 
mutations to support structure-function analysis.  To enable such studies of the 
porcine protein, and to further optimise expression, a synthetic codon-optimised 
cDNA encoding the active amino acids was generated.  The purified material was 
provided by colleagues at Pfizer Animal Health as part of the BBSRC CASE 
Studentship that funded my project.  Using the bioassay with Ba/F3pCSF-1R cells, 
purified recombinant porcine CSF-1 was also shown to be biologically active on the 
porcine CSF-1R expressed in Ba/F3 cells (Figure 3.15).  The EC50 of purified 
recombinant porcine CSF-1 and rh-CSF-1 on Ba/F3 cells expressing porcine CSF-1R 
was essentially identical (29 ng/ml and 34 ng/ml respectively) (Figure 3.15).  As 
expected, Ba/F3 cells cultured with rh-CSF-1 alone do not survive due to the lack of 
CSF-1R.   
 
 
Figure 3.15:  Biological activity of purified recombinant porcine CSF-1 expressed in E.Coli.   
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
bioassay with E.Coli expressed porcine CSF-1 for 48 hours.  Following addition of MTT solution and 
solubilization, optical density was read at 570nm using a plate reader.  Results show the average of 
triplicate determinations + SEM.  Experiment repeated three times. 
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By comparison to expression of CSF-1, and previous expression of avian IL-34 in 
HEK293T cells (Garceau et al., 2010) the expression of pig IL-34 proved more 
challenging. Stable HEK293T cells expressing porcine IL-34 were cultured for three 
days prior to collection and filtration (0.2µm) of the supernatant before storage at 
4
o
C.  The supernatant was stored for 48 hours prior to use in optimised MTT cell 
viability assay.  Although recombinant human CSF-1 or IL-34 both allowed the pig 
CSF-1R-expressing cells to survive and proliferate, no cells cultured with porcine IL-
34 (10-50% supernatant) survived beyond the background level of proliferation 
observed in the absence of added growth factors (Figure 3.16). 
 
Figure 3.16:  Biological activity of cloned secreted porcine IL-34 transfected into HEK293T cells.  
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and used in an MTT 
assay with reducing concentrations of HEKpIL34 supernatant and incubated for 48 hours. Following 
addition of MTT solution and solubilization, optical density was read at 570nm using a plate reader.  
Results show the average of triplicate determinations + SEM.  Experiment repeated five times. 
 





C to determine whether the IL-34 protein was being degraded by 
storage.  Figure 3.17 shows the cell viability assay results of Ba/F3pCSF-1R cells 
cultured in these supernatants stored as described above together with freshly 
harvested, filtered supernatant after 72 hours in culture.  None of the storage 
conditions investigated (freshly harvested, refrigerated or frozen) using porcine IL-
34 supernatant from transfected HEK293T cells permitted replacement of CSF-1 in 
the Ba/F3-CSF-1R cell assay. 





Figure 3.17:  Bioassay of Ba/F3pCSF-1R cells with porcine IL-34 supernatant to assess the effect 
of storage on biological activity.   
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and used in an MTT 
assay with either 50% (A) or 20% (B) HEKpIL34 supernatant that had been stored under different 
conditions (fresh, frozen, refrigerated).  Cells were incubated for 48 hours. Following addition of 
MTT solution and solubilization, optical density was read at 570nm using a plate reader.  Results 
show the average of triplicate determinations + SEM.  Experiment repeated four times. 
 
Following repeated attempts to demonstrate biological activity using the bioassay, 
none of which had proved to be successful, RNA was prepared from the HEKpIL-34 
and cDNA made which was sent for sequencing.  RT-PCR was performed using this 
cDNA and porcine splenic cDNA (which was used to PCR amplify IL-34 originally) 
with porcine IL-34 primers.  A band of the expected size band of 700 base pairs 
could be identified by PCR (Figure 3.18A).  The band was purified and sequenced, 
and the sequence was identical to the expected pig IL-34 (Figure 3.18B).  Hence, the 
absence of biological activity could not be attributed to any mutation introduced 
during creation of the cell line.    
 




Figure 3.18:  Demonstration of correct size and sequence of secreted porcine IL-34 from HEK293T 
cells.   
HEK293T cells transfected with porcine IL-34 were harvested and RNA extracted. RT-PCR was 
performed using HEKpIL34 cell RNA and pig spleen cDNA as a control using porcine IL-34 primers 
used for cloning (A). Following purification of the 700 bp band seen in the agarose gel, sequencing 
was performed, the results of which were aligned to the published porcine IL-34 sequence (B).   
 
HEK293T cells are commonly used for their ability to produce proteins into the 
supernatant in large quantities; it is known that by adapting the cells to grow as 
suspension cells, they can increase the protein secretion 8 fold within 6 days of 
adaption (Lin et al., 2008).  One possible explanation for the lack of detectable IL-34 
activity in HEKpEF6_pIL34 cells was that the concentration produced was 
insufficient for detection.  Accordingly, the cells were adapted to grow as suspension 
cells by using Ex-Cell293 serum free medium for HEK293 cells.  HEKpEF6_pIL34 
cells were recovered from cryopreservation and cultured as adherent cells for 7 days 
prior to exchange of the medium for Ex-Cell medium (Figure 3.19).  Three days 
after changing the medium, most of the HEKpEF6_pIL34 cells were detached from 
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the culture flask, had lost their normal spinal shaped morphology and were floating 
in clumps.  The suspension HEKpEF6_pIL-34 cells produced approximately a 3-fold 
increase in total protein produced as measured using a Nanodrop. 
 
Figure 3.19:  Adaption of HEKpEF6_pIL-34 cells from adherent to suspension cells in culture.   
Adherent HEKpEF6_pIL34 cells were cultured in standard HEK293T medium (DMEM) for 7 days 
(A) before harvesting, washing and culture with Ex-Cell medium for suspension cells (B).  
 
After 7 days in culture, supernatant was harvested from both adherent and suspension 
cell populations, filtered as before (fresh supernatant only) and used the bioassay to 
compare the effectiveness of suspension and adherent HEKpEF6_pIL34 supernatant 
(Figure 3.20).  Two concentrations were used; 50% (Figure 3.20A) and 20% 
(Figure 3.20B) for both culture conditions.  An additional explanation for the lack of 
activity was considered, namely that the V5-His Tag used in the vector compromised 
biological activity of IL-34.  An alternative vector, in which the porcine IL-34 open 
reading frame (ORF) ended with a stop codon (pIL34_Stop), was also assessed for 
biological activity under the same conditions (Figure 3.20).  None of the culture 
conditions as described above produced any detectable biological activity in the 
CSF-1 –dependent cell line.  




Figure 3.20:  Bioassay of Ba/F3pCSF-1R cells comparing the effects of using HEK-pEF6_pIL34 
from adherent and suspension cells.   
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and used in a cell 
viability assay with either 50% (A) or 20% (B) HEKpIL34 or HEKpIL-34_Stop supernatant from 
suspension (susp) or adherent (adh) cells.  Cells were incubated for 48 hours. Following addition of 
MTT solution and solubilization, optical density was read at 570nm using a plate reader.  Results 
show the average of triplicate determinations + SEM.  Experiment repeated twice. 
 
Stable cells in suspension were then cultured for 5 days prior to supernatant harvest 
to try and maximise the concentration of protein in the HEKpEF6_pIL34 and 
HEKpEF6_IL34_Stop cell supernatants.  Although at the time of harvest, the cells 
themselves did not look healthy and could not be maintained in culture for any length 
of time, this allowed supernatant to be collected and assessed immediately in the cell 
viability assay (Figure 3.21).  No supernatant was stored long term.  A further 
bioassay was performed, again using the Ba/F3pCSF-1R cells using either 
HEKpEF6_pIL34 (Figure 3.21A) or HEKpEF6_pIL34_Stop (Figure 3.21B) 
supernatant from suspension cells that had been in culture for 5 days.  Under these 
conditions, maximum activity was seen with 20% conditioned medium and declined 
at higher concentrations (Figure 3.21A).  This suggests that the HEK cells produce 
some kind of factor that interferes with the biological activity of IL-34 on the CSF-
1R.  The insertion of the stop codon did not produce a massive change in activity, 
suggesting that the V5-His tag could be used for purification of the protein.  




Figure 3.21:  Bioassay of Ba/F3pCSF-1R cells with HEKpEF6_pIL34 and HEKpEF6_pIL34_Stop 
supernatant collected from cells after 5 days in culture.  
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and used in an MTT 
assay with reducing concentrations of HEKpEF6_pIL34 (A) or HEKpEF6_pIL-34_Stop (B) 
supernatant.  Cells were incubated for 48 hours. Following addition of MTT solution and 
solubilization, optical density was read at 570nm using a plate reader.  Results show the average of 
triplicate determinations + SEM.  Experiment repeated four times. 
 
The HEKpEF6_pIL34 cell supernatant was also tested for the ability to maintain 
survival of Ba/F3pCSF-1R cells over longer time periods (Figure 3.22).  By day 8 of 
culture, Ba/F3pCSF-1R cells maintained in 20% HEKpEF6_pIL34 as the only 
growth factor were alive and proliferating, although large numbers of dead cells were 
also noted (Figure 3.22A).  Cells cultured with no growth factors (20% HEKpEF6 
supernatant) were less confluent and contained greater numbers of dead cells 
compared to the IL-34 cultured cells (Figure 3.22B).  By day 12, with the addition of 
freshly harvested HEKpEF6_pIL34 (day 5 culture) and without the cell population 
being split, cells were 100% confluent (Figure 3.22C), while cells cultured with no 
growth factors were mainly dead. 
 




Figure 3.22: Culture of Ba/F3pCSF-1R cells with HEKpEF6_pIL34 supernatant.   
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured at 
0.5x106 cells/mL with either 20% HEKpEF6_pIL34 (A) or HEKpEF6 (B) supernatant for 8 days.  
Ba/F3pCSF-1R cells were confluent by day 12 (C).  
 
These results demonstrated that the porcine IL-34 could bind and activate the cloned 
porcine CSF-1R expressed ectopically.  To demonstrate biological activity in the 
native context and confirm the macrophage growth factor activity, primary porcine 
bone marrow cells were recovered from cryopreservation and cultured with fresh 
0.2um filtered HEKpEF6_IL34 supernatant (day 5 culture).  Cells cultured with 20% 
HEKpEF6_IL-34  supernatant survived, proliferated and adhered to the tissue culture 
dish after 7 days in culture (Figure 3.23A) compared to cells cultured with 20% 
HEKpEF6 supernatant where there were few surviving cells (Figure 3.23B) 
(negative control).  Cells cultured with recombinant human CSF-1(1000ng/ml) also 
survived and proliferated and appeared similar in density and morphology to those 
cultured with IL-34 (Figure 3.23C).  
 
 
Figure 3.23:  Culture of porcine bone marrow cells with HEKpEF6_pIL34 supernatant.  
Pig bone marrow cells were recovered from cryopreservation and 1x10
6
 cells/mL were cultured for 
7days with either 20% HEKpEF6_pIL-34 supernatant (A), HEKpEF6 (B) supernatant or 1000ng/mL 
rh-CSF-1(C).  




The work in this chapter describes the production of stable Ba/F3 cell lines 
expressing porcine CSF-1R which can be utilised in cell viability bioassays to assess 
the biological activity of CSF-1 and IL-34.  As discussed in the introduction, 
numerous receptors and oncogenes have been tested in Ba/F3 cells for their ability to 
generate factor-independent or novel factor-dependent growth (de Brito et al., 2011; 
Irvine et al., 2006).  I have successfully reproduced the approach described by Irvine 
et al. (2006) using porcine CSF-1R and then selected cells for their ability to grow in 
rh-CSF-1.  Although transfected Ba/F3 cells with the porcine CSF-1R grew well in 
CSF-1 and provided a useful assay, they nevertheless generally proliferated less 
rapidly than in IL-3.  Ba/F3 cells were originally identified as pro-B cells that 
express surface Ig and lack endogenous CSF-1R (Dosil et al., 1993; Palacios and 
Steinmetz, 1985; Sherr and Stanley, 1990). However, although other members of my 
lab (Lindsey Moffat) have confirmed the presence of surface Ig, they also express the 
myeloid markers CD11b and F4/80 antigens (Figure 3.10).  In this respect, they 
share some features with other myeloid lines such as PU5/1.8 and P388D1 (Ross et 
al., 1994).  The addition of CSF-1 to the porcine receptor-expressing cells apparently 
induces some of them to undergo differentiation, growth arrest and adhesion.  
Western blotting of the Ba/F3 cells expressing porcine CSF-1R revealed differential 
levels of receptor expression, depending on the culture conditions.  When cells were 
cultured in rh-CSF-1, there was a reduction in the level of CSF-1R expression 
(Figure 3.9).  This result may be explained by ligand-receptor activation followed by 
degradation and internalization of the CSF-1/CSF-1R complex (Pakuts et al., 2007; 
Wilhelmsen et al., 2002).  The ability of IL-3 to prevent the loss of CSF-1R was 
unexpected; it may be due to IL-3 producing a signal that inhibits CSF-1/CSF-1R 
interactions, degradation of the CSF-1R after binding of CSF-1, or CSF-1R 
internalization.  An alternative explanation is that IL-3 acts on the EF1A promoter in 
the expression plasmid to increase CSF-1R production. 
 
Due to the link between CSF-1 and postnatal growth, a most valuable tool that will 
allow further dissection of the role of CSF-1 will come from the production and 
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application of  porcine anti-CSF-1R antibodies.  Currently, no human or mouse anti-
CSF-1R antibodies have been found to cross-react with the porcine CSF-1R. 
Additional benefits of a porcine anti-CSF-1R antibody include its use in porcine 
models of inflammation as a model for human disease and comparative studies of 
macrophage transcriptional responses.  At the time of starting my project, the 
discovery of IL-34 as a second ligand for CSF-1R was not published.  The best way 
in which to evaluate the effects of CSF-1 on postnatal growth was therefore 
considered to be by the production of anti-CSF-1R antibodies, to block the biological 
actions of circulating CSF-1.  Since we now know that CSF-1 and IL-34 share the 
same receptor, an anti- CSF-1R antibody might block one or both of the ligands. 
There may be a requirement for neutralizing antibodies to both ligands to determine 
any non-redundant role of CSF-1.  Anti-CSF-1 antibodies have been used in mice to 
demonstrate reduced growth  rates, adult weights and display a similar phenotype to 
the op/op mice (Marshall et al., 2007; Wei et al., 2005).  A further mouse anti-CSF-1 
antibody was produced by (Lokeshwar and Lin, 1988) and subsequently used to 
demonstrate the role of CSF-1 in inflammation and arthritis (Campbell et al., 2000). 
 
The first neutralizing antibody against CSF-1R (AFS98) produced by Sudo et al. 
(1995), blocked the actions of CSF-1 and has been used in several studies 
investigating the role of CSF-1 dependent macrophages in pathological processes 
such as atherosclerosis (Murayama et al., 1999) , diabetic neuropathy (Lim et al., 
2009) skeletal muscle pathology (Segawa et al., 2008) and tumour pathology 
(Kubota et al., 2009).  In these models the administration of AFS98 reduced 
macrophage infiltration and/or proliferation.  This is in contrast to the findings using 
a recently produced IgG anti-CSF-1R antibody, M279 (MacDonald et al., 2010).  
M279 is a more potent inhibitor of the CSF-1R and selectively ablated the Ly6C 
negative monocyte population whilst having no effect on the total monocyte number.   
An alternative to the production of monoclonal antibody against the CSF-1R would 
be the production of CSF-1R kinase inhibitors that act on the cytosolic ATP binding 
domain thus causing inhibition of phosphorylation.  A major disadvantage is the lack 
of specificity associated with these drugs, although GW2580 is the most selective 
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(Irvine et al., 2006).  The effects of using these drugs to determine the role of CSF-1 
in postnatal growth could never be clearly defined owing to the effects not produced 
by CSF-1R signalling.  
 
Efforts that I was involved in initially, but which were taken over and completed by 
Lindsey Moffat in the laboratory, succeeded in generating several monoclonal 
antibodies against the pig CSF-1R.  This was achieved by immunizing 4 adult female 
BALB/c mice every 28 days for a total of 4 injections with my Ba/F3pCSF-1R cells 
and/or an Fc-CSF-1R protein (produced by Dr Lisa Rothwell, The Roslin Institute).  
Hydridoma cells were generated by fusion of mouse spleen cells with the immortal 
SP2/0 cell line and supernatant screened by direct ELISA using the Fc-CSF-1R 
protein for the production of pig specific anti-CSF-1R antibodies.  Positive 
hybridomas were also screened against human IgG (part of the Fc-fusion construct) 
to ensure specific binding to the CSF-1R.  Positive hybridoma cells were subcloned 
and assessed by FACS for their ability to bind porcine CSF-1R both in its native state 
(PBMC and AM) and on the cloned CSF-1R cell line (Figure 3.24).  The anti-CSF-
1R antibody bound to both PBMC and AM cells expressing the CSF-1R in its native 
state and also the Ba/F3pCSF-1R cells expressing cloned CSF-1R.  This confirmed 
that anti-CSF-1R antibodies had been successfully produced.  Characterization has 
included the investigation of the cross-species activity of the antibodies and their use 
in other applications e.g. ELISA, western blotting, immunocytochemistry, 
immunohistochemistry.  To date, we have identified that the porcine anti-CSF-1R 
antibodies cross-react with sheep, horse, cat and dog CSF-1R (data not shown).  
Unfortunately, and somewhat surprisingly, none of the antibodies appears to be able 
to either mimic or inhibit the actions of CSF-1 in the Ba/F3 assay, on-going efforts 
are directed towards screening additional fusions to seek antibodies with this 
desirable biological activity.     
 
In conclusion, I have developed and optimized an in-vitro bioassay for the study of 
porcine CSF-1 and IL-34 by producing a stable cell line expressing porcine CSF-1R.  
Additionally, this system will allow for further analysis of the cross-species activity 
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of these proteins (Chapter 4).  The Ba/F3 cells expressing porcine CSF-1R have 
been used successfully to immunize mice and generate anti-CSF-1R monoclonal 
antibodies that following further characterization and purification can be used to 
study the CSF-1/IL-34/CSF-1R system in the pig.  This assay also offers the 
possibility of screening for antagonists, including blocking antibodies, which might 
have applications in inflammatory disease and malignancy (Hume and Macdonald, 
2012).  Therapeutic options for CSF-1 in a number of preclinical applications have 
been explored by numerous groups, mainly to do with tissue repair (Alikhan et al., 
2011; Hume and Macdonald, 2012; Menke et al., 2009; Okazaki et al., 2007).  The 
successful expression of recombinant CSF-1, IL-34 and CSF-1R in the pig and 
evaluation of cross-species activity of IL-34 provide the tools for evaluation of both 










Figure 3.24:  Analysis of porcine CSF-1R expressing cells by flow cytomerty using porcine anti-
CSF-1R antibodies.   
Porcine PBMC and AM cells were recovered from cryopreservation, washed, starved overnight of rh-
CSF-1 and prepared for FACS analysis by Lindsey Moffat, Hume Lab.  Ba/F3pCSF-1R and Ba/F3 
cells were cultured in IL-3 for 3 days prior to cell harvest and preparation of cells for FACS. Cells 
were stained with either secondary antibody only (black line) or anti-CSF-1R antibody (red line).  
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Chapter 4: Analysis of the species specificity of 
CSF-1 and IL-34 
 
4.1 Introduction 
Since the discovery of CSF-1 in the 1970s and subsequent production and 
commercialization of recombinant human and mouse proteins, the cross-species 
activity of human and mouse CSF-1 has been well documented.  Many groups have 
demonstrated that human CSF-1 is almost as effective as mouse CSF-1 at stimulating 
the mouse CSF-1R (Das et al., 1980, 1981), and indeed is equally active on all 
mammalian species tested (mouse, cat, sheep, and dog).  Conversely, mouse CSF-1 
bioactivity is restricted to non-primate species (Abrams et al., 2003; Francey et al., 
1992; Garceau et al., 2010; Stanley and Guilbert, 1981; Woolford et al., 1988; 
Yoshihara et al., 1998).  In fact, mouse CSF-1 binds 500 times less tightly to human 
CSF-1R than to mouse CSF-1R (Elegheert et al., 2011).  By contrast, the original 
discovery of IL-34 (Lin et al., 2008) suggested in contrast to human CSF-1, it does 
not cross species.  Additionally, Wei et al. (2010) demonstrated that human IL-34 is 
less potent at stimulating mouse CSF-1R mediated macrophage proliferation; EC50 
for human IL-34 was 30 fold higher than for human CSF-1 (Wei et al., 2010).  
Interestingly, human CSF-1 and IL-34 have the same activity on human CSF-1R 
expressed to replace the mouse CSF-1R in mouse macrophages in-vitro (Wei et al., 
2010).  Also, previous studies have shown than human IL-34 stimulates human 
monocyte derived macrophages at similar concentrations to those at which human 
CSF-1 is effective (Lin et al., 2008).  
 
Previous studies using non-species specific colony stimulating factors for therapy 
have been hampered by the development of auto-antibodies.  Recombinant colony 
stimulating factors and/or antibodies directed against the ligand or the receptor, 
namely CSF-1, GM-CSF, G-CSF have been tested in a range of animal models and 
human patients (Hume and Macdonald, 2012; Martinez et al., 2012; Nemunaitis et 
al., 1993; Wei et al., 2005). There has been limited use of stimulating factors in 
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companion animals, for example, the administration of rh-GM-CSF to healthy dogs 
has been reported to produce neutralising antibodies after 10-12 days (Mayer et al., 
1990).  Similarly, the administration of rh-GM-CSF to cats with FIV triggered 
neutralising antibodies in 75% of the cats, 35 days after a 2 week treatment protocol 
(Arai et al., 2000).  In-vivo neutralisation of the rh-GM-CSF was not further 
investigated, therefore it is difficult to determine the true effect of these antibodies 
against both endogenous feline GM-CSF and also the exogenous recombinant human 
protein administered (Arai et al., 2000).  While I have successfully produced porcine 
CSF-1 and IL-34 that can be used in its target species, thus preventing development 
of auto-antibodies, further cross-species analysis of these proteins with other species 
may reduce the requirement to produce further species-specific proteins.  This may 
be particularly important for companion animal species where access to tissues and 
samples may be limited. 
  
To extend our knowledge further with regard to the cross-species reactivity of CSF-1 
and IL-34, I have chosen to investigate the response in companion animals, namely 
feline and canine.  There are limited publications relating to the CSF-1/CSF-1R 
system in these species.   Abrams et al. (2003) administered rh-CSF-1 to dogs and 
induced dose dependent thrombocytopenia as observed in humans in clinical trials.  
Many solid tumours of mice and humans express CSF-1R, and this is also the case 
for canine mammary adenocarcinomas (Krol et al., 2011).  The cloning and 
expression of canine CSF-1R, production of canine anti-CSF-1R antibodies and 
further analysis of the cross-species reactivity of CSF-1 in this species is currently 
being investigated by a fellow PhD student and does not fall into the remit of this 
thesis.  However, I have performed initial investigation into the cross-species activity 
of porcine and human CSF-1 with canine CSF-1R and also developed and optimized 
harvesting and culture of canine bone marrow and peripheral blood mononuclear 
cells with CSF-1.  Since there are no published reports of the use of IL-34 in either 
cats or dogs, it was also of interest to determine whether reagents from other species 
would cross react.  
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The CSF-1R was first discovered as the oncogene responsible for Feline McDonough 
Sarcoma (SM-FeSV), hence its name FMS (Donner et al., 1982; El-Gamal et al.).  
Another transformed version of the CSF-1R gene has also been identified in a further 
feline viral isolate, the Hardy-Zukerman 5 strain of feline sarcoma virus (HZ5) 
(Besmer et al., 1986).  These transformed receptors were identified in fibrosarcomas 
from domestic cats with feline leukaemia virus (FeLV).  Both SM-FeSV and HZ5 
contain an intact ligand binding domain compared to CSF-1R (Woolford et al., 
1988).  SM-FeSV differs from CSF-1R by 17 nucleotide differences which results in 
a nine point amino acid substitution mutation and a C-terminal truncation (Sherr, 
1990; Woolford et al., 1988).  The presence of transformed versions of CSF-1R 
(vFMS) can transform cultured cat fibroblasts to tumorigenic derivatives (Sherr, 
1988).  Therefore the production of feline CSF-1R expressing cells will be a valuable 
resource for studying the feline CSF-1R system and to extend current knowledge on 
CSF-1 and IL-34 cross-species activity.  
 
The growth of macrophages from bone marrow cells using recombinant CSF-1 has 
been described previously for human, mouse, chicken, guinea pig and pig bone 
marrow cells (Garceau et al., 2010; Hume et al., 1985; Hume and Gordon, 1983, 
1984; Kapetanovic et al., 2012; Stanley and Guilbert, 1981; Yu et al., 2013).  
Additionally, other members of our lab have successfully cultured horse PBMC with 
rh-CSF-1
10
.  However, other colony stimulating factors, including GM-CSF-1 and 
fms-like tyrosine kinase 3 ligand may also be used, although these drive cells toward 
a distinct antigen-presenting cell.  Many reports exist for the generation of feline 
antigen presenting cells using GM-CSF (Bienzle et al., 2003; Sprague et al., 2005; 
Vermeulen et al., 2012).  Some would call these dendritic cells,  although this has 
been debated (Hume, 2008).  Conversely, there are no reports of using human CSF-1 
to generate feline monocyte-derived macrophages.  The ability to culture feline and 
canine macrophages is a valuable tool to allow the in-vitro study of the effects of 
                                                 
10
 Anna Karagianni, manuscript in preparation 
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drugs in companion animal species, e.g. chemotherapeutic agents, which may cause 
immune-suppression or immune-modulation in cats and dogs.  Equally, the 
mechanisms of disease, for example, infectious disease, that can infect macrophages, 
e.g. FIV or mycobacteria, may be further investigated.  Further investigations may be 
to compare the response of feline BMDMs to LPS in a similar fashion to the analysis 
performed for mice, human and porcine BMDMs (Kapetanovic et al., 2012; Schroder 
et al., 2012).  
 
The aims of this chapter were to further analyse my porcine CSF-1R expressing 
Ba/F3 cells with other species CSF-1 and IL-34 and to produce another cell line 
expressing CSF-1R from a companion animal.  An additional benefit of working 
with companion animal materials was that it allowed me to develop and optimize a 
system for harvesting, culturing and cryopreservation of cells that were limited in 
their supply.  
 
4.2 Results 
4.2.1 Production of a stable cell line expressing feline CSF-
1R 
Cloning of feline CSF-1R 
As discussed in the introduction, production of a stable cell line expressing feline 
CSF-1R would allow for cross-species reactivity of both CSF-1 and IL-34 to be 
determined and also provide a valuable source of cells in a bioassay that could be 
used to assess the therapeutic effects of these proteins in cats.  Previously, Woolford 
et al. (1988) had cloned feline CSF-1R cDNA from a splenic cDNA template but I 
identified a greater abundance of CSF-1R cDNA using the lymph node template.  
Agarose gel electrophoresis of the PCR products revealed the expected single band 
of approximately 3000 base pairs in this tissue.  Following gel purification, feline 
CSF-1R was successfully cloned in-frame with V5-His C-terminal tag of pEF6 V5-
His TOPO plasmid (Figure 4.1).  




Figure 4.1:  Plasmid map of feline CSF-1R pEF6 expression construct.  
PCR amplified feline CSF-1R cDNA sequence in frame with pEF6 expression construct that confers 
blasticidin resistance. The restriction sites used for analytical digestion are also shown in red.  
Restriction enzyme PvuII was used for analytical digestion of CSF-1R to generate five fragments. 
 
The cDNA and protein sequences were confirmed and multiple species alignments of 
CSF-1R performed (Chapter 3, Figure 3.3).  The feline CSF-1R extracellular 
domain shares 88% homology with canine CSF-1R, 83% homology with human 
CSF-1R, and 75% with the mouse CSF-1R, while feline and pig share 80% 
homology.  The cloned feline CSF-1R encodes the full-length receptor of 982 amino 
acids, including a 19 amino acid signal peptide (Met1 – Gly19) and a 963 amino acid 
mature chain (Val20 to Cys982).  The sequence is identical to the previously-
published feline CSF-1R (Woolford et al., 1988).  
 
Stable transfections 
To enable studies of the cat CSF-1R binding specificity, the IL-3 dependent Ba/F3 
cell line was stably transfected with feline CSF-1R, as described for pig receptor 
(Chapter 3), and the human and chicken receptors (Garceau et al., 2010; Irvine et 
al., 2008).  Stable clones were initially selected for their survival in blasticidin, 
followed by further selection in rh-CSF-1.  The presence of feline CSF-1R in Ba/F3 
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cells (Ba/F3fCSF-1R) permitted proliferation in response to rh-CSF-1 and removed 
the dependence of these cells for IL-3. Cells were cultured in rh-CSF-1 prior to 
collection of cell lysate for western blot analysis.  Cell lysate was collected from both 
Ba/F3 cells transfected with feline CSF-1R, but also a Ba/F3 cell transfected with 
empty pEF6 vector as a negative control.  A band at 150 kDa, corresponding to the 
predicted size of the feline CSF-1R is clearly visible for the feline CSF-1R cell 
lysate, with no band identified for the negative control (Figure 4.2).  
 
 
Figure 4.2:  Western blot of transfected Ba/F3 cells expressing feline CSF-1R.   
Ba/F3fCSF-1R cells were cultured in rh-CSF-1 for 4 days prior to harvesting and preparation of cell 
lysate.   Immunoblotting was performed using the V5-epitope for detection of the protein.  
 
4.2.2 Species specificity of CSF-1  
Mouse and human CSF-1 are readily available as recombinant proteins expressed in 
bacteria.  Human CSF-1 is active on mouse CSF-1R, but not vice versa (Hume et al., 
1988; Roussel et al., 1988; Wiktor-Jedrzejczak et al., 1991).  Mouse CSF-1 
expressed by L929 fibroblasts was shown previously to be active on the porcine 
CSF-1R expressed on peripheral blood mononuclear cells and bone marrow 
progenitor cells (Genovesi et al., 1989; Mayer, 1983), but the precise efficacy was 
not previously determined.  I therefore tested their relative efficacy on the porcine 
CSF-1R using the Ba/F3pCSF-1R cells.  As shown in Figure 4.3, the ligands from 
the two species had almost identical half maximal effective concentrations.    





Figure 4.3:  The activity of recombinant human and mouse CSF-1 on porcine CSF-1R expressed in 
Ba/F3 cells.    
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
optimized cell viability assay with either human or mouse CSF-1 for 48 hours.  Following the addition 
of MTT solution and solubilization, optical density was read at 570nm using a plate reader.  Results 
show the average of triplicate determinations.  Experiment repeated three times. 
 
The observation that mouse CSF-1 is as active as human on the pig CSF-1R (Figure 
4.3), indicated that the pig provides an apparent intermediate between the species, 
enabling analysis of the molecular basis of the species-specificity.  The planned 
experiments to be carried out in-vivo in this thesis also envisaged the use of the 
mouse as an initial model to test the efficacy of recombinant pig proteins.  I therefore 
assessed the biological activity of porcine CSF-1 on the mouse CSF-1R. Using the 
previously optimized cell viability assay (Chapter 3), mouse bone marrow 
macrophages (BMM) were cultured in the presence of 10
4
 Units/ml rh-CSF-1, or 
increasing concentrations of HEK pEF6_pCSF-1 supernatant (Figure 4.4A), or 
increasing concentrations of  purified recombinant porcine CSF-1 (Figure 4.4B).  
There was a dose-dependent increase in BMM survival with HEK pEF6_pCSF-1 
supernatant (Figure 4.4A) or purified recombinant porcine CSF-1 (Figure 4.4B).  
 




Figure 4.4:  The activity of cloned secreted porcine CSF-1 transfected into HEK293T cells and 
purified recombinant porcine CSF-1 on mouse BMDM.    
Mouse bone marrow cells were harvested and cultured for 5 days with rh-CSF-1 prior to use in a cell 
viability assay with HEKpEF6_pCSF-1 supernatant.  Mouse BMMs were harvested, washed twice in 
PBS and cultured with either 20% or 50% supernatant from transfected HEK293T cells with porcine 
CSF-1 (A), or purified recombinant porcine CSF-1 (B) for 48 hours. Following addition of MTT 
solution and solubilization, optical density was read at 570nm using a plate reader.  Results are the 
average of triplicate determinations + SEM. Experiment repeated twice. 
 
The cell viability assay previously optimised for Ba/F3 cells expressing porcine CSF-
1R was used with the same optimized conditions (20,000 cells/well and 48 hour 
incubation) using Ba/F3 cells expressing feline CSF-1R.  Using this assay, both the 
parent Ba/F3 and Ba/F3 cells expressing feline CSF-1R survived and proliferated in 
IL-3 (Figure 4.5).  With the removal of IL-3, the now CSF-1 dependent Ba/F3fCSF-
1R cells produced comparable levels of cell proliferation using 1000ng/mL of rh-
CSF-1 compared to 10% IL-3.   




Figure 4.5:  The activity of recombinant human CSF-1 on feline CSF-1R expressed in Ba/F3 cells.    
Ba/F3fCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
optimized cell viability assay with human CSF-1 for 48 hours.  Following addition of MTT solution 
and solubilization, optical density was read at 570nm using a plate reader.  Results are the average of 
triplicate determinations + SEM. Experiment repeated three times. 
 
Human, mouse and porcine recombinant CSF-1 allowed the Ba/F3 cells expressing 
feline CSF-1R to survive, but with distinct efficacy (Figure 4.6).  The actual EC50 
differs between experiments.  Because the cells consume the factor, the assay is 
sensitive to precise cell number and duration.  In a side-by-side comparison, mouse 
CSF-1 was substantially less active than human CSF-1 (Figure 4.6A) whereas 
human and pig CSF-1 demonstrated virtually identical activity on the feline CSF-1R 
(Figure 4.6B), comparable to their activity on the pig CSF-1R (Chapter 3, Figure 
3.15). 
 




Figure 4.6: The activity of recombinant human, mouse or purified recombinant porcine CSF-1 on 
feline CSF-1R expressed in Ba/F3 cells.    
Ba/F3fCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
optimized cell viability assay with recombinant human (Rh), mouse (Rm) (A), or porcine (Rp) CSF-1 
(B) for 48 hours.  Following addition of MTT solution and solubilization, optical density was read at 
570nm using a plate reader.  Results are the average of triplicate determinations.  Experiment repeated 
three times. 
 
Porcine and human CSF-1 had identical activity on the cloned feline CSF-1R 
expressed in Ba/F3 cells (Figure 4.6B).  To extend these findings to feline primary 
cells, and to the dog, I obtained primary bone marrow cells from both species.  This 
part of the experiment was required to advance my knowledge on the cross-species 
activity of porcine and human CSF-1 and secondly to optimize the conditions to 
culture these cells as it had not been previously reported.  Surplus feline bone 
marrow obtained from a bone marrow aspirate and flushed canine bone marrow cells 
were harvested and cultured (10x10
6
 cells) with either porcine, human CSF-1 or no 
growth factors for 12 days.  By day 5 of differentiation, canine and feline bone 
marrow cells with no growth factors were no longer viable (Figure 4.7 Canine A & 
feline D).  Conversely, numerous macrophages were attached to the culture dish in 
cultures containing either rh-CSF-1 (Figure 4.7 Canine B & Feline E) or porcine 
CSF-1 (Figure 4.7 Canine C & Feline F).  Bone marrow progenitor cells from both 
species proliferated, became adherent and differentiated into a mature population of 
bone marrow derived macrophages (BMDM) (Figure 4.7), although the canine 
primary cells apparently responded less well compared to feline with porcine CSF-1 
(Figure 4.7 Canine C & Feline F).  Hence, porcine CSF-1, like human CSF-1, is 
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biologically active in all mammal species tested.  The species barrier appears to be 
restricted to the relative lack of activity of the mouse protein on human cells.  From 
this result, I have demonstrated that canine bone marrow cells can be cultured in rh-
CSF-1 to allow development of macrophages for further assessment.  Additionally, I 
have also cultured canine PBMC with rh-CSF-1 (data not shown).  This aspect of the 
work is being pursued further by another student.  
 
 
Figure 4.7:  The effect of human and purified recombinant porcine CSF-1 on canine and feline 
bone marrow cells.   
Canine bone marrow cells were flushed from the left femur, cells harvested and washed in PBS. Cells 
were cultured in either no growth factors (A), rh-CSF-1 (B) or porcine CSF-1 (C) for 12 days.  For 
feline cells, surplus bone marrow from a bone marrow aspirate sample was harvested.  Cells were 
cultured for 12 days with either no growth factor (D), human CSF-1 (E), or porcine CSF-1 (F). 
 
Bone marrow-derived macrophages have been produced in large numbers from 
frozen and thawed bone marrow cells of the pig, providing a reproducible and 
renewable resource for macrophage studies in vitro (Kapetanovic et al., 2012).  To 
extend this system to the cat, feline primary bone marrow cells were flushed and 
harvested from the femur of a euthanized domestic cat and PBMC were isolated 
using Lymphoprep (Axis-shield).  Previous reports isolating feline PBMC have used 
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Ficoll-Hypaque (Arai et al., 2000; Bienzle et al., 2003; Takano et al., 2007).  The 
reported composition and quantity of cells obtained when using either of these two 
products is not reported to be significantly different, thus, either product could be 
used for the effective isolation of human PBMC (Yeo et al., 2009).  The PBMC 
numbers that I obtained are comparable to others of feline PBMC obtained using the 
Ficoll gradient.  This suggests that either product (Lymphoprep or Ficoll-Hypaque) 
can also be used successfully in the cat. 
 
In line with other studies that have cultured  BMC, using this flushed bone marrow 
technique (Kapetanovic et al., 2012), feline PBMC (Figure 4.8A) and BMC (Figure 
4.8B) cultivated in rh-CSF-1 increased in number, granularity, and size, and became 
adherent over an 8 day period, demonstrating clear macrophage-like morphology.  
Cells not cultured with CSF-1 did not adhere, grow or survive.  Cytospin analysis of 
both the CSF-1 driven macrophage populations showed that the cells are granular, 
vacuolated and with cytoplasmic processes (Figures 4.8C & 4.8D).  This was 
particularly evident for the bone marrow-derived-macrophages (Figures 4.8B & 
4.8D).  Both macrophage populations of primary cell populations were potently 
phagocytic and ingested particles after one hour of incubation (Figure 4.9).  This 
result demonstrates that feline CSF-1R in its native context is able to bind and 
respond to human CSF-1.  By analogy to Kapetanovic et al. (2012), this method 
would allow the freezing of marrow progenitors from euthanized cats for multiple 
future studies in-vitro.  




Figure 4.8: Culture of feline monocyte derived and bone marrow derived macrophages with rh-
CSF-1.   
Feline BMC and PBMC were isolated as described in materials and methods.  Both PBMC (A) and 
BMC (B) were cultured with rh-CSF-1 for 8 days.  Cells were harvested by gentle repeated flushing 
with a needle and syringe and 0.5 x 106 cells/mL used for cytospin.  Following cytospin, PBMC(C) 
and BMC (D) slides were stained with Leishman’s stain for identification of macrophage nuclei.  
 
 
Figure 4.9:  The phagocytic activity of feline bone marrow (BMC) and monocyte derived (PBMC) 
macrophages using FITC-labelled Zymosan particles.   
Feline BMC (A) and PBMC (B) were cultured for 10 days in rh-CSF-1, prior to the addition of FITC-
labelled Zymosan particles for one hour.  Fluorescence was visualized by fluorescence microscopy.  
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4.2.3 Species specificity of IL-34 
Previous studies suggest that CSF-1 and IL-34 bind different parts of the CSF-1R 
(Garceau et al., 2010), but with similar outcomes in terms of the survival and 
proliferation of human blood monocytes and colony formation from bone marrow 
progenitors (Lin et al., 2008).  Recombinant mouse and human IL-34 became 
commercially available from R&D Systems during the course of this project.  Both 
products are the more active isoforms that include an indel (+Q81) generated by an 
alternative splice acceptor (Wei et al., 2010), which is also present in the pig IL-34 
gene (Section 3.2.1). The comparative efficacy of recombinant human and mouse 
IL-34 was assessed on the Ba/F3 cells expressing porcine CSF-1R (Figure 4.10A).  
By contrast to their differential effects on mouse cells, mouse and human IL-34 were 
almost equally active on the pig receptor (Figure 4.10A).  Human IL-34 was found 
to have a similar activity to rh-CSF-1 on the porcine CSF-1R (rhIL-34 EC50 
137ng/ml and rhCSF-1 EC50 100ng/ml) (Figure 4.10B).  This finding indicates that 
pig is an intermediate species in which it will be possible to test therapeutic 
applications of recombinant human IL-34.  
 
Figure 4.10:  The activity of recombinant human IL-34 and CSF-1 and mouse IL-34 on porcine 
CSF-1R expressed in Ba/F3 cells.    
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
optimized cell viability assay with recombinant human (rh), mouse (rm) IL-34 (A) or recombinant 
human (rh) IL-34 or  CSF-1 (B) for 48 hours.  Following addition of MTT solution and solubilization, 
optical density was read at 570nm using a plate reader.  Results are the average of triplicate 
determinations + SEM. Experiment repeated three times. 
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In contrast to CSF-1, human IL-34 is considerably less active than the mouse protein 
in stimulating CSF-1R-mediated mouse macrophage proliferation (Wei et al., 2010). 
This conclusion was confirmed by comparing the ability of mouse and human IL-34 
to promote the growth and differentiation of mouse bone marrow cells.  Detectable 
proliferation was observed only at the highest concentration of human IL-34 tested 
(1000ng/ml) (Figure 4.11), while mouse IL-34 produced cell proliferation in a dose-
dependent manner.  
 
 
Figure 4.11:  The activity of recombinant human and mouse IL-34 on mouse bone marrow 
macrophages.   
Mouse bone marrow cells were flushed from the femur of an 8-week old BALB/c mouse, washed in 
RPMI by Valerie Garceau of the Hume Lab, and cultured for 7 days with rh-CSF-1. Following 
differentiation of cells into bone marrow macrophages, cells were harvested, washed twice with PBS 
and cultured in the optimized cell viability assay with human or mouse IL-34 for 48 hours.  Following 
addition of MTT solution and solubilisation, optical density was read at 570nm using a plate reader.  
Results are the average of triplicate determinations + SEM. Experiment repeated twice. 
 
The same differential sensitivity was confirmed in bone marrow-derived 
macrophages.  Mouse BMCs were cultured for 7 days with the addition of 
1000ng/mL of either recombinant mouse or human IL-34 or human CSF-1 and 
assessed for the presence of macrophage-like populations using the microscope 
(Figure 4.12).  Mouse bone marrow cells cultured with human (Figure 4.12A) or 
mouse IL-34 (Figure 4.12B) produced adherent populations of cells with distinct 
macrophage morphology, however, the cells cultured with human IL-34 (Figure 
4.12A) were less confluent and demonstrated a more rounded morphology compared 
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to the mouse IL-34 population.  Both IL-34 culture dishes were less confluent than 
the dish using rh-CSF-1 at the same concentration (Figure 4.12C).  
 
Figure 4.12:  Culture of mouse bone marrow derived macrophages with either human or mouse IL-
34 or human CSF-1.   
Mouse bone marrow cells were flushed from the femur of an 8-week old BALB/c mouse, washed in 
RPMI by Valerie Garceau of the Hume Lab, and cultured for 7 days with either 1000ng/ml rh-IL34 
(A), 1000ng/ml rm-IL-34 (B) or 1000ng/ml rh-CSF-1(C). 
 
Since IL-34 is known to be more species restricted than CSF-1, the actions of IL-34 
on the feline CSF-1R were examined.  In the cell viability bioassay with Ba/F3 cells 
expressing feline CSF-1R, both human and mouse IL-34 were able to bind and 
activate the feline CSF-1R, in a dose-dependent manner (Figure 4.13), but the EC50 
for mouse IL-34 on the feline CSF-1R was approximately threefold higher than for 
human IL-34.  This has been identified for other interleukins investigated in the cat: 
mouse IL-4 produces a much weaker response on feline DC cells compared to human 
IL-4 (Bienzle et al., 2003; Wei et al., 2010).  Both human (Figure 4.14A) and mouse 
(Figure 4.14B) recombinant IL-34 were substantially less active than CSF-1, 
suggesting that neither is a perfect replacement for the feline IL-34.  
 
 




Figure 4.13:  The activity of recombinant human and mouse IL-34 on feline CSF-1R expressed in 
Ba/F3 cells.    
Ba/F3fCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
optimized cell viability assay with recombinant human (rh), or mouse (rm) IL-34 for 48 hours.  
Following addition of MTT solution and solubilization, optical density was read at 570nm using a 
plate reader.  Results are the average of triplicate determinations.  Experiment repeated three times. 
 
 
Figure 4.14:  The activity of recombinant human and mouse IL-34 and CSF-1 on feline CSF-1R 
expressed in Ba/F3 cells.    
Ba/F3fCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
optimized cell viability assay with either recombinant human (rh) IL-34 or CSF-1 (A) or recombinant 
mouse (rm) IL-34 or CSF-1 (B) for 48 hours.  Following addition of MTT solution and solubilization, 
optical density was read at 570nm using a plate reader.  Results are the average of triplicate 
determinations.  Experiment repeated three times. 
 




The work in this chapter confirmed the published cDNA and protein sequence of 
feline CSF-1R and stably cloned the cat receptor into the Ba/F3 cell line. Activation 
of feline CSF-1R  by recombinant human CSF-1 was previously tested by Woolford 
et al. (1988).  Expression of oncogenic forms of feline CSF-1R in Rat-2 cells, which 
ordinarily are unable to grow in soft agar (Lania et al., 1979), permitted the  
formation of colonies in soft agar upon the addition of human CSF-1 (Woolford et 
al., 1988).  However, the native receptor was insufficient to cause transformation 
even in the presence of human CSF-1. This study also gave no insight into relative 
efficacy.   
 
The production of stable cell lines expressing porcine (Chapter 3) and feline CSF-
1R provided a convenient bioassay.  Furthermore, I developed a system to harvest, 
culture and preserve companion animal macrophages.  Using commercially available 
recombinant proteins, and recombinant porcine CSF-1, I have been able to dissect 
the species-specificity of CSF-1 and IL-34.  Porcine CSF-1 was able to activate 
porcine (Chapter 3, Figure 3.14), murine (Figure 4.4), feline (Figure 4.6), and 
canine (Figure 4.7) CSF-1 receptors with similar efficacy, a property shared by 
recombinant human CSF-1 (Abrams et al., 2003; Genovesi et al., 1989; Hume et al., 
1988; Woolford et al., 1988).  Conversely, mouse CSF-1 which lacks activity on 
human cells (Das and Stanley, 1982; Mayer, 1983; Roussel et al., 1988), was able to 
activate the porcine receptor (Figure 4.3) and to a lesser extent, the feline receptor 
(Figure 4.6A).  Publication of the mouse CSF-1:CSF-1R contact amino acids (Chen 
et al., 2008) permits a structure-based analysis of receptor specificity.  There must be 
a difference between human, mouse and porcine CSF-1R and between mouse and 
human CSF-1 to explain the differential activity across species.  There are 19 contact 
amino acids between mouse CSF-1 and CSF-1R (Chen et al., 2008), 13 of which are 
conserved across species (Table 4.1).  The remaining 6 amino acids (His6, Asn13, 
Phe55, Glu 78, Arg79, Asn85 in mouse) are different in both pig and human CSF-1.  
Figure 4.15 highlights these non-conserved amino acids and their location on the 
binding surface of mouse (Figure 4.15A), pig (Figure 4.15B) and human (Figure 
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4.15C) CSF-1.  Of these, only 2 also have a corresponding change in the CSF-1R 
contact amino acid between all three species, His6 and Glu78.   
 
 
Table 4.1:  Table of contact amino acids between mouse, human and porcine CSF-1 and CSF-1R.   
Bold indicates conserved amino acids between these three species.  
 
 
MCSF1 PCSF1 HCSF1 MCSF-1R PCSF1R HCSF1R 
Asp59  Asp Asp Arg146 Arg Arg 
Glu78  Val Val Lys151 Gln His 
Glu78  Val Val Lys168 Lys Lys 
Met10  Met Met Tyr257 Tyr Tyr 
Asn13  Asp Ser Asp251 Asp Asp 
Gly14  Gly Gly Arg146 Arg Arg 
Gln58  Gln Gln Arg150 Arg Arg 
Asp62  Asp Asp Arg150 Arg Arg 
Asn85  Leu Leu Leu170 Ile Ile 
His6  Asn Tyr Val231 Gly232 Val, His Val, Asn 
His9  His His Val231 Ser250 Tyr257 Val, Ser, Tyr Val, Ser, 
Tyr  
Met10  Met Met Val231 Tyr257 Val & Tyr Val Tyr 
Gly12  Gly Gly Asp251 Asp Asp 
Asn13  Asp Ser Asp251 Asp Asp 
Gly14  Gly Gly Asp251 Phe252 Asp, Phe Asp, Phe 
His15  His His Phe252 Tyr257 Phe, Tyr Phe, Tyr 
Phe55  Leu Leu Arg146 Arg Arg 
Gln58  Gln Gln Arg142 Arg146 Leu, Arg Arg, Arg  
Asp62  Asp Asp Leu149 Arg150 Leu, Arg  Met, Arg 
Arg66  Arg Arg Arg150 Arg Arg 
Arg79  Gln Gln Phe252 Asn255 Phe, Asn Phe, Asn  
Gln81 Gln Gln Leu149 Leu Met 
Glu82  Glu Glu Val169 Phe Phe 
Asn85  Leu Leu Leu170 Ser172 Asn173 Ile, Gly, Gln Ile, Ser, Gln 
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Glu78 of the mouse CSF-1 is Val78 in both human and porcine CSF-1.  Glu78 
contacts Lys151 on the mouse CSF-1R, which is His151 in human CSF-1R.  The 
bulkier amino acid at this position could constrain the binding of the mouse protein 
(Figures 4.16 A,B & C).  In the pig, Lys151 is replaced with Gln, structurally 
similar but smaller and uncharged.  The same substitution occurs in the cow, which 
can also respond to mouse CSF-1 (Adler et al., 1994).  His6 forms Van der Waals 
contacts with Gly232 in the mouse receptor.  However, in this position, dog and cow 
share Asn232 with human, where pig has His232.  So, this variation is less likely to 
determine binding specificity.  Since mouse CSF-1 was less active than human CSF-
1 at stimulating feline CSF-1R, the same differences in CSF-1 contact amino acids 
(His6, Asn13, Phe55, Glu 78, Arg79, Asn85 in mouse) between these species may be 
the answer to this reduction in activity.  His6 is conserved in the cat, is Asn in pigs, 
but is the bulky aromatic amino acid, Tyr, in humans.  Amino acids 78 and 79 of 
CSF-1 are Glu and Arg (positive) in mice, Val and Thr in cat (neutral), and Val and 
Gln (neutral) in both human and porcine CSF-1.  Collectively, these differences 
could explain why mouse CSF-1 can bind the pig (Figure 4.3) and cat CSF-1R 
(Figure 4.6A), but not the human receptor.  In this respect, the cat CSF-1R is 
idiosyncratic compared to the other species tested.  Having established the bacterial 
expression system for the pig CSF-1 protein, structure function predictions can be 










Figure 4.15:  3D models of non-conserved contact amino acids between human and mouse and 
porcine CSF-1 and CSF-1R.   
3D models demonstrating the charged amino acid changes of human, porcine and mouse CSF-1 were 
generated using the PDB file for mouse CSF-1 (3EJJ) was used as a template for both human and 
porcine CSF-1 models.  Published contact amino acids of mouse CSF-1 were analysed and non-
conserved contact amino acids highlighted using First Glance (http://firstglance.jmol.org).  (A) 3D 
model of mouse CSF-1 non-conserved contact amino acids, (B) 3D model of porcine CSF-1 non-
conserved contact amino acids and (C) human CSF-1non-conserved contact amino acids.  Positively 
charged atoms are represented by blue and negatively charged atoms by red.  Medium blue atoms 
denote partially charged atoms. 
 
 
Figure 4.16:  3D models of non-conserved contact amino acids between mouse, human and porcine 
CSF-1 binding sites of CSF-1R.   
3D models highlighting the non-conserved CSF-1 contact binding sites of mouse, human and porcine 
CSF-1R.  Human and mouse CSF-1R models were generated using the PDB file 4DKD (human) and 
4EXP (mouse).  Porcine CSF-1R was generated using human CSF-1R (4DKD) as a template).  The 6 
non-conserved amino acids involved in CSF-1 binding to CSF-1R (Glu78, Asn13, Asn85, His6, 
Phe55, Arg79) were identified and the corresponding binding site of CSF-1R identified (A) Mouse 
CSF-1R highlighting the position of Lys 151 and Gly 232. (B) Human CSF-1R and (C) Porcine CSF-
1R highlighting these amino acids.  Positively charged atoms are represented by blue and negatively 
charged atoms by red.  Medium blue atoms denote partially charged atoms. 
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Whilst the change from Lys to His on the human CSF-1R does not alter the amino 
acid properties, there is an increase in both the molecular and residue weight which 
could potentially constrain the binding of the mouse protein to the human receptor. 
The substitution of Gly232 in the mouse receptor with the larger Asn232 in the 
human might produce a steric hindrance that is not seen when histidine is substituted 
as in the pig.   
 
Mouse and human IL-34, which lack cross-reactivity across these two species (Lin et 
al., 2008), were both active on the porcine receptor (Figure 4.10A) and feline CSF-
1R, again the mouse ligand was less active on the feline receptor (Figure 4.13). 
Human IL-34 and CSF-1 were similarly active on the pig CSF-1R (Figure 4.10B) 
but with the cat receptor, the EC50 for human IL-34 was substantially higher than for 
CSF-1 (Figure 4.14B).  The contact amino acids between human CSF-1R and IL-34 
have also recently been published (Ma et al., 2012b).  As is the case with CSF-1, 
logically, the CSF-1R from mouse, human and pig must differ from each other in 
contact amino acids with IL-34. Figures 4.17A and 4.17B show the models of 
human and mouse CSF-1R viewed from the perspective of IL-34, highlighting the 
contact amino acids that are not conserved between human and mouse.  The 
sequence alignment in Figure 3.3 of Chapter 3, shows that the contiguous binding 
patch from amino acid 169-173 is VLDSNT in mouse CSF-1R, FIEGQD in pig CSF-
1R and FIQSQD in human CSF-1R.  CSF-1R contact amino acids 248 and 249 are 
Pro and Leu in mouse, Ser and Gln in pig and Pro and Gln in human.  A third 
significant difference between the species exists around amino acid 144-150 of the 
CSF-1R. Gly103 in IL-34, which is conserved in mouse, human and pig, forms a salt 
bridge with Arg142 and Arg146 in human CSF-1R (Ma et al., 2012b).  In mouse, the 
sequence is REGGR, in human it is RVRGR and in pig, there is a complex insertion 
of 6 amino acids relative to all other mammalian CSF-1R (LLRRLSVLPGR) 
(Figure 3.3 Chapter 3).  The amino acid differences between the receptors from 
mouse and human also cause subtle changes in the predicted topology, as shown in 
Figures 4.17A and 4.17B.  If we consider the ligand IL-34, Figures 4.17C and 
4.17D show the binding faces of human and mouse ligands, again highlighting the 
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non-conserved contact amino acids.  Despite the substantial conservation across 
species, and low DN/DS ratios, noted by Garceau et al. (2010), the majority of the 
amino acids shown are divergent between mouse, pig and humans.  For example, 
amino acids 127 to 134 are NVQQGLTD in human, DVRQGLAG in pig and 
NVQRSLMD in mice.   
Again, the differences between the species probably reflect differences in CSF-1R 
contact amino acids for IL-34 that may account for the reduced activity of mouse IL-
34 on the cat CSF-1R.  The difference that is most likely to disrupt function is 
Gln258 (human and cat) which is substituted with a charged Lys in the mouse CSF-
1R.   The availability of the crystal structure for the human CSF-1/IL-34 complexes 
with CSF-1R permits a structure-based modelling of the same complexes in other 
species.  The contact residues for the ligands are not conserved across species.  The 
human and feline CSF-1R binding sites for CSF-1 and IL-34 differ by 7 non-
conserved amino acids (Figures 4.18A and 4.18B).  Similarly, there are 10 contact 
amino acid differences between mouse and feline CSF-1R for the CSF-1 and IL-34 
binding sites (Figures 4.18C and 4.18D).  Since the cat and dog CSF-1R also differ 
from each other (Chapter 3, Figure 3.3), and from mouse, human and pig, in the 
key contact amino acids, cross-species reactivity of IL-34 will probably need to be 
determined empirically.  Accordingly, there is no simple model to explain the species 
specificity of IL-34 actions and despite the apparent overall conservation of IL-34 
(Garceau et al., 2010), the contact amino acids are under positive selection, 
consistent with a role in the immune system.   
 
 





Figure 4.17:  3D models of non-conserved contact amino acids between human and mouse CSF-1R 
and IL-34.   
3D models demonstrating the charged amino acid changes of human and mouse CSF-1R and IL-34 
were generated using the PDB file 4DKD (human) and 4EXP (mouse).  Published contact amino acids 
for both human and mouse CSF-1R and IL-34 were analysed and non-conserved contact amino acids 
highlighted using First Glance (http://firstglance.jmol.org).  (A) 3D model of human CSF-1R non-
conserved amino acids for IL-34 binding and (B) mouse CSF-1R non-conserved amino acids for IL-
34 binding. (C) 3D model of human IL-34 non-conserved contact amino acids and (D) 3D model of 
mouse IL-34 non-conserved contact amino acids.  Positively charged atoms are represented by blue 
and negatively charged atoms by red.  Medium blue atoms denote partially charged atoms. 
 
 







Figure 4.18: 3D models of non-conserved CSF-1 and IL-34 contact amino acids between human, 
mouse and cat CSF-1R.   
3D models demonstrating the charged amino acid changes between human (A) and cat (B) CSF-1R 
and between mouse (C) and cat (D) CSF-1R.  Models were generated using the PDB files for the 
mouse CSF-1R (3EJJ) and the human CSF-1R (4DKD chain X).  The mouse PDB file (3EJJ) was 
used as a template to generate the cat CSF-1R.  Published contact amino acids for both human and 
mouse CSF-1R binding sites for CSF-1 and IL-34 were analysed and non-conserved contact amino 
acids highlighted using First Glance (http://firstglance.jmol.org).  Non-conserved amino acids for 
CSF-1 binding are represented by black numbers; red numbers indicate CSF-1 and IL-34 binding, 
while blue numbers indicates IL-34 binding. Positively charged atoms are represented by blue and 
negatively charged atoms by red.  Medium blue atoms denote partially charged atoms.   
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Both recombinant human and porcine CSF-1 proteins can activate feline and canine 
CSF-1Rs using bone marrow aspirates, bone marrow flushing or isolated PBMC 
(Figures 4.7 and 4.8).  An earlier study by Daniel et al. (1993) noted that feline 
primary bone marrow cultures could be successfully maintained without the addition 
of exogenous CSF-1 due to the production of CSF-1 by the adherent bone-marrow 
cell population.  This is a rather less-reproducible and inefficient approach.  Bone-
marrow cells can be frozen and thawed, so that cells preserved from a small number 
of animals can provide a long-term resource for studies of macrophage biology.  
 
In conclusion, I have confirmed that IL-34 is more constrained in its mammalian 
species cross-reactivity than CSF-1.  The pig has potentially emerged as an 
intermediate species in which human CSF-1 and IL-34 proteins may be further 
investigated.  Additionally,  I have developed an in-vitro system for the study of 
feline and canine macrophages which will allow further investigation of macrophage 
related diseases and the effects of therapy on these cells.  The feline CSF-1R has 
been cloned and expressed in Ba/F3 cells and used to assess the activity of non-
species-specific CSF-1 and IL-34.  This assay also offers the possibility of screening 
for antagonists, including blocking antibodies, which might have applications in 
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Chapter 5: Effects of porcine CSF-1 and Fc 
CSF-1 on adult mice 
 
5.1 Introduction  
Chapter 3 demonstrated that both porcine CSF-1 produced from transfected 
HEK293T cells, and purified recombinant porcine CSF-1 expressed in bacteria, can 
activate the porcine CSF-1R expressed in a factor-dependent cell line and is as active 
in mice as the human protein.  Prior to in-vivo assessment of the porcine CSF-1 
molecule in its target species, the biological actions, safety and dose-titration needed 
to be assessed in mice.  The Csf1r-EGFP
+
 (Macgreen) transgenic mice provided a 
novel and valuable tool enabling visualization of tissue macrophage populations as 
means to document efficacy.   
 
As discussed in the introduction (Chapter 1, Section 1.3.1), CSF-1 is produced in 
multiple protein isoforms.  The major circulating form is a proteoglycan, and the 
peptide backbone is also longer than the minimal active 150 amino acid fragment. 
Nevertheless, CSF-1 has a very short half-life in the circulation of mice (1.6 hours) 
(Bartocci et al., 1987).   By fate tracing 
125
I-labeled CSF-1, Bartocci et al. (1987) 
showed that CSF-1 is mainly cleared from the circulation by CSF-1R mediated 
internalization and degradation by Kupffer cells of the liver, although renal excretion 
also plays a role.  Studies investigating the effects of CSF-1 in-vivo have often used 
intravenous routes of administration to deliver a high dose of CSF-1 to maintain 
plasma CSF-1 concentrations, or have used high-dose and/or prolonged therapy 
protocols (Hume et al., 1988; Lloyd et al., 2009).  In this circumstance, receptor-
mediated clearance is saturated.  The recombinant active protein produced in bacteria 
is well below the renal clearance threshold of around 68kDa (the size of albumin), 
and consequently the majority of any injected bolus dose is cleared by the kidney.  
The original studies of human CSF-1 actions in mice by Hume et al. (1988), used the 
longer glycoprotein form of the protein produced in mammalian cell culture.  It was 
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active with daily injections of around 0.5 to 1mg/kg. Subsequent studies using the 
protein expressed in bacteria indicated a 5-10 fold higher dose was required to 
achieve an increase in circulating monocyte numbers (Doyle et al., 1992).  
One method of extending circulating half-life of biological proteins may include 
modification with polyethylene glycol (PEG).  PEGylation has been used previously 
to increase the effective molecular size of several cytokines (Interferon2α, rhG-CSF, 
rhGM-CSF, SCF, MGDF), to extend the plasma retention by reducing urinary 
excretion (Cortes et al., 2011; Hokom et al., 1995; Kaminskas et al., 2013; Kinstler et 
al., 1996; Molineux et al., 1994).  PEGylation was used to increase the half-life of an 
Fab fragment of anti-CSF-1 antibody (Wei et al., 2005).  Although PEGylation 
reduces receptor binding affinity, increased exposure of the protein to target 
receptors generally increases therapeutic efficacy (Kang et al., 2009).    However, 
there are exceptions.  The modification of recombinant human G-CSF with PEG, 
significantly reduced in-vitro biological activity without any reduction in in-vivo 
circulating times (Tanaka et al., 1991).  An alternative that has been inspired by the 
relative high rate at which therapeutic antibodies have been approved is the 
production of conjugates with the Fc region of immunoglobulin (Beck and Reichert, 
2011).  Aside from increasing the molecular size, such conjugates bind the recycling 
neonatal Fc-receptor (FcRN) which salvages the protein from endosome degradation 
(Czajkowsky et al., 2012; Kuo and Aveson, 2011).  This prolongs the activity of the 
molecule which may allow less frequent dosing of patients (Powell et al., 2012).  The 
most studied example is Fc-erythropoietin (EPO), which is in clinical use.  
Erythropoietin, like CSF-1, is another 4 helix bundle cytokine.  Remarkably, the 
FcRN-mediated transport was able to carry Fc-EPO across the lung epithelia 
allowing pulmonary delivery (Bitonti et al., 2004).  The Fc-EPO molecule has been 
produced in plants (Castilho et al., 2013)  and in chicken eggs (Penno et al., 2010), a 
technology currently being explored at The Roslin Institute to produce the porcine 
CSF-1 Fc fusion protein described here.   
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The presence of an Fc domain attached to the molecule enables interaction with Fc-
receptors (FcRs) on immune cells (Nimmerjahn and Ravetch, 2008), and for some 
Fc-fusion proteins can modulate Fc functions and allow participation in antibody-
dependent cellular cytotoxicity and complement-dependent cytotoxicity (Landolfi, 
1991; Tseng et al., 2010).  Some Fc-fusion proteins have modification of the Fc 
domain to improve these immune functions (Czajkowsky et al., 2012).  Furthermore, 
the stability of proteins is improved both in-vivo and in-vitro by the addition of an Fc 
domain with additional advantages including to allow for easier expression and 
purification (Beck and Reichert, 2011).  There are several other reports of Fc fusion 
proteins with growth factors or cytokines, including IL-2 (Landolfi, 1991) and IL-10 
(Zheng et al., 1995), IL-15  (Xia et al., 2008) and G-CSF (Cox et al., 2004), several 
of which, like EPO, are structurally related to CSF-1.  Czajkowsky et al. (2012), 
reported that there are currently six Fc-fusion based drugs on the market, with four in 
phase 3 clinical trials.  
While it is clear that the addition of an Fc domain can not only improve the 
availability of its fusion partner but also it can improve effector functions, the 
addition of an Fc region to proteins can be associated with reduced biological 
activity, as evident from early efforts with erythropoietin (EPO) (Schriebl et al., 
2006; Way et al., 2005).  Subsequent studies have concentrated on producing an Fc 
EPO molecule with greater biological activity by modifications such as 
rearrangements in the disulphide bond to improve activity (Way et al., 2005), 
generation of monomeric-EPO Fc (Bitonti et al., 2004), fusing to “hybrid Fc (IgD 
and IgG4 regions) (Yang et al., 2012), or, fusing full-length EPO (Zhu et al., 2008).  
In fact, some Fc fusion proteins such as the fibroblast growth factor-Fc fusion 
actually require higher concentrations to produce the same effects as the un-fused 
protein (Dikov et al., 1998).  The discrepancy in activity is likely due to differences 
in binding affinities (Van Den Brande et al., 2003) or stoichiometry (Horiuchi et al., 
2010).  
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Based upon all of the precedents, our partners produced a porcine CSF-1 active 
fragment conjugated to CH-3 region of porcine IgG1a.  The IgG1a was chosen over 
other classes of immunoglobulins since human IgG1a has a circulating half-life of 21 
days.  This level of stability is not commonly seen with fusion proteins, but there is 
commonly a substantial improvement (Dikov et al., 1998).  The success of this 
approach in increasing the plasma half-life of porcine CSF-1 was assessed in weaner 
pigs for plasma CSF-1 concentrations (Chapter 6, Figure 6.1).  Some Fc-fusion 
proteins require biological “chaperones” that act to stabilise the fused protein in an 
effort to retain biological activity.  Therefore an essential step in optimizing and 
developing the porcine Fc CSF-1 protein was to evaluate its binding properties in-
vitro by using the optimized cell viability assay (Figure 5.1).  There was also the 
formal possibility that the Fc conjugate would stimulate macrophages directly 
through their Fc receptors.  So, this Chapter aimed to assess the relative activities of 
the two forms of porcine CSF-1 in mice before progressing to a larger animal. 
 
The original study of CSF-1 actions in mice used the macrophage-restricted surface 
marker F4/80 to detect effects on blood monocytes and tissue macrophages (Hume et 
al., 1988).  The F4/80 antibody  detects a member of the EGF-TM7 family of surface 
receptors (McKnight and Gordon, 1996), now known as EMR1.  However, the F4/80 
antigen is not expressed on all cells of the mononuclear phagocyte system (Hume, 
2006).   To overcome this, mice expressing EGFP from the Csf1r 7.2 Kb promoter 
consisting of the promoter, first intron and part of exon 2 were generated by 
Sasmono et al. (2003).  In these cells, all CSF-1 dependent cells express the 
transgenic EGFP reporter.  These mice have been used extensively in many studies 
to locate tissue macrophages in organs, tumours and disease models (Alikhan et al., 
2011; MacDonald et al., 2010; Menke et al., 2009; Qian et al., 2009; Thomas et al., 
2011).  It was later discovered that the expression of Csf1r-EGFP actually detects all 
myeloid cells including granulocytes.  This accurately reflects the fact that Csf1r 
mRNA, but not the protein, is expressed by neutrophils (Sasmono et al., 2007).  The 
Csf1r-EGFP mice
+
 were used to demonstrate the depletion of tissue macrophages 
following treatment with anti-CSF-1R antibody (MacDonald et al., 2010).  Inter alia, 
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this study found that EGFP levels varied amongst monocyte subsets, with the higher 




 cells which are believed to be precursors of resident 
macrophages (MacDonald et al., 2010).  
 
CSF-1 has previously been used in clinical trials in humans with advanced melanoma 
(Cole et al., 1994; Jakubowski et al., 1996) and as a therapy for fungal disease 
(Nemunaitis et al., 1993).  Treatment of humans with rh-CSF-1 has been well-
tolerated and demonstrated the ability to increase monocyte numbers.  However, 
thrombocytopenia has been a dose limiting toxicity that can be reversed upon 
caseation of treatment.  The thrombocytopenia has been attributed to the activation of 
the monocyte-macrophage system rather than by the development of antibodies or 
derangements in platelets themselves (Abrams et al., 2003).  The work in this chapter 
addresses not only the efficacy of the Fc CSF-1, but also the possibility that the Fc 
CSF-1 may be used as a therapeutic agent.  
 
5.2 Results 
5.2.1 Comparing biological activity of porcine CSF-1 with 
porcine Fc CSF-1 in-vitro 
Data in Chapter 4 demonstrated that porcine CSF-1 is biologically active on the 
mouse CSF-1R.  However, since CSF-1 absolutely requires dimerization to signal, 
and Fc also dimerizes, it was not self-evident that the Fc CSF-1 would retain 
biological activity.  Accordingly, the protein as tested in parallel with native 
recombinant porcine CSF-1 on the Ba/F3pCSF-1R cell assay described in Chapter 
3, and on pig bone marrow cells.  Rather surprisingly, since the Fc CSF-1 protein is 
more than twice as large (43 KDa compared to 25 KDa), it was equally active on a 
ng/ml basis on the cell line, and even more active on pig marrow cells (Figure 5.1).  
The latter observation could possibly reflect some contribution of Fc receptor 
signalling or FcRN-mediated recycling, but was not investigated further. Clearly, the 
Fc fusion does not compromise biological activity.  The next step was to perform in-
vivo studies assessing porcine CSF-1 and Fc CSF-1.  





Figure 5.1: The effect of recombinant porcine CSF-1 and porcine Fc CSF-1 on Ba/F3pCSF-1R 
cells and primary bone marrow cells.    
Ba/F3pCSF-1R cells cultured in rh-CSF-1 were harvested, washed twice in PBS and cultured in the 
optimized cell viability assay with either porcine CSF-1 or porcine Fc CSF-1 48 hours.  Pig bone 
marrow cells were flushed from an adult pig rib and placed in culture with either porcine CSF-1 or 
porcine Fc CSF-1 48 hours.  Following addition of MTT solution and solubilization, optical density 
was read at 570nm using a plate reader.  Results are the average of triplicate determinations + SEM. 
Experiment repeated three times. 
 
5.2.2 In-vivo studies comparing porcine CSF-1 with porcine 
Fc CSF-1  
To test the relative efficacy of the Fc CSF-1, mice were injected with either PBS as 
control, or 1 µg/g of either porcine CSF-1 or porcine Fc CSF-1.  This dose was 
chosen because is comparable to previous studies injecting mice with rh-CSF-1 
(Alikhan et al., 2011; Chapoval et al., 1998; Hume et al., 1988).  The administration 
of recombinant human CSF-1 to mice has been shown to increase body weight 
compared to litter-mate controls (Alikhan et al., 2011; Lloyd et al., 2009; Wiktor-
Jedrzejczak et al., 1991).  After 4 days, there was a significant increase in the body 
weight of the mice injected with porcine Fc CSF-1 compared to either CSF-1 or PBS 
control (p=0.0018) (Figure 5.2A).  Figure 5.2B demonstrates that male mice of the 
same age are larger and the increase in body weight is mainly attributed to the male 
Fc CSF-1 treated mice.  Previous studies injecting CSF-1 into mice have traditionally 
used male mice because of the short oestrous cycle in females (4 days) and the 
potential for progesterone to desensitize macrophages to CSF-1 and oestrogen to 
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decrease the production of CSF-1 (Eastell, 2005; Hapel et al., 1985; Hume et al., 
1988).   
 
 
Figure 5.2:  Effect of porcine CSF-1 and Fc CSF-1 on body weight of adult Csf1r-EGFP
+ 
mice.   
Csf1r-EGFP
+ 
mice were injected with PBS, porcine CSF-1 or porcine Fc CSF-1 for four days prior to 
sacrifice on day 5.  Body weight was recorded before each injection.  Total body weight change over 
the duration of the experiment was graphed (A) and shows individual mice, mean weight change (thin 
black line) + SEM (thicker black lines).  Male mice are represented by colour red.  Additionally, the 
mean body weight from each group was graphed over time (B).  A Kruskal-Wallis test with Dunn’s 
multiple comparison test was performed with significance set as *p<0.05, **p<0.01, ***p<0.001. 
 
The most obvious effect of the Fc CSF-1 was hepatosplenomegaly, which was 
visibly evident upon necropsy.  Administration of porcine Fc CSF-1 almost doubled 
the size of the spleen (p=0.0027) (Figure 5.3A) and increased the liver weights by 
nearly 50% (p=0.00193) (Figure 5.3B), whereas the un-conjugated CSF-1 had no 
effect relative to the PBS control. 
 










mice were injected with PBS, porcine CSF-1 or porcine Fc CSF-1 for four days prior to 
sacrifice on day 5.  Spleen and liver were removed post-mortem and weighed.  Each individual mouse 
spleen (A) and liver (B) weights are shown.  Graphs show the mean (thin black line) + SEM (thicker 
black lines).  Male mice are represented by colour red. A Kruskal-Wallis test with Dunn’s multiple 
comparison test was performed with significance set as *p<0.05, **p<0.01, ***p<0.001. 
 
The first study with CSF-1 in mice reported expansion of the CSF-1 responsive 
population in the bone marrow (Hume et al., 1988).  The Csf1r-EGFP reporter gene 
used in the current study permitted a reanalysis of this phenomenon.  To determine 
the monocyte/macrophage populations in bone marrow cells flushed from the femur, 
cells were double stained with the macrophage specific antibody F4/80 (Austyn and 
Gordon, 1981) and myeloid marker Gr1.  Gr1 antibody cross-reacts with Ly6C and 
Ly6G; the latter is restricted to granulocytes.  F4/80 is expressed on bone marrow 
progenitors with expression increasing with cell maturity (Hirsch et al., 1981; Lee et 
al., 1985).  Although macrophages defined by F4/80 expression can be identified in 
most tissues in the body, the antigen is relatively weakly expressed or absent in 
subpopulations of cells in the lung and lymphoid organs (Sasmono et al., 2003).   As 
expected, the administration of porcine Fc CSF-1 produced an increase in the number 
of EGFP
+
 cells in the bone marrow of adult mice (p=0.0034) (Figure 5.4A).  Again, 




 cells was 
marginally increased relative to CSF-1, but not to PBS (Figure 5.4B).  Conversely, 




cells in the Fc CSF-1-
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treated mice (Figure 5.4C).  These observations would suggest that there is a relative 
expansion of immature myeloid cells.  It is possible that mature F4/80
+
 cells are 
leaving the marrow, in view of the large increases in their numbers elsewhere.  
 
 






 cell populations 
of adult Csf1r-EGFP
+ 
mice.   
Csf1r-EGFP
+ 
mice were injected with PBS, porcine CSF-1 or porcine Fc CSF-1 for four days prior to 
sacrifice on day 5.  Fresh bone marrow cells were harvested from each mouse femur and prepared for 










 populations (C) 
were determined using Summit 5 analysis by gating on alive cells.  The graphs show the result for 
each individual mouse with the mean (thin black line) + SEM (thicker back lines).  A Kruskal-Wallis 
test with Dunn’s multiple comparison test was performed with significance set as *p<0.05, **p<0.01, 
***p<0.001. 
 
The administration of rh-CSF-1 to mice can increase populations of F4/80
+ 
macrophages in many organs (Cecchini et al., 1994; Hume et al., 1988).  The Csf1r-
EGFP
+
 reporter mice also provided a unique tool to re-examine this effect in detail.  
Tissues collected post-mortem from mice injected with PBS, porcine CSF-1 or 
porcine Fc CSF-1 were processed to allow quantification of the Csf1r-EGFP 
transgene.  The amount of fluorescence was quantified using Image J by counting the 
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number of fluorescent particles and the total fluorescence per 400x field of view 
from 5 representative sections.  The administration of porcine Fc CSF-1 caused a 
significant increase in the number of EGFP
+
 cells in the lung (p=0.0092) spleen 
(p=0.0124), and liver (p=0.0271) (Figure 5.5A), and therefore increased the total 




Figure 5.5:  Effect of porcine Fc CSF-1 on adult Csf1r-EGFP
+
 mice tissue populations.  
Csf1r-EGFP
+ 
mice were injected with PBS, porcine CSF-1 or porcine Fc CSF-1 for four days prior to 
sacrifice on day 5.  Organs were removed post-mortem and frozen as cryosections (see materials and 
methods) prior to cutting and examination of EGFP
+
 cells at  x400 magnification.  Tile images of 3x3 
x400 field of view were generated (A) and the total number of EGFP
+ 
cells calculated along with 
mean total fluorescence + SEM from five representative images/mouse/organ (B).   RP=red pulp, 
WP=white pulp.  A Kruskal-Wallis test with Dunn’s multiple comparison test was performed with 
significance set as *p<0.05, **p<0.01, ***p<0.001. 




In the lung of Fc CSF-1 treated mice, the increase in EGFP
+
 cells appeared to be 
confined to the interstitium (additional images in Chapter 8, Appendix 2).  The 
spleen of PBS control mice demonstrates the location of EGFP
+
 cells described 
previously, concentrated within the marginal zone of lymphoid follicles and within 
the red pulp (Sasmono et al., 2003).  There is a diffuse network of positive cells 
within lymphoid follicles (the white pulp), the so-called inter-digitating dendritic 
cells.  The numbers of these cells were shown previously to be expanded with CSF-1 
treatment (MacDonald et al., 2005).  The increased numbers and diffuse infiltration 
of EGFP
+
 cells within the spleen of Fc CSF-1 treated mice made it impossible to 
identify the boundaries of the red and white pulp, implying that there was extensive 
infiltration of the lymphoid follicles by EGFP
+
 cells (Figure 5.5A).  In the liver the 
EGFP reporter gene is expressed in Kupffer cells which constitute about 8% of the 
whole population (Sasmono et al., 2003).  The relative proportion of EGFP
+ 
cells was 
increased around 2-fold by Fc CSF-1 (Figures 5.5A/B).  The location of the positive 
cells was unchanged, and was consistent with the sinusoidal location of Kupffer 
cells.  This was the only site where there was an apparent effect of CSF-1, but there 
was significant variation between the mice, and it has not been replicated.  
This initial in-vivo experiment demonstrated that porcine Fc CSF-1 is more potent 
than the unconjugated CSF-1 at stimulating CSF-1 dependent macrophages and 
increasing the body weight of adult mice.   
 
5.2.3 Dose titration study of porcine Fc CSF-1 
The dose chosen for the initial trial with Fc CSF-1 was approximately equal to the 
dose used in early studies with the large form of human CSF-1 (Hume et al., 1988).  
To test where it might have even greater efficacy, a dose-response trial was carried 
out.  Mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g of porcine 
Fc CSF-1 daily for 4 days and sacrificed on day 5.  As before, the effect of porcine 
Fc CSF-1 on body weight, organ weights, tissue macrophage populations and bone 
marrow cells were determined.  Additionally, whole blood was harvested and 
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assessed for monocyte count by differential count and by FACS with antibodies 
against the F4/80 and Gr1 antigens.  
As seen in the preliminary in-vivo experiment (Figure 5.2), 1 µg/g of porcine Fc 
CSF-1 increased the body weight of mice with a trend towards an effect at the next 
two lower doses (Figure 5.6).  Consistent with the marginal effect on body weight, 
the effects of  Fc CSF-1 on organ weight were only significant at the highest dose 
administered (Figure 5.7). 
 
 









mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine 
Fc CSF-1 for four days prior to sacrifice on day 5.  Body weight was recorded before each injection.  
Total body weight change over the duration of the experiment was graphed.  Graphs show the mean 

















mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine 
Fc CSF-1 for four days prior to sacrifice on day 5.  Spleen, liver, lung and kidney were removed post-
mortem and weighed.  The mean organ weight of 4 mice/treatment group (thin black line) + SEM 
(thicker black line) is graphed.   A Kruskal-Wallis test with Dunn’s multiple comparison test was 
performed with significance set as *p<0.05, **p<0.01, ***p<0.00. 
 
In the first in-vivo experiment, blood was harvested for FACS assessment of EGFP
+
 
cells but due to technical issues with effect red cell lysis, no results were obtained.  
In this titration experiment, a manual white blood cell differential count revealed a 
dose-dependent significant increase in the total white blood cell (p=0.0042) and a 
very large increase in monocyte counts (p=0.066), in the mice injected with porcine 
Fc CSF-1 (Figure 5.8).  Unexpectedly, there were also increases in neutrophils and a 
marginal increase in lymphocytes, which were less clearly dose-dependent (Figure 
5.8).  There was no effect of Fc CSF-1 treatment on eosinophil or basophil numbers 
(data no shown).  




Figure 5.8:  Effect of porcine Fc CSF-1 on white blood cell counts of adult Csf1r-EGFP
- 





mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine 
Fc CSF-1 for four days prior to sacrifice on day 5.   Blood was collected into EDTA tubes post-
mortem and sent to the R(D)SVS clinical pathology lab for complete blood count assessment.  The 
differential blood cell count was obtained. The graphs show the mean of four mice/treatment group + 
SEM.  A Kruskal-Wallis test with Dunn’s multiple comparison test was performed with significance 
set as *p<0.05, **p<0.01, ***p<0.00. 
 
Figure 5.9 shows the impact of Fc CSF-1 doses on blood, bone marrow and spleen 
cell populations detected by FACS.  The results were rather more variable between 
individuals; the most convincing changes were an increase in the proportion of 
F4/80
+
 cells in blood and bone marrow.  The effect of the lowest dose on blood 
profiles appears to be an outlier, but has not been repeated (Figure 5.9A).  
Conversely, the proportion of Gr1
+ 
cells, which includes granulocytes, was less 
affected (Figure 5.9B).  Figure 5.9 also confirms the large increase in F4/80 
macrophage numbers in the spleen at the highest dose tested. 













mice.   
Csf1r-EGFP
- 
wild-type mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine 
Fc CSF-1 for four days prior to sacrifice on day 5.   Blood, spleen and BM were prepared for FACS as 




(B) cell populations were 
determined after exclusion of dead cells using Sytox blue.  The graphs show the mean of four 
mice/treatment group + SEM.  
 
To link the cellular phenotyping with events occurring in the bone marrow, sections 
were cut and stained with H&E for histological analysis of the cellularity by Prof. 
Elspeth Milne, a specialist in Veterinary Pathology.  No overt pathological features 
distinguished the control from treated mice (Figure 5.10A).  Mice treated with the 
highest dose of porcine Fc CSF-1 were identified as having a 20-25% increase in the 
myeloid:erythroid ratio (M:E) (p=0.0408) (Figure 5.10B). The controls had an M:E 
ratio entirely consistent with published values  for mouse and rat, reported to be 1.49 
(Travlos, 2006). 









mice.   
Csf1r-EGFP
- 
wild-type mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine 
Fc CSF-1 for four days prior to sacrifice on day 5.  The right femur from each mouse were harvested 
and prepared for histological examination.  Representative images of 1 µg/g Fc CSF-1 treated and 
PBS control mice are shown (A). The myeloid:erythroid ratio was determined and graphed as the 
mean of four mice/treatment group  + SEM (B).  Significance is indicated by *p<0.05, **p<0.01, 
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Together with RANK ligand, CSF-1 can activate multiple intracellular signalling 
pathways resulting in osteoclast-specific genes involved in proliferation, survival and 
differentiation, such as tartrate-resistant acid phosphatase (TRAP) (Kikuta and Ishii, 
2012).  The ostopetrosis in the op/op  mouse is due to an almost complete lack of 
osteoclasts (Marks and Lane, 1976), which can be rescued by administration of 
exogenous CSF-1 (Felix et al., 1990a).  Exogenous CSF-1 has been reported to 
promote intramembranous ossification in wound healing (Alexander et al., 2011), 
and macrophages interact with osteoblasts to promote calcification (Chang et al., 
2008).  Hence, there were several reasons to expect a possible impact of Fc CSF-1 
upon bone.   Osteoclasts (OCL) express Tartrate-resistant acid phosphatase (TRAP) 
which can be identified using immunohistochemistry.  Under normal conditions OCL 
are present in the epiphyseal plate under the zone of hypertrophy.  The OCL within 
this region called “zone of cartilage degeneration” are responsible for the transition 
from cartilage to bone.  The administration of 1 µg/g of porcine Fc CSF-1 caused an 
obvious increase in the number of TRAP
+ 
osteoclasts within the epiphyseal plate 
(P=0.0066) compared to PBS control mice (Figures 5.11A/5.11B).  No osteoclasts 
were noted with any of the other epiphyseal plate regions.  There appeared to be an 
increase in OCL in the diaphysis of the bone in the treated mice, but this did not 
reach statistical significance.    
 
 




Figure 5.11:  Effect of porcine Fc CSF-1 on osteoclast numbers of adult wild-type Csf1r-EGFP
- 
mice.   
Csf1r-EGFP
- 
mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice 
on day 5.  The right femur from each mouse was harvested and prepared for TRAP IHC (A).  The 
numbers of positive cells in each section were counted and the mean of four mice/treatment group + 
SEM graphed (B).  Significance is indicated by *p<0.05, **p<0.01, ***p<0.001 using a Mann-
Whitney test.  Black arrows represent OCL in epiphyseal plate.  
 
Following collection of lung, liver and spleen from mice post-mortem and 
preparation of slides with H&E, slides were examined blind by Dr Pip Beard, The 
Roslin Institute, for the presence of any Fc CSF-1 induced pathology.  No significant 
pathology was noted from any of the lung or kidney sections.  This was unexpected 
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as I identified a significant increase in the number of lung EGFP-positive cells in 
Csf1r-EGFP
+
 mice in the initial in-vivo experiment (Figure 5.5) and lung weight was 
increased in this current study (Figure 5.7).   
 
As shown in Figure 5.3, a major effect of Fc CSF-1 is to increase the size of the 
spleen 2-3 fold. The spleen is divided into areas of red and white pulp.  The red pulp 
is the site of haematopoiesis in rodents particularly in neonatal mice and contains 
reticular fibres, reticular cells and macrophages (Cesta, 2006).  It is the red pulp that 
acts as a blood filter and removes foreign material and exhausted red blood cells.  In 
contrast, the white pulp that surrounds central arterioles is composed of lymphoid 
cells and initiates immune responses against blood borne antigens (Cesta, 2006).  
White pulp is composed of periarteriolar lymphoid sheath (PALS), follicles (F) and 
marginal zone (MZ).  The follicles contain mainly B cells and may contain germinal 
centres formed by antigenic stimulation.  Macrophages are found within the marginal 
zone that separate the PALS from red pulp (Hume et al., 1983).  Marginal zone 
macrophages can be reduced by anti-CSF-1R treatment, unlike red pulp macrophages 
(MacDonald et al., 2010).  Examination of sections of spleen identified that mice 
injected with Fc CSF-showed a perifollicular histiocytic “collar” of cells surrounding 
the lymphoid follicles in the white pulp (Figure 5.12), thus increasing the MZ 
thickness.  This was evident only in mice treated with the highest 3 doses of Fc CSF-
1.  The finding that these mice also have a greater increase in the number of F4/80
+
 
cells compared to Gr1
+ 
cells in a single cell spleen suspension of cells using flow 
cytometry (Figures 5.9A/B) indicates that the histiocytic cells are likely to be F4/80
+ 
macrophages.  To confirm this, F4/80 immunohistochemistry was performed on the 
spleens.  
 




Figure 5.12:  Effect of porcine Fc CSF-1 on spleen pathology of adult wild-type Csf1r-EGFP
- 
mice.   
Csf1r-EGFP
- 
mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine Fc CSF-1 
for four days prior to sacrifice on day 5.  The spleen was removed post-mortem and placed in 10% 
formal saline prior to sections being cut and stained with H&E for blind histological examination.  
Representative images of 1 µg/g Fc CSF-1 treated and PBS control mice are shown. F=follicle, 
MZ=marginal zone, RP=red pulp.  Images from Dr Pip Beard.  
 
As detailed earlier, macrophages of the spleen are located within the MZ and red 
pulp and are renewed by bone marrow-derived blood monocytes that proliferate in 
response to CSF-1, compared to the red pulp, white pulp is usually devoid of 
macrophages and is renewed by local proliferation (Wijffels et al., 1994).  Previous 
reports of injecting mice with rh-CSF-1 have demonstrated an increase in the number 
of F4/80
+ 
macrophages within the non-lymphoid red pulp region, with no effect on 
germinal centre formation (Hume et al., 1988).  I have identified a significant 
increase (p=0.0391) in the number of F4/80
+ 
cells within the red pulp by the 
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administration of porcine Fc CSF-1 to mice (Figure 5.13A/B).  From Figure 5.13A, 
it can clearly be seen that there are very few F4/80
+ 
macrophages within the white 
pulp of normal mouse spleen and the majority of the F4/80
+ 
cells are within the 
marginal zone and red pulp regions.  As the dose of Fc CSF-1 increases the number 
of F4/80
+ 
cells increases which can be seen visually (Figure 5.13A), and also by 
quantification using Image J (Figure 5.13B).  Since red pulp macrophages are 
known to be CSF-1 independent, the presence of the cells within the red pulp of my 
mice spleens highlights that it is most likely the marginal zone CSF-1-dependent 
F4/80
+ 
macrophages that have expanded in response to Fc CSF-1 treatment into the 
red pulp region.  Additionally, in the highest treatment group (1 µg/g), there appears 
to be an expansion of F4/80
+ 
cells into the white pulp B cell follicles (Figure 5.13A), 
a process reported to occur during immune responses by the MZ macrophages (den 
Haan and Kraal, 2012).  Similar to Hume et al. (1988), no immunological activation 








Figure 5.13:  Effect of porcine Fc CSF-1 on F4/80-positive macrophages in the spleen of wild-type 
Csf1r-EGFP
- 
mice.   
Csf1r-EGFP
- 
mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine Fc CSF-1 
for four days prior to sacrifice on day 5.  The spleen was removed post- mortem and prepared for 
F4/80 IHC.  Slides were examined under x100 magnification for the identification of F4/80-positive 
cells (brown). Representative slides from each treatment group are shown (n=4) (A).  The number of 
F4/80-positive cells per x200 field of view from each mouse was obtained using Image J (B).  Graph 
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The liver of mice treated with the Fc CSF-1 had marked sinusoidal infiltrate 
consisting of histiocytes, lymphocytes and neutrophils (Figure 5.14A).  The severity 
of the sinusoidal infiltrate increased with dose (Figure 5.14B), with a significant 
increase in sinusoidal infiltrate noted for the highest treatment group (p=0.0032).  
Although the presence of anisocytosis in the livers of mice is a strain-specific feature 
(Hedrich and Bullock, 2004), the degree of variation of cell size was considered 
above the normal expected level and was associated with increasing dose (Figures 
5.14A/B).  Figure 5.14C shows a representative image from a control PBS mouse 
liver.  Mitotic figures are a rare finding in mice livers (Roos et al., 1995), but were 
specifically associated with the highest treatment group (Figures 5.14A/B).  
The macrophage marker F4/80 has previously been shown to identify liver 
macrophages (Hume et al., 1983; Lee et al., 1985).  Immunohistochemistry using this 
antigen has demonstrated there was a significant increase (p=0.0073) in the number 
of F4/80
+ 
cells in the liver of Fc CSF-1 treated mice compared to control PBS mice 
(Figure 5.15A/B).  From the representative images in Figure 5.15A, it can be seen 
that the amount of F4/80
+ 
cells increased as the dose of Fc CSF-1 increased and this 
was further quantified using Image J (Figure 5.15B).  In control liver, the F4/80 in 
the liver increased towards the peri-portal regions and declined around the central 
vein.  Whilst in the Fc CSF-1 treated mice, the F4/80
+ 
cells were almost uniformly 
distributed.  




Figure 5.14:  Effect of porcine Fc CSF-1 on liver pathology of adult wild-type Csf1r-EGFP
- 
mice.   
Csf1r-EGFP
- 
mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine Fc CSF-1 
for four days prior to sacrifice on day 5.  The liver was removed post-mortem and placed in 10% 
formal saline prior to sections being cut and stained with H&E for blind histological examination.  
Representative images at x400 magnification of Fc CSF-1 treated mice are shown (A).  Full arrow 
demonstrates increased sinusoidal infiltrate; dashed arrow highlights anisocytosis and MF=mitotic 
figure.  The severity of sinusoidal infiltrate, anisocytosis and number of mitotic figures are graphed 
(B) which shows the mean + SEM.  Significance is indicated by *p<0.05, **p<0.01, ***p<0.001 
using a Mann-Whitney test.  A representative image from control PBS mouse liver is also shown (C).  
 
 




Figure 5.15:  Effect of porcine Fc CSF-1 on F4/80-positive macrophages in the liver of adult wild-
type Csf1r-EGFP
- 
mice.   
Csf1r-EGFP
- 
mice were injected with PBS, 1 µg/g, 0.5 µg/g, 0.1 µg/g or 0.05 µg/g porcine Fc CSF-1 
for four days prior to sacrifice on day 5.  The liver was removed post-mortem and placed in 10% 
formal saline prior to sections being cut and stained with F4/80.  Slides were examined under x100 
magnification for the identification of F4/80 positive cells (brown). Representative slides from each 
treatment group are shown (A).  The number of F4/80-positive cells per x200 field of view from each 
mouse (n=4/treatment group) was obtained using Image J (B).  Graph shows mean + SEM.  
Significance is indicated by *p<0.05, **p<0.01, ***p<0.001 using a Mann-Whitney test. 
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5.2.4 Effect of 1 µg/g porcine Fc CSF-1 on adult mice 
The results thus far have demonstrated that 1 µg/g of porcine Fc CSF-1 consistently 
induces an increase in blood monocytes, tissue macrophage populations, organ 
weights and body weights.  The changes that occurred in the liver were especially 
marked and clearly warranted further investigation.  I therefore performed a larger 
study using this dose to dissect further the effect of Fc CSF-1 on liver proliferation.  
Additionally, due to the increase in TRAP
+
 OCL in the treated mice and the recent 
study by Lloyd et al. (2011) demonstrating that CSF-1 can alter bone density, the 
effect of Fc CSF-1 on bone density was further investigated.  
For this study, 24 C57BL/6 mice were used consisting of equal numbers of male and 
female treated and control mice (n=6).  Consistent with the preliminary finding, there 
was a significant increase in total body weight gain in the Fc CSF-1 treated group 
(p=0.0002) compared to control PBS group (Figure 5.16).   Further analysis by sex 
has revealed that it is the females that contributed the most to this weight increase 
(males p=0.274 and females p=0.0058).   
 
Figure 5.16:  Effect of porcine Fc CSF-1 on body weight of adult C57BL/6 mice.   
C57BL/6 mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  Body weight was recorded before each injection.  Total body weight change over the duration 
of the experiment was graphed.  Graphs show the mean (thin black line) + SEM (thicker black lines).  
Male mice are represented by red colour.  Significance is indicated by *p<0.05, **p<0.01, 
***p<0.001 using a Mann-Whitney test. 
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The administration of 1 µg/g of porcine Fc CSF-1 increased the spleen and liver 
weights in the preliminary experiments (Figures 5.3 & 5.7).   Due to variation in 
body weight between mice, a more sensitive method of detecting a true difference 
between control and treated groups is to measure organ-liver weight ratios (Bailey et 
al., 2004), Amemiya et al. (2011).  Both liver (p=<0.0001) and spleen-body weight 
ratios (p=<0.0001) increased significantly in the mice treated with porcine Fc CSF-1 
compared to PBS control mice (Figure 5.17).  There was no difference in kidney or 
lung weights either analysed/per organ/mouse or when expressed as organ-body 
weight ratios.  
 
 
Figure 5.17:  Effect of porcine Fc CSF-1 on organ-body weight ratio of adult C57BL/6 mice.  
C57BL/6 mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  At post-mortem organs were weighed and individual mouse organs graphed as proportion of 
body weight.  Graphs show the mean (thin black line) + SEM (thicker black lines).  Significance is 
indicated by *p<0.05, **p<0.01, ***p<0.001 using a Mann-Whitney test.  
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The total white blood cell count was significantly increased in mice treated with 
porcine Fc CSF-1 compared to control mice (p=0.0051), and is above the reference 
range reported for this age of mice.  From the results it is clear that the overall 
leukocytosis is due to a monocytosis (p=0.0007) and neutrophilia (p=<0.0001) 
(Figure 5.18).  There was no significant reduction in lymphocytes, which were 
previously found to be reduced by the administration of CSF-1 (Hume et al., 1988; 
Ulich et al., 1990).  This is the expected result for the monocyte count and initially 
demonstrates that Fc CSF-1 can influence the neutrophil count perhaps via induction 
of GM-CSF (Evans et al., 1998; Hume et al., 1988).  This result is in agreement the 
earlier findings (Figure 5.8).   
 
Figure 5.18:  Effect of porcine Fc CSF-1 on white blood cell count of adult C57BL/6 mice.   
C57BL/6
 
mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  Blood was collected into EDTA tubes post-mortem and sent to the clinical pathology lab for 
complete blood count assessment.  The differential blood cell count was obtained. The graphs show 
the mean (thin black line) + SEM (thicker black line).  Significance is indicated by *p<0.05, 
**p<0.01, ***p<0.001 using a Mann-Whitney test. 
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The function of CSF-1 in osteoclast biology and bone density is evident from the 
phenotype of the op/op mouse (Harris et al., 2012).  The rescue of the op/op mouse 
osteopetrosis with CSF-1 was previously assessed with micro-CT, and bone densities 
are found to be restored to wild-type after rescue (Abboud et al., 2002).   There is a 
known difference between male and female C57BL/6 mice with respect to their bone 
density and age-related declines in distal femoral trabecular bone volume is more 
pronounced in females than males (Glatt et al., 2007).  Male mice have a higher 
percentage bone volume, trabecular number, trabecular thickness and connectivity 
density, whereas females have a higher structure model index.  In agreement with 
this study, other lab members have also demonstrated these sex-related differences in 
C57BL/6 and Csf1r-EGFP
+
 mice in a study investigating the effects of anti-CSF-1R 
treatment to these mice
11
.  Femurs from control and treated mice were sent to Dr Rob 
van’t Hof, The University of Edinburgh for micro-CT scan and analysis.  Trabecular 
bone measurements were taken since trabecular bones are more metabolically active 
than cortical bone and provide a more sensitive measure of bone density (Reinbold et 
al., 1986).  There was no difference in any of the bone measurements between PBS 
control mice and porcine Fc CSF-1 treated mice, although there was a clear 
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Figure 5.19:   Effect of porcine Fc CSF-1 on bone density of adult C57BL/6 mice.  
C57BL/6
 
mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  The left femur form each mouse was placed in 4% PFA for 16 hours prior to storage in 70% 
ethanol.  Micro-CT scan and analysis was performed by Dr Rob van’t Hof, The University of 
Edinburgh.  The graphs show the mean (thin black line) + SEM (thicker black line).  Male mice are 
represented by red colour (A).  Representative images of male and female PBS and Fc CSF-1 treated 
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 cells in the bone marrow (Figures 5.4 & 
5.9).  This analysis was repeated again on fresh bone marrow cells harvested from 





 (p=0.0006) cells in mice treated with porcine Fc CSF-1 (Figure 5.20).  
 
Figure 5.20:  Effect of porcine Fc CSF-1 on bone marrow F4/80 and Gr1 populations of adult 
C57BL/6 mice.   
C57BL/6
 
mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  Bone marrow cells were flushed from the femurs post-mortem and prepared for FACS as 
described in materials and methods.  The percentage of F4/80 and Gr1 cell populations were 
determined by exclusion of dead cells using Sytox blue.  The graphs show the mean (thin black line) + 
SEM (thicker black line).  Significance is indicated by *p<0.05, **p<0.01, ***p<0.001 using a Mann-
Whitney test. 
 
Evidence that CSF-1 is involved in up-regulation of macrophage IGF-1 comes from 
immunohistochemical identification of IGF-1 and IGF-1R localised in the tibia of 
normal and tl/tl rats following treatment with rh-CSF-1 (Joseph et al., 1999).  
Additionally these rats have a gross deficiency of circulating IGF-1 that correlates 
with the defective postnatal growth (Gow et al., 2010).  Conversely in the mouse, 
injection of rh-CSF-1 can increase circulating IGF-1 alongside the increase in 
postnatal growth (Alikhan et al., 2011).  Based upon these findings, IGF-1 
expression was investigated using immunohistochemistry and serum IGF-1 levels by 
ELISA.  There was no apparent difference in the level of IGF-1 protein or its 
location in the livers of PBS control mice compared to Fc CSF-1 treated mice 
(Figure 5.21A).  The IGF-1-positive cells are concentrated around the portal vein 
(Figure 5.21A, arrow), which is the normal distribution reported for rodents (Hazel 
Chapter 5:  Effect of CSF-1 & Fc CSF-1 on adult mice 
158 
 
et al., 1998).  The presence of an IGF-1 peri-portal gradient most likely reflects the 
fact that cells within the liver are functionally zonally distributed.  Peri-portal 
hepatocytes produce IGF-1 that enters the circulation via the hepatic vein to drain 
into the caudal vena-cava.  There was no obvious association of IGF-1 
immunoreactivity with Kupffer cells.  Interestingly, the mice treated with porcine Fc 
CSF-1 appeared to have significantly lower circulating levels compared to PBS 
control mice (p=0.0411) (Figure 5.21B).  This is surprising since CSF-1 was shown 
by others to induce circulating IGF-1 in mice treated with the same dose of rh-CSF-1 
(Alikhan et al., 2011).  These mice in the published study were treated with CSF-1 7 
days prior to IGF-1 measurement and the mice in the current study were treated 24 
hours prior to organ sacrifice.  Therefore, the discrepancy in IGF-1 concentrations 








Figure 5.21:  Effect of porcine Fc CSF-1 on liver and serum IGF-1 of adult C57BL/6 mice.  
C57BL/6
 
mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  At post-mortem, the liver was removed, placed in 10% formal saline prior to sections cut and 
stained for IGF-1.  Slides were examined under x100 and x200 magnification for the identification of 
IGF-1-positive cells (brown). Representative slides are shown in figure (A) with arrows indicating the 
portal vein.  EDTA plasma was harvested from blood collected post-mortem into an EDTA.  Plasma 
was frozen at -20
o
C until an IGF-1 ELISA was performed on serum using only male mice plasma in 
duplicate (B).  The graph shows the mean IGF-1 of six mice/treatment group  + SEM. Significance is 
indicated by *p<0.05, **p<0.01, ***p<0.001 using a Mann-Whitney test. 
 
There were no changes identified in the lung, kidney, uterus or ovary of the treated 
mice.  Liver histological examination again revealed sinusoidal infiltrate present in 
all the Fc CSF-1 treated animals.  The infiltrate consisted of darkly stained cells with 
an irregular nucleus and cells with a round to oval nucleus present in sinusoids and 
surrounding vessels in the portal areas (Figure 5.22, arrow).  There was an 
increased number of Kupffer cells lining sinusoids, (detected by F4/80), an increased 
mitotic rate of hepatocytes with an average of 11 mitotic figures and 5 bizarre mitotic 
figures present in 10 high powered fields, similar to the rate that is noted in liver 
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proliferation induced by  Hepatic Growth Factor administration (Roos et al., 1995).  
There was also increased anisocytosis and anisokaryosis of hepatocytes as before 
with an overall loss of normal hepatocyte architecture. 
 
 
Figure 5.22:  Effect of porcine Fc CSF-1 on liver pathology of adult C57BL/6 mice.   
C57BL/6 mice were injected with PBS or 1 µg/g Fc CSF-1 for four days prior to sacrifice on day 5.  
The liver was removed post-mortem and placed in 10% formal saline prior to sections being cut and 
stained with H&E or F4/80 for blind histological examination.   Representative images are shown. 
Arrows represent sinusoidal infiltrate.  H&E images from Dr Pip Beard.  
 
Examination of the spleen confirmed the earlier finding that Fc CSF-1 increases the 
number of cells within the marginal zone (MZ).  There was also diffuse hyperplasia 
of the red pulp most likely due to the presence of marked trilineage haematopoiesis 
(erythroid, myeloid and megakaryocytes) (Figure 5.23). 





Figure 5.23:  Effect of porcine Fc CSF-1 on spleen pathology of adult C57BL/6mice.   
C57BL/6 mice were injected with PBS or 1 µg/g Fc CSF-1 for four days prior to sacrifice on day 5.  
The spleen was removed post-mortem and placed in 10% formal saline prior to sections being cut and 
stained with H&E for blind histological examination.   Representative images are shown. F=follicle, 
MZ=marginal zone, RP=red pulp.  Images from Dr Pip Beard.  
While the increase in hepatic infiltrate in the highest treatment group was noted to be 
severe and can clearly be identified using light microscopy (Figures 5.14A & 5.22), 
this alone was not considered enough to explain the unprecedented 62% increase in 
the weight of the livers (mean PBS liver weight 1.001g, compared to mean Fc CSF-1 
liver weight 1.606g).  By comparison, Roos et al. (1995) identified between 15-37% 
increase in liver weight of mice infused with Hepatocyte Growth Factor (HGF) to 
stimulate liver proliferation compared to control mice.  To determine if Fc CSF-1 
influenced mitotic rate (proliferation), the number of hepatocytes/field of view (x400 
magnification) were counted.  There was a significant increase in the number of 
hepatocytes/field of view in the Fc CSF-1 treated mice livers (p=0.0079) compared 
to PBS controls.   
Mitotic figures are rarely identified in normal liver as cells are in G0 phase of cell 
cycle (Taub, 2004; Zou et al., 2012), but were associated with liver proliferation in 
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mice receiving infusion of HGF (Roos et al., 1995).  In keeping with this finding, no 
mitotic figures were detected in the livers of mice treated with PBS whereas an 
average of 11 mitotic figures and 5 bizarre mitotic figures were present in the liver of 
porcine Fc CSF-1 mice/10 high-powered fields of view.  To further quantify the 
proliferation, immunohistochemistry for proliferating cellular nuclear antigen 
(PCNA) was used to identify cells undergoing mitosis and quantified using Image J.  
PCNA is a protein found in the nucleus that plays a role in initiation of cellular 
proliferation by mediating DNA polymerase.  The level of PCNA staining is broadly 
correlated with the level of mitotic activity since cells undergoing mitosis have high 
levels of PCNA in the S, G2 and M phase of mitosis.  A similar marker of hepatocyte 
proliferation Ki-67 which is present in the nucleus of hepatocytes during active 
phases of cell cycle has been also been shown to correlate with extent of hepatic 
proliferation, although differences in chromosomal affinity exist (van Dierendonck et 
al., 1991; Zou et al., 2012).   
 
Sections of liver, spleen, lung and kidney from both control and treated mice were 
examined blind for PCNA
+
 cells.  There was a significant increase in the number of 
PCNA
+
 cells in the liver (p=0.0033) and spleen (p=0.0013) of Fc CSF-1 treated mice 
compared to PBS control mice (Figures 5.24 & 5.25).  In the liver, the majority of 
PCNA
+
 cells are hepatocytes (Figure 5.24, black arrow), but there are also PCNA
+
 
cells within the sinusoids that resemble Kupffer cells (Figure 5.24A, red arrow) and 
hematopoietic cells (Figure 5.24A, blue arrow).  Both nuclear and cytoplasmic 
PCNA staining was identified in the treated mice livers (Figure 5.24A, dashed 
arrow), with cytoplasmic staining identified in highly mitotic cells (van Dierendonck 
et al., 1991).  Interestingly, the pattern of distribution of the PCNA
+
 cells appears to 
be diffuse throughout the parenchyma and not concentrated around the peri-portal 
region where proliferating hepatic progenitor cells are reported to be located (Duncan 
et al., 2009). This may suggest that hepatic proliferation induced by porcine Fc CSF-
1 has induced mature hepatocyte proliferation analogous to that seen after partial 
hepatectomy (Michalopoulos, 2010), a process by which mice are known to derive 
hepatocytes from pre-existing hepatocytes (Malato et al., 2011).  




Figure 5.24:  Effect of porcine Fc CSF-1 on liver PCNA in adult C57BL/6 mice.  
C57BL/6
 
mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  Following harvest of organs and preservation in 10% formal saline, 8 µm sections were cut 
and PCNA immunohistochemistry performed.  Slides from each mouse were examined for the 
presence of PCNA-positive cells (brown colour) from which a representative sample is included (A).  
The mean number of PCNA-positive cells + SEM is graphed (B). Black arrow= bi-nucleate 
hepatocyte, dashed arrow= cytoplasmic PCNA staining, red arrow= Kupffer cells, blue arrow= 
PCNA-positive haematopoietic cells.  
 
The spleens from both control and treated mice contained PCNA
+
 cells.  There was 
clearly a greater number of PCNA
+ 
cells within the white pulp of the treated mice 
spleens (Figure 5.25A/B), compared to the control where the PCNA
+ 
cells are 
sporadically present throughout the entire section. The PCNA
+ 
cells within the white 
pulp may indicate proliferation of white pulp macrophages which are known to 
undergo local proliferation (Wijffels et al., 1994) or marginal zone macrophages that 
have migrated from red pulp into the white pulp (Figure 5.13A) in response to Fc 
CSF-1 stimulation. 
There was no difference in PCNA
+ 
cells from both the kidney and lungs of treated 
mice compared to control mice (Figure 5.25).   




Figure 5.25:  Effect of porcine Fc CSF-1 on spleen, kidney and lung PCNA in adult C57BL/6 mice.   
C57BL/6
 
mice were injected with PBS or 1 µg/g porcine Fc CSF-1 for four days prior to sacrifice on 
day 5.  Following harvest of organs and preservation in 10% formal saline, 8 µm sections were cut 
and PCNA immunohistochemistry performed.  Slides from each mouse were examined for the 
presence of PCNA-positive cells (brown colour) from which a representative sample is included (A).  
The mean number of  PCNA-positive cells + SEM is graphed for spleen (B).  Significance is indicated 
by *p<0.05, **p<0.01, ***p<0.001 using a Mann-Whitney test.   
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5.2.5 Microarray data of liver gene expression  
Gene expression arrays were used to determine whether there were any changes in 
liver function associated with the evident hyperplasia demonstrated in the 
histological examination.  It was also of interest to determine whether the infiltrating 
macrophages were activated to produce inflammatory cytokines and whether there 
was expression of known hepatocyte growth factors.  Following extraction of RNA 
from PBS (n=2) and Fc CSF-1 treated (n=3) mouse livers, the quality was analyzed 
by running the samples on the RNA 6000 LabChip Kit (Agilent).  Samples with a 
RNA integrity number (RIN) greater than 7 were used for microarray. 
All expression data were normalized and using the RMA package within the 
Affymetrix Expression Console software.  The Empirical Bayes function within the 
Bioconductor package
12
 was used to find genes most differentially expressed 
between control (PBS) livers and Fc CSF-1 treated livers.  Using this test, 2969 
transcripts were found to be differentially expressed by at least a 1.5 fold change at 
an adjusted p value of 0.05. 1020 genes were repressed by Fc CSF-1 treatment of the 
liver, and 1948 genes were induced by Fc CSF-1 treatment.  From this list of 
differentially expressed genes, the top 60 most differentially expressed genes were 
identified (Figure 5.26).  The top 30 genes induced by porcine Fc CSF-1 are all 
involved in various aspects of cell cycle/division, including; M phase, cell cycle, 
nuclear division, mitosis, and organelle fission.  Genes induced by porcine Fc CSF-1 
included Serpinb10 which is involved in cellular differentiation and migration 
processes, Ccna2 which encodes Cyclin A2 which function as regulators of CDK 
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Figure 5.26:  Top 60 genes either repressed or induced by porcine Fc CSF-1. 
Microarray data of genes induced and repressed by porcine Fc CSF-1 was generated.  From this list, 
the 30 genes either induced or repressed by Fc CSF-1 were identified by the fold change of the gene.  
The genes were graphed to show the fold change.  
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To evaluate the functional differences between the genes induced and repressed by 
porcine Fc CSF-1, the Gene Ontology Analysis tool DAVID (Database for 
Annotation, Visualization and Integrated Discovery) tool was used (Huang da et al., 
2009a, b) (Figure 5.27).  This showed genes involved cell in cycle, cell division and 
immune response were the main groups of genes induced by porcine Fc CSF-1.  This 
is consistent with cell proliferation and macrophage infiltration.  
 
 
Figure 5.27:  Main gene functional groups influenced by porcine Fc CSF-1 using DAVID gene 
groups.   
Microarray data from mice injected with PBS or porcine Fc CSF-1 was filtered and analysed to show 
genes induced (A) or repressed (B) by porcine Fc CSF-1.  Gene lists were then analysed with DAVID 
to determine the main functional groups.  
 
Clearly the administration of Fc CSF-1 induced genes involved in both cell cycle to 
stimulate hepatic proliferation and macrophage specific genes.  To better 
contextualize the list of differentially expressed genes, their expression data from the 
liver +/- Fc CSF-1 study was analysed alongside that of bone marrow derived 
macrophage (BMDM) data generated from the same strain of mice (C57BL/6) (Raza, 
2011).  Network analysis of the normalized expression data was performed using 
BioLayout Express
3D
 (Freeman et al., 2007; Theocharidis et al., 2009).  Using this 
tool, a Pearson correlation matrix of a transcript-to-transcript profile comparison was 
used to filter for expression correlation relationships of r > 0.96 across the 
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microarray samples.  This generated a graph of 2,555 nodes connected by 265,108 
transcripts (Figure 5.28).  Nodes within the network graph represent transcripts and 
the edges between them represent expression correlations above the set threshold (r 
>0.96 in this case).  To identify groups of tightly co-expressed genes, the graph was 
clustered using the graph-based clustering algorithm MCL (van Dongen and Abreu-
Goodger, 2012) set at an inflation value (which determines the granularity of the 
clusters) of 1.8. 45 clusters of co-expressed genes were generated ranging from 690 
to 4 nodes in membership size.  Gene lists associated with the clusters were exported 
for GO annotation analysis (Biological and Metabolic Processes Level-FAT) again 
using the DAVID (Huang da et al., 2007) (Figure 5.29). 
The clusters delineated patterns of expression based on the changes in the liver upon 
Fc CSF-1 treatment and their expression in BMDMs +/-LPS treatment.  Cluster-1 
comprised 690 transcripts whose expression was repressed in Fc CSF-1 treated livers 
relative to the control, but were absent or low-expressed in the BMDM samples 
(regardless of treatment).  The cluster (-1) was enriched for genes involved in 
catabolism and metabolic processes, suggesting that there is some decline in liver-
specific functions associated with the extensive proliferation.  Cluster-2, (545 
transcripts) contained genes expressed in BMDMs (regardless of LPS treatment) and 
these genes were inducible in Fc CSF-1 treated livers.  This cluster is clearly 
enriched in known macrophage-specific genes, including EMR1 (F4/80) and Csf1r, 
and is consistent with the infiltration of macrophages.  Clusters-3 and 5 also 
contained genes inducible in Fc CSF-1 treated livers, but in contrast to cluster-2, 
these 378 transcripts were down-regulated by LPS in BMDMs.  Both clusters are 
enriched for cell-cycle associated genes; they may differ in the stages of the cycle 
they represent.  Their repression in the macrophages is consistent with the known 
ability of LPS to cause growth arrest in these cells (Sester et al., 1999).  Finally, and 
importantly, there is a cluster of genes (Cluster-4) that is induced by LPS in the 
macrophages, and also induced to some extent in the Fc CSF-1 treated livers.  These 
include inflammatory cytokines such as IL6 and TNFα that are also induced in liver 
regeneration (Fausto, 2000; Zimmermann, 2004).  The set of genes in each of the top 
10 clusters is provided in Appendix 3. 





Figure 5.28:  Network analysis of transcripts found to be differentially expression between control 
and CSF-1 treated livers.   
Expression data for mouse livers +/- CSF-1 was analysed alongside that of bone marrow derived 
macrophage expression data (+/- LPS). A network graph of transcript-to-transcript Pearson correlation 
relationships was filtered to show relationships of r >0.96, resulting in a graph of 2,555 nodes 
(transcripts) connected by 265,108 edges (Pearson correlation relationships). The graph was then 
clustered using the MCL clustering algorithm into groups of co-expressed genes. Nodes with the same 
colour belong to the same cluster of co-expressed genes and tend to be highly connected within the 
network.  




Figure 5.29:  The average expression profiles of transcripts within the five largest clusters of co-
expressed genes.   
 
The size (no of transcripts), the most over-represented G.O. terms, and examples of genes within the 
cluster, are shown to the right-hand-side of each graph. Each point on graph represents individual 
mouse. 




This chapter describes the biological efficacy of an Fc conjugate of porcine CSF-1 
tested in mice.  It was not self-evident, especially since macrophages possess Fc 
receptors, that this molecule would have enhanced activity.  Most importantly, by 
contrast to some fusion proteins, the Fc conjugate did not reduce the activity on the 
receptor in- vitro (Figure 5.1).  Like other fusion proteins such as (IL-10) (Guo et al., 
2012) and recombinant colony stimulating factors (G-CSF) (Cox et al., 2004), the 
porcine Fc CSF-1 was more active in-vivo.  Fc CSF-1 stimulated a greater increase in 
body weight, organ weight, white blood cell count, monocyte count and infiltration 
of tissues with macrophages, compared to the native protein.  The increases in white 







 cells within bone marrow cell population and enhanced myelopoieses 
as determined by a significant increase in the M:E ratio.  Although not assessed in 
mice, the circulating half-life of the fused porcine Fc CSF-1 was found to be 
significantly increased when compared to CSF-1 administered to weaner pigs 
(Chapter 6).  This finding confirms other reports of Fc-fusion proteins having 
extended circulating half-life.   The Fc domain of Fc-fused proteins can potentially 
have effector functions through interaction with Fc receptors inducing antibody-
dependent cell mediated cytotoxicity (ADCC) (Beck and Reichert, 2011).  In the 
case of macrophages, it might have provided a secondary signal.   However, there 
were no effects of the Fc CSF-1 that could not be attributed to CSF-1 alone, and no 
evidence of toxicity as evident from the lack of any adverse effect on weight gain of 
tissues other than the liver.    
 
The administration of 1 µg/g of porcine Fc CSF-1 consistently increased the total 
white blood cell count and monocyte count, presumably as a result of bone-marrow 
activation of CSF-1 maturing and releasing marrow monocytes (Ulich et al., 1990).  
In fact, using either 0.5 or 1 µg/g has increased the level above the normal reference 
range for this age and strain of mouse (Hedrich and Bullock, 2004).  There are many 
previous reports of CSF-1 inducing this behavior (Hume et al., 1988; Koren et al., 
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1986; Munn et al., 1990; Ulich et al., 1990).  The increased number of circulating 
neutrophils was less expected based upon previous findings (Hume et al., 1988; 
Ulich et al., 1990), but is consistent with the generalized myeloid enhancement seen 
in the bone marrow.  This effect was subsequently confirmed in the pig studies 
(Chapter 6).  Neutrophilia and mild lymphopenia has also been reported in CSF-1 
treated rats (Ulich et al., 1990),  and there is also evidence that CSF-1 can promote 
neutrophil production (Zhang et al., 2007).  Since Fc CSF-1 is clearly a more 
effective treatment than CSF-1, it is possible that neutrophilia is a reflection of the 
magnitude of the stimulus.  Increased neutrophil production could be advantageous if 
Fc CSF-1 were used in humans following bone marrow transplantation.  
Examination of the EGFP
+
 cells in the lung of Csf1r-EGFP
+
 mice administered 
porcine Fc CSF-1 indicated that the increase in EGFP
+
 cells was confined to the 
interstitium, with no alveolar macrophages identified (Appendix 2).  In contrast to 
alveolar macrophages that are CSF-1 dependent, lung interstitial macrophages are 
not derived directly from monocytes and are unaffected by anti-CSF-1R antibody 
treatment (MacDonald et al., 2010).  Although they clearly are not CSF-1 dependent, 
exogenous Fc CSF-1 has produced an increase in the number of the cells either as a 
direct effect of CSF-1 acting via the CSF-1R, or due to CSF-1 stimulating GM-CSF 
which will induce interstitial macrophages.  This may reflect the fact that lung 
macrophages are more responsive to GM-CSF as evident from studies using GM-
CSF knock-out mice (Hibbs et al., 2007; Stanley et al., 1994). 
 
The Fc CSF-1 increased the number of osteoclasts within the epiphyseal plate and to 
a greater degree than the diaphysis.  A similar response was reported in rats 
administered high dose rh-GM-CSF (Suzuki et al., 1997a, b).  Rescue of the op/op 
mouse osteopetrosis with administration of rh-CSF-1 or CSF-1 transgene expression 
also induces TRAP
+
 cells in the epiphyseal and methaphyseal region (Abboud et al., 
2002; Wiktor-Jedrzejczak et al., 1991).  Analysis of  serum levels of TRAP-5b and 
osteocalcin would provide further information on the activity of osteoclasts and 
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osteoblasts respectively in the treated mice since there is a coupling mechanism 
between these two cells involved in bone remodelling (Lloyd et al., 2011). 
 
While bone micro-CT scans of mice in this study have not revealed any changes in 
the trabecular architecture, bone density or strength, what can clearly be seen from 
my results is that male and female C57BL/6 mice have different bone densities and 
properties (Figure 5.19).  In agreement with Glatt et al. (2007), male mice had 
higher bone volume %, trabecular number, trabecular thickness and connectivity 
density compared to female and females had a higher trabecular separation, pattern 
factor and SMI compared to males.  The lack of effect of porcine Fc CSF-1 on bone 
density is most likely a reflection of the short duration treatment and dose.  Lloyd et 
al. (2009) demonstrated increases in bone density in mice administered high-dose rh-
CSF-1 for 21 days.  Since it can take up to 10 days for osteoclasts to resorb bone 
(Seibel, 2005), it is likely that longer treatment with recombinant CSF-1 
administration would produce more marked changes.   
 
The reduction in circulating IGF-1 in mice treated with porcine Fc CSF-1 was 
surprising since CSF-1 is known to induce IGF-1 production by macrophages (Gow 
et al., 2010).   The result is not comparable to the study by others where CSF-1 
increased IGF-1 levels (Alikhan et al., 2011).  This study was carried out on 
neonates, where the liver is not a major source of IGF-1.  Circulating IGF-1 levels 
are known to be suppressed after PH, this most likely reflects the fact that IGF-1 is 
produced by the liver in adult mice (Delhanty et al., 2001).  IGF-1 may also be 
consumed by the proliferating hepatocytes in the Fc CSF-1-treated animals.  Mice 
with IGF-1 receptor knockout have reduced hepatic regeneration after PH and mice 
lacking IGF-1 ligand in liver have reduced hepatocyte proliferation (Desbois-
Mouthon et al., 2006).  
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As discussed in the introduction, macrophages and CSF-1 play an important role in 
tissue repair in most tissues where it has been examined including kidney, liver, 
heart, brain and lung (Duffield et al., 2005; Leor et al., 2006; Nakamura et al., 2005; 
Ricardo et al., 2008; Vinuesa et al., 2008), although the mechanisms of such 
processes are less clearly defined (Stefater et al., 2011).  CSF-1 administration has 
been shown to promote regeneration in a number of models, presumably by the 
induction of local macrophage proliferation and expression of growth factors e.g. 
IGF-1, PDGFb and VEGFA (Hume and Macdonald, 2012).  In particular, studies 
investigating the role of macrophages in chronic liver disease have shown that scar 
associated macrophages (SAM) mediate hepatic scar remodelling (Duffield et al., 
2005).  Similarly, intra-portal administration of CSF-1-stimulated bone marrow cells 
to mice with experimentally induced liver fibrosis (using carbon tetrachloride), 
produced  improvement in liver fibrosis, regeneration and function (Thomas et al., 
2011).  The mechanism involved the production of MMP-13 from recruited 
macrophages to activate collagen degradation (Thomas et al., 2011).  During liver 
regeneration by hepatocyte proliferation, Kupffer cell proliferation is also a 
prominent feature.  These cells not only produce liver proliferation priming cytokines 
(TNFα and IL-6) but also modulate the production of hepatocyte growth factor 
(HGF) (Takeishi et al., 1999).  Depletion of Kupffer cells in mice after partial 
hepatectomy using liposome-entrapped MDP delayed liver regeneration (Takeishi et 
al., 1999).  Hepatic macrophages also play a role in hepatocyte progenitor cell 
mediated regeneration of hepatocytes by Wnt signalling which is required for hepatic 
progenitor cell (HPC) specification into hepatocytes (Boulter et al., 2012), as 
demonstrated by the ablation of liver macrophages resulting in loss of Wnt pathway.  
Additionally, CSF-1 deficient op/op mice, have reduced Kupffer cell production of 
TNFα and IL-6 both before and after partial hepatectomy compared to litter mate 
controls (Amemiya et al., 2011).  Injection of rh-CSF-1 into the op/op mice for 2 
days before PH restored F4/80
+
 macrophages within the liver, expression of TNFα 
and IL-6 and hepatocyte proliferation (Amemiya et al., 2011).   
The control of liver size involves the complex interaction of cytokines, growth 
factors, resident hepatic cells and bone marrow-derived cells, with sequential 
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changes in gene expression (Michalopoulos and DeFrances, 1997; Stutchfield et al., 
2010; Taub, 2004).  Following removal of two-thirds of the liver, the remaining liver 
becomes hyperplastic and mature hepatocytes replicate to restore the original liver 
mass (Kung et al., 2010; Michalopoulos, 2010; Stutchfield et al., 2010).  This process 
does not require liver stem cells or progenitor cells.  In certain circumstances, such as 
chronic disease, the resident hepatocytes may become overwhelmed thus there is a 
requirement for liver stem cells (oval cells or hepatocyte progenitor cells (HPC)), 
within the portal regions to differentiate into hepatocytes.   
The migration of oval cells from portal regions towards the hepatic vein has been 
termed “streaming liver hypothesis” and is an area of much debate, reviewed by 
Duncan et al. (2009).  Both the NOTCH and Wnt signalling pathways are also 
involved in this process of HPC differentiating into either cholangiocytes or 
hepatocytes (Boulter et al., 2012; Hayward et al., 2008; Zong et al., 2009).  In the Fc 
CSF-1-treated livers, there was no evidence of peri-portal PCNA staining that would 
be expected for stem cell driven proliferation.  Analysis of the microarray data in this 
chapter for genes associated with HPC regeneration did not detect any induction of 
these pathways in response to Fc CSF-1.  Boulter et al. (2012), showed that Wnt3 is 
expressed by macrophages where it signals the differentiation of HPCs into 
hepatocytes.  Neither Wnt3 nor its targets (Axin2, Sox9, Myc, Twist1) were induced 
by porcine Fc CSF-1 treatment.  Additionally, the selective oval cell growth factor 
called TWEAK (TNF-like weak inducer of apoptosis) that acts via its receptor Fn14 
(Jakubowski et al., 2005; Winkles, 2008), was not induced to detectable levels by Fc 
CSF-1.   All these findings are consistent with the view that the proliferation 
identified in the Fc CSF-1 mice livers is due to mature hepatocyte proliferation rather 
than stem cell (HPC or oval cell) driven.  
Liver regeneration following partial hepatectomy has been shown to be a multistep 
process.  As many as 95% of normally quiescent hepatocytes enter into the cell cycle 
in response to the priming cytokines (TNFα and IL-6) followed by progression 
through the cell cycle in response to growth factors such as hepatocyte growth factor 
(HGF), epidermal growth factor (EGF) and transforming growth factors (TGFα) 
(Fausto, 2000; Zimmermann, 2004).  The initial step in liver regeneration following 
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PH involves the transient induction of classical early-response genes (Taub, 1996).  
These genes include C-fos, C-jun, C-myc (Fausto, 2000; Haber et al., 1993).  Both 
TNFα and IL-6 have been identified as initiators of liver regeneration after PH, based 
upon inhibitory effects of anti-TNFα antibodies (Akerman et al., 1992), and defective 
regeneration in mice lacking IL-6 (Blindenbacher et al., 2003; Cressman et al., 
1996).  Both TNFα and IL-6 are pro-inflammatory cytokines that under normal 
conditions would elicit an inflammatory response.  However, the proliferative effect 
of these cytokines only exists after PH and involves a protective effect of nitric oxide 
synthase (Fausto, 2000).  A major source of TNFα and IL-6 is from hepatic 
macrophages and depletion of these cells by liposome-encapsulated 
dichloromethylene diphosphonate delayed liver regeneration (Takeishi et al., 1999).  
Subsequent to priming by TNFα and IL6,  progress beyond the G1 restriction point 
into DNA replication in response to specific growth factors (HGF, TGFa) peaks after 
40-44 hours (Taub, 2004).  Delayed early genes such as Bcl-X are identified 8 hours 
after PH prior to the initiation of cell cycle specific gens (p53, p21, mdm2, cyclins 
and cyclin-dependent kinases).  The induction of cyclin D1 is the most reliable 
marker for cell cycle progression (Fausto, 2000).  Known hepatocyte proliferation 
cell cycle components are elevated after PH including; cyclins D1 and E are 
activated 12 hours after PH, while cyclin A2 is elevated 36 hours post PH.  In fact, 
cyclins stay elevated throughout hepatocyte proliferation where their activation and 
persistence underlies hepatocyte replication during regeneration (Zou et al., 2012).  
All of these genes were induced in the Fc CSF-1 treated mouse livers, consistent with 
the view that the proliferation seen is similar to that induced in response to PH 
(Table 5.1 and Appendix 3).  Genes induced by porcine Fc CSF-1 shown previously 
to be involved in liver regeneration are listed in Table 5.1.  Interestingly, there was 
no detectable induction of HGF, TGF, EGF or STAT3.  All of the previous data 
indicates that these factors are induced transiently following hepatectomy 
(Michalopoulos and DeFrances, 1997), so it is likely that that they are no longer 
elevated by the time the animals are sacrificed after 5 days of Fc CSF-1 treatment.  
Consistent with this view,  none of the immediate-early transcription factor genes (C-
fos, C-jun) (Fausto, 2000), remained detectably induced after Fc CSF-1 treatment 
despite the obvious extensive proliferation.  Other substances that are not 
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significantly mitogenic themselves but will enhance the effects of HGF, EGF and 
TGFα include prostaglandins, norepinephrine, oestrogens, insulin (Michalopoulos, 
2010) were not induced.  Genes that are induced by porcine Fc CSF-1 therefore fall 
into one of three groups; cell cycle genes, DNA replication and mitosis genes or 








Cluster 2 Expressed in BMDMs 
Induced in Fc CSF-1 
livers 
Cyclin B1 14.63093 DNA replication & 
mitosis 
p21 2.023677 Cell cycle 
Cluster 3 Repressed in LPS 
BMDMs 
Induced in Fc CSF-1 
livers 
Cyclin A2 16.16077 DNA replication & 
mitosis 
Cyclin E2 3.508245 DNA replication & 
mitosis 
Cyclin E1 3.31732 DNA replication & 
mitosis 
Cyclin D1 2.837626 DNA replication & 
mitosis 
Mdm2 1.768393 Cell cycle 
Cluster 4 Induced in LPS BMDMs 
Induced in Fc CSF-1 
livers 
Tnf 2.4385090 Priming 
IL6 1.957373 Priming 
Cyclin D2 1.614121 DNA replication & 
mitosis 
 
Table 5.1:  Table of genes involved in liver regeneration induced by porcine Fc CSF-1 in mouse 
liver. 
 
In summary, the genes that are induced are involved early on in the process and are 
the priming cytokines TNFα and IL-6 that are required to initiate liver regeneration.  
Both IL-6 and TNF are produced by Kupffer cells by stimulation of LPS that is up-
regulated after liver injury or PH.  The levels of these, alongside several other 
Chapter 5:  Effect of CSF-1 & Fc CSF-1 on adult mice 
178 
 
inflammation-associated genes expressed (Table 5.1 and Appendix 3) were 
significantly less that in LPS stimulated BMDMs (Figure 5.29).  In view of the lack 
of significant inflammatory pathology and weight loss in the treated mice, it would 
seem likely that the genes are induced in the macrophages entering the liver in 
response to LPS and other bacterial products arriving from the gut in the portal 
circulation.  
Among other cytokines and inhibitors, the termination of liver regeneration by 
TGFβ1 may ensure that liver mass does not exceed the original.  The actions of 
TGFβ1 is to orchestrate multiple events rather than to act as a direct terminator of 
regeneration itself (Michalopoulos and DeFrances, 1997).  The induction of TGFβ1 
in mice treated with porcine Fc CSF-1 may demonstrate that the liver proliferative 
response is beginning to terminate 24 hours after the last injection of Fc CSF-1.  
As noted in the introduction, CSF-1 is itself cleared from the circulation by the liver.  
Liver regeneration does not occur in the CSF-1 deficient op/op mouse (Amemiya et 
al., 2011), and the data presented here demonstrates that increased CSF-1 can 
increase the size of the liver.  In a parallel study in the laboratory, prolonged 
treatment with anti-CSF1R reduced the size of the liver by 20-25%
13
.  Taken 
together, these observations suggest there is a homeostatic relationship between 
circulating CSF-1 concentration, monocyte production by the bone marrow and the 
size of the liver.   
 
                                                 
13
 Sauter et al 2013, manuscript in preparation 
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Chapter 6: Effects of porcine Fc CSF-1 on 
neonatal pigs 
6.1 Introduction 
As discussed in detail in the introduction, this project was based upon the 
observation that CSF-1 can increase postnatal growth in mice (Alikhan et al., 2011), 
and the intent was to extend these findings to a larger animal.  Both humans and mice 
have a postnatal surge of CSF-1 shortly after birth (Roth et al., 1998; Roth and 
Stanley, 1995), but the effect of exogenous CSF-1 in neonatal mice suggested that it 
is not saturating for monocyte production (Alikhan et al., 2011).  The previous 
chapter demonstrated the biological activity of porcine Fc CSF-1 fusion protein in-
vitro using cell lines and primary cells in a cell proliferation/viability assay, as well 
as in-vivo using Csf1r-EGFP
+
 and C57BL/6 mice.  The addition of the Fc moiety did 
not interfere with biological activity of CSF-1, detected using a factor-dependent cell 
line (Ba/F3pCSF-1R) (Chapter 5, Figure 5.1).  As previously mentioned, the 
addition was anticipated to increase the circulating half-life, both through an increase 
in molecular size to reduce renal clearance and through binding to the Fc-binding 
protein FcRN (Czajkowsky et al., 2012; Kuo and Aveson, 2011).  As predicted, the 
conjugated Fc CSF-1 protein was considerably more effective than the core un-
conjugated CSF-1 protein when administered to mice (Chapter 5). 
 
These in-vivo mouse studies provided the proof of principle that porcine Fc CSF-1 
was biologically active as well as establishing a dose range that could be used to test 
the protein in its target species, pig.  The next stage in assessment of CSF-1 as a 
therapy was to move to a larger animal that is more mature at birth since in 
comparison to human infants, new-born mice are rather immature (Puiman and Stoll, 
2008).  Pigs have been used extensively to produce experimental models of human 
disease (Fairbairn et al., 2011), and their applications have been enhanced with the 
completion of the first draft of  the pig genome (Groenen et al., 2012).  Studies in our 
group have demonstrated that pig bone marrow-derived macrophages resemble 
human monocyte-derived macrophages in their response to LPS (Kapetanovic et al., 
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2012), by contrast to the very distinct patterns of response of mouse macrophages 
(Schroder et al., 2012).  
 
Our commercial partner, Pfizer Animal Health, undertook a preliminary 
pharmacokinetic (PK) comparison of the two forms of CSF-1 proteins in weaner 
pigs, using an anti-CSF-1 antibody ELISA developed in the company, as shown in 
Figure 6.1.  As anticipated, the administration of Fc CSF-1 achieved a 10-100-fold 
higher peak concentration than CSF-1 alone, and the elevated concentration was 
maintained for up to 72 hours.  They then proceeded to a preliminary efficacy study.  
A dose of 0.12 mg/Kg every other day for 3 injections was sufficient to induce a 
three-fold increase in monocyte numbers after the third injection, with a higher dose 
(0.4mg/kg) being no more effective (Figure 6.2A).  At both doses, there was also 
evidence of histiocytic infiltration in the spleen and liver (Figure 6.2B).  The dose of  
0.12 mg/Kg every other day was selected since it induced less organ histiocytosis 
compared to higher doses (Figure 6.2B).  Based upon these considerations, including 
the economic imperatives of our partners, and the pharmacokinetics, a neonatal pig 
treatment trial was undertaken.  The initial experiment used a relatively low dose of 
0.12mg/kg for three injections, as tested previously for safety (Figure 6.2).  In the 
second experiment, piglets were injected with a relatively higher dose of 0.5 mg/Kg 
every other day for 6 injections, and sacrificed at day 24 to allow for any impacts on 
bone volume and density after a longer duration of CSF-1 treatment compared to the 
mice studies.    
 




Figure 6.1:  Circulating plasma half-life of porcine CSF-1 and Fc CSF-1.   
Three weaner pigs were injected with either 0.5 mg/Kg or 1.2 mg/Kg porcine CSF-1 or Fc CSF-
1respectively and blood collected at time points above for CSF-1 and Fc CSF-1 levels to be 
determined by ELISA (Figure produced by Pfizer Animal Health).  The mean + SEM is graphed. 
 
 
Figure 6.2:  Results of the Pfizer Animal Health dose trial of porcine Fc CSF-1.   
Three weaner pigs in each group were injected with either PBS or porcine Fc CSF-1 using the doses 
above and blood collected at time points as above for total monocyte count to be measured (A).  At 
post-mortem, tissues were collected 24 hours after the last injection and assessed for degree of organ 
histiocytosis (B). The total histiocytosis from both pigs in each group is graphed with the red dose 
highlighted as the chosen dose. Data from Pfizer Animal Health.  
 
Our commercial partner was focussed on the possibility that increased postnatal 
growth of pigs may be of economic impact to producers.  Low birth weights of 
neonatal pigs are associated with increased mortality and morbidity, as well as 
reducing the economic benefits to the producer.  Piglets born with a low birth weight 
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may be unable to feed as effectively as their other larger littermates and crucially 
may suffer in regards to colostrum and milk intake.   Growth promoters have been 
used world-wide to manipulate the growth of food producing animals (Stephany et 
al., 2010).  An example of this is the use of porcine somatotropin (IGF-1) to increase 
the weight of grower and finisher pigs (Dunshea et al., 2002).  The European Union 
instigated a ban on hormonal growth factors in 1988 which has led to producers 
optimizing the growth of their food producing animals by other means such as food 
supplements and addressing basic husbandry and health issues.  Additional research 
has been produced looking at the effects of transgenic animals with better muscle: 
lean weight mass (Hartke et al., 2005).   
 
Although there is a positive correlation between plasma IGF-1 concentrations and 
growth rate of pigs (Buonomo and Klindt, 1993; Buonomo et al., 1987),  and IGF-1 
administered to finisher pigs can improve lean tissue mass,  there is evidence that it 
has little effect, or actually negatively impacts on the growth of weaner and younger 
pigs (Dunshea et al., 2002; Walton et al., 1995).  As discussed in the introduction, 
CSF-1 is a known inducer of macrophage IGF-1.  It was hypothesized that 
macrophages could be a significant source of IGF-1 in the postnatal period, and 
consequently, CSF-1 might promote early weight gain.  Generally, piglets with a 
higher birth weight will have a greater weaning and therefore slaughter weight.  
Increasing piglet birth weight by 0.1 Kg will have a reciprocal effect of increasing 
weaning weight and potentially slaughter weight by 0.5 Kg.  Increasing the daily live 
weight gain of piglets in the postnatal period will reduce the number of days to 
slaughter which would be economically beneficial for pig producers.  
 
There could also be secondary benefits of Fc CSF-1 treatment.  Lloyd et al. (2009), 
injected mice with 5 mg/Kg recombinant mouse CSF-1 each day for 21 days and 
observed the anabolic and catabolic effects of CSF-1 on bone growth and 
development.  The mice injected with CSF-1 had significant increases in bone 
volume fractions, connectivity density and trabecular number.  As previously 
discussed in Chapter 5, mice injected with 1 μg/g porcine Fc CSF-1 every day for 4 
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days had increased osteoclasts in the femur with no alterations in bone density or 
trabecular parameters assessed.  Since it can take up to 10 days for osteoclasts to 
resorb bone (Seibel, 2005), it is likely that longer treatment with recombinant CSF-1 
administration would produce more marked changes.   
 
6.2 Results 
6.2.1 Effect of porcine Fc CSF-1 on TNFα and IL-1β 
production in-vitro 
CSF-1 has been used in phase 1 clinical trials in humans, with little evidence of 
toxicity (Hume and Macdonald, 2012).  By contrast to an archetypal macrophage 
activator such as LPS, CSF-1 alone does not stimulate pig, mouse and human 
BMDMs to produce IL-1β or TNFα (Fleetwood et al., 2009; Irvine et al., 2008; 
Kapetanovic et al., 2012).  However, there was a formal possibility that the Fc 
component of the conjugate would provide a second signal via the Fc receptor. 
Accordingly, to determine the effect of porcine Fc CSF-1 on TNFα and IL-1β 
production, commercially available ELISA kits were used to measure the production 
of these cytokines in the supernatant of porcine BMDMs produced using rh-CSF-1 as 
previously reported (Kapetanovic et al., 2012).  Following cell harvest and PBS 
washes, day 7 porcine BMDMs were then left un-stimulated (no CSF-1) or were 
stimulated by porcine CSF-1, porcine Fc CSF-1, or human CSF-1.   A 24 hour time 
course was performed whereby supernatant was harvested from the cells at time 0, 1, 
2,6,12 and 24 hours for cytokine measurement.  It is known that LPS will induce 
both TNFα and IL-1β in pig BMDMs, therefore this was used as a positive control 
(Kapetanovic et al., 2012).  As shown in Figure 6.3, there was no induction of either 
TNFα or IL-1β protein by porcine BMDMs stimulated by any of the recombinant 
CSF-1 proteins.  Based on this result and the previous dose-trial performed by Pfizer 
(Figure 6.2), it was considered safe (from a welfare viewpoint) to investigate the 
effects of porcine Fc CSF-1 administration to neonatal pigs.  
 




Figure 6.3:  Effect of porcine Fc CSF-1 on TNFα and IL-1β production from porcine BMDMs. 
Porcine bone marrow cells were recovered and cultured in rh-CSF-1 for 7 days to generate BMDMs.  
Following harvest and 2 washes in PBS, 1 x 10
6
 cells/mL were plated/well of a 24 well plate with 
porcine CSF-1, porcine Fc CSF-1, human CSF-1 or no CSF-1, both with and without the addition of 
LPS.  Cells were plated in duplicate.  Supernatant was harvested at time 0, 1, 2,6,12 and 24 hours.  
The graphs show the 2 hour time point mean + SEM results for both TNFα and IL-1β. Experiment 
repeated twice. 
 
6.2.2  Effect of porcine Fc CSF-1 on growth of neonatal 
piglets 
Piglets were treated as described in the materials and methods and the body weight 
was recorded for each piglet 24 hours after birth, prior to each injection and every 2-
3 days until the end of the experiment day 20 (for the low dose experiment) and day 
24 (for the high dose experiment).  The overall weight change for each piglet was 
calculated for each treatment group and by sex (Figures 6.4 and 6.5).  All of the 
piglets gained weight rapidly during the treatment period, on average close to the 
average daily weight gain expected of  210g/day (Beaulieu et al., 2010).  There were 
no significant differences in the rate of body weight gain using either of the treatment 
protocols comparing the control group to the groups injected with porcine Fc CSF-1.  
The mean increase in weight of the control piglets in the 0.12 mg/Kg experiment by 
day 20 was 3.9 Kg compared to 3.84 Kg for the porcine Fc CSF-1 treated piglets.  
This equates to approximately a 195g and 192g increase in body weight 
per/piglet/day respectively.  The mean weight change for the control piglets in the 
0.5 mg/Kg experiment was 5.9 Kg compared to the porcine Fc CSF-1 treated pigs 
mean change of 5.3 Kg at day 24 postnatal.  This increase in body weight is 
approximately 245g and 220g per/piglet/day. The differences are not significant, and 
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certainly not sufficient to warrant the use of Fc CSF-1 to promote growth in 
otherwise healthy piglets in a production context.  If anything, in the second 
experiment, there may be a subset of animals that have responded to the Fc CSF-1 
with a small decline in growth rate (Figure 6.5). 
 
 
Figure 6.4:  The effect of porcine Fc CSF-1 on total weight change of neonatal pigs. 
Pigs were injected with either PBS or 0.12 mg/Kg porcine Fc CSF-1 on days 1, 3, 5 or 0.5 mg/Kg 
porcine Fc CSF on days 1, 3, 5, 7, 9 and 11.  Body weight was recorded before each injection and 
every 2-3 days until the end of the experiment, day 20 (0.12 mg/Kg group) or day 24 (0.5 mg/Kg 
group). The graphs show each individual piglet weight change, the mean weight change (thin black 
line) + SEM (thicker black lines).  Male piglets are represented by red symbols.  
 
The mean weight of piglets from each treatment group was calculated for each time 
point and growth curves of their weight changes over time were graphed.  There 
were no differences in the weight pattern distribution between the PBS and porcine 
Fc CSF-1 groups using the lower 0.12 mg/Kg group (Figure 6.5).  Comparing the 
growth trend for the piglets injected with the higher 0.5 mg/Kg dose of porcine Fc 
CSF-1, it appears that the treated group (or a subset of those animals as evident in 
Figure 6.4) diverged from the control group and showed a slightly slower growth 
rate after the final injection (Figure 6.5).  
 




Figure 6.5:  The effect of porcine Fc CSF-1 on the change in body weight of neonatal pigs during 
the duration of the experiment.   
Pigs were injected with either PBS or 0.12 mg/Kg porcine Fc CSF-1 on days 1, 3, 5 or 0.5 mg/Kg 
porcine Fc CSF on days 1, 3, 5, 7, 9 and 11. Body weight was recorded before each injection and 
every 2-3 days until the end of the experiment, day 20 (0.12 mg/Kg group) or day 25 (0.5 mg/Kg 
group). The mean body weight + SEM for the treatment and control groups were calculated and 
graphed.  Red stars represent days Fc CSF-1 was administered.  
 
At post-mortem, multiple organs (spleen, liver, kidney and lungs) were removed and 
weighed from each piglet.  The application of low dose (0.12 mg/Kg) porcine Fc 
CSF-1 for 3 injections or the high dose (0.5 mg/Kg) porcine Fc CSF-1 for 6 
injections did not produce any significant changes in the organ weights between the 
PBS and porcine Fc CSF-1 injected groups (Figures 6.6 and 6.7).  Furthermore, 
adjusting the organ weight relative to body weight did not identify any significant 
organ weight changes (data not shown).  
 




Figure 6.6:  The effect of low-dose porcine Fc CSF-1 on liver, spleen, lung and kidney weights.  
Pigs were injected with either PBS or 0.12 mg/Kg porcine Fc CSF-1 on days 1, 3, 5 or PBS injected as 
control at the same time points.  Liver, kidney, lungs and spleen were collected at post-mortem from 
each piglet and weighed. Individual piglet organ weights are graphed with the mean (thin black line) + 
SEM  (thicker black lines).  Male piglets are represented by red colour.  
 
 




Figure 6.7: The effect of high-dose porcine Fc CSF-1 on liver, spleen, lung and kidney weights.  
Pigs were injected with either PBS or 0.5 mg/Kg porcine Fc CSF-1 on days 1, 3, 5, 7, 9 and 11.  Liver, 
kidney, lungs and spleen were collected at post-mortem from each piglet and weighed. Individual 
piglet organ weights are graphed with the mean (thin black line) + SEM (thicker black lines).  Male 
piglets are represented by red colour.  
 
To crudely assess the potential direct or indirect effects of CSF-1 on muscle growth 
and/or changes in bone density and fat (Dumont and Frenette, 2013; Lloyd et al., 
2009), the carcase weight after removal of all organs was recorded for each piglet.  
No significant differences in empty carcase weight were detected between the control 
and treated groups (Figure 6.8).  In case there was an influence due to the sex of the 
piglet, carcase weights were also compared by sex and relative to live body weight 
on cull day (data not shown). No significant differences were detected looking at 
individual sex or relative to body weights.  




Figure 6.8:  The effect of porcine Fc CSF-1 on carcase weight of neonatal pigs.   
Pigs were injected with either PBS or 0.12 mg/Kg porcine Fc CSF-1 on days 1, 3, 5 or 0.5 mg/Kg 
porcine Fc CSF on days 1, 3, 5, 7, 9 and 11. Following removal of all organs at post-mortem, the 
empty carcase was weighed with head and feet remaining.  Individual piglet organ weights are 
graphed with the mean (thin black line) + SEM (thicker black lines).  Male piglets are represented by 
red colour.  
 
6.2.3 Effect of porcine Fc CSF-1 on the blood  
The low dose (0.12 mg/Kg) of porcine Fc CSF-1 did not produce any significant 
changes in the total white blood cell count, or any convincing increases in 
lymphocytes, monocytes, granulocytes or red blood cell parameters compared to 
controls (Figure 6.9).  Previous studies have noted a rapid and transient increase in 
leukocyte numbers in the blood of new born piglets (Brooks and Davis, 1969).  This 
trend was also observed in the control piglets in the current study (Figures 6.9 and 
6.10).  By contrast, the increased dose and duration treatment with the high dose (0.5 
mg/Kg) of porcine Fc CSF-1 produced significant changes in all of the white blood 
cells, including an increased neutrophil count (day 6 p=0.0051,  day 12 p=0.0210 and 
day 24 p=0.0383).  Although increases in white blood cells were identified using 
porcine Fc CSF-1, the levels are still within the normal reference range for the age of 
pig (Brooks and Davis, 1969; Muirhead and Alexander, 1997).  The total WBC (day 
6 p=0.0145, day 12 p=0.0025, day 24 p=0.014), monocyte (day 7 p=0.0410), and 
lymphocyte (p=0.0001 day 7 and p=0.0136 day 24) counts all increased over time 
after birth in the high dose group.  Between the last injection and the sacrifice of the 
animals, the leukocyte counts in the Fc CSF-1-treated animals fell rapidly, but were 
still elevated compared to controls (Figure 6.10).  




Figure 6.9:  The effect of low-dose porcine Fc CSF-1 on the complete blood count of neonatal pigs.  
Pigs were injected with either PBS (n=5) or 0.12 mg/Kg porcine Fc CSF-1 (n=6) on days 1, 3, 5 and 
sacrificed on day 20.  Piglets were blood sampled 24 hours after birth, after the 3
rd
 injection and day 
20, 14 days after the last injection. Blood was collected and full blood count including manual 
differential count performed.  The mean blood count + SEM are graphed for each blood cell type 
analysed. 





Figure 6.10: The effect of high-dose porcine Fc CSF-1 on the complete blood count of neonatal 
pigs.   
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF-1 (n=7) on days 1, 3, 5, 7, 11, 
and  sacrificed on day 24.   Piglets were blood sampled 24 hours after birth, day 7 24 hours after the 
3
rd
 injection, day 13, 24 hours after the 6
th
 injection and day 24, 13 days after the 6
th
 injection. Blood 
was collected and full blood count including manual differential count performed.  The mean blood 
count + SEM are graphed for each blood cell type analysed.  Significance is indicated by *p<0.05, 
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To further dissect the effect of the treatment on monocyte differentiation, surface 
markers were assessed by FACS.  Pig monocytes can be subdivided based upon 
expression of cluster of differentiation (CD) molecules e.g. CD14, CD163, CD16 and 
Cd172a (Chamorro et al., 2005; Fairbairn et al., 2011; Sanchez et al., 1999; Ziegler-
Heitbrock et al., 1994).   Pig CD14
hi
 monocytes resemble human CD14
+
 monocytes 
and are the inflammatory (classical) subset which also have lower levels of CD163 







 subset, which more closely resemble non-classical or intermediate human 
monocytes.  The monocyte subpopulations are probably a maturation series 
controlled by CSF-1 (Fairbairn et al., 2013; Hume and Macdonald, 2012; 
MacDonald et al., 2010; Munn et al., 1990), so we might expect that the addition of 




 population of cells in neonatal pigs 
PBMC.  Following collection of blood at post-mortem and isolation of the PBMC 
fraction, flow cytometry was performed using CD14, CD16, CD163 and CD172α 





in piglets treated with Fc CSF-1 compared to control piglets (Figure 6.11).  
 
 
Figure 6.11: Effect of PBS or porcine Fc CSF-1 on CD14, CD16, CD163 and CD172a expression 
on PBMC of day 24 piglets.   
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF (n=7) on days 1, 3, 5, 7, 9 and 
11.  Blood was harvested post-mortem, PBMC fraction isolated and cells stained with an isotype 
control (FITC and PE) or antibodies CD14-FITC, CD16-PE/CD163-PE/CD172αPE, and analysed 
using flow cytometer.  Sytox blue was used for exclusion of dead cells.  The graphs show the mean + 
SEM.   
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Euthanasia of the five piglets from sow 1 for humane reasons provided the 
opportunity to assess monocyte biology in new-borns, which was also relevant to 
understanding the likely impact of Fc CSF-1 treatment.  Blood was collected from 
the piglets’ post-mortem and the PBMC fraction was isolated.  Flow cytometry 
analysis was performed using CD14 and CD163 to provide a base-line level of these 
monocyte markers.  From Figure 6.12A, it is clear that new-born pigs are deficient 
in CD163
+
 cells.  Therefore the monocyte population that is identified by the 
complete blood cell count (Figure 6.10) is likely to be entirely the CD14 (hi) 
subpopulation (Figure 6.12B).  Over time the CD163
+
 cell population significantly 
increased for both the control (p=0.0167) and treated (p=0.0041) pigs prior to a 
reduction by day 24.  Conversely, CD14 was reduced to a greater extent in Fc CSF-1 
treated pigs than controls (control p=0.0077 treated p=0.0046) (Figure 6.12B).  This 
mirrors the complete blood cell count profiles identified in Figures 6.9 and 6.10 and 
highlights that in the pig CD163 is also expressed on more mature monocytes and 
macrophages.  As part of a collaborative study at The Roslin Institute with Professor 
Alan Archibald who is investigating the role of CSF-1 in Porcine Reproductive and 
Respiratory Syndrome virus (PRRSV),   I have demonstrated that culturing porcine 
lung macrophages in either human CSF-1,  porcine CSF-1 or porcine Fc CSF-1 
actually reduces the expression of CD163 (Figure 6.13).  The discrepancy between 
in-vivo and in-vitro results may reflect the dose, age of pig and time-point of Fc CSF-









Figure 6.12:  Effect of PBS or porcine Fc CSF-1 on PBMC CD163 and CD14 expression overtime.   
Blood was collected post-mortem from five 24 hour old piglets that were sacrificed for welfare and 
ethical issues (n=5).  The remaining piglets were injected with either PBS (n=5) or 0.5 mg/Kg porcine 
Fc CSF (n=7) on days 1, 3, 5, 7, 9 and 11.  Piglets were blood sampled 24 hours after birth, on day 7 
after the 3
rd
 injection, and day 24, 14 days after the 6
th
 injection.  The PBMC fraction was isolated 
and cells stained with an isotype control (FITC and PE) or antibodies CD163-PE  (A) or CD14-FITC 
(B) and analysed using flow cytometer.   Sytox blue was used for exclusion of dead cells.  The graphs 
show the mean + SEM.  A  Kruskal-Wallis test with Dunn’s multiple comparison test was performed 




Figure 6.13:  The effect of Fc CSF-1 on porcine alveolar macrophage CD163 expression.   
Porcine alveolar macrophages were recovered from cryopreservation and cultured with no CSF-1, rh-
CSF-1, pig CSF-1 or porcine Fc CSF-1 for 7 days.  Cells were harvested, washed and prepared for 
FACS with anti-CD163-PE antibody or isotype control.  The number of CD163
+
 cells from each 
culture condition was determined and graphed with mean + SEM (A).  Representative culture images 
are shown (B).  Experiment repeated twice. 
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6.2.4 Effect of porcine Fc CSF-1 on CD14, CD16, CD163 and 
CD172α populations in BMC and AM 
At post-mortem the right femur and whole lung were removed from each piglet for 
isolation of bone marrow cells (BMC) and alveolar macrophages (AM).  Both cell 
populations were harvested and prepared for FACS using the same antibodies 
described for the PBMC fraction.  For the BMCs there were small increases in the 




 cell populations in marrow from 
piglets treated with Fc CSF-1 (Figure 6.14).  Porcine bone marrow cells cultured in 






 with a very low level of 
CD163
+ 
cells (Kapetanovic et al., 2012).  In keeping with this finding, the freshly 
isolated BMC from piglets treated with porcine Fc CSF-1 lacked CD163.    
Piglet AMs express CD14, CD16, CD163 and CD172α, with no differences 
identified between control and treated samples (Figure 6.14).  Unfortunately, it was 
not feasible to collect the lung cells quantitatively, so it was not possible to determine 
whether there was a net increase in their numbers.  Culture of adult pig AMs with rh-
CSF-1 for 7 days does not significantly alter the expression of CD14, CD16, CD163 
and CD172α
14
, so the absence of any change in surface markers was not unexpected.  
Adult porcine alveolar macrophages are known to express high levels of CD163
+
 
compared to bone marrow cells (Kapetanovic et al., 2012), this can clearly be seen in 
Figure 6.14. 
 
                                                 
14
 L. Fairbairn unpublished observations 




Figure 6.14:  Effect of PBS or porcine Fc CSF-1 on CD14, CD16, CD163 and CD172α expression 
on BMC and AM.   
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF (n=7) on days 1, 3, 5, 7, 9 and 
11.  Blood was harvested post-mortem and the PBMC fraction isolated and cells stained with an 
isotype control (FITC and PE) or antibodies CD14-FITC, CD16-PE/CD163-PE/CD172αPE, single 
stained or double stained and analysed using flow cytometer.   Sytox blue was used for exclusion of 
dead cells.  The graphs show the mean + SEM.  BMC=bone marrow cells, AM=alveolar 
macrophages. 
 
6.2.5 Effect of porcine Fc CSF-1 on MHCII expression in 
PBMC 
Figure 6.11 demonstrated that the main monocyte populations in PBMC from 




.  These populations of cells also have high 
class II major histocompatibility complex (MHCII) expression (Fairbairn et al., 
2011).  MHCII is a transmembrane molecule required for antigen presentation to 
CD4 helper T cells (Davis and Bjorkman, 1988).  The immunosuppressive functions 
of CSF-1, particularly in relation to T cell responses have been reported in other 
species. CSF-1 can supress MHCII expression in-vitro (Munn et al., 1996; Sweet and 
Hume, 2003; Vassiliadis and Athanassakis, 1994; Willman et al., 1989) and in 
preliminary studies, Pfizer suggested this might occur with Fc CSF-1 in the pig.  
Accordingly, PBMCs were cultured from all piglets for 16 hours with either porcine 
Fc CSF-1 in the culture medium or RPMI alone.  Cells were then analysed using 
flow cytometry for the expression of MHCII (Figure 6.15).  Following overnight 
culture with Fc CSF-1 there was no significant decrease in the number of MHCII
+
 
cells compared to the controls (Figure 6.15A).  Similarly, administration of porcine 
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Fc CSF-1 13 days prior to harvest also had no effect on the MHCII expression 
(Figure 6.15B).  The PBMC fraction in this study was isolated using Lymphoprep, 
therefore the population of cells obtained would have included both lymphocytes and 
monocytes.  MHCII is expressed equally on T cells and macrophages in the pig 
(Tizard, 2008).  Without further analysis using monocyte markers, a minor change in 
the monocytes is not completely excluded but is unlikely.    
 
 
Figure 6.15:  Effect of PBS or porcine Fc CSF-1 on MHCII expression on PBMC.   
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF (n=7) on days 1, 3, 5, 7, 9 and 
11.  Blood was harvested post-mortem and the PBMC fraction isolated and 1x10
6
 cells/mL cultured 
for 16 hours with or without 200ng/mL porcine Fc CSF-1.  Cells were stained with an isotype control 
(FITC) or anti-MHCII antibody and analysed using flow cytometer.   Sytox blue was used for 
exclusion of dead cells.  The graphs show the mean + SEM from all piglets (A) and split by in-vivo 
treatment group (B).  
 
6.2.6 Effect of porcine Fc CSF-1 on IGF-1  
As discussed in the introduction and reviewed by Gow et al. (2010), CSF-1 is known 
to induce macrophage IGF-1 mRNA and protein.  To determine the effects of 
porcine Fc CSF-1 on circulating IGF-1 concentrations in neonatal pigs, a 
commercially available porcine IGF-1 ELISA was performed (Figure 6.16).  Mean 
plasma IGF-1 concentration 24 hours after birth and prior to subsequent injections 
for all the piglets in the low dose (0.12 mg/Kg) experiment was 15.3 ng/mL, while in 
the high dose (0.5 mg/Kg) experiment the mean value at this time was 21.7 ng/mL. 
This difference most likely reflects the difference in litter size number; 17 piglets 
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from sow 1 and 13 from sow 2 (Paredes et al., 2012).  For the control piglets there 
was an incremental increase in plasma IGF-1 concentrations over time consistent 
with previously published reports (Ladurner et al., 2009; Owens et al., 1991).  
Treatment with high dose (0.5 mg/Kg) Fc CSF-1 prevented this increase in plasma 
IGF-1 measured after the 3
rd
 (p=0.0439) and 6
th
 injections (p=0.0030) (Figure 6.16), 
which could be related to the decline in growth rate seen in Figure 6.5 since the 
concentration of IGF-1 correlates with the growth rate of pigs (Clapper et al., 2000).  
The difference was reversed by the time the animals were sacrificed, 13 days after 
the last treatment.   
 
 
Figure 6.16:  The effect of porcine Fc CSF-1 on plasma IGF-1 concentrations.   
Pigs were injected with either PBS (n=5) or 0.12 mg/Kg (n=6) porcine Fc CSF-1 on days 1, 3, 5 or 0.5 
mg/Kg (n=7) porcine Fc CSF on days 1, 3, 5, 7, 9 and 11.  Blood was collected into EDTA tubes at 
the indicted time points and at time of sacrifice.   Blood plasma was separated and stored at -20 
o
C 
until the ELISA was performed. IGF-1 concentration for each piglet was measured in duplicate. 
Graphs show the mean + SEM.  Significant was determined using Kruskal-Wallis test with Dunn’s 
multiple comparison test with significance set as *p<0.05, **p<0.01, ***p<0.001. 
 
The results of the blood plasma IGF-1 ELISA demonstrate that although IGF-1 is 
increasing with postnatal age, by day 24 the plasma IGF-1 concentration is still low 
(approx. 40 ng/mL) (Figure 6.16).  It has been shown elsewhere that it continues to 
rise to ~350 ng/mL by 15 weeks of age (Rogan et al., 2010).  Therefore, from the 
IGF-1 ELISA result, at the time of this study, hepatocytes are not producing much 
IGF-1.  The livers of control and treated piglets were stained for IGF-1.  Viewing the 
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sections under higher power x 200 magnification revealed that the blood cells within 
the hepatic venous system are positive for IGF-1 (Figure 6.17A).  There was no 
discernible difference in the amount of IGF-1 positively stained cells in the PBS 
control group compared to the porcine Fc CSF-1 (0.5 mg/Kg) treated group (Figure 
6.17B), and in particular no obvious expression by Kupffer cells or infiltrating 
histiocytes.
 
Figure 6.17:  The effect of high-dose porcine Fc CSF-1 on liver IGF-1 expression using 
immunohistochemistry.   
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF-1 (n=7) on days 1, 3, 5, 7, 9 
and 11.  Pigs were sacrificed at day 24.  Liver was collected post-mortem from each piglet and 
sections stored in 10% formal saline until tissues prepared for immunohistochemistry.  Following 
IGF-1 staining slides were examined blind for the presence of IGF-1-positive cells (brown staining).  
Representative images from treated and PBS controls at x100 and x200 magnification are shown (A).  
IGF-1-positive cells were counted from each piglet at x100 magnification and graphed (B) which 
shows the mean + SEM.  
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6.2.7 Histological analysis of the effects of porcine Fc CSF-1  
At post-mortem, tissues were collected as described in materials and methods.  Blind 
pathological assessment by Dr Pip Beard, The Roslin Institute and Dr David Garcia-
Tapia, Pfizer Animal Health, Kalamazoo was performed.   For the low dose (0.2 
mg/Kg) treatment group, no pathology associated with the administration of porcine 
Fc CSF-1 was identified in any tissue, although mild incidental pathology was noted 
in three piglets which included mild focal chronic nephritis, mild focal enteritis and 
mild focal chronic active pneumonia.  These changes were sub-clinical since no 
piglet was detected as being clinically ill during the duration of the experiment.  In 
both the low and high-dose porcine Fc CSF-1 treated pigs and all PBS control piglets 
physiological hepatic lipidosis and glycogen deposition was observed (Figure 6.18).  
There is a greater degree of hepatic lipidosis compared to glycogen deposition.  
Hepatic lipidosis is seen as vacuolated hepatocytes with the nucleus pushed to the 
side (Figure 6.18, full arrow), compared to glycogen deposition, which is seen less 
frequently in the liver sections as a central nucleus with a “lacy” cytoplasm (Figure 
6.18, dashed arrow).  These are normal findings in young neonates especially from 
species with milk that is high in fat such as pigs, that have 7.6% fat in mature milk 
(Maxie et al., 2007).  




Figure 6.18: The effect of high-dose porcine Fc CSF-1 on liver pathology.   
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF-1 (n=7) on days 1, 3, 5, 7, 9 
and 11.  Pigs were sacrificed at day 24.  Liver was collected post-mortem from each piglet and 
sections stored in 10% formal saline until tissues prepared for H&E.  Following H&E staining, slides 
were examined blind for the presence of abnormal histology.  Representative images from treated and 
PBS controls at x100 and x200 magnification are shown.  Full arrow demonstrates lipidosis and 
dashed arrow indicates glycogen deposition.  
 
In 4 out of the 7 high-dose treated piglets there was a diffuse infiltration of 
histiocytes within the interstitial space.  A pathological diagnosis of mild interstitial 
histiocytosis was documented (Figure 6.19).   




Figure 6.19:  The effect of porcine Fc CSF-1 on lung pathology.   
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF-1 (n=7) on days 1, 3, 5, 7, 9 
and 11.  Pigs were sacrificed at day 24 and  lung collected at post-mortem from each piglet and 
sections stored in 10% formal saline until tissues prepared for H&E.  Following H&E staining, slides 
were examined blind for the presence of pathology.  Representative images from treated and PBS 
controls at x100 magnification are shown.   
 
Since marked hepatic proliferation was identified in mice treated with porcine Fc 
CSF-1 (Chapter 5, Figure 5.24), Proliferating Cell Nuclear Antigen (PCNA) 
immunohistochemistry was also performed on postnatal day 24 piglet liver.  Both 
control (n=5) and porcine Fc CSF-1 treated piglet livers (n=7) were prepared for 
PCNA immunohistochemistry.  All sections were then examined blind for the 
presence of PCNA
+
 cells (brown staining) (Figure 6.20A).  High levels of PCNA
+ 
cells were detected in all sections examined with no apparent change in the 
distribution of positive cells.  Based on their morphology, the PCNA
+ 
cells were 
identified as hepatocytes, which are the only cell type known to be PCNA
+ 
in 
neonatal livers (Dumble et al., 2001).  The PCNA
+ 
cells were not present in any 
defined pattern and were diffusely spread throughout the parenchyma which 
confirms other reports of PCNA
+ 
cells in neonatal pig liver (Nygard, 2013) and the 
diffuse pattern of neonatal hepatocyte growth (Duncan et al., 2009; Friedman and 
Kaestner, 2011).  The apparent increase in the number of PCNA
+ 
cells in the Fc CSF-
1 treated piglets (Figure 6.20B) was not statistically significant at p<0.05.  Neonatal 
liver is known to have a higher level of PCNA gene expression compared to adult 
liver (Dumble et al., 2001; Dvir-Ginzberg et al., 2008).  It would appear therefore 
that neonatal piglet livers are already highly proliferative and demonstration of any 
Chapter 6:  Effect of Fc CSF-1 on neonatal pigs 
203 
 
incremental effect of Fc CSF-1 would require larger group sizes.   The lack of any 
substantial difference is consistent with the lack of effect on liver size following 
treatment.  
 
Figure 6.20:  The effect of porcine Fc CSF-1 on liver proliferation using PCNA.  
Pigs were injected with either PBS (n=5) or 0.5 mg/Kg porcine Fc CSF-1 (n=7) on days 1, 3, 5, 7, 9 
and 11. Pigs were sacrificed at day 24 and liver collected at post-mortem from each piglet and sections 
stored in 10% formal saline until preparation for immunohistochemistry.  Following PCNA staining 
slides were examined blind for the presence of proliferating cells (brown staining).  Representative 
images from treated and PBS controls at x100 and x200 magnification are shown (A).  PCNA-positive 
cells were counted from each piglet at x200 magnification and graphed (B) which shows the mean + 
SEM.  
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6.2.8 Effect of porcine Fc CSF-1 on bone density 
To determine the effects of  high dose (0.5 mg/Kg) porcine Fc CSF-1 on bone, 
muscle or fat density of the femur, computed tomography (CT) was performed 
following post-mortem collection of the right femur from each piglet.  The fat and 
muscle areas within the bone represent areas of less dense bone within the marrow.  
Comparing the CT calculated values for bone, fat and muscle density, there was no 
difference between the bones of PBS or porcine Fc CSF-1 treated piglets (Figure 
6.21).  Further analysis of the measurements by sex comparison did not reveal any 
sex related change.    
 
 
Figure 6.21:  The effect of porcine Fc CSF-1 on femur bone density.    
Pigs were injected with either PBS or 0.5 mg/Kg porcine Fc CSF-1 on days 1, 3, 5, 7, 9 and 11. Pigs 
were sacrificed at day 24 and femurs collected post-mortem from all piglets, placed in 10% formal 
saline for 24 hours prior to storage in 70% ethanol.  Each bone was spiral CT scanned at 1.5 mm 
sections for assessment of bone, muscle and fat density.  Average values were calculated and graphed.  
The graphs show each individual piglet bone measurements with the mean change (thin black line) + 
SEM (thicker black lines).  Male piglets are represented by red symbols.  
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Longitudinal bone growth is known to be promoted by both GH and IGF-1 (Wang et 
al., 2004; Yakar et al., 2002), therefore to gain an insight into the effects of porcine 
Fc CSF-1 on long-bone growth possibly acting via GH/IGF-1 axis, femoral length 
was measured from each piglet and graphed (Figure 6.22A).  The piglets treated 
with porcine Fc CSF-1 had reduced plasma IGF-1 concentrations compared to 
control piglets (Figure 6.16).  Reduced serum IGF-1 concentrations are associated 
with decreases in cortical area and thickness (Yakar et al., 2009; Yakar et al., 2010). 
The effect of porcine Fc CSF-1 on cortical thickness in piglet bones was examined in 
detail (Figures 6.22B/C).  Although individual variation was noted, no differences 
between control and treated piglets were detected.  
 
 
Figure 6.22:  The effect of porcine Fc CSF-1 on femur length and cortex thickness.    
Pigs were injected with either PBS or 0.5 mg/Kg porcine Fc CSF-1 on days 1, 3, 5, 7, 9 and 11. Pigs 
were sacrificed at day 24 and femurs collected post-mortem from all piglets, placed in 10% formal 
saline for 24 hours prior to storage in 70% ethanol.  Each bone was spiral CT scanned at 1.5 mm 
thick.  Femur length (A) was determined from longitudinal sections and cortex width from transverse 
sections (B&C).  The graphs show each individual piglet measurements with the mean value (thin 
black line) + SEM (thicker black lines).  Male piglets are represented by red symbols.  
 




This chapter has described a preliminary efficacy and safety trial of porcine Fc CSF-
1 on neonatal pigs.  Two experiments were performed.  Treatment with a lower dose 
was based upon preliminary data from our industry partners, and was also dictated in 
part by Animal Ethics considerations.  Overall, the conclusion is that low dose (0.12 
mg/Kg every other day for 3 injections) had little effect on any of the parameters 
assessed, including body weight and blood cell numbers.  One consideration is that 
this experiment started with smaller animals from a much larger litter.   Since larger 
litters have more variable individual weights, this large litter size would have limited 
pre-natal uterine space, thus producing piglets that were uterine growth retarded and 
therefore associated with slower growth  rates (Paredes et al., 2012).  Piglets that are 
intrauterine growth retarded, defined as a birth weight below two standard deviation 
of the mean, cannot compensate their growth later in life and have slower growth 
rates and lighter carcase traits (Paredes et al., 2012).  Ideally, the trial for growth 
promoting activity would be conducted on such animals, but it is impossible to 
identify them in sufficient numbers a priori.   
 
The immune system of the neonatal pig is not fully developed at birth, as shown by 
assessment of the complete blood count (Figures 6.9 and 6.10) and monocyte 
marker expression in PBMC from 24 hour old piglets (Figure 6.12).  Therefore, 
unlike human new-born infants that are born with high monocyte counts (Roth and 
Stanley, 1995), and a fully developed immune system, maturation of the pig’s 
immune system begins after birth (Becker and Misfeldt, 1993).  In fact, the neonatal 
pig’s immune system is quickly maturing during the first 3-4 weeks of life and 
continuously changing as the piglet ages.  During this period, due to exposure to 
environmental challenges and pathogens, the neonatal pig’s immune system is often 
severely stimulated.  Growth hormone (GH) and prolactin are important for immune 
development by promoting the development of T lymphocytes from the thymus into 
the peripheral blood (Berczi et al., 1998).  Neonatal piglet GH levels are high 
immediately after birth to activate the immune response and also increase IL-6, IL-2 
and GM-CSF to further activate the immune system (Borghetti et al., 2006).  
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Clinically, this is identified by increasing numbers of the total white blood cells, 
monocytes and lymphocytes with age and immunological experience (Becker and 
Misfeldt, 1993; Brooks and Davis, 1969; Brown et al., 2006; Pescovitz et al., 1994).  
This view of postnatal development was confirmed in the piglets in this study 
(Figures 6.9 & 6.10).  The administration of high-dose porcine Fc CSF-1 produced 
mild increases in immune system development, notably the monocytes (Figure 6.10) 
which appeared to represent the CD16 and CD163-positive populations (Figure 
6.11).  The influence of CSF-1 on CD163 expression is unclear.  In humans CD163 
is expressed on monocytes and increases with maturation of the cells into 
macrophages (Backe et al., 1991; Kowal et al., 2011).  Reports of CSF-1 either 
enhancing or having no effect on CD163 expression exist (Buechler et al., 2000; 
Fairbairn et al., 2013; Kowal et al., 2011).   
The natural decline in monocytes observed in this age of piglet, perhaps as a result of 
reducing endogenous CSF-1 concentrations from the postnatal CSF-1 surge, was 
prevented by administration of Fc CSF-1 (Figure 6.10).  Neonatal mice and humans 
demonstrate a postnatal surge in serum CSF-1 (three-times the serum CSF-1 
concentration to that of the adult), by the transfer to CSF-1 across placenta from 
maternal to the developing foetus (Roth et al., 1998; Roth and Stanley, 1996).  The 
result of CSF-1 crossing the placenta is the ability of CSF-1 to exert its effects on 
developing the perinatal immune system such as development of mononuclear 
phagocytes in the liver, spleen, kidney and lung (Roth and Stanley, 1995).  There is 
circumstantial evidence of a postnatal surge of CSF-1 in neonatal pigs from the 
demonstration that white blood cell parameters in both control and treated neonatal 
piglets increased in the postnatal period and then reduced to equal or less than the 
birth value (Figure 6.10).  Additionally both porcine endometrium and placenta 
express CSF-1 mRNA (Tuo et al., 1995), so one may hypothesise that CSF-1 can 
cross the placenta and induce a CSF-1 surge.  To measure porcine CSF-1, a porcine 
CSF-1 specific ELISA was developed in-house by Pfizer, but the results obtained in 
neonatal samples were uninterruptible, and did not allow permit assessment of the 
size or duration of any postnatal surge in CSF-1.  Further optimization is necessary 
for any future experiment.  To further investigate the serum CSF-1 concentration in 
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neonatal piglets, maternal and foetal blood samples during gestation and early 
postnatal life.  It would be especially interesting to test the administration of 
radioiodine
125
 labelled CSF-1 (I
125
 rh-CSF-1) and to determine if CSF-1 does cross 
the pig placenta from the maternal side to the developing foetus.   
The change in blood cell numbers seen in the pig study were not as great as the 
changes observed in mice (Chapter 5, Figures 5.8 and 5.18).  In the high-dose pig 
study, I used the equivalent of  0.5 µg/g, which was constrained by Animal Ethics 
considerations as well as the amounts of material required.  Early safety dose testing 
by Pfizer suggested that a dose of 1.2 mg/Kg could produce severe adverse effects in 
weaner pigs, necessitating termination of the trial.  This was only a small number of 
animals, and has not been replicated.  It is possible that there are other variables, 
such as health status.  However, mice are known to be resistant to inflammatory 
pathology.  The maximum tolerated dose of LPS is 1000-10,000 times the dose that 
would induce septic-shock in humans (Warren, 2009).  Since pigs respond to LPS in 
a similar fashion to humans (Kapetanovic et al., 2012), it may be that mice and pigs 
respond differentially to porcine Fc CSF-1.  Conversely, studies in rats (Ulich et al., 
1990), and Phase I trials in humans (Cole et al., 1994; Jakubowski et al., 1996), show 
up to 150 µg/kg by continuous infusion caused very large increases in monocyte 
count.  These studies identified thrombocytopenia as the dose-limiting toxicity, and 
otherwise the treatment was well-tolerated.  The same lower dose of 0.5µg/g in mice 
was also significantly less effective.  Nevertheless, there was a trend towards an 
increase in body weight (Chapter 5, Figure 5.6), organ weight (Chapter 5, Figure 
5.7) as well as WBC, monocytes and neutrophil counts (Chapter 5, Figure 5.8).  
Previously, Koren et al. (1986) and Ulich et al. (1990) demonstrated  lymphopenia 
and neutrophilia in mice receiving rh-CSF-1 injections.  In my study, using 0.5 
mg/Kg porcine Fc CSF-1 every other day for 6 injections I have significantly 
increased the lymphocyte and neutrophil counts compared to the control piglets 
(Figure 6.10).  This may be the result of indirect effects of CSF-1 by the activation 
of IL-1 and TNF, both of which can induce lymphocytes and neutrophils (Ulich et 
al., 1987) and by the induction of GM-CSF (Evans et al., 1998).  In both the pig 
experiments, the neutrophil count decreased over time in the control piglets.  
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Previous studies that have also assessed neonatal pig neutrophil counts and 
demonstrated variation in the results from either no change in neutrophils over the 
first 30 days of postnatal life (Becker and Misfeldt, 1993), a slight reduction 
(Borghetti et al., 2006), to an increase in neutrophils by day 14 of age (Brown et al., 
2006).  These variations most likely reflect the different environmental conditions in 
which the pigs were reared.  The reduction in neutrophils in this study may therefore 
reflect the fact that the piglets were born and reared in a clean research facility and 
thus their immune system would have been under minimal immunological stress 
compared to piglets born and reared on commercial farms.  
 
Further evidence of a post-natal surge of CSF-1 in neonatal pigs comes from the 
IGF-1 ELISA results both of adult mice (Chapter 5, Figure 5.21) and neonatal pigs 
(Figure 6.16).  As shown in mice, administration of Fc CSF-1 to neonatal pigs 
appeared to prevent the postnatal increase in plasma IGF-1 (Figure 6.16).  This was 
not expected since it is known that macrophages can produce IGF-1 in response to 
CSF-1 (Gow et al., 2010).  It is well documented that maternal IGF-1 does not cross 
pig placenta, perhaps as a result of their diffuse epitheliochorial placenta where the 
maternal and foetal layers are maintained, thus IGF-1 concentrations increases with 
age from birth (Wang et al., 1991).  This is a finding I have confirmed.  Although the 
IGF-1 plasma concentration of piglets in this study were less than the reported level 
by Rogan et al. (2010) for piglets of a comparable age (50-60 ng/mL), the results 
clearly demonstrate that IGF-1 does increase as postnatal age increases (Figure 
6.16).  The piglets in this study were sacrificed at day 20 and 24 with IGF-1 
concentrations having increased from approximately 15 ng/mL to approximately 40 
ng/mL.  Previous reports suggest that IGF-1 concentrations would continue to rise 
before peaking at 15-25 weeks of age at 350 ng/mL (Rogan et al., 2010), which also 
corresponds with an increase in IGF binding proteins (Lee et al., 1991).  This 
developmental increase in IGF-1 is well documented and is seen with a concurrent 
decline in growth hormone (Carroll et al., 1999; Lee et al., 1991).  The birth-related 
increase in IGF-1 is a reflection of the maturation of the somatotrophic axis and IGF-
1 concentrations highly correlate with hepatic GH receptor binding in pigs (Breier et 
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al., 1989; Lee et al., 1991).  The effect of porcine Fc CSF-1 on IGF-1 is clearly 
apparent in both adult and neonatal animals.  One possible explanation for the 
apparent reduction in circulating IGF-1, could be the reduction of available IGF-1 
binding proteins.  IGF-1 circulates in blood bound to one of six IGF-1 binding 
proteins, (IGFBP designated IGFBP1-6), which regulate and modulate the biological 
activity and accessibility of IGF-1.  IGFBP-3 is the most abundant, accounting for 
80-95% of IGF-1 binding (Le Roith, 1997).  Binding of IGF-1 with IGFBP-3 allows 
interaction with a second protein subunit, the acid labile subunit (ALS), which 
prolongs the half-life of IGF-1 in the circulation acting to facilitate its endocrine 
action, enhancing circulation time from 10 minutes for unbound IGF-1 to 12 hours 
when bound to IGFBP3 and ALS (Boisclair et al., 2001).   Within the mouse liver 
microarray data (Appendix 3), there were significant reductions in the genes 
encoding ALS (Igfals) and growth hormone receptor (Ghr) in response to porcine Fc 
CSF-1, which may partly explain the apparent reduction in circulating IGF-1.  Both 
the ALS knock-out, and GHR knock-out mouse models have reduced IGF-1 
concentrations, and in the case of the ALS KO, is also associated with reduced 
IGFBP3 concentrations (Al-Regaiey et al., 2005; Ueki et al., 2000).  It may therefore 
actually be that IGF-1 is produced in equal amounts in both control and Fc CSF-1 
treated animals, as confirmed by the IGF-1 immunohistochemistry (Figures 5.21 
and 6.17) and microarray data (Appendix 3), but the circulation time of IGF-1 is 
reduced by reductions in ALS, IGFBP3 and GHR. 
The effect of CSF-1 on IGFBP production is unclear.  Li et al. (1996)  demonstrated 
production of IGFBP4 protein from CSF-1 stimulated mouse macrophages while in 
contrast, analysis of biogps data (www.biogps.org) shows that mouse macrophages 
treated with CSF-1 do not make mRNA encoding any of the IGFBPs, nor the acid 
labile subunit (ALS) (Gow et al., 2010).  Further investigation will be required using 
quantitative PCR to determine the relative amount of IGF-1 mRNA and perhaps 
IGFBP ELISA to quantify serum IGFBP.  
 
To determine the effects of porcine Fc CSF-1 on tissue histology, sections of organs 
were prepared and stained with H&E for histological assessment.  No significant 
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histological differences associated with the administration of low dose (0.12 mg/Kg) 
porcine Fc CSF-1 every other day for 3 injections was detected.  This is in contrast to 
administration of high dose (0.5 mg/Kg) porcine Fc CSF-1 for 6 injections which 
produced mild lung histiocytosis in 4 out of 7 piglets (Figure 6.19).  Lung pathology 
is a common finding in pigs at slaughter with gross lung lesions identified in up to 
52% of porcine lungs examined (Jirawattanapong et al., 2010).  This often reflects 
the high stocking densities of intensively reared pigs on commercial units and poor 
environmental conditions.  The mild pathology noted in the piglets may be 
considered an incidental finding in older growing pigs on commercial units.  The 
piglets in this study were young (Day 24), and housed in a research facility with a 
lower stocking density and improved husbandry compared to commercial units.  
Since control piglets displayed no overt pathology, the pathology (diffuse lung 
histiocytosis) is attributable to the porcine Fc CSF-1 administration.  Higher doses of 
Fc CSF-1 also caused a significant increase in the number of EGFP
+
 cells in the 
lungs of Csf1r-EGFP
+
 mice (Chapter 5, Figure 5.5).  It is not clear whether this 
change is due to infiltration or local proliferation. Earlier studies demonstrated that 
CSF-1 can stimulate proliferation of alveolar macrophages (Akagawa et al., 1988).  
 
The mouse studies in Chapter 5 demonstrated extensive hepatocyte proliferation in 
adult mice treated with 1 µg/g of porcine Fc CSF-1, determined by PCNA 
immunohistochemistry, and the induction of known hepatocyte proliferation genes. 
This was less evident in the neonatal pigs, in which there was already extensive 
evidence of proliferation in the controls (Figure 6.20).  Normal adult human liver 
has a basal proliferative rate of approx. 0.5% of hepatocytes in the cell cycle at any 
one time (Duncan et al., 2009).  Mechanisms determining liver regeneration in mice 
were discussed in Chapter 5.  Similar observations of the liver regaining its liver 
mass by regeneration in pigs after liver resection is due to significant hyperplasia of 
hepatocytes within the portal fields (Ladurner et al., 2009).  Neonatal pig liver is 
enriched with multipotent stem cells and characterised by a high proliferation rate.  
Physiological enlargement of the liver in neonatal animals due to increased 
connective tissue deposition, active liver haematopoiesis, and increased liver 
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glycogen storage  (Blackburn, 2013).  It would clearly be of interest to examine the 
effect of Fc CSF-1 in older pigs, and in the context of liver regeneration.  
 
In conclusion, administration of porcine Fc CSF-1 to neonatal piglets demonstrated 
that CSF-1 is not saturating in this species at this time point since exogenous Fc 
CSF-1 caused significant and expected changes to the blood leukocyte counts.  From 
the blood cell counts performed and the pattern of changes over time, it appears 
likely that pigs do have a postnatal surge in CSF-1 although further investigation is 
warranted.  No effects on piglet postnatal growth were identified using either of the 
porcine Fc CSF-1 doses used in my experiments, but it is likely that the amounts 
used are not saturating.  Older pigs may be a more suitable experimental model to 
pursue when CSF-1 concentrations have increased and reached adult levels.  Piglets 
in commercial production units at weaning time (15-22 weeks) present producers 
with multiple problems associated with this period that includes physiological and 
environmental stressors.  The introduction of nutritionally balanced food results in 
marked gastrointestinal changes that ultimately lead to reduced digestive and 
absorptive capacity of the small intestine.  Collectively, these effects at weaning 
result in reduced weight gain and often weight loss which can result in 25-40% 
reduction in growth (Varley, 1995).  Further applications of porcine Fc CSF-1 could 
be considered during the weaning period to alleviate this weight reduction and 
associated increase to days to market.  This would positively impact on pig 
producers.  Furthermore, pigs on commercial units grow 20-30% slower than pigs on 
a research facility which are housed individually.  This relates to less food intake 
compared to research pigs and greater competition for food with commercial units 
having more pigs/building and less floor space and more pigs/pen. Investigation of 
the effects of porcine Fc CSF-1 on postnatal growth could therefore be investigated 
in commercial pigs as opposed to research pigs.  The interaction between IGF-1 and 
CSF-1 in neonatal pigs is intriguing and highlights what we already hold true for 
adult animals does not always translate through to neonatal animals. In particular the 
relationship between IGF-1 and CSF-1 will need to be examined further as IGF-1 is 
positively correlated with an average daily gain (ADG), carcase weights and 
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reproductive performance (Clapper et al., 2000).  Although CSF-1 may stimulate the 
release of macrophage IGF-1 and increase postnatal growth, I have shown that the 
action of Fc CSF-1 is to reduce IGF-1 binding proteins.  This could negatively 
impact on postnatal growth.  Further investigation into the true effects and 
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Chapter 7: Conclusions and future perspectives 
 
The initial aims of this thesis were to clone porcine CSF-1 and CSF-1R and to 
establish and optimize an in-vitro bioassay for assessing the biological activity of 
CSF-1 which would ultimately allow study of the porcine CSF-1 and CSF-1R 
system.  These objectives were achieved.  The commercial availability of mouse and 
human CSF-1 and the subsequent availability of feline tissue, allowed the cross-
species analysis of human and mouse CSF-1 on a range of species receptors.  Much 
of this work has been published (Gow et al., 2012; Gow et al., 2013).   
 
The second CSF-1R ligand, IL-34, which was discovered during my PhD, led to a 
secondary focus.  The production of biologically active porcine IL-34 was not as 
straight forward as porcine CSF-1.  Low levels of the protein were present in the 
supernatant of transfected HEK293T cells and it appeared to be unstable when 




C.  While this property of IL-34 has not been 
demonstrated for commercially available human or mouse IL-34, it is also a property 
of chicken IL-34 produced in the same system
15
, and was recently reported by Felix 
et al. (2013), in the production of human IL-34 from HEK293T cells.  Alternative 
systems could include the stable tetracycline-inducible HEK293S GnTi-/- cell line 
that can express up to 2 mg/L of recombinant IL-34 protein (Felix et al., 2013), or 
expression of IL-34 using a yeast expression system, Pichia pastoris (Chen et al., 
2011).  At the outset of the project, I also initiated efforts to produce anti-pig CSF-1R 
antibodies.  This work was taken up in my absence on maternity leave by Lindsey 
Moffatt and led to the characterisation of five antibodies that detect the receptor on 
pig monocytes and on the factor-dependent line I generated.  Unfortunately, none of 
them appear to block receptor activity.  
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The industry partner, Pfizer, produced large amount of CSF-1 by E.coli expression.  
In-vivo studies performed by Pfizer, identified that this CSF-1 had a very short half-
life.  They subsequently produced an Fc CSF-1 fusion protein, and the data in 
Chapters 5 and 6 shows that this protein is active in both mice and pigs at inducing 
large increases in blood monocytes and tissue macrophages.  Unfortunately, the 
original intended application of CSF-1 was not supported by the treatment trial in 
neonatal pigs.  Despite a significant effect on macrophage numbers, there was no 
increase in postnatal growth rate.  It could be argued that these production pigs grow 
extremely rapidly anyway.   
Unexpectedly, the preclinical evaluation in mice revealed that CSF-1 causes a 
profound increase in liver weight in mice.  This was not seen in the pig trials, but 
again, the liver was already growing rapidly in the controls.  Further investigation 
into the mechanism and the full potential of porcine Fc CSF-1 in liver regeneration is 
currently being investigated in mice models and includes the use of porcine Fc CSF-
1 in a range of liver disease models (PH, paracetamol intoxication, acute-on-chronic 
liver injury).  In these models, which are well established models for human disease, 
mice treated with Fc CSF-1 at the time of liver injury demonstrate hepatocyte 




The availability of the pig Fc CSF-1 will expedite a trial on liver regeneration in this 
species.  The complete sequencing of the swine genome has expedited the use and 
development of swine models for human disease and assessment of therapeutics 
(Walters et al., 2012).  Pig anatomy and physiology shares a close proximity with 
humans in many organ systems (Kobayashi et al., 2012), and the pig is rapidly 
emerging as an important model for human disease.  Examples include the pig as a 
model to study;  renal ischemia reperfusion injury (Giraud et al., 2011), the 
gastrointestinal tract (Zhang et al., 2013), acute myocardial infarction  
(Gahremanpour et al., 2013), chronic liver disease (Kobayashi et al., 2012; Liska et 
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al., 2009b), acute liver failure (Lee et al., 2013a), and exocrine pancreatic 
insufficiency (Mosseler et al., 2012).  Additionally, transgenic pigs provide further 
advances in the study of diseases such as cystic fibrosis and the dominant-negative 
glucose-dependent insulinotrophic polypeptide receptor transgenic pig (GIPR
dn
) that 
resembles type 2 diabetes in humans.  Swine models are therefore valuable tools for 
testing and optimizing pre-clinical interventions and thus reduce the risk for patients 
(Walters et al., 2012).  Further work that would be essential to determine the full 
potential in liver regeneration of porcine Fc CSF-1 would be to assess the liver 
regenerative capacity after PH in this species, or by using portal vein ligation which 
is reported to be more comparable to human medicine (Liska et al., 2009c).  Partial 
hepatectomy has been used as a model of liver regeneration in porcine studies where 
the expected results of increased liver weight, hepatocyte hypertrophy and mitotic 
hepatocytes 3-7 days post PH  are identified (Ladurner et al., 2009; Wege et al., 
2007).  Although liver PH in pigs has not been used as extensively as in rodent 
models, the reports of its use thus far have presented good safety data, with no 
reported reduction in survival (Ladurner et al., 2009; Liska et al., 2009b; Liska et al., 
2009c; Wege et al., 2007).  Paracetamol-induced acute liver failure is the most 
common cause of acute liver failure in the UK and USA (Lee et al., 2013a).  With 
this in mind, a pig model of paracetamol-induced acute liver failure causing hepatic 
necrosis and multiple organ failure has been developed (Lee et al., 2013a), which 
could provide the ideal opportunity to validate and test the application of porcine Fc 
CSF-1.  Additionally, the use of genetically modified pigs that express EGFP in 
hepatocytes may provide a useful tool for further study of the effects of porcine Fc 
CSF-1 on the liver (Kawarasaki et al., 2009).  
The alternative to CSF-1 that has been extensively tested is hepatocyte growth factor 
(HGF), which is a potent mitogen for hepatocytes, stimulates hepatocyte 
proliferation, and in rats has been shown to stimulate hepatic progenitor cells 
(Hasuike et al., 2005).  A clinical trial of HGF administered to patients with 
fulminant hepatitis or late-onset hepatic failure conducted by Ido et al. (2011), did 
not show any improvement in hepatic encephalopathy associated with the liver 
disease, or any improvements in laboratory data results or patient survival.  Like the 
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unmodified CSF-1, HGF has a short half-life of 3-5 minutes and is very unstable in 
the circulation (Kawaida et al., 1994).  HGF gene therapy, whereby the HGF is 
persistently expressed in-vivo may allow HGF to remain in plasma for up to 3 weeks.  
HGF gene therapy promoted liver regeneration by proliferation and was considered a 
potential therapeutic approach for hepatic resection after cirrhosis (Xue et al., 2003).  
However, there has been no follow up to these findings.  
One potential limitation of Fc CSF-1 therapy would be potential effects on platelets.  
Patients with chronic liver disease often have clinical thrombocytopenia, defined as  
platelet count <150,000/µL (Afdhal et al., 2008).  This is reported in up to 76% of 
patients  with liver cirrhosis (Giannini, 2006).  In most cases, the thrombocytopenia 
is mild-moderate and does not clinically affect the patient or cause mortality.  
However, in severe cases when the platelet count is <50,000/µL, there is a significant 
increase in the risk of fatal bleeding such as cerebral haemorrhage or gastrointestinal 
bleeding (Giannini, 2006).  The development of thrombocytopenia is often 
multifactorial with platelet sequestration, bone marrow suppression and reduced 
thrombopoietin (a haematopoietic growth factor) are all known to play a role.  In 
early clinical studies using continuous infusion of  human CSF-1 in patients with 
metastatic cancer, the dose-limiting toxic effect reported was that of severe 
thrombocytopenia (<50,000/µL).  Although the thrombocytopenia was dose-
dependent, it was still noted at the lower doses used in this study (Cole et al., 1994; 
Jakubowski et al., 1996).  Thrombocytopenia was not observed in the treated pigs in 
the current study.  There is no way of knowing without testing whether Fc CSF-1 
would exacerbate the problem in liver disease.   
Macrophages play an important role in tissue repair in a number of tissues including 
kidney, liver, heart, brain and lung (Duffield et al., 2005; Leor et al., 2006; 
Nakamura et al., 2005; Ricardo et al., 2008; Vinuesa et al., 2008) and CSF-1 
administration has been shown to promote regeneration in a number of models.  For 
example, in ischaemia-reperfusion in mice  as a model of acute renal injury, 
recombinant human CSF-1 administration was able to stimulate macrophage 
infiltration to promote epithelial repair and to prevent interstitial fibrosis (Alikhan et 
al., 2011).  CSF-1 actively recruited macrophages to the injury site, caused 
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accelerated  renal cell replacement and tissue remodelling, while attenuating down-
stream interstitial extracellular matrix accumulation (Alikhan et al., 2011).  
Acute renal failure in cats is defined as an abrupt decrease in glomerular filtration 
rate (GFR), leading to retention of nitrogenous waste, and may be a result of reduced 
blood flow to the kidneys or as a result of ischaemia (Schrier et al., 2004).  Acute 
renal failure in cats can arise from numerous causes (Bischoff and Rumbeiha, 2012; 
Fitzgerald, 2010; Gowan et al., 2011; O'Keefe and Schaeffer, 1992; O'Keefe et al., 
1993; Reiman et al., 2008; Ross, 2011) and has a very poor prognosis (Ross, 2011; 
Worwag and Langston, 2008).  Many cats that survive to discharge are azotaemic 
and, as a result, are likely to have high morbidity and a greatly-reduced lifespan, 
while a second “wave” of apoptosis seems to occur in the recovery phase which may 
limit further regeneration (Awad et al., 2009).  Treatment, apart from removal of 
inciting cause, is purely supportive.  Therefore, development of more specific 
therapies may improve survival rates, and/or the morbidity/mortality of the survivors. 
The studies in the mouse model (Alikhan et al., 2011), suggest that CSF-1 could have 
a therapeutic benefit in cats with acute renal injury.  Previous studies using non-
species specific colony stimulating factors for therapy have been hampered by the 
development of auto-antibodies.  For example, the administration of rh-GM-CSF to 
healthy dogs has been reported to produce neutralising antibodies after 10-12 days 
(Mayer et al., 1990).  Similarly, the administration of rh-GM-CSF to cats with FIV 
triggered neutralising antibodies in 75% of the cats, 35 days after a 2 week treatment 
protocol (Arai et al., 2000).  In-vivo neutralisation of the rh-GM-CSF was not further 
investigated, therefore it is difficult to determine the true effect of these antibodies 
again both endogenous feline GM-CSF and also the exogenous recombinant human 
protein administered (Arai et al., 2000).  I have cloned and produced full length 
feline CSF-1R expressed in the factor-dependent IL-3 cell line which allowed the 
cross-species analysis of CSF-1.  The results in Chapter 4 have demonstrated that 
either human or porcine CSF-1 could be used to drive CSF-1R-mediated signaling in 
cats, therefore, the requirement to produce feline specific CSF-1 is reduced at least 
for short-term treatments.  
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The effect of CSF-1 in renal repair in cats is currently being investigated.  Although, 
as discussed above, the most suitable model would be cats with acute renal failure, 
cats presenting with this condition are uncommon.  Clinicians in The Hospital for 
Small Animals at the R(D)SVS see on average 2 cases/year
17
, and a review by 
Worwag and Langston (2008), of cases that fitted their criteria for acute renal failure 
identified 32 cases over a 7 year period.  Hence it would be more realistic to study 
the effects of CSF-1 with chronic kidney disease (CKD) which is common in older 
cats affecting up to 49% of cats older than 15 years (Chakrabarti et al., 2013).  
Although chronic renal failure is irreversible, perhaps if caught early enough, the 
condition may be improved or in some cases, an acute-on-chronic situation may be 
prevented.  A method of detecting cats at early stages of chronic renal failure to 
determine a cohort of cats that CSF-1 therapy may be applied, is currently being 
investigated with the help of veterinary specialists at the R(D)SVS.   In human 
medicine, urinary inulin clearance for estimating glomerular filtration rate (GFR) is 
the gold standard measurement of renal function (Murphy and Hsu, 2013).  In feline 
patients, this method is often not practiced or ethical since it involves timely repeated 
blood sample measurements and bladder catheterization to determine urine volume 
which is not practical in veterinary practice.  Recently, an alternate to this method, a 
single blood-sample method has been reported in cats (Katayama et al., 2013).  In 
feline medicine, a combination of serum concentrations of urea and creatinine, 
presence of proteinuria, urine specific gravity (USG) and renal ultrasonography are 
used.  While the primary factor for staging cats with CKD is increased creatinine 
concentrations, a significant proportion of the kidney must be damaged before this 
indicator is detectable.  Therefore both proteinuria and inappropriate ability to 
concentrate urine (USG <1.035) are more appropriate to detect cats in stage I of the 
IRIS (International Renal Interest Society) scoring system which grades CKD based 
on plasma creatinine (Elliott and Grauer, 2007).  It is in this cohort of cats that are 
non-azotaemic, may demonstrate abnormal renal ultrasound findings but will have a 
USG<1.035 and persistent proteinuria of renal origin that I believe CSF-1 therapy 
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may prove to be helpful.  The production of feline CSF-1 may become a necessity if 
CSF-1 therapy is to be used longer-term to patients with CKD, due to the reasons 
described above. 
 
Recent studies investigating the effects of mesenchymal stem cell (MSC) therapy in 
rodent models including chronic renal failure and glomerulonephritis have 
demonstrated that MSC therapy can result in beneficial effects (Cheng et al., 2013; 
Choi et al., 2009; Guillot et al., 2008).  In cats, autologous intra-renal injections of 
either adipose tissue-derived or bone-marrow-derived mesenchymal stem cells 
demonstrated modest improvements in glomerular filtration rate (GFR) and serum 
biochemical markers of renal disease (Quimby et al., 2011).  MSCs are highly 
proliferative, undifferentiated cells that can self-renew (Kern et al., 2006; Pittenger et 
al., 1999).  It is know that MSC secrete a number of cytokines of which CSF-1 is one 
of the identified.  Furthermore, CSF-1 mRNA is constitutively expressed (Kilroy et 
al., 2007; Majumdar et al., 2000; Majumdar et al., 1998).  Human adipose tissue-
derived MSC can produce 976 pg/ml after 24 hours (Kilroy et al., 2007), which 
compares to normal human concentrations of 2000-30,000 pg/ml (Cebon et al., 1994; 
Suzu et al., 1991).  Both adipose tissue-derived and marrow-derived human MSCs 
have been well characterised and using FACS analysis, macrophages are identified in 
these populations as CD14
+
 cells, constituting 1.2% of the cells in marrow-derived 
and 2.4% of cells in adipose tissue-derived MSCs (Kern et al., 2006).  MSCs are 
being suggested as therapeutic options for a range of diseases including chronic renal 
failure in cats (Quimby et al., 2011; Webb et al., 2012), and given the trophic 
functions, CSF-1 would be candidate to mediate of some of the effects of MSC.  
Additionally, from the work I have described in Chapter 5 of porcine Fc CSF-1 
inducing hepatic proliferation, perhaps further evidence of CSF-1 as a mediator of 
MSC therapy comes from the finding that portal vein administration of MSC to pigs 
following ligation of the portal vein as a model of liver resection can increase liver 
volume in the initial stages (Liska et al., 2009a).  In fact, the effect of administration 
of MSCs has been assessed in a range of disease models including; bone remodelling 
and repair (Kraus and Kirker-Head, 2006),  myocardial infarction (Karpov et al., 
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2013), and cutaneous wound healing (Hanson et al., 2013; Wu et al., 2013).   In these 
studies, treatment has led to increased bone regeneration, reduction of the infarct scar 
tissue area, and improvements in healing and attenuation of fibrosis.  Work by 
Alexander et al. (2011), using rh-CSF-1 administered to mice with tibial injury 
demonstrated that CSF-1 increased the number of F4/80
+
 macrophages within the  
injury site and noted accelerated matrix deposition and mineralization.  If  CSF-1 is 
responsible for these effects seen in MSC administration then the future applications 
of CSF-1 treatment are wide and varied.  
 
Although it is obviously a haematopoietic growth factor, CSF-1 has not generally 
been used in human myelorestorative therapies.  G-CSF is commonly used to 
accelerate the recovery of neutrophil counts following whole body irradiation and 
bone marrow transplantation and prophylactically during chemotherapy (Hamilton 
and Achuthan, 2012; Heuser et al., 2007; Lee et al., 2013b).  The presence of febrile 
neutropenia (FN) from myelosupressive chemotherapy results in substantial 
morbidity and mortality, often combined with increased duration of hospitalization 
and therefore increased costs per patient (Wright et al., 2013).  Furthermore, patients 
receiving chemotherapy such as CHOP
18
 for non-Hodgkin lymphoma will also have 
a reduction in their monocyte count within the first 8 days of treatment, where the 
monocyte count is significantly correlated with the development of  FN (Shikata et 
al., 2013).  The experiments in both mice (Chapter 5) and pigs (Chapter 6) have 
demonstrated an unexpected elevation of neutrophils as well as the predicted increase 
in monocytes in response to Fc CSF-1.  Therefore, administration of Fc CSF-1 may 
be of benefit to patients undergoing treatment with CHOP for non-Hodgkin 
lymphoma where it may ameliorate the myelosuppressive effects of chemotherapy, 
reducing morbidity and mortality.  
 
                                                 
18
 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone 
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Finally, as discussed in Chapter 6, a potential further and more beneficial effect of 
postnatal growth of porcine Fc CSF-1 may be noted in weaner pigs going through a 
period of post-weaning growth check.  An additional group of pigs that may also 
show potential benefits would be the use of low birth weight pigs which would 
provide a model of preterm and low-birth weight infants.  Preterm infants with a 
gestational age of 23-36 weeks are known to have significantly reduced serum CSF-1 
concentrations compared to full-term infants (Roth and Stanley, 1995).  Therefore, 
an exogenous administration of CSF-1 during this period, which is associated with 
high morbidity and mortality, may be beneficial.  Preterm pigs have recently been 
identified as a relevant and translational animal model for studying preterm infants, 
particularly in relation to the gastrointestinal tract  (Buddington et al., 2012).  Piglets 
that are intrauterine growth retarded, defined as a birth weight below two standard 
deviation of the mean, cannot compensate their growth later in life and have slower 
growth rates and lighter carcase traits (Paredes et al., 2012).  Ideally, the trial for 
growth promoting activity would be conducted on such animals, but it is impossible 
to identify them in sufficient numbers, since administration of dexamethasone to 
induce premature labour would have no guarantee of working (Benediktsson et al., 
1993).   The production of preterm piglets by caesarean section at days 105/106 post 
conception (91-92% of full gestation) has been reported (Azcarate-Peril et al., 2011; 
Rasch et al., 2010).  Although this would provide a cohort of piglets with low birth 
weights commonly 20% less body weight compared to full term, the preterm piglet 
will also be hampered by other aspects of premature birth particularly related to 
feeding such as difficulty sucking, swallowing, regurgitation as a result of reduced 
peristaltic activity and oesophageal motility and reduced lung surfactant production, 
which may lead to respiratory distress syndrome (Qian et al., 2008; Rasch et al., 
2010).  Additional issues may include the development of necrotizing enterocolitis if 
premature piglets required formula feeding which can allow bacterial colonization of 
the premature gut (Azcarate-Peril et al., 2011).  Therefore, although this group of 
pigs may be useful to investigate the effects of exogenous CSF-1 administration, 
particularly as they may bear close resemblance to premature infants, studies using 
these subjects would be hampered by serious ethical and welfare considerations. 




The work in this thesis has therefore generated an important in-vitro system for 
assessing the activity of CSF-1 and IL-34.  The in-vivo effects of the larger Fc CSF-1 
molecule on liver proliferation points towards further investigation and research into 
the use of Fc CSF-1 as a potential liver therapeutic agent.  The role of CSF-1 on 
postnatal growth has not been further advanced, and will benefit from additional 
research using modified doses and ages of animals.  
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Table 9.1:  Antibodies used in FACS, western and IHC 
 
 
Antibody Concentration Identification Application 
Anti-v5 tag  1:5000 MCA1360G (AbD Serotec) Western 
Anti-mouse IgG HRP 1:5000 7076 (Cell Signalling 
Technology) 
Western 
Mouse anti-pig CD14 1:50 MCA1218F (AbD Serotec) FACS 
Mouse anti-pig CD16 1:200 MCA1971PE (AbD Serotec) FACS 
Mouse anti-pig CD163 1:200 MCA2311PE (AbD Serotec) FACS 
Mouse anti-pig CD172a 1:400 4525-09 (Southern Biotech FACS 
Anti-mouse F4/80-PE 1:20 122616 (BioLegend) FACS 
Anti-mouse GR1 1:80 108408 (BioLegend) FACS 
Rat IgG2b isotype Ctrl 1:20 400608 (BioLegend) FACS 
Rat anti-mouse F4/80 1:200 MCA497G (AbD Serotec) IHC 
HRP Streptavidin 1:100 405210 (BioLegend) IHC 
Goat anti-rat IgG F(ab) 1:200 Sc-3822 (Santa Cruz) IHC 
Rat anti-mouse CD11b 1:100 BD Pharmingen (557686) FACS 
Rat anti-mouse F4/80 1:100 Invitrogen (MF48021) FACS 
Rat IgG2b isotype control 1:100 Invitrogen (R2b21) FACS 
Anti-human MHCII 1:200 VMRD (H42A) FACS 
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9.2 Appendix 2:  EGFP
+
 lung images 
 
 
Figure 9.1:  Effect of porcine Fc CSF-1 on adult Csf1rEGFP
+
 mice lung.  
Csf1r-EGFP
+ 
mice were injected with PBS or 1 µg/g of porcine CSF-1 or porcine Fc CSF-1 for four 
days prior to sacrifice on day 5.  The lungs were removed post-mortem and frozen as cryosections (see 
materials and methods) prior to cutting and examination of  EGFP
+
 cells using Zeiss and x400 and 
x600 magnification.   Tile images of 3x3 x400 and x600 field of view were generated. 
 
The images above of EGFP
+
 cells in mice treated with porcine Fc CSF-1 demonstrate 
the location of EGFP
+
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9.4 Appendix 4:  Publications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
